<SEC-DOCUMENT>0001213900-21-050592.txt : 20210929
<SEC-HEADER>0001213900-21-050592.hdr.sgml : 20210929
<ACCEPTANCE-DATETIME>20210929163711
ACCESSION NUMBER:		0001213900-21-050592
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		30
CONFORMED PERIOD OF REPORT:	20210924
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Changes in Registrant's Certifying Accountant
ITEM INFORMATION:		Changes in Control of Registrant
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Change in Shell Company Status
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210929
DATE AS OF CHANGE:		20210929

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Amplitude Healthcare Acquisition Corp
		CENTRAL INDEX KEY:			0001788028
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				842984849
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39138
		FILM NUMBER:		211292166

	BUSINESS ADDRESS:	
		STREET 1:		1177 AVENUE OF THE AMERICAS FL 40
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		212- 823-1900

	MAIL ADDRESS:	
		STREET 1:		1177 AVENUE OF THE AMERICAS FL 40
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea147929-8k_jasper.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:AMHC="http://amplitudehealthcare.com/20210924">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_AMHC_amplitudehealthcare.com_20210924 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20210924_20210924 -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001788028 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-09-24to2021-09-24" name="dei:EntityCentralIndexKey">0001788028</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-09-24to2021-09-24" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-09-24to2021-09-24" id="xdx2ixbrl0011" name="dei:EntityRegistrantName">Amplitude Healthcare Acquisition Corp</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="amhc-20210924.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-09-24to2021-09-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-24</xbrli:startDate>
        <xbrli:endDate>2021-09-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-242021-09-24_dei_FormerAddressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-24</xbrli:startDate>
        <xbrli:endDate>2021-09-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-242021-09-24_custom_VotingCommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AMHC:VotingCommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-24</xbrli:startDate>
        <xbrli:endDate>2021-09-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-242021-09-24_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001788028</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AMHC:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-24</xbrli:startDate>
        <xbrli:endDate>2021-09-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>UNITED
STATES </b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Washington,
D.C. 20549 </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>FORM
<span id="xdx_906_edei--DocumentType_c20210924__20210924_zOqsQ7o6WsN6"><ix:nonNumeric contextRef="From2021-09-24to2021-09-24" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Date
of Report (Date of Earliest Event Reported): September 29, 2021 (<span id="xdx_907_edei--DocumentPeriodEndDate_c20210924__20210924_zw702Dl7ZmT9"><ix:nonNumeric contextRef="From2021-09-24to2021-09-24" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 24, 2021</ix:nonNumeric></span>)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 14pt Times New Roman, Times, Serif"><b><span id="xdx_90C_edei--EntityRegistrantName_dxL_c20210924__20210924_z7aHn2GnINVk" title="::XDX::Amplitude%20Healthcare%20Acquisition%20Corp"><span style="-sec-ix-hidden: xdx2ixbrl0011">JASPER
THERAPEUTICS, INC.</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20210924__20210924_z43qKvQNbGZa"><ix:nonNumeric contextRef="From2021-09-24to2021-09-24" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityFileNumber_c20210924__20210924_z8IHnOiHdW3k"><ix:nonNumeric contextRef="From2021-09-24to2021-09-24" name="dei:EntityFileNumber">001-39138</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20210924__20210924_zdfU54RAa60i"><ix:nonNumeric contextRef="From2021-09-24to2021-09-24" name="dei:EntityTaxIdentificationNumber">85-2984849</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(State or other jurisdiction</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;of incorporation)</b></p></td>
    <td style="text-align: center">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Commission</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>File Number)</b></p></td>
    <td style="text-align: center">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(I.R.S. Employer</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Identification No.)</b></p></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--EntityAddressAddressLine1_c20210924__20210924_z7j8T8rP4R5a"><ix:nonNumeric contextRef="From2021-09-24to2021-09-24" name="dei:EntityAddressAddressLine1">2200 Bridge Pkwy Suite #102</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityAddressCityOrTown_c20210924__20210924_z9Fw9qkDET9h"><ix:nonNumeric contextRef="From2021-09-24to2021-09-24" name="dei:EntityAddressCityOrTown">Redwood City</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20210924__20210924_z7bgIBkDNQK"><ix:nonNumeric contextRef="From2021-09-24to2021-09-24" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></b></p></td>
    <td style="padding-bottom: 1.5pt; vertical-align: top; width: 2%; font-size: 10pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 49%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90A_edei--EntityAddressPostalZipCode_c20210924__20210924_zeSiSGGEJQ0f"><ix:nonNumeric contextRef="From2021-09-24to2021-09-24" name="dei:EntityAddressPostalZipCode">94065</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>(Address of principal executive offices)</b></span></td>
    <td style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>(Zip Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_905_edei--CityAreaCode_c20210924__20210924_zuB9zQowcpSf"><ix:nonNumeric contextRef="From2021-09-24to2021-09-24" name="dei:CityAreaCode">(650)</ix:nonNumeric></span>
<span id="xdx_902_edei--LocalPhoneNumber_c20210924__20210924_zBfGLSCIE8zj"><ix:nonNumeric contextRef="From2021-09-24to2021-09-24" name="dei:LocalPhoneNumber">549-1400</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Registrant&#8217;s
telephone number, including area code</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90C_edei--EntityInformationFormerLegalOrRegisteredName_c20210924__20210924_zOcZFDKJIxBl"><ix:nonNumeric contextRef="From2021-09-24to2021-09-24" name="dei:EntityInformationFormerLegalOrRegisteredName">Amplitude
Healthcare Acquisition Corporation</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90A_edei--EntityAddressAddressLine1_c20210924__20210924__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_zy2eW2vMkADj"><ix:nonNumeric contextRef="From2021-09-242021-09-24_dei_FormerAddressMember" name="dei:EntityAddressAddressLine1">1177
Avenue of the Americas</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressAddressLine2_c20210924__20210924__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_zrnDq1MvzSZ7"><ix:nonNumeric contextRef="From2021-09-242021-09-24_dei_FormerAddressMember" name="dei:EntityAddressAddressLine2">Fl 40</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90D_edei--EntityAddressCityOrTown_c20210924__20210924__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_zjijJMz2Rghh"><ix:nonNumeric contextRef="From2021-09-242021-09-24_dei_FormerAddressMember" name="dei:EntityAddressCityOrTown">New
York</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20210924__20210924__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_zFpSf4vNX4uc"><ix:nonNumeric contextRef="From2021-09-242021-09-24_dei_FormerAddressMember" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_904_edei--EntityAddressPostalZipCode_c20210924__20210924__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_zMtYdAOStjTa"><ix:nonNumeric contextRef="From2021-09-242021-09-24_dei_FormerAddressMember" name="dei:EntityAddressPostalZipCode">10036</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Former
name or former address, if changed since last report)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--WrittenCommunications_c20210924__20210924_zD1CeTvuMjC"><ix:nonNumeric contextRef="From2021-09-24to2021-09-24" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the
    Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span id="xdx_90E_edei--SolicitingMaterial_c20210924__20210924_zUu3c3bt4P8e"><ix:nonNumeric contextRef="From2021-09-24to2021-09-24" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the
    Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span id="xdx_907_edei--PreCommencementTenderOffer_c20210924__20210924_z3n2bi4dczC3"><ix:nonNumeric contextRef="From2021-09-24to2021-09-24" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b)
    under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"></span><span id="xdx_90E_edei--PreCommencementIssuerTenderOffer_c20210924__20210924_ziXDitiE8BTj"><ix:nonNumeric contextRef="From2021-09-24to2021-09-24" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c)
    under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 44%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title
    of each class</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 20%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading
    Symbol(s)</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name
    of each exchange on which<br />
    registered</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_edei--Security12bTitle_c20210924__20210924__us-gaap--StatementClassOfStockAxis__custom--VotingCommonStockParValue0.0001PerShareMember_zadLKcdSqMRc"><ix:nonNumeric contextRef="From2021-09-242021-09-24_custom_VotingCommonStockParValue0.0001PerShareMember" name="dei:Security12bTitle">Voting Common Stock,
    par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_edei--TradingSymbol_c20210924__20210924__us-gaap--StatementClassOfStockAxis__custom--VotingCommonStockParValue0.0001PerShareMember_zph9IP8Oo5Y2"><ix:nonNumeric contextRef="From2021-09-242021-09-24_custom_VotingCommonStockParValue0.0001PerShareMember" name="dei:TradingSymbol">JSPR</ix:nonNumeric></span></span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
    <span id="xdx_905_edei--SecurityExchangeName_c20210924__20210924__us-gaap--StatementClassOfStockAxis__custom--VotingCommonStockParValue0.0001PerShareMember_z6Jhwk3Ybwsi"><ix:nonNumeric contextRef="From2021-09-242021-09-24_custom_VotingCommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  <tr style="background-color: White">
    <td style="text-align: center; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_edei--Security12bTitle_c20210924__20210924__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member_z1Ltj3DWnaV7"><ix:nonNumeric contextRef="From2021-09-242021-09-24_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member" name="dei:Security12bTitle">Redeemable Warrants,
    each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50</ix:nonNumeric></span></span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--TradingSymbol_c20210924__20210924__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member_zkSNStdin5C1"><ix:nonNumeric contextRef="From2021-09-242021-09-24_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member" name="dei:TradingSymbol">JSPRW</ix:nonNumeric></span></span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
    <span id="xdx_90D_edei--SecurityExchangeName_c20210924__20210924__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member_zwnwIzLU36Q"><ix:nonNumeric contextRef="From2021-09-242021-09-24_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2
of the Securities Exchange Act of 1934.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Emerging
growth company <span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20210924__20210924_zUJaockl93J3"><ix:nonNumeric contextRef="From2021-09-24to2021-09-24" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_909_edei--EntityExTransitionPeriod_c20210924__20210924_zpvXINoZFLyh"><ix:nonNumeric contextRef="From2021-09-24to2021-09-24" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Introductory
Note</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Due to the large number of events reported under the specified items of Current Report on Form 8-K, this Current Report on Form 8-K is
being filed in two parts. An amendment to this Current Report on Form 8-K (this &#8220;Current Report&#8221;) is being submitted for filing
on the same date to include additional matters under Items 3.03, 5.03 and 5.05 of Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On
September 24, 2021 (the &#8220;Closing Date&#8221;), Amplitude Healthcare Acquisition Corporation, a Delaware corporation and our predecessor
company (&#8220;AMHC&#8221;), consummated the previously announced business combination (the &#8220;Business Combination&#8221;) pursuant
to the terms of the Business Combination Agreement, dated as of May 5, 2021 (the &#8220;Business Combination Agreement&#8221;), by and
among AMHC, Ample Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of AMHC (&#8220;Merger Sub&#8221;), and Jasper
Therapeutics, Inc., a Delaware corporation (together with its consolidated subsidiaries, &#8220;Old Jasper&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the Business Combination Agreement, on the Closing Date, (i)&#160;Merger Sub merged with and into Old Jasper (the &#8220;Merger&#8221;),
with Old Jasper as the surviving company in the Merger, and, after giving effect to such Merger, Old Jasper became a wholly-owned subsidiary
of AMHC and changed its name to Jasper Tx Corp., and (ii) AMHC changed its name to &#8220;Jasper Therapeutics, Inc.&#8221; (together
with its consolidated subsidiaries, &#8220;New Jasper&#8221; or the &#8220;Company&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
accordance with the terms and subject to the conditions of the Business Combination Agreement, at the effective time of the Merger (the
&#8220;Effective Time&#8221;), (i)&#160;each share of Old Jasper common stock and Old Jasper preferred stock outstanding immediately
prior to the Effective Time was automatically cancelled, extinguished and converted into the applicable number of shares of voting common
stock, par value $0.0001 per share, of New Jasper (&#8220;New Jasper Voting Common Stock&#8221;) or, in certain circumstances, non-voting
common stock, par value $0.0001 per share, of New Jasper (&#8220;New Jasper Non-Voting Common Stock&#8221;, and together with New Jasper
Voting Common Stock, the &#8220;New Jasper Common Stock&#8221;), based on Old Jasper&#8217;s equity value, (ii) each vested and unvested
option to purchase shares of Old Jasper&#8217;s common stock outstanding as of immediately prior to the Effective Time was cancelled
in exchange for a comparable option to purchase shares of New Jasper Voting Common Stock, based on Old Jasper&#8217;s equity value, and
(iii) each unvested award of restricted shares of Old Jasper&#8217;s common stock outstanding immediately prior to the Effective Time
was converted into a comparable right to receive restricted shares of New Jasper Common Stock, based on Old Jasper&#8217;s equity value.
For purposes herein and in the Business Combination Agreement, Old Jasper&#8217;s equity value was deemed to be an agreed upon amount
equal to $275.0 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, as previously disclosed, concurrently with the execution of the Business Combination Agreement, on May 5, 2021, AMHC entered
into subscription agreements (the &#8220;Subscription Agreements&#8221;) with certain investors (the &#8220;PIPE Investors&#8221;), pursuant
to which the PIPE Investors agreed to subscribe for and purchase, and AMHC agreed to issue and sell to the PIPE Investors, an aggregate
of 10,000,000 shares of Class&#160;A Common Stock of AMHC at a price of $10.00 per share, for aggregate gross proceeds of $100.0 million
(the &#8220;PIPE Financing&#8221;). The PIPE Financing was consummated concurrently with the closing of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with the Merger, immediately prior to the Closing, each share of AMHC Class B Common Stock outstanding immediately prior to
the Merger was converted into one share of AMHC&#8217;s Class A Common Stock, and following such conversion, all outstanding shares of
AMHC&#8217;s Class A Common Stock were converted into an equivalent number of shares of New Jasper Voting Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Unless
the context otherwise requires, &#8220;New Jasper,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221;
refer to Jasper Therapeutics, Inc., a Delaware corporation, and its consolidated subsidiaries. All references herein to the &#8220;Board&#8221;
refer to the board of directors of the Company. All references herein to the &#8220;Closing&#8221; refer to the closing of the transactions
contemplated by the Business Combination Agreement, including the Business Combination and the PIPE Financing (collectively, the &#8220;Transactions&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
                            1.01.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Entry
into a Material Definitive Agreement.</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Amended
and Restated Registration Rights Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On
the Closing Date, New Jasper, Amplitude Healthcare Holdings LLC, a Delaware limited liability company (&#8220;Sponsor&#8221;), and certain
former stockholders of Old Jasper (the &#8220;Jasper Holders&#8221; and, collectively with Sponsor, the &#8220;Holders&#8221;) entered
into an Amended and Restated Registration Rights Agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to which, among
other things, the Holders agreed not to, subject to certain exceptions set forth therein, effect any sale or distribution of any equity
securities of New Jasper held by any of them during the 180-day lock-up period described therein and&#160;New Jasper agreed to register
for resale, pursuant to Rule 415 of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), certain shares of New
Jasper Common Stock and other equity securities of New Jasper Common Stock that are held by the parties thereto from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
particular, the Registration Rights Agreement provides for the following registration rights:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Shelf
registration rights</i>. As soon as practicable but no later than 30 calendar days following the Closing Date, New Jasper is required
to file a shelf registration statement pursuant to Rule 415 of the Securities Act covering the resale of all the Holders&#8217; registrable
securities on a delayed or continuous basis and use commercially reasonable efforts to have such shelf registration statement declared
effective as soon as practicable after the filing thereof. At any time New Jasper has an effective shelf registration statement on file
with the Securities and Exchange Commission (the &#8220;SEC&#8221;), Sponsor or &#160;Holders of a majority-in-interest of registrable
securities held by the Jasper Holders may make a written request to effect an underwritten shelf takedown to sell all or any portion
of their registrable securities; provided that New Jasper is only obligated to effect any such underwritten shelf takedown if the total
offering price of the registrable securities to be sold is reasonably expected to exceed, in the aggregate, $30.0 million, and New Jasper
is not required to effect more than one underwritten shelf takedown in any twelve-month period.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr>
    <td style="width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Piggyback
    registration rights</i>. At any time after the Closing Date, if New Jasper proposes to file a registration statement under the Securities
    Act to register equity securities, or securities or other obligations exercisable or exchangeable for, or convertible into equity
    securities, for its own account or for the account of any stockholders of New Jasper, subject to certain exceptions, the Holders
    are entitled to include their registrable securities in such registration statement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Expenses
and indemnification</i>. All fees, costs and expenses incurred in connection with registrations under the Securities Act will be borne
by New Jasper, and all underwriting discounts and commissions, brokerage fees, underwriting marketing costs and, subject to certain exceptions,
all reasonable fees and expenses of any legal counsel representing the Holders, will be borne by each Holder, with respect to such Holder&#8217;s
registrable securities being sold. The Registration Rights Agreement contains cross-indemnification provisions under which New Jasper
is obligated to indemnify Holders of registrable securities in the event of any untrue or alleged untrue statement of material fact in
any registration statement or prospectus, or any amendment thereof or supplement thereto, covering registrable securities pursuant to
the Registration Rights Agreement or any omission or alleged omission of a material fact required to be stated therein or necessary to
make the statements therein not misleading, except to the extent such statement or omission was furnished in writing by such Holder,
and each Holder of registrable securities is obligated to indemnify New Jasper for any such untrue or alleged untrue statements of material
fact or any such omissions or alleged omissions of material fact to the extent such untrue or alleged untrue statement, or such omission
or alleged omission, is contained in any information or affidavit furnished to New Jasper in writing by such Holder.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr>
    <td style="width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Registrable
    securities</i>. Securities shall cease to be registrable securities under the Registration Rights Agreement upon the earliest to
    occur of:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a
registration statement with respect to the sale of such securities shall have become effective under the Securities Act and such securities
shall have been sold, transferred, disposed of or exchanged in accordance with such registration statement by the applicable Holder;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">such
securities have otherwise been transferred, subject to certain exceptions set forth in the Registration Rights Agreement, and new certificates
for such securities not bearing a legend restricting further transfer has been delivered by New Jasper and subsequent public distribution
of such securities shall not require registration under the Securities Act;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">such
securities have ceased to be outstanding;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">such
securities may be sold without registration pursuant to Rule 144 or any successor rule promulgated under the Securities Act (but with
no volume or manner of sale or current public information requirement);</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">such securities have been
    sold without registration pursuant to Section 4(a)(1) of the Securities Act or Rule 145 under the Securities Act or any successor
    rules promulgated under the Securities Act; and</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">such securities have been
    sold to, or through, a broker, dealer or underwriter in a public distribution or other public securities transaction.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr>
    <td style="width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Lock-up</i>.
    Notwithstanding the foregoing, each Holder may not, without the consent of New Jasper, transfer any shares of New Jasper Common Stock
    or any other equity securities convertible into or exercisable or exchangeable for shares of New Jasper Common Stock held by the
    Jasper Holders immediately following the Closing or any shares of New Jasper Common Stock issued with respect to or in exchange for
    equity awards on or after the Closing as permitted under the Registration Rights Agreement for 180 days following the Closing Date,
    subject to certain customary exceptions and transfers to certain permitted transferees. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The
foregoing summary of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by the full text
of the Registration Rights Agreement, a copy of which is filed as Exhibit 10.2 to this Current Report and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Indemnification
Agreements </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with the Business Combination, New Jasper entered into indemnification agreements with its directors and executive officers
as of the Closing Date. Each indemnification agreement provides for, among other things, indemnification by New Jasper of each director
and executive officer to the fullest extent permitted by law, including indemnification of expenses such as attorney&#8217;s fees, judgements,
fines and settlement amounts reasonably incurred by the director or executive officer in any action or proceeding, including any action
or proceeding by or in right of New Jasper arising out of such person&#8217;s services as a director or executive officer of New Jasper.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
foregoing summary of the indemnification agreements does not purport to be complete and is qualified in its entirety by the terms and
conditions of the indemnification agreements, the form of which is filed as Exhibit 10.12 to this Current Report and is incorporated
herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Amendment
to Sponsor Support Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Immediately
prior to the Closing, Sponsor, AMHC and Old Jasper entered into an amendment (the &#8220;Support Agreement Amendment&#8221;) to that
certain Sponsor Support Agreement, dated May 5, 2021 (the &#8220;Sponsor Support Agreement&#8221;), pursuant to which (i) Sponsor agreed
to place into escrow 1,050,000 of its shares of New Jasper Common Stock (the &#8220;Sponsor Earnout Shares&#8221;), which Sponsor Earnout
Shares will be released as follows: (a) 250,000 Sponsor Earnout Shares will be released if, during the period from and after the Closing
until the third anniversary of the Closing (the &#8220;Earnout Period&#8221;), over any twenty (20) trading days within any thirty (30)
day consecutive trading day period, the volume-weighted average price of the New Jasper Voting Common Stock (the &#8220;Applicable VWAP&#8221;)
is greater than or equal to $11.50, (b) 500,000 Sponsor Earnout Shares will be released if, during the Earnout Period, the Applicable
VWAP is greater than or equal to $15.00, and (c) 300,000 Sponsor Earnout Shares will be released if, during the Earnout Period, the Applicable
VWAP is greater than or equal to $18.00; and (ii) Sponsor forfeited, effective as of immediately prior to the Closing, 200,000 shares
of AMHC&#8217;s Class B Common Stock beneficially owned by Sponsor to AMHC for cancellation without any consideration for such forfeiture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
foregoing summary of the Support Agreement Amendment does not purport to be complete and is qualified in its entirety by the terms and
conditions of the Sponsor Support Agreement and the Support Agreement Amendment, which are filed as Exhibits 10.13 and 10.14 to this
Current Report, respectively, and are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
                            2.01.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Completion
of Acquisition or Disposition of Assets.</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
disclosure set forth under &#8220;<i>Introductory Note</i>&#8221; above is incorporated into this Item 2.01 by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
September 22, 2021, AMHC held a special meeting of stockholders (the &#8220;Special Meeting&#8221;) at which the stockholders of AMHC
considered and approved, among other matters, a proposal to adopt the Business Combination Agreement. On the Closing Date, the parties
to the Business Combination Agreement consummated the Transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Prior
to the Special Meeting, holders of 9,262,099 shares of AMHC&#8217;s Class&#160;A Common Stock exercised their right to redeem such
shares for cash at a price of $10.0088193 per share for aggregate payments of $92,702,675.25. In connection with the Merger,
immediately prior to the Closing, each share of AMHC Class B Common Stock outstanding immediately prior to the Merger was converted
into one share of AMHC&#8217;s Class A Common Stock, and following such conversion, an aggregate of 13,037,901 shares of
AMHC&#8217;s Class A Common Stock (inclusive of 10,000,000 shares of AMHC&#8217;s Class A Common Stock that were issued to the PIPE
Investors) were converted into an equivalent number of shares of New Jasper Voting Common Stock. At the Closing, (i)&#160;an
aggregate of 24,778,409 shares of New Jasper Common Stock were issued in exchange for shares of common stock and preferred stock of
Old Jasper outstanding as of immediately prior to the Effective Time, based on Jasper&#8217;s equity value, and (ii)&#160;an
aggregate of 10,000,000 shares of AMHC&#8217;s Class A Common Stock were issued to the PIPE Investors in connection with the PIPE
Financing, which were converted into an equivalent number of shares of New Jasper Common Stock<i>. </i>Moreover, at the Closing, (i)
each vested and unvested option to purchase shares of Old Jasper common stock outstanding as of immediately prior to the Effective
Time was converted into a comparable option to purchase shares of New Jasper Voting Common Stock, based on Jasper&#8217;s equity
value, and (ii) each unvested award of restricted shares of Old Jasper&#8217;s common stock was converted into a comparable right to
receive restricted shares of New Jasper Common Stock, based on Jasper&#8217;s equity value. Immediately after giving effect to the
Transactions, there were 36,520,288 shares of New Jasper Voting Common Stock outstanding (which includes 611,818 shares of New Jasper Common Stock subject to restricted share awards), 1,296,022 shares of New Jasper Non-Voting
Common Stock outstanding and 2,721,557 shares of New Jasper Common Stock subject to outstanding options to purchase shares of New
Jasper Common Stock. After the Closing Date,
AMHC&#8217;s Class&#160;A Common Stock and public warrants will cease trading on The Nasdaq Stock Market LLC, and the New Jasper
Voting Common Stock and public warrants will begin trading on the Nasdaq Capital Market under the symbols &#8220;JSPR&#8221; and
&#8220;JSPRW,&#8221; respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Additionally,
in connection with the Closing, Sponsor deposited into escrow at Closing the 1,050,000 Sponsor Earnout Shares, which Sponsor Earnout
Shares will be released as follows: (1) 250,000 Sponsor Earnout Shares will be released if, during the Earnout Period, over any twenty
(20) trading days within any thirty (30) day consecutive trading day period, the Applicable VWAP is greater than or equal to $11.50,
(ii) 500,000 Sponsor Earnout Shares will be released if, during the Earnout Period, the Applicable VWAP is greater than or equal to $15.00,
and (iii) 300,000 Sponsor Earnout Shares will be released if, during the Earnout Period, the Applicable VWAP is greater than or equal
to $18.00. Sponsor has also forfeited 200,000 shares of AMHC&#8217;s Class B Common Stock and, as a result, Sponsor received 2,300,000
shares of New Jasper Voting Common Stock at Closing, with 1,050,000 of such shares subject to the Sponsor earnout described in the foregoing
sentence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
material terms and conditions of the Business Combination Agreement and its related agreements are described on pages 102 to 132 of AMHC&#8217;s
definitive proxy statement/prospectus dated August 26, 2021 (the &#8220;Definitive Proxy Statement&#8221;) included in AMHC&#8217;s Registration
Statement on Form S-4 (File No. <b>&#160;</b>333-256875), filed with the SEC on August 25, 2021, as amended (the &#8220;Registration
Statement&#8221;) under the sections titled &#8220;<i>Business Combination Proposal</i>&#8212;<i>The Business Combination Agreement</i>&#8221;
and &#8220;<i>Business Combination Proposal</i>&#8212;<i>Related Agreements</i>&#8221;, each of which is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i></i></b></span></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>FORM
10 INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Item
2.01(f) of Form 8-K states that if the predecessor registrant was a &#8220;shell company&#8221; (as such term is defined in Rule 12b-2
under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), as AMHC was immediately before the Business
Combination, then the registrant must disclose the information that would be required if the registrant were filing a general form for
registration of securities on Form 10. Accordingly, the Company, as the successor registrant to AMHC following the consummation of the
Business Combination, is providing the information below that would be included in a Form 10 if the Company were to file a Form 10. Please
note that the information provided below relates to the Company as the combined company after the consummation of the Business Combination
unless otherwise specifically indicated or the context otherwise requires.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Forward-Looking
Statements </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Certain
statements contained in this Current Report and in the documents incorporated herein by reference may constitute &#8220;forward-looking
statements&#8221; for purposes of federal securities laws. Such statements can be identified by the fact that they do not relate strictly
to historical or current facts. In addition, any statements that refer to projections, forecasts or other characterizations of future
events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;<i>anticipate</i>,&#8221;
&#8220;<i>believe</i>,&#8221; &#8220;<i>contemplate</i>,&#8221; &#8220;<i>continue</i>,&#8221; &#8220;<i>could</i>,&#8221; &#8220;<i>estimate</i>,&#8221;
&#8220;<i>expect</i>,&#8221; &#8220;<i>intends</i>,&#8221; &#8220;<i>may</i>,&#8221; &#8220;<i>might</i>,&#8221; &#8220;<i>plan</i>,&#8221;
&#8220;<i>possible</i>,&#8221; &#8220;<i>potential</i>,&#8221; &#8220;<i>predict</i>,&#8221; &#8220;<i>project</i>,&#8221; &#8220;<i>should</i>,&#8221;
&#8220;<i>will</i>,&#8221; &#8220;<i>would</i>&#8221; and similar expressions (including the negative of any of the foregoing) may identify
forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Forward-looking
statements in this Current Report may include, for example, but are not limited to, statements about:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
or our management team&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future, including those relating
to the Transactions and their expected benefits;</span></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">New
                                            Jasper&#8217;s ability to research, discover and develop additional product candidates;</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                                    </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
                                            success, cost and timing of New Jasper&#8217;s product development activities and clinical
                                            trials;</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                    </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
                                            potential attributes and benefits of New Jasper&#8217;s product candidates;</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                        </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">New
                                            Jasper&#8217;s ability to obtain and maintain regulatory approval for its product candidates;</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                                          </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">New
                                            Jasper&#8217;s ability to obtain funding for its operations;</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                         </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
                                            projected financial information, anticipated growth rate, and market opportunity of New Jasper;</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                                            </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
                                            ability to maintain the listing of New Jasper&#8217;s public securities on Nasdaq;</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                               </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">New
                                            Jasper&#8217;s public securities&#8217; potential liquidity and trading;</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">New
                                            Jasper&#8217;s success in retaining or recruiting, or changes required in, officers, key
                                            employees or directors;</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                    </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">New
                                            Jasper&#8217;s ability to grow and manage growth profitably;</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                         </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
                                            implementation, market acceptance and success of New Jasper&#8217;s business model, developments
                                            and projections relating to New Jasper&#8217;s competitors and industry;</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">New
                                            Jasper&#8217;s ability to obtain and maintain intellectual property protection and not infringe
                                            on the rights of others;</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">New
                                            Jasper&#8217;s ability to identify, in-license or acquire additional technology;</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                             </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">New
                                            Jasper&#8217;s ability to maintain its existing license agreements and manufacturing arrangements;
                                            and</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
                                            effect of the COVID-19 pandemic on the foregoing.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">These
forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects.
There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements
involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or
performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties
include, but are not limited to, those factors described under the heading &#8220;<i>Risk Factors</i>&#8221; in the Definitive Proxy
Statement beginning on page 32. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove
incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks
and uncertainties may in the future be amplified by the COVID-19 outbreak, and there may be additional risks that we consider immaterial
or which are unknown. It is not possible to predict or identify all such risks. Readers are cautioned not to place undue reliance on
forward-looking statements because of the risks and uncertainties related to them and to the risk factors. We do not undertake any obligation
to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may
be required under applicable securities laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
businesses of Old Jasper and AMHC prior to the Business Combination are described in the Definitive Proxy Statement in the sections titled
&#8220;<i>Information About AMHC</i>&#8221; and &#8220;<i>Information About Jasper</i>&#8221; beginning on pages 179 and 189, respectively,
and that information is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Risk
Factors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
risk factors related to the Company&#8217;s business and operations and the Transactions are set forth in the&#160;Definitive Proxy Statement&#160;in
the section titled &#8220;<i>Risk Factors</i>&#8221; beginning on page 32 and are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Financial
Information</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
information set forth under Item 9.01 of this Current Report is incorporated herein by reference. The disclosure contained in the Definitive
Proxy in the sections titled &#8220;<i>Selected Historical Financial Information of AMHC</i>&#8221; beginning on page 164, &#8220;<i>Selected
Historical Financial Information of Jasper</i>&#8221; beginning on page 166, &#8220;<i>Unaudited Historical Comparative and Pro Forma
Combined Per Share Data of AMHC and Jasper</i>&#8221; beginning on page 167, &#8220;<i>Unaudited Pro Forma Condensed Combined Financial
Statements</i>&#8221; beginning on page 169, &#8220;<i>AMHC&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations</i>&#8221; beginning on page 184, and &#8220;<i>Jasper&#8217;s Management&#8217;s Discussion and Analysis of
Financial Condition and Results of Operations</i>&#8221; beginning on page 219, are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
disclosure contained in the Definitive Proxy Statement in the section titled &#8220;<i>Jasper&#8217;s Management&#8217;s Discussion and
Analysis of Financial Condition and Results of Operations</i>&#8221; beginning on page 219 is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Quantitative
and Qualitative Disclosures about Market Risk</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
disclosure contained in the&#160;Definitive Proxy Statement&#160;in the section titled &#8220;<i>Jasper&#8217;s Management&#8217;s Discussion
and Analysis of Financial Condition and Results of Operations&#8212;Quantitative and Qualitative Disclosures About Market Risk</i>&#8221;
beginning on page 237 is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Properties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
disclosure contained in the Definitive Proxy Statement in the section titled &#8220;<i>Information About Jasper&#8212;Facilities</i>&#8221;
beginning on page 218 is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Security
Ownership of Certain Beneficial Owners and Management</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth information regarding the beneficial ownership of New Jasper Common Stock immediately following consummation
of the Transactions by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr>
    <td style="width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">each
    person known to be the beneficial owner of more than 5% of New Jasper&#8217;s outstanding Common Stock immediately following the
    consummation of the Transactions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr>
    <td style="width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">each of New Jasper&#8217;s
    current named executive officers and directors; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr>
    <td style="width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">all executive officers
    and directors of New Jasper as a group following the consummation of the Transactions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Beneficial
ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security
if he, she or it possesses sole or shared voting or investment power over that security. Under those rules, beneficial ownership includes
securities that the individual or entity has the right to acquire, such as through the exercise of stock options, within 60 days. Shares
subject to options that are currently exercisable or exercisable within 60 days of the Closing Date are considered outstanding and beneficially
owned by the person holding such options for the purpose of computing the percentage ownership of that person but are not treated as
outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, New Jasper believes
that the persons and entities named in the table below have sole voting and investment power with respect to all shares shown as beneficially
owned by them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>New Jasper Voting<br />
 Common Stock</b> &#160;</span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">New Jasper Non-Voting <br />
Common Stock</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name and Address of Beneficial Owner<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of<br />
 Shares</b> &#160;</span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">% of <br />
Class</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number
of <br />
Shares</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">% of<br />
 Class</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: justify">Directors and Named Executive Officers:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">William Lis<sup>(2)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">921,763</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.5</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Anna French, D.Phil.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Lawrence Klein, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Christian W. Nolet</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Judith Shizuru, M.D., Ph.D.<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,275,682</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Kurt von Emster<sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,628,558</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Kevin N. Heller, M.D.<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">205,553</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Jeet Mahal<sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,079</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">All directors and named executive officers as a group (8 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><b>8,171,635</b></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">21.6</td><td style="font-weight: bold; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#8212;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: justify">Five Percent Holders:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Abingworth Bioventures VII LP<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,628,558</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Amgen Inc.<sup>(6)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,700,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Amplitude Healthcare Holdings LLC<sup>(7)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Citadel Multi-Strategy Equities Master Fund LTD.<sup>(8)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,979,504</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,296,022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Qiming U.S. Healthcare Fund II, L.P.<sup>(9)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,852,982</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Roche Finance Ltd<sup>(10)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,624,606</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  </table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicates
less than 1%</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Unless
otherwise noted, the business address of each of those listed in the table above is 2200 Bridge Pkwy Suite #102, Redwood City, CA 94065.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Consists
solely of shares of New Jasper Voting Common Stock issuable upon exercise of options that are exercisable within 60 days of the Closing
Date.</span></td>
</tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Consists
of (i) 1,129,512 shares of New Jasper Voting Common Stock, of which 847,134 shares are vested or will vest within 60 days of the Closing
Date, and (ii) 146,170 shares of New Jasper Voting Common Stock issuable upon exercise of options that are exercisable within 60 days
of the Closing Date.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">(4)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Abingworth
Bioventures VII GP LP, a Scottish limited partnership, serves as the general partner of ABV VII. Abingworth General Partner VII LLP,
an English limited liability partnership (together with Abingworth Bioventures VII GP LP, the &#8220;General Partners&#8221;), serves
as the general partner of Abingworth Bioventures VII GP LP. ABV VII (acting by its general partner Abingworth Bioventures VII GP LP,
acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth all investment and dispositive power over
the securities held by ABV VII. An investment committee of Abingworth, currently comprised of Timothy Haines, Kurt von Emster, a member
of the Board, Bali Muralidhar, Brian Gallagher, Andrew Sinclair and Genghis Lloyd-Harris (collectively the &#8220;Investment Committee&#8221;),
approves investment and voting decisions by a specified majority vote, and no individual member has the sole control or voting power
over the securities held by ABV VII. Each of Abingworth, Abingworth Bioventures VII GP LP, Abingworth General Partner VII LLP, and each
member of the Investment Committee disclaims beneficial ownership of the shares held by ABV VII. The address of Abingworth Bioventures
VII LP is 38 Jermyn Street, London, SW1Y6DN, UK.</span></td>
</tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(5)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Consists
of (i) 109,627 shares of New Jasper Voting Common Stock, and (ii) 30,452 shares of New Jasper Voting Common Stock issuable upon exercise
of options that are exercisable within 60 days of the Closing Date.</span></td>
</tr>
     </table>


<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(6)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
mailing address of Amgen Inc. is One Amgen Center Drive, Thousand Oaks, CA 91320.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(7)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Sponsor
is the record holder of the New Jasper Voting Common Stock reported herein. Metalmark Amplitude Healthcare Holdings LLC and Avego Healthcare
Capital, L.P., affiliates of Metalmark and Avego, respectively, are the managing members of Sponsor. The partners of Metalmark indirectly
control Metalmark Capital Holdings LLC, which is the general partner of Metalmark Capital Partners III GP, L.P., itself the sole member
of Metalmark Amplitude Healthcare Holdings LLC; Howard Hoffen, AMHC&#8217;s Chairman, and Kenneth Clifford, AMHC&#8217;s Chief Financial
Officer, are partners of Metalmark. Each of Messrs. Hoffen and Clifford disclaim any beneficial ownership of the reported shares other
than to the extent of their respective pecuniary interest therein, directly or indirectly. Bala Venkataraman, AMHC&#8217;s Chief Executive
Officer, is the managing member of Avego Healthcare Capital Holdings, LLC, which is the general partner of Avego Healthcare Capital,
L.P., a managing member of New Jasper Voting Common Stock. Mr. Venkataraman disclaims any beneficial ownership of the reported shares
other than to the extent of his pecuniary interest therein, directly or indirectly. In addition, each of AMHC&#8217;s officers and directors
is a member of New Jasper Voting Common Stock and accordingly has pecuniary interest in the shares reported herein. Each such person
disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest they may have therein, directly
or indirectly. 1,050,000 shares of New Jasper Common Stock are currently held in escrow, pursuant to which (A) 250,000 shares will be
released from escrow if, during the period from and after the Closing until the third anniversary of the Closing (the &#8220;Earnout
Period&#8221;), over twenty (20) trading days within any thirty (30) day consecutive trading day period, the volume-weighted average
purchase price of New Jasper Voting Common Stock (the &#8220;Applicable VWAP&#8221;) is greater than or equal to $11.50, (B) 500,000
of the shares will be released if, during the Earnout Period, the Applicable VWAP is greater than or equal to $15.00, and (C) 300,000
of the shares will be released if, during the Earnout Period, the applicable VWAP is greater than or equal to $18.00.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(8)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Consists
of (i) 2,979,504 shares of New Jasper Voting Common Stock, and (ii) 1,296,022 shares of New Jasper Non-Voting Common Stock held by Citadel
Multi-Strategy Equities Master Fund Ltd. (&#8220;CM&#8221;). Citadel Advisors LLC (&#8220;Citadel Advisors&#8221;) is the portfolio manager
for CM. Citadel Advisors Holdings LP (&#8220;CAH&#8221;) is the sole member of Citadel Advisors. Citadel GP LLC (&#8220;CGP&#8221;) is
the general partner of CAH. Mr. Kenneth Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest
in CGP. Each of Citadel Advisors, CAH CGP and Mr. Griffin may be deemed to beneficially own the shares held by CM, and may be deemed
to share voting and dispositive power over shares held by CM. The address of CM is 131 S. Dearborn Street, 32nd Floor, Chicago, Illinois
60603.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(9)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
general partner of Qiming U.S. Healthcare Fund II, L.P. is Qiming U.S. Healthcare GP II, LLC. Gary Rieschel and Mark D. McDade are the
managing partners of Qiming U.S. Healthcare GP II, LLC. Each of Qiming U.S. Healthcare GP II, LLC, Mr. Rieschel and Mr. McDade may be
deemed to beneficially own the shares beneficially owned by Qiming U.S. Healthcare Fund II, L.P., but each disclaims beneficial ownership
of such shares. The address for each of these entities and individuals is 11100 NE 8th St., Suite 200, Bellevue, WA 98004.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(10)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Roche
Finance Ltd is a wholly-owned subsidiary of Roche Holding Ltd, a publicly-held corporation. The principal business address of Roche Finance
Ltd is Grenzacherstrasse 122, 4070 Basel, Switzerland.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Directors
and Executive Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Directors</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Effective
upon the Closing, and in accordance with the terms of the Business Combination Agreement, each of Howard Hoffen, Bala Venkataraman, Fred
Eshelman, Ernest Mario, Peter Dolan and Glenn Reicin ceased serving as a director of AMHC. Effective as of the Closing Date, Anna French,
D. Phil., William Lis, Christian W. Nolet, Judith Shizuru, M.D., Ph.D. and Kurt von Emster were elected to serve as directors on the
Board. In addition, effective as of the Closing Date, Sponsor designated, and the Board appointed, Lawrence Klein, Ph.D. to the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s business and affairs are organized under the direction of the Board. The Board currently consists of six members. Mr.&#160;Lis
serves as Executive Chairman of the Board. The primary responsibilities of the Board are to provide oversight, strategic guidance, counseling
and direction to the Company&#8217;s management. The Board will meet on a regular basis and on an&#160;<i>ad hoc</i>&#160;basis as required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Board is divided into three classes, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Class
I, which consists of Dr. Klein and Mr.&#160;von Emster, whose terms will expire at the Company&#8217;s annual meeting of stockholders
to be held in 2022;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Class
II, which consists of Dr.&#160;French and Dr. Shizuru, whose terms will expire at the Company&#8217;s annual meeting of stockholders
to be held in 2023; and</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Class
III, which consists of Mr.&#160;Lis and Mr.&#160;Nolet, whose terms will expire at the Company&#8217;s annual meeting of stockholders
to be held in 2024.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">At
each annual meeting of stockholders to be held after the initial classification, the successors to directors whose terms then expire
will serve until the third annual meeting following their election and until their successors are duly elected and qualified. The authorized
number of directors that shall constitute the Board will be fixed exclusively by resolutions adopted by a majority of the authorized
number of directors constituting the Board. No decrease in the number of directors constituting the Board will shorten the term of any
incumbent director. This classification of the Board may have the effect of delaying or preventing changes in its control or management.
The Company&#8217;s directors may be removed only for cause by the affirmative vote of the holders of at least 66&#8532;% of the Company&#8217;s
capital stock entitled to vote generally at an election of directors, voting together as a single class (provided that as of the three-year&#160;anniversary
of the Closing Date, such reference to &#8220;66&#8532;%&#8221; shall be deemed to be &#8220;50%&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Subject
to applicable law and subject to the rights of the holders of any series of preferred stock of the Company, any vacancies on the Board
resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase
in the number of directors, shall, unless the Board determines by resolution that any such vacancies or newly created directorships shall
be filled by the stockholders and except as otherwise provided by applicable law, be filled only by the affirmative vote of a majority
of the directors then in office, even though less than a quorum, and not by the stockholders. Any director elected in accordance with
the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred
and until such director&#8217;s successor shall have been elected and qualified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
biographical information concerning the Company&#8217;s directors (other than Dr. Klein, whose biographical information appears below),
see the disclosure in the Definitive Proxy Statement in the section titled &#8220;<i>Management of New Jasper Following the Business
Combination</i>&#8221; beginning on page 247 and in AMHC&#8217;s Current Report on Form 8-K, filed with the SEC on September 20, 2021,
which is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b><i>Lawrence
Klein, Ph.D.</i></b> has served in various positions at CRISPR Therapeutics AG (Nasdaq: CRSP), a biotechnology company, including Chief
Operating Officer since January 2020, Chief Business Officer from January 2019 to January 2020, Senior Vice President, Business Development
and Strategy from November 2017 to December 2018 and as Vice President, Strategy from February 2016 to November 2017. Before joining
CRISPR, Dr. Klein was an Associate Partner at McKinsey &amp; Company, a global management consulting firm, from October 2014 to February
2016. He has served as a director of Dyne Therapeutics, Inc. (Nasdaq: DYN) since September 2019. Dr. Klein received his B.S. in biochemistry
and physics from the University of Wisconsin-Madison and his Ph.D. in biophysics from Stanford University. </span><span style="font: 10pt Times New Roman, Times, Serif">Dr.
Klein&#8217;s qualifications to sit on the Board include his extensive background in immunology, hematologic malignancies, stem cell
transplant and cell therapies, as well as his current and prior service with pharmaceutical and biotechnology companies on matters pertaining
to strategy and operations<span style="background-color: white">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Executive
Officers</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">New
Jasper&#8217;s executive officers after the consummation of the Transactions are described in the&#160;Definitive Proxy Statement&#160;in
the section titled &#8220;<i>Management of New Jasper Following the Business Combination&#8212;Executive Officers and Directors after
the Business Combination</i>&#8221; beginning on page 247, and that information is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Family
Relationships</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">There
are no family relationships among any of the individuals serving as directors or executive officers of the Company following the consummation
of the<sup>&#160;</sup>Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Board
Leadership Structure and Role of the Board in Risk Oversight</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
information in the Definitive Proxy Statement&#160;in the section titled &#8220;<i>Management of New Jasper Following the Business Combination&#8212;Board
Leadership Structure</i>&#8221; beginning on page 250 and in the section titled &#8220;<i>Management of New Jasper Following the Business
Combination&#8212;Role of the New Jasper Board in Risk Oversight</i>&#8221; beginning on page 251 is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Independence
of the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Board has determined that each of the directors on the Board, other than Mr.&#160;Lis and Dr. Shizuru, qualify as independent directors,
as defined by Rule 5605(a)(2) of the Nasdaq Listing Rules and the Board consists of a majority of &#8220;independent directors&#8221;
as defined under the rules of the SEC and Nasdaq Stock Market listing rules relating to director independence requirements. In addition,
the Company will be subject to the rules of the SEC and the Nasdaq Stock Market relating to the membership, qualifications and operations
of the audit committee, as discussed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Committees
of the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Furthermore,
effective as of the Closing, the Board established three standing committees: an audit committee, a compensation committee and a nominating
and corporate governance committee. Information with respect to the functions of the committees of the Board immediately after the Closing
is set forth in the&#160;Definitive Proxy Statement in the section titled &#8220;<i>Management of New Jasper Following the Business Combination&#8212;Board
Committees</i>&#8221; beginning on page 251 and that information is incorporated herein by reference. The members of the audit committee
are Dr. French, Mr. Nolet and Mr. von Emster, and Mr. Nolet chairs the audit committee. The members of the compensation committee are
Dr. French, Mr. Nolet and Mr. von Emster, and Dr. French chairs the compensation committee. The members of the nominating and corporate
governance committee are Dr. French, Dr. Klein and Mr. von Emster, and Mr. von Emster chairs the nominating and corporate governance
committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Compensation
Committee Interlocks and Insider Participation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
information in the Definitive Proxy Statement&#160;in the section titled &#8220;<i>Management of New Jasper Following the Business Combination&#8212;Compensation
Committee Interlocks and Insider Participation</i>&#8221; beginning on page 254 is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Executive
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
description of the compensation of the named executive officers of Old Jasper and the compensation of the executive officers of AMHC
before the consummation of the Transactions is set forth in the&#160;Definitive Proxy Statement in the sections titled &#8220;<i>Executive
Compensation&#8212;Executive Compensation &#8212; Jasper</i>&#8221; beginning on page 239 and &#8220;<i>Executive Compensation&#8212;Executive
Compensation &#8212; AMHC</i>&#8221; beginning on page 239 and that information is incorporated herein by reference. A description of
the compensation of the executive officers of New Jasper following the consummation of the Transactions is set forth under the heading
&#8220;<i>Employment Agreements with Named Executive Officers</i>&#8221; in Item 5.02 of this Current Report, which disclosure is incorporated
herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">At
the Special Meeting, the AMHC stockholders approved the Equity Incentive Plan (as defined below) and the ESPP (as defined below). The
summary of each of the Equity Incentive Plan and the ESPP is set forth in the&#160;Definitive Proxy Statement in the sections titled
&#8220;<i>Equity Incentive Plan Proposal</i>&#8221; beginning on page 142 and &#8220;<i>ESPP Proposal</i>&#8221; beginning on page 150,
respectively, and that information is incorporated herein by reference. Such summary is qualified in its entirety by reference to the
full texts of the Equity Incentive Plan and the ESPP, which are filed as Exhibits 10.3 and 10.6 to this Current Report, respectively,
and are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Director
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
description of the compensation of the directors of AMHC before the consummation of the Transactions is set forth in the Definitive Proxy
Statement in the section titled &#8220;<i>Executive Compensation&#8212;Executive Compensation &#8212; AMHC</i>&#8221; beginning on page
239 and that information is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
description of the compensation of the non-employee directors of Old Jasper before the consummation of the Transactions is set forth
in the&#160;Definitive Proxy Statement in the section titled &#8220;<i>Director Compensation&#8212;Director Compensation &#8212; Jasper</i>&#8221;
beginning on page 246 and that information is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
description of the compensation of the directors of New Jasper following the consummation of the Transactions is set forth in the Definitive
Proxy Statement in the section titled &#8220;<i>Director Compensation&#8212;New Jasper Director Compensation Following the Business Combination</i>&#8221;
beginning on page 246 and that information is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Certain
Relationships and Related Person Transactions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Certain
relationships and related person transactions are described in the&#160;Definitive Proxy Statement in the section titled &#8220;<i>Certain
Relationships and Related Person Transactions</i>&#8221; beginning on page 260 and that information is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Legal
Proceedings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Information
about legal proceedings is set forth in the&#160;Definitive Proxy Statement in the sections&#160;titled &#8220;<i>Information about AMHC&#8212;Legal
Proceedings&#8221;</i>&#160;beginning on page 183 and &#8220;<i>Information about Jasper&#8212;Legal Proceedings&#8221;</i> beginning
on page 218 and that information is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Market
Price of and Dividends on the Registrant&#8217;s Common Equity and Related Stockholder Matters</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Prior
to the Closing Date, AMHC&#8217;s publicly traded Class A Common Stock, public warrants and units were listed on The Nasdaq Stock Market
LLC under the symbols &#8220;AMHC,&#8221; &#8220;AMHCW&#8221; and &#8220;AMHCU,&#8221; respectively. The New Jasper Voting Common Stock
and Jasper&#8217;s public warrants are expected to begin trading on the Nasdaq Capital Market under the symbols &#8220;JSPR&#8221; and
&#8220;JSPRW,&#8221; respectively, on September 27, 2021. AMHC&#8217;s publicly traded units automatically separated into their component
securities upon the Closing, and as a result, no longer trade as a separate security and will be delisted from The Nasdaq Stock Market
LLC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of immediately after the Closing, there were 36,520,288 shares of New Jasper Voting Common Stock issued and outstanding and held of record
by 54 holders, and 5,000,000 public warrants outstanding held of record by two holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has not paid any cash dividends on shares of its New Jasper Common Stock and does not anticipate paying any cash dividends in
the foreseeable future. Any decision to declare and pay dividends in the future will be made at the sole discretion of the Board and
will depend on, among other things, the Company&#8217;s results of operations, cash requirements, financial condition, contractual restrictions
and other factors that the Board may deem relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Recent
Sales of Unregistered Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Reference
is made to the disclosure set forth below under Item 3.02 of this Current Report&#160;concerning the issuance and sale of certain unregistered
securities, which is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Description
of New Jasper&#8217;s Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
description of New Jasper&#8217;s securities is contained in the Definitive Proxy Statement in the section titled &#8220;<i>Description
of New Jasper Securities</i>&#8221; beginning on page 277 and that information is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Indemnification
of Directors and Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Information
about indemnification of the Company&#8217;s directors and officers is set forth in the Definitive Proxy Statement in the section titled
&#8220;<i>Management of New Jasper Following the Business Combination&#8212;Limitation of Liability and Indemnification</i>&#8221; beginning
on page 254 and that information is incorporated herein by reference. In connection with the Business Combination, New Jasper entered
into indemnification agreements with each of its directors and executive officers as of the Closing Date. The description of the indemnification
agreements set forth above under Item 1.01 of this Current Report is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Change
in and Disagreements with Accountants on Accounting and Financial Disclosure</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Reference
is made to the disclosure set forth below under Item 4.01 of this Current Report, which is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Financial
Statements and Exhibits</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
information set forth under Item 9.01 of this Current Report is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
                            3.02.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Unregistered
Sales of Equity Securities.</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Concurrently
with the execution of the Business Combination Agreement and as described under &#8220;<i>Introductory Note</i>&#8221; above, AMHC entered
into Subscription Agreements with each of the PIPE Investors, pursuant to which, at the Closing, the PIPE Investors subscribed for and
purchased an aggregate of 10,000,000 shares of Class A Common Stock of AMHC at a price of $10.00 per share for aggregate gross proceeds
of $100.0 million. Affiliates of Sponsor funded $28,350,000 in the PIPE Financing. The shares of Class&#160;A Common Stock of AMHC issued
pursuant to the Subscription Agreements (the &#8220;PIPE Financing Shares&#8221;) were not registered under the Securities Act and were
issued in reliance upon the exemption provided in Section&#160;4(a)(2) of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the Subscription Agreements, the Company agreed that, within 30 calendar days after the Closing Date, it will file with the SEC (at
the Company&#8217;s sole cost and expense) a registration statement (the &#8220;Resale Registration Statement&#8221;) registering the
resale of the PIPE Financing Shares. The Company will use its commercially reasonable efforts to have the Resale Registration Statement
declared effective as soon as practicable after the filing thereof, but no later than the earlier of (i) 60 calendar days (or 90 calendar
days if the SEC notifies the Company that the SEC will review the Resale Registration Statement) following the filing thereof and (ii)
five business days after the Company is notified by the SEC that the Resale Registration Statement will not be reviewed or will not be
subject to further review. The Company agreed to cause such Resale Registration Statement to remain effective until the earliest of (x)
the date on which no PIPE Investor holds PIPE Financing Shares, (y) the first date on which each PIPE Investor is able to sell all of
its PIPE Financing Shares under Rule 144 of the Securities Act within 90 days without limitation as to the manner of sale or the amount
of such securities that may be sold and without the requirement for the Company to be in compliance with the current public information
required under Rule 144(c)(i) (or Rule 144(i)(2), if applicable) and (z) three years from the date of effectiveness of the Resale Registration
Statement. The foregoing summary of the Subscription Agreements does not purport to be complete and is qualified in its entirety by the
terms and conditions thereof, the form of which is filed as Exhibit 10.1 to this Current Report and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
                            4.01.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Changes
in Registrant&#8217;s Certifying Accountant</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Dismissal
of WithumSmith+Brown, PC</i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Effective
upon the Closing, on September 24, 2021, the audit committee of the Board (the &#8220;Audit Committee&#8221;) dismissed WithumSmith+Brown,
PC (&#8220;Withum&#8221;), which served as AMHC&#8217;s independent registered public accounting firm prior to the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
report of Withum on the financial statements of AMHC as of December 31, 2019 and 2020 did not contain an adverse opinion or a
disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope or accounting principles except for an
explanatory paragraph in such report regarding substantial doubt about AMHC&#8217;s ability to continue as a going concern. During the
fiscal years ended December 31, 2019 and 2020 and the subsequent interim period through September 24, 2021, there were no
disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K) with Withum on any matter of accounting principles or practices,
financial statement disclosure or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of Withum,
would have caused Withum to make reference to the subject matter of the disagreements in its reports covering such periods. In
addition, no &#8220;reportable events,&#8221; as defined in Item 304(a)(1)(v) of Regulation&#160;S-K,&#160;occurred within the
period of Withum&#8217;s engagement and the subsequent interim period preceding Withum&#8217;s dismissal other than the material weakness in internal controls identified by management related to the accounting for warrants issued in connection
with AMHC&#8217;s initial public offering, which resulted in the restatement of AMHC&#8217;s financial statements as set forth in Amendment
No. 1 to AMHC&#8217;s Form 10-K for the year ended December 31, 2020, as filed with the SEC on May 24, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company provided Withum with a copy of the disclosures made pursuant to this Item 4.01 prior to the filing of this Current Report and
requested that Withum furnish a letter addressed to the SEC dated September 29, 2021, which is filed as Exhibit 16.1 to this Current
Report, stating whether it agrees with such disclosures, and, if not, stating the respects in which is does not agree.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Appointment
of PricewaterhouseCoopers LLP</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Effective
upon the Closing, on September 24, 2021, the Audit Committee appointed PricewaterhouseCoopers LLP (&#8220;PwC&#8221;) as the Company&#8217;s
independent registered public accounting firm for the fiscal year ending December 31, 2021. PwC audited the balance sheets
of Old Jasper as of December 31, 2019 and 2020, and the related statements of operations and comprehensive loss, of redeemable convertible
preferred stock and stockholders&#8217; deficit and of cash flows for the years then ended, including the related notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the years ended December 31, 2019 and 2020 and the subsequent interim period through September 24, 2021, neither the Company nor anyone
on its behalf consulted with PwC regarding (i)&#160;the application of accounting principles to a specified transaction, either completed
or proposed, or the type of audit opinion that might be rendered on the Company&#8217;s financial statements, and no written report or
oral advice was provided to the Company that PwC concluded was an important factor considered by the Company in reaching a decision as
to any accounting, auditing or financial reporting issue, or (ii)&#160;any matter that was the subject of a disagreement within the meaning
of Item&#160;304(a)(1)(iv) of Regulation&#160;S-K&#160;or any reportable event within the meaning of Item&#160;304(a)(1)(v) of Regulation&#160;S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
                            5.01.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Changes
in Control of Registrant.</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Reference
is made to the disclosure in the&#160;Definitive Proxy Statement in the section titled &#8220;<i>Business Combination Proposal&#8212;The
Business Combination Agreement</i>,&#8221; beginning on page 102, which is incorporated herein by reference. Further reference is made
to the information set forth under &#8220;<i>Introductory Note</i>&#8221; above and in the section titled &#8220;<i>Form 10 Information&#8212;Security
Ownership of Certain Beneficial Owners and Management</i>&#8221; within Item 2.01 to this Current Report,&#160;which is incorporated
herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
                            5.02.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></span></td>
</tr></table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Appointment
and Departure of Directors and Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
information under headings &#8220;<i>Form 10 Information&#8212;Directors and Executive Officers</i>&#8221; and &#8220;<i>Form 10 Information&#8212;Committees
of the Board of Directors</i>&#8221; within Item 2.01 of this Current Report above is incorporated into this Item 5.02 by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
description of the compensation of the directors of AMHC and non-employee directors of Old Jasper before the consummation of the Transactions
is set forth in the Definitive Proxy Statement in the respective sections titled &#8220;<i>Executive Compensation&#8212;Executive Compensation
&#8212; AMHC</i>&#8221; beginning on page 239 and &#8220;<i>Director Compensation&#8212;Director Compensation &#8212; Jasper</i>&#8221;
beginning on page 246 and that information is incorporated herein by reference. A description of the compensation of the directors of
New Jasper following the consummation of the Transactions is set forth in the Definitive Proxy Statement in the section titled &#8220;<i>Director
Compensation&#8212;New Jasper Director Compensation Following the Business Combination</i>&#8221; beginning on page 246 and that information
is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Executive
Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Effective
upon the Closing, and in accordance with the terms of the Business Combination Agreement, each of Bala Venkataraman, Kenneth Clifford
and Vishal Kapoor ceased serving as an executive officer of AMHC. The following persons are serving as executive officers of the Company
following the Closing. For biographical information concerning such executive officers, see the disclosure in the Definitive Proxy Statement
in the section titled &#8220;<i>Management of New Jasper Following the Business Combination</i>,&#8221; beginning on page 247, which
is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 20%"><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name</b></span></p></td>
    <td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 78%; padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Position</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">William Lis</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">President, Chief Executive
    Officer and Executive Chairman of the New Jasper Board</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Jeet Mahal</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Chief Financial and Business
    Officer and Corporate Secretary </span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Kevin N. Heller, M.D.</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Executive Vice President,
    Research and Development</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Jasper
Therapeutics, Inc. 2021 Equity Incentive Plan </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">At
the Special Meeting, the AMHC stockholders considered and approved the Jasper Therapeutics, Inc. 2021 Equity Incentive Plan (the &#8220;Equity
Incentive Plan&#8221;). The Equity Incentive Plan allows the Company to grant incentive stock options (&#8220;ISOs&#8221;) within the
mean of Section 422 of the <span style="background-color: white">&#160;United&#160;States Internal Revenue Code of 1986, as amended (the
&#8220;Code&#8221;),</span> to the Company&#8217;s employees and its parent and subsidiary corporations&#8217; employees, and for the
grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards
and other forms of awards to its employees, directors and consultants and any of its affiliates&#8217; employees and consultants. The
Board believes that awards to be issued under the Equity Incentive Plan will motivate award recipients to offer their maximum effort
to New Jasper and help focus them on the creation of long-term value consistent with the interests of the Company&#8217;s stockholders.
In addition, the Board believes that grants of incentive awards are necessary to enable New Jasper to attract and retain top talent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has initially reserved up to 4,400,000 shares of New Jasper Common Stock for the issuance of awards under the Equity Incentive
Plan. The Equity Incentive Plan provides that the number of shares of New Jasper Common Stock that will be reserved for issuance under
the Equity Incentive Plan will automatically increase on January 1 of each year for a period of ten years, beginning on January 1, 2022
and ending on (and including) January 1, 2031 in an amount equal to the lesser of (i) 4% of the total number of shares of New Jasper
Common Stock outstanding on December 31 of the immediately preceding year or (2) 2,750,000 shares of New Jasper Common Stock; provided,
however, that the Board may act prior to January 1 of a given year to provide that the increase for such year will be a lesser number
of shares of New Jasper Common Stock. Notwithstanding anything to the contrary in the foregoing sentence, the aggregate maximum number
of shares of New Jasper Common Stock that may be issued on the exercise of ISOs under the Equity Incentive Plan is 4,400,000&#160;shares,
which amount will be increased commencing on January&#160;1, 2022 and ending on (and including) January&#160;1, 2031, in an amount equal
to the lesser of (i) 4% of the total number of shares of New Jasper Common Stock outstanding on December 31 of the preceding year, (ii)
2,750,000&#160;shares of New Jasper Common Stock, and (iii)&#160;such amount as may be determined by the Board. Under the Equity Incentive
Plan, the Board will appropriately and proportionately adjust each of the foregoing share numbers as necessary to implement any changes
in the Company&#8217;s capital structure, such as a stock split, reverse stock split, or recapitalization. Initially, the maximum, aggregate
number of shares that may be issued under the Equity Incentive Plan is the amount equal to (i) 4,400,000 shares, plus (ii) an additional
number of Returning Shares (as defined in the Equity Incentive Plan).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
more complete summary of the terms of the Equity Incentive Plan is set forth in the&#160;Definitive Proxy Statement in the section titled
&#8220;<i>Equity Incentive Plan Proposal</i>&#8221; beginning on page 142. Such summary and the foregoing description of the Equity Incentive
Plan do not purport to be complete and are qualified in their entirety by reference to the text of the Equity Incentive Plan, which is
filed as Exhibit 10.3 to this Current Report and incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Jasper
Therapeutics, Inc. 2021 Employee Stock Purchase Plan </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">At
the Special Meeting, the AMHC stockholders considered and approved the Jasper Therapeutics, Inc. 2021 Employee Stock Purchase Plan (the
&#8220;ESPP&#8221;). The purpose of the ESPP is to secure the services of new employees, to retain the services of existing employees,
and to provide incentive for such individuals to exert maximum efforts toward the Company&#8217;s success and that of its related corporations.
The ESPP allows for eligible U.S. employee to purchase shares of New Jasper Common Stock in a manner that may qualify for favorable treatment
under Section 423 of the Code (the &#8220;423 Component&#8221;) and will be construed in a manner that is consistent with the requirements
of Section 423 of the Code. In addition, the ESPP permits the grant of purchase rights that do not qualify for such favorable tax treatment
in order to allow deviations necessary to permit participation by eligible employees who are foreign nationals or employed outside the
U.S. while complying with applicable foreign laws, and except as otherwise provided in the ESPP or determined by the Board, it will operate
and be administered in the same manner as the 423 Component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has initially reserved up to 550,000 shares of New Jasper Common Stock that may be issued under the ESPP. The ESPP provides that
the number of shares of New Jasper Common Stock that will be reserved for issuance under the ESPP will automatically increase on January
1 of each year for a period of ten years, commencing on January 1 following the year in which the ESPP is adopted by the Board and approved
by the Company&#8217;s stockholders and ending on (and including) January 1, 2031, in an amount equal to the lesser of (i) 1% of the
total number of shares of New Jasper Common Stock outstanding on December 31 of the immediately preceding calendar year, and (ii) 550,000
shares; provided however, that the Board may act prior to January 1 of a given calendar year to provide that there will be no increase
for such calendar year or the increase for such year will be a lesser number of shares than the amounts set forth in clauses (i) and
(ii) above. Under the ESPP, the Board will appropriately and proportionately adjust each of the foregoing share numbers as necessary
to implement any changes in the Company&#8217;s capital structure, such as a stock split, merger, consolidation, reorganization, recapitalization,
reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, &#160;liquidating dividend,
combination of shares, exchange of shares, change in corporate structure, or similar transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
more complete summary of the terms of the ESPP is set forth in the&#160;Definitive Proxy Statement in the section titled &#8220;<i>ESPP
Proposal</i>&#8221; beginning on page 150. Such summary and the foregoing description of the ESPP do not purport to be complete and are
qualified in their entirety by reference to the text of the ESPP, which is filed as Exhibit 10.6 to this Current Report and incorporated
herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Employment
Agreement with William Lis</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with Closing, on September 24, 2021, the Company entered into an Employment Agreement with William Lis (the &#8220;Lis Employment
Agreement&#8221;) as the Company&#8217;s Executive Chairman and Chief Executive Officer. The Lis Employment Agreement initially provides
for an annual base salary of $530,000, subject to adjustment from time to time (the &#8220;Lis Base Salary&#8221;), and a target annual
incentive bonus of 50% of the Lis Base Salary. The Lis Employment Agreement also provides that, subject to approval by the Board or its
compensation committee, Mr. Lis will be granted, in the form of equity awards, an equal amount of shares of the Company&#8217;s common
stock (the &#8220;Lis Shares&#8221;) and options to purchase shares of the Company&#8217;s common stock (the &#8220;Lis Options&#8221;)
in an aggregate amount such that Mr. Lis&#8217; beneficial ownership of the Company&#8217;s capital stock is equal to 3.0% of the outstanding
shares of the Company&#8217;s capital stock as of the Closing. The Lis Shares will vest 50% on the six-month anniversary of the date
of grant and 50% on the nine-month anniversary of the date of grant, and the Lis Options will be 25% vested on the date of grant and
an additional 25% shall vest on each six-month anniversary thereafter if certain corporate milestones are met. Mr. Lis also is eligible
to participate in the benefit plans that are generally available to all of the Company&#8217;s executive employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Mr.
Lis&#8217; employment with the Company is at-will, meaning either the Company or Mr. Lis may terminate the employment relationship with
or without cause. However, Mr. Lis must provide at least 30 days&#8217; advance written notice of any termination of his employment under
the Lis Employment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Mr.
Lis will also continue to be eligible for payments and benefits under the Company&#8217;s employee severance plan applicable to executive
committee members (the &#8220;Severance Plan&#8221;), which is described in the Definitive Proxy Statement in the section titled &#8220;<i>Executive
Compensation&#8212;Executive Compensation &#8212; Jasper&#8212;Employment Arrangements with Named Executive Officers&#8212;Employee Severance
Plan</i>&#8221; beginning on page 244, and which summary is incorporated herein by reference. Such summary is qualified in its entirety
by reference to the full text of the Severance Plan, which is filed as Exhibit 10.10 to this Current Report and is incorporated herein
by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Employment
Agreement with Jeet Mahal</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with Closing, on September 24, 2021, the Company entered into an Employment Agreement with Jeet Mahal (the &#8220;Mahal Employment
Agreement&#8221;) as the Company&#8217;s Chief Financial Officer and Business Officer. The Mahal Employment Agreement initially provides
for an annual base salary of $400,000, subject to adjustment from time to time (the &#8220;Mahal Base Salary&#8221;), and a target annual
incentive bonus of 40% of the Mahal Base Salary. The Mahal Employment Agreement also provides that Mr. Mahal will initially be granted
equity compensation, in the same form and on such terms consistent with his existing equity holdings, such that Mr. Mahal&#8217;s beneficial
ownership of the Company&#8217;s capital stock is equal to at least 0.75% of the outstanding shares of the Company&#8217;s capital stock
as the date of grant as well as a second grant, to be made no later than by March 31, 2022, of an amount of equity interests in the Company,
and on such terms and in such form approved by the Company&#8217;s Executive Chairman, such that Mr. Mahal&#8217;s beneficial ownership
of the Company&#8217;s capital stock is equal to at least 1.0% of the outstanding shares of the Company&#8217;s capital stock as the
date of grant. Mr. Mahal also is eligible to participate in the benefit plans that are generally available to all of the Company&#8217;s
executive employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Mr.
Mahal&#8217;s employment with the Company is at-will, meaning either the Company or Mr. Mahal may terminate the employment relationship
with or without cause. However, Mr. Mahal must provide at least 30 days&#8217; advance written notice of any termination of his employment
under the Mahal Employment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Mr.
Mahal will also continue to be eligible for payments and benefits under the Severance Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Employment
Agreement with Kevin N. Heller, M.D.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with Closing, on September 24, 2021, the Company entered into an Employment Agreement with Kevin N. Heller, M.D. (the &#8220;Heller
Employment Agreement&#8221;) as the Company&#8217;s Executive Vice President, Research and Development. The Heller Employment Agreement
initially provides for an annual base salary of $455,274.59, subject to adjustment from time to time (the &#8220;Heller Base Salary&#8221;),
and a target annual incentive bonus of 40% of the Heller Base Salary. Dr. Heller also is eligible to participate in the benefit plans
that are generally available to all of the Company&#8217;s executive employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Dr.
Heller&#8217;s employment with the Company is at-will, meaning either the Company or Dr. Heller may terminate the employment relationship
with or without cause. However, Dr. Heller must provide at least 30 days&#8217; advance written notice of any termination of his employment
under the Heller Employment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Dr.
Heller will also continue to be eligible for payments and benefits under the Severance Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
foregoing summaries of the employment agreements between the Company and each of Mr. Lis, Mr. Mahal and Dr. Heller are qualified in their
entirety by the full text of such employment agreements, which are filed as Exhibits 10.7, 10.8 and 10.9 to this Current Report, respectively,
and are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Potential
Payments Upon a Termination or Change of Control</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Reference
is made to the disclosure in the&#160;Definitive Proxy Statement in the section titled &#8220;<i>Executive Compensation&#8212;Employment
Arrangements with Named Executive Officers&#8212;Employee Severance Plan</i>&#8221; beginning on page 244, &#8220;<i>Equity Incentive
Plan Proposal&#8212;Summary of the Equity Incentive Plan&#8212;Corporate Transactions</i>&#8221; beginning on page 146 and &#8220;<i>ESPP
Proposal&#8212;Summary of the ESPP&#8212;Corporate Transactions</i>&#8221; beginning on page 154, which are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Indemnification
Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">As
of the Closing Date, the Company entered into indemnification agreements with each of its directors and executive officers. The description
of the indemnification agreements set forth above under Item 1.01 of this Current Report is incorporated herein by reference</span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Certain
Relationships and Related Person Transactions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
information set forth in the section titled &#8220;<i>Certain Relationships and Related Person Transactions</i>&#8221; in the&#160;Definitive
Proxy Statement beginning on page 260 is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
                            5.06.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Change
in Shell Company Status.</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
a result of the Transactions, the Company ceased to be a shell company upon the Closing. The material terms of the Transactions are described
in the section titled &#8220;<i>Business Combination Proposal</i>&#8221; in the&#160;Definitive Proxy Statement beginning on page 102
and are incorporated herein by reference. The disclosure set forth under &#8220;<i>Introductory Note</i>&#8221; above is also incorporated
into this Item 5.06 by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
                            7.01.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Regulation
FD Disclosure.</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
September 24, 2021, the Company issued a press release announcing the consummation of the Business Combination. The press release is
filed as Exhibit 99.1 to the Current Report and is incorporated herein by reference. The foregoing (including Exhibit 99.1) is being
furnished pursuant to Item 7.01 and will not be deemed to be filed for purposes of Section 18 of the Exchange Act, or otherwise subject
to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act or the
Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
                            9.01.</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Financial
Statements and Exhibits.</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(a)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Financial
statements of businesses acquired.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
audited consolidated financial statements of Old Jasper as of December 31, 2020 and 2019 and the related notes are included in the&#160;Definitive
Proxy Statement&#160;beginning on page&#160;F-51 and are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The
unaudited condensed consolidated financial statements of Old Jasper as of June 30, 2021 and for the six months ended June 30, 2021 and
2020 and the related notes </span><span style="font: 10pt Times New Roman, Times, Serif">are included in the&#160;Definitive
Proxy Statement&#160;beginning on page&#160;F-82 and are incorporated herein by reference<span style="background-color: white">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
audited financial statements of AMHC as of December 31, 2020 and 2019 and for the period from August 13, 2019 (inception) through December
31, 2019 and the related notes are included in the&#160;Definitive Proxy Statement&#160;beginning on page&#160;F-2 and are incorporated
herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
unaudited condensed financial statements of AMHC as of June 30, 2021 and for the three and six months ended June 30, 2021 and 2020
and the related notes are included in the&#160;Definitive Proxy Statement&#160;beginning on page&#160;F-27 and are incorporated
herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(b)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pro
forma financial information.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
unaudited pro forma condensed combined financial information as of June 30, 2021 and for the six months ended June 30, 2021 and the period
ended December 31, 2020 is attached hereto as Exhibit 99.2 and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(d)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Exhibits.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 9%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number</b></span></p></td>
    <td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 90%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description</b></span></td></tr>
  <tr>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">2.1+</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021024792/ea140401ex2-1_amplitude.htm">Business Combination Agreement, dated as of May 5, 2021, by and among Amplitude Healthcare Acquisition Corporation, Ample Merger Sub, Inc. and Jasper Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Company on May 6, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">3.1*</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ea147929ex3-1_jasper.htm">Second
    Amended and Restated Certificate of Incorporation of Jasper Therapeutics, Inc.</a></span></td></tr>
  <tr style="background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">3.2*</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ea147929ex3-2_jasper.htm">Second
    Amended and Restated Bylaws&#160;of Jasper Therapeutics, Inc.</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">4.1</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390019022224/fs12019a1ex4-4_amplitude.htm">Form of Warrant Agreement between Continental Stock Transfer &amp; Trust Company and Amplitude Healthcare Acquisition Corporation (incorporated by reference to Exhibit 4.4 to the Form S-1/A of Amplitude Healthcare Acquisition Corporation, filed on November 6, 2019, as amended).</a></span></td></tr>
  <tr style="background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.1</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021024792/ea140401ex10-1_amplitude.htm">Form of Subscription Agreement (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Company on May 6, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.2*</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ea147929ex10-2_jasper.htm">Amended and Restated Registration Rights Agreement, dated September 24, 2021, by and among Jasper Therapeutics, Inc. and the stockholders party thereto.</a></span></td></tr>
  <tr style="background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.3*&#8224;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ea147929ex10-3_jasper.htm">Jasper Therapeutics, Inc. 2021 Equity Incentive Plan.</a></span></td></tr>
  <tr style="background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.4*&#8224;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ea147929ex10-4_jasper.htm">Jasper Therapeutics, Inc. 2021 Equity Incentive Plan Form of Stock Option Grant Notice and Stock Option Agreement.</a></span></td></tr>
  <tr style="background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.5*&#8224;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ea147929ex10-5_jasper.htm">Jasper Therapeutics, Inc. 2021 Equity Incentive Plan Form of RSU Award Grant Notice and Award Agreement (RSU Award).</a></span></td></tr>
  <tr style="background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.6*&#8224;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ea147929ex10-6_jasper.htm">Jasper Therapeutics, Inc., 2021 Employee Stock Purchase Plan.</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.7*&#8224;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ea147929ex10-7_jasper.htm">Employment Agreement, dated as of September 24, 2021, by and between Jasper Therapeutics, Inc. and William Lis.</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.8*&#8224;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ea147929ex10-8_jasper.htm">Employment Agreement, dated as of September 24, 2021, by and between Jasper Therapeutics, Inc. and Jeet Mahal.</a></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; width: 9%"><span style="font: 10pt Times New Roman, Times, Serif">10.9*&#8224;</span></td>
    <td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify; width: 90%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ea147929ex10-9_jasper.htm">Employment Agreement, dated as of September 24, 2021, by and between Jasper Therapeutics, Inc. and Kevin Heller.</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.10&#8224;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021037334/fs42021a1ex10-11_amplitude.htm">Jasper Therapeutics, Inc. Employee Severance Plan for Vice Presidents and Executive Committee Members (incorporated by reference to Exhibit 10.11 to the Registration Statement on Form S-4/A filed by the Company on July 19, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.11&#8224;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021037334/fs42021a1ex10-12_amplitude.htm">Jasper Therapeutics, Inc. 2019 Equity Incentive Plan (incorporated by reference to Exhibit 10.12 to the Registration Statement on Form S-4/A filed by the Company on July 19, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.12&#8224;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021037334/fs42021a1ex10-28_amplitude.htm">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.28 to the Registration Statement on Form S-4/A filed by the Company on July 19, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.13</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021024792/ea140401ex10-2_amplitude.htm">Sponsor Support Agreement, dated as of May 5, 2021, by and among Amplitude Healthcare Acquisition Corporation, Amplitude Healthcare Holdings LLC and Jasper Therapeutics, Inc. (incorporated by reference to Exhibit 10.2 to the Form&#160;8-K of Amplitude Healthcare Acquisition Corporation, filed on May 6, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.14*</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="ea147929ex10-14_jasper.htm"><span style="font: 10pt Times New Roman, Times, Serif">Amendment to Sponsor Support Agreement, dated as of September 24, 2021, by and among Amplitude Healthcare Acquisition Corporation, Amplitude Healthcare Holdings LLC and Jasper Therapeutics, Inc.</span></a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.15&#8224;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021037334/fs42021a1ex10-29_amplitude.htm">Consulting Agreement, dated December 16, 2019, by and between Jasper Therapeutics, Inc. and Judith Shizuru, M.D., Ph.D. (incorporated by reference to Exhibit 10.29 to the Registration Statement on Form S-4/A filed by the Company on July 19, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.16&#94;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021040851/fs42021a2ex10-30_amplitude.htm">Clinical Trial Agreement for Clinical Trials Conducted at the National Institutes of Health Clinical Center, executed May 7, 2021, by and between Jasper Therapeutics, Inc. and The National Institute of Allergy and Infectious Diseases (NIAID) (incorporated by reference to Exhibit 10.30 to the Registration Statement on Form S-4/A filed by the Company on August 9, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.17&#94;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021040851/fs42021a2ex10-31_amplitude.htm">Material Transfer and Option Agreement, dated June 17, 2021, by and between Jasper Therapeutics, Inc. and Aruvant Sciences GmbH (incorporated by reference to Exhibit 10.31 to the Registration Statement on Form S-4/A filed by the Company on August 9, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.18&#94;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021040851/fs42021a2ex10-13_amplitude.htm">Exclusive License Agreement, dated November 21, 2019, by and between Jasper Therapeutics, Inc. and Amgen Inc. (incorporated by reference to Exhibit 10.13 to the Registration Statement on Form S-4/A filed by the Company on August 9, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.19</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021040851/fs42021a2ex10-14_amplitude.htm">Assignment Agreement, dated as of November 21, 2019, by and between Jasper Therapeutics, Inc. and Amgen Inc. (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-4/A filed by the Company on August 9, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.20&#94;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021040851/fs42021a2ex10-15_amplitude.htm">Investigator Sponsored Research Agreement, Amgen Protocol No. 20119244, effective as of June 18, 2013, between Jasper Therapeutics, Inc., as successor in interest to Amgen Inc., and The Board of Trustees of the Leland Stanford Junior University for Stanford University (incorporated by reference to Exhibit 10.15 to the Registration Statement on Form S-4/A filed by the Company on August 9, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.21&#94;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021040851/fs42021a2ex10-16_amplitude.htm">Amendment #1 to the Investigator Sponsored Research Agreement, Amgen Protocol No. 20119244, dated February 27, 2017, between Jasper Therapeutics, Inc., as successor in interest to Amgen Inc., and The Board of Trustees of the Leland Stanford Junior University for Stanford University (incorporated by reference to Exhibit 10.16 to the Registration Statement on Form S-4/A filed by the Company on August 9, 2021)</a>.</span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.22&#94;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021040851/fs42021a2ex10-17_amplitude.htm">Amendment #2 to the Investigator Sponsored Research Agreement, Amgen Protocol No. 20119244, dated November 15, 2017, between Jasper Therapeutics, Inc., as successor in interest to Amgen Inc., and The Board of Trustees of the Leland Stanford Junior University for Stanford University (incorporated by reference to Exhibit 10.17 to the Registration Statement on Form S-4/A filed by the Company on August 9, 2021).</a></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; width: 9%"><span style="font: 10pt Times New Roman, Times, Serif">10.23&#94;</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify; width: 90%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021040851/fs42021a2ex10-18_amplitude.htm">Quality
    Agreement, dated October 7, 2015, by and between Jasper Therapeutics, Inc., as successor in interest to Amgen Inc., and The Board
    of Trustees of the Leland Stanford Junior University for Stanford University (incorporated by reference to Exhibit 10.18 to the Registration
    Statement on Form S-4/A filed by the Company on August 9, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.24&#94;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021040851/fs42021a2ex10-19_amplitude.htm">Exclusive
    License Agreement, effective as of March 25, 2021, by and between Jasper Therapeutics, Inc. and The Board of Trustees of the Leland
    Stanford Junior University (incorporated by reference to Exhibit 10.19 to the Registration Statement on Form S-4/A filed by the Company
    on August 9, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.25&#94;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021040851/fs42021a2ex10-20_amplitude.htm">Sponsored
    Research Agreement, effective September 1, 2020, by and between Jasper Therapeutics, Inc. and The Board of Trustees of the Leland
    Stanford Junior University (incorporated by reference to Exhibit 10.20 to the Registration Statement on Form S-4/A filed by the Company
    on August 9, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.26&#94;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021037334/fs42021a1ex10-21_amplitude.htm">Material
    Transfer Agreement, dated December 14, 2020, by and between Jasper Therapeutics, Inc. and Zai Lab Limited (incorporated by reference
    to Exhibit 10.21 to the Registration Statement on Form S-4/A filed by the Company on July 19, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.27&#94;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021037334/fs42021a1ex10-22_amplitude.htm">Intramural
    Clinical Trial Agreement, executed February 11, 2021, by and between Jasper Therapeutics, Inc. and National Heart, Lung, and Blood
    Institute, Part of the National Institutes of Health (incorporated by reference to Exhibit 10.22 to the Registration Statement on
    Form S-4/A filed by the Company on July 19, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.28&#94;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021040851/fs42021a2ex10-23_amplitude.htm">Clinical
    Trial Agreement for Clinical Trials Conducted at the National Institutes of Health Clinical Center, executed July 28, 2020, by and
    between Jasper Therapeutics, Inc. and The National Institute of Allergy and Infectious Diseases (NIAID) (incorporated by reference
    to Exhibit 10.23 to the Registration Statement on Form S-4/A filed by the Company on August 9, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.29&#94;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021040851/fs42021a2ex10-24_amplitude.htm">Material
    Transfer Agreement, effective as of January 9, 2021, by and between Jasper Therapeutics, Inc. and Graphite Bio, Inc. (incorporated
    by reference to Exhibit 10.24 to the Registration Statement on Form S-4/A filed by the Company on August 9, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.30&#94;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021044097/fs42021a3ex10-25_amplitude.htm">Development
    and Manufacturing Services Agreement, dated November 29, 2019, by and between Jasper Therapeutics, Inc. and Lonza Sales AG (incorporated
    by reference to Exhibit 10.25 to the Registration Statement on Form S-4/A filed by the Company on August 20, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.31&#94;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021044097/fs42021a3ex10-26_amplitude.htm">Amendment
    No.&#160;1 to Development and Manufacturing Services Agreement, executed April 24, 2020 by and between Jasper Therapeutics, Inc.
    and Lonza Sales AG (incorporated by reference to Exhibit 10.26 to the Registration Statement on Form S-4/A filed by the Company on
    August 20, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">10.32&#94;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1788028/000121390021044097/fs42021a3ex10-27_amplitude.htm">Amendment
    No. 2 to Development and Manufacturing Services Agreement, executed December 1, 2020, by and between Jasper Therapeutics, Inc. and
    Lonza Sales AG (incorporated by reference to Exhibit 10.27 to the Registration Statement on Form S-4/A filed by the Company on August
    20, 2021).</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">14.1*</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ea147929ex14-1_jasper.htm">Code
    of Business Conduct and Ethics.</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">16.1*</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="ea147929ex16-1_jasper.htm"><span style="font: 10pt Times New Roman, Times, Serif">Letter to SEC from WithumSmith+Brown, PC.</span></a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">21.1*</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ea147929ex21-1_jasper.htm">List
    of Subsidiaries.</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">99.1*</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ea147929ex99-1_jasper.htm">Press
    Release, dated September 24, 2021.</a></span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">99.2*</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="ea147929ex99-2_jasper.htm"><span style="font: 10pt Times New Roman, Times, Serif">Unaudited pro forma condensed combined financial information of the Company as of and for the six months ended June 30, 2021 and for the year December 31, 2020.</span></a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">104*</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Filed herewith.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font: 10pt Times New Roman, Times, Serif">+</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Certain of the exhibits
    and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2). The Registrant agrees to furnish
    supplementally a copy of all omitted exhibits and schedules to the SEC upon its request.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font: 10pt Times New Roman, Times, Serif">&#8224;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicates a management
    contract or compensatory plan, contract or arrangement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font: 10pt Times New Roman, Times, Serif">&#94;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Certain confidential portions
    (indicated by brackets and asterisks) have been omitted from this exhibit <span style="background-color: white">pursuant to Item
    601(b)(10) of Regulation S-K because such information is both (i) not material and (ii) would likely cause competitive harm to the
    Registrant if publicly disclosed. The Registrant hereby undertakes to furnish supplemental copies of the unredacted exhibit upon
    request by the SEC.</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Dated: September 29, 2021</span></td>
    <td colspan="2"><span style="font: 10pt Times New Roman, Times, Serif"><b>JASPER THERAPEUTICS, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; width: 6%"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 34%"><span style="font: 10pt Times New Roman, Times, Serif">/s/
    Jeet Mahal</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font: 10pt Times New Roman, Times, Serif">Name:</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Jeet Mahal</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font: 10pt Times New Roman, Times, Serif">Title:</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Chief Financial and Business Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">21</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJx1kk1uwjAQhU/AHUYRSwROEItmRxGgqlAQIOjWhAlYJJ5obP6O1FvWdpSyaBtFiux5b943o0RRJ5rSRBXI8Pm6msEGy6qQFmGFOTLqDJ1i9Paegvuu8KiMZaltODbGETkPOs+gGwvpCkF6VQYPKYiXXjLoJTGIftpPYDiPWr4+Ip2rA2qrZAFSH2DJVLFCK/lRd9jIO2kqHyFqi2wU6RTirqjLX5CIOIEPusob8dnAbDaKWp3wtKIp06XyMRdjqYRxgaXLMrX1+QaULGjSFR4QS7kvcCfZz2jGMjvtTvRzMb4jZ8p4yYR4oXF9koyLfEtW6aPbQkl6bSk7DxspLlllThHH3YGYY7lHdoGxSBz7UDSbanKhCe4Aumi4+Wy41ZeAz3TIiYE0gvEAQDnUCFAzQIAAad1iGxtC5VG8th1o/tjArzmWkreyuKDoCiHiJXIY+J85/kDoQCUZrr4FtOsmULkfJmA3AN93mspG -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ea147929ex3-1_jasper.htm
<DESCRIPTION>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF JASPER THERAPEUTICS, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 3.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECOND AMENDED AND RESTATED<BR>
CERTIFICATE OF INCORPORATION<BR>
OF<BR>
AMPLITUDE HEALTHCARE ACQUISITION CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Jeet Mahal hereby certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>ONE: </B>He is the duly elected and acting Chief
Financial Officer, Chief Business Officer and Corporate Secretary of Amplitude Healthcare Acquisition Corporation, a Delaware corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>TWO: </B>The date of filing of said corporation&rsquo;s
original certificate of incorporation with the Secretary of State of the State of Delaware was August 13, 2019 under the name &ldquo;Amplitude
Healthcare Acquisition Corporation.&rdquo; The initial certificate of incorporation was amended and restated by the Amended and Restated
Certificate of Incorporation of said corporation filed with the Secretary of State of the State of Delaware on November 19, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>THREE: </B>The Amended and Restated Certificate
of Incorporation of the corporation, as amended, is hereby amended and restated to read in its entirety as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>I.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The name of this corporation is Jasper Therapeutics,
Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>II.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The registered office of the Company in the State
of Delaware is to be located at 251 Little Falls Drive, in the City of Wilmington, County of New Castle, Delaware 19808. The registered
agent in charge thereof is Corporation Service Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>III.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The purpose of the Company is to engage in any lawful
act or activity for which a corporation may be organized under the Delaware General Corporation Law (&ldquo;<B><I>DGCL</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IV.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>A.</B></TD><TD STYLE="text-align: justify">The total number of shares of capital stock which the Company
shall have authority to issue is 502,000,000, of which (i) 490,000,000 shares shall be a class&nbsp;designated as voting common stock,
par value $0.0001 per share (the &ldquo;<B><I>Voting Common Stock</I></B>&rdquo;), (ii) 2,000,000 shares shall be a class&nbsp;designated
as non-voting common stock, par value $0.0001 per share (the &ldquo;<B><I>Non-Voting Common Stock</I></B>&rdquo;) and (iii) 10,000,000
shares shall be a class&nbsp;designated as undesignated preferred stock, par value $0.0001 per share (the &ldquo;<B><I>Preferred Stock</I></B>&rdquo;).
Any reference to &ldquo;<B><I>Common Stock</I></B>&rdquo; in this Second Amended and Restated Certificate of Incorporation (this &ldquo;<B><I>Restated
Certificate</I></B>&rdquo;) shall refer to Voting Common Stock and Non-Voting Common Stock, collectively. Any reference to &ldquo;Common
Stock&rdquo; issued by the Company in any contract, agreement or otherwise to which the Company is a party, whether before or after the
date of filing of this Restated Certificate, shall refer to Voting Common Stock, unless specific reference is made to Non-Voting Common
Stock; <I>provided</I>, <I>however</I>, that this sentence shall not alter or affect the rights of the Non-Voting Common Stock hereunder.
For the avoidance of doubt, except as expressly set forth in this Article&nbsp;IV.A (with respect to voting power only), in Article&nbsp;IV.D,
and in Article&nbsp;VIII (with respect to waiver, amendment, modification or repeal of certain provisions), the Non-Voting Common Stock
shall have the same rights of, and be identical in all respects and as to all matters to, the Voting Common Stock, including in connection
with any merger or consolidation of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>B.</B></TD><TD STYLE="text-align: justify">The Preferred Stock may be issued from time to time in one
or more series. The Board of Directors of the Company (the &ldquo;<B><I>Board of Directors</I></B>&rdquo;) is hereby expressly authorized
to provide for the issue of any or all of the unissued and undesignated shares of the Preferred Stock in one or more series, and to fix
the number of shares and to determine or alter for each such series, such voting powers, full or limited, or no voting powers, and such
designation, preferences, and relative, participating, optional or other rights and such qualifications, limitations or restrictions
thereof, as shall be stated and expressed in the resolution or resolutions adopted by the Board of Directors providing for the issuance
of such shares and as may be permitted by the DGCL. The Board of Directors is also expressly authorized to increase or decrease the number
of shares of any series subsequent to the issuance of shares of that series, but not below the number of shares of such series then outstanding.
In case the number of shares of any series shall be decreased in accordance with the foregoing sentence, the shares constituting such
decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such
series. The number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares thereof
then outstanding) by the affirmative vote of the holders of a majority of the voting power of the stock of the Company entitled to vote
thereon, without a separate vote of the holders of the Preferred Stock, or of any series thereof, unless a vote of any such holders is
required pursuant to the terms of any certificate of designation filed with respect to any series of Preferred Stock.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>C.</B></TD><TD STYLE="text-align: justify">Each outstanding share of Voting Common Stock shall entitle
the holder thereof to one vote on each matter properly submitted to the stockholders of the Company for their vote; <I>provided, however</I>,
that, except as otherwise required by law, holders of Voting Common Stock shall not be entitled to vote on any amendment to this Restated
Certificate (including any certificate of designation filed with respect to any series of Preferred Stock) that relates solely to the
terms of one or more outstanding series of Preferred Stock if the holders of such affected series of Preferred Stock are entitled, either
separately or together as a class with the holders of one or more other such series of Preferred Stock, to vote thereon by law or pursuant
to this Restated Certificate (including any certificate of designation filed with respect to any series of Preferred Stock); and <I>provided,
further, </I>that the Non-Voting Common Stock (i)&nbsp;shall be non-voting except as may be required by law and (ii)&nbsp;shall not entitle
the holder thereof to vote on the election of directors at any time.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>D.</B></TD><TD STYLE="text-align: justify">(1) Each holder of shares of Non-Voting Common Stock shall
have the right to convert each share of Non-Voting Common Stock held by such holder into one (1)&nbsp;share of Voting Common Stock at
such holder&rsquo;s election by providing written notice to the Company; provided, however, that such shares of Non-Voting Common Stock
may only be converted into shares of Voting Common Stock to the extent that, as a result of such conversion, such conversion would not
result in the holder(s) thereof beneficially owning (for purposes of Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended
and the rules and regulations promulgated thereunder (collectively, the &ldquo;<B>Exchange Act</B>&rdquo;)), when aggregated with affiliates
with whom such holder is required to aggregate beneficial ownership for purposes of Section&nbsp;13(d) of the Exchange Act (collectively,
the &ldquo;<B>Related Holders</B>&rdquo;), in excess of the Beneficial Ownership Limitation. For avoidance of doubt, in the event that
the Related Holders beneficially own in the aggregate, directly or indirectly, shares of Voting Common Stock in excess of the Beneficial
Ownership Limitation without taking into account the conversion of Non-Voting Common Stock, then none of the Non-Voting Common Stock
held by such Related Holders shall be convertible into Voting Common Stock until such time as such Related Holders no longer beneficially
own in the aggregate, directly or indirectly, shares of Voting Common Stock in excess of the Beneficial Ownership Limitation. The &ldquo;<B>Beneficial
Ownership Limitation</B>&rdquo; means initially 9.9% of the Voting Common Stock. Any holder of Non-Voting Common Stock may elect to increase
the Beneficial Ownership Limitation applicable to such holder (and only such holder and its Related Holders) upon 61&nbsp;days&rsquo;
prior written notice of such election to the Company and may decrease the Beneficial Ownership Limitation applicable to such holder (and
only such holder and its Related Holders) at any time upon providing written notice of such election to the Company; provided, however,
that no holder may make such an election to change the Beneficial Ownership Limitation applicable to such holder unless all holders managed
by the same investment advisor as such electing holder make the same election and each such written election is provided to the Company
by the applicable deadlines set forth herein.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="text-align: justify">(2) A converting holder&rsquo;s acquisition of the shares of Voting Common Stock pursuant to the
                                                 election provided for in such holder&rsquo;s conversion notice under this Article&nbsp;IV, Section D shall not result in Related
                                                 Holders becoming in the aggregate, directly or indirectly, the beneficial owner of shares of Voting Common Stock that exceed the
                                                 Beneficial Ownership Limitation, and any Voting Common Stock to which the converting holder would be otherwise entitled but for the
                                                 Beneficial Ownership Limitation will remain Non-Voting Common Stock. Any purported delivery of shares of Voting Common Stock upon
                                                 conversion of Non-Voting Common Stock shall be void ab initio and shall have no effect to the extent (but only to the extent) that
                                                 such delivery would result in the Related Holders becoming in the aggregate, directly or indirectly, the beneficial owner of shares
                                                 of Voting Common Stock that exceed the Beneficial Ownership Limitation. Any conversion of Non-Voting Common Stock into Voting Common
                                                 Stock shall be deemed to have been made immediately prior to the close of business on the date of the written conversion notice, and
                                                 the person or persons entitled to receive the shares of Voting Common Stock issuable upon such conversion shall be treated for all
                                                 purposes as the record holder or holders of such shares of Voting Common Stock as of such date and time. Each share of Non-Voting
                                                 Common Stock that is converted pursuant to this Article&nbsp;IV, Section D shall be retired by the Company and shall not be
                                                 reissued. Within five (5) business days of any written request by a holder of Non-Voting Common Stock to the Company, the Company
                                                 shall inform such holder in writing of the then current number of outstanding shares of Voting Common Stock and Non-Voting Common
                                                 Stock.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="text-align: justify">(3) Any shares of Non-Voting Common Stock shall be converted into a corresponding number of fully
                                                 paid and nonassessable shares of Voting Common Stock promptly upon written request to the Company in writing following a
                                                 Non-Affiliate Transfer. A &ldquo;<B>Non-Affiliate Transfer</B>&rdquo; shall mean a transfer of shares of Non-Voting Common Stock to
                                                 any person that is not an affiliate of a holder of the Non-Voting Common Stock immediately following the issuance thereof. The
                                                 Company shall, upon the request of each such holder and a written certification from such transferee holder of such holder&rsquo;s
                                                 non-affiliation with the original holder of such Non-Voting Common Stock, in a form reasonably acceptable to the Company, issue and
                                                 deliver to such holder new certificates (unless shares of Voting Common Stock are then maintained in book-entry form) representing
                                                 such non-affiliate holder&rsquo;s shares of Voting Common Stock. Such conversion shall be deemed to have been made immediately prior
                                                 to the close of business on the date of such request and certification is received by the Company, and the person or persons
                                                 entitled to receive the shares of Voting Common Stock issuable upon such conversion shall be treated for all purposes as the record
                                                 holder or holders of such shares of Voting Common Stock as of such date and time. Each share of Non-Voting Common Stock that is
                                                 converted pursuant to this section shall be retired by the Company and shall not be reissued.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>E.</B></TD><TD STYLE="text-align: justify">Dividends may be declared and paid or set apart for payment
upon the Common Stock out of any assets of funds of the Company legally available for the payment of dividends, but only when and as
declared by the Board of Directors or any authorized committee thereof, subject to any preferential dividend or other rights of any then
outstanding Preferred Stock.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>F.</B></TD><TD STYLE="text-align: justify">Upon the voluntary or involuntary liquidation, dissolution
or winding up of the Company, the net assets of the Company shall be distributed pro rata to the holders of Common Stock, subject to
any preferential or other rights of any then outstanding Preferred Stock. The Non-Voting Common Stock shall rank on parity with the Voting
Common Stock as to distributions of assets upon the voluntary or involuntary liquidation, dissolution or winding up of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the management of the business and for the conduct
of the affairs of the Company, and in further definition, limitation and regulation of the powers of the Company, of its directors and
of its stockholders or any class thereof, as the case may be, it is further provided that:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>A.</B></TD><TD STYLE="text-align: justify">The management of the business and the conduct of the affairs
of the Company shall be vested in its Board of Directors. The number of directors that shall constitute the Board of Directors shall
be fixed exclusively by resolutions adopted by a majority of the authorized number of directors constituting the Board of Directors.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>B.</B></TD><TD STYLE="text-align: justify">Subject to the rights of the holders of any series of Preferred
Stock to elect additional directors under specified circumstances, the directors shall be divided into three classes designated as Class
I, Class II and Class III, respectively. The Board of Directors is authorized to assign members of the Board of Directors already in
office to such classes at the time the classification becomes effective. At the first annual meeting of stockholders following the initial
classification of the Board of Directors, the term of office of the Class I directors shall expire and Class I directors shall be elected
for a full term of three years. At the second annual meeting of stockholders following such initial classification, the term of office
of the Class II directors shall expire and Class II directors shall be elected for a full term of three years. At the third annual meeting
of stockholders following such initial classification, the term of office of the Class III directors shall expire and Class III directors
shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected for a
full term of three years to succeed the directors of the class whose terms expire at such annual meeting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">Notwithstanding
the foregoing provisions of this section, each director shall serve until his or her successor is duly elected and qualified or until
his or her earlier death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten
the term of any incumbent director.<B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>C.</B></TD><TD STYLE="text-align: justify">Subject to the rights of any series of Preferred Stock that
may be designated from time to time to elect additional directors under specified circumstances, neither the Board of Directors nor any
individual director may be removed without cause. Subject to any limitations imposed by applicable law, any individual director or directors
may be removed with cause by the affirmative vote of the holders of at least 66&frac23;%
of the voting power of all then-outstanding shares of capital stock of the Company entitled to vote generally at an election of directors,
voting together as a single class (provided that as of the three-year anniversary of this Restated Certificate, such reference to &ldquo;66&frac23;%&rdquo;
shall be deemed to be &ldquo;50%&rdquo;).</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>D.</B></TD><TD STYLE="text-align: justify">Subject to any limitations imposed by applicable law and
subject to the rights of the holders of any series of Preferred Stock that may be designated from time to time, any vacancies on the
Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting
from any increase in the number of directors, shall, unless the Board of Directors determines by resolution that any such vacancies or
newly created directorships shall be filled by the stockholders and except as otherwise provided by applicable law, be filled only by
the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors, and not
by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term
of the director for which the vacancy was created or occurred and until such director&rsquo;s successor shall have been elected and qualified.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>E.</B></TD><TD STYLE="text-align: justify">The Board of Directors is expressly empowered to adopt, amend
or repeal the Amended and Restated Bylaws of the Company (the &ldquo;<B><I>Bylaws</I></B>&rdquo;). Any adoption, amendment or repeal
of the Bylaws by the Board of Directors shall require the approval of a majority of the authorized number of directors. The stockholders
shall also have power to adopt, amend or repeal the Bylaws; <I>provided, however, </I>that, in addition to any vote of the holders of
any class or series of stock of the Company required by law or by this Restated Certificate, such action by stockholders shall require
the affirmative vote of the holders of at least 66&frac23;%
of the voting power of all of the then-outstanding shares of the capital stock of the Company entitled to vote generally in the election
of directors, voting together as a single class (provided that as of the three-year anniversary of this Restated Certificate, such reference
to &ldquo;66&frac23;%&rdquo; shall be deemed to be &ldquo;50%&rdquo;).</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>F.</B></TD><TD STYLE="text-align: justify">The directors of the Company need not be elected by written
ballot unless the Bylaws so provide.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>G.</B></TD><TD STYLE="text-align: justify">No action shall be taken by the stockholders of the Company
except at an annual or special meeting of stockholders called in accordance with the Bylaws. No action shall be taken by the stockholders
of the Company by written consent or electronic transmission.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>H.</B></TD><TD STYLE="text-align: justify">Advance notice of stockholder nominations for the election
of directors and of business to be brought by stockholders before any meeting of the stockholders of the Company shall be given in the
manner provided in the Bylaws.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>VI.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>A.</B></TD><TD STYLE="text-align: justify">The liability of a director of the Company for monetary damages
shall be eliminated to the fullest extent under applicable law.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>B.</B></TD><TD STYLE="text-align: justify">To the fullest extent permitted by applicable law, the Company
is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Company (and any other
persons to which applicable law permits the Company to provide indemnification) through Bylaw provisions, agreements with such agents
or other persons, vote of stockholders or disinterested directors or otherwise in excess of the indemnification and advancement otherwise
permitted by such applicable law. If applicable law is amended after approval by the stockholders of this Article&nbsp;VI to authorize
corporate action further eliminating or limiting the personal liability of directors, then the liability of a director to the Company
shall be eliminated or limited to the fullest extent permitted by applicable law as so amended.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><B></B></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>C.</B></TD><TD STYLE="text-align: justify">Any repeal or modification of this Article&nbsp;VI shall
only be prospective and shall not affect the rights or protections or increase the liability of any director under this Article&nbsp;VI
in effect at the time of the alleged occurrence of any act or omission to act giving rise to liability or indemnification.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>VII.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>A.</B></TD><TD STYLE="text-align: justify">Unless the Company consents in writing to the selection of
an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware
lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack
subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall be the
sole and exclusive forum for the following claims or causes of action under the Delaware statutory or common law: (i)&nbsp;any derivative
claim or cause of action brought on behalf of the Company; (ii)&nbsp;any claim or cause of action for breach of a fiduciary duty owed
by any current or former director, officer or other employee of the Company to the Company or the Company&rsquo;s stockholders; (iii)&nbsp;any
claim or cause of action against the Company or any current or former director, officer or other employee of the Company, arising out
of or pursuant to any provision of the DGCL, this Restated Certificate or the Bylaws (as each may be amended from time to time); (iv)&nbsp;any
claim or cause of action seeking to interpret, apply, enforce or determine the validity of this Restated Certificate or the Bylaws (as
each may be amended from time to time, including any right, obligation or remedy thereunder); (v)&nbsp;any claim or cause of action as
to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; and (vi)&nbsp;any claim or cause of action
against the Company or any current or former director, officer or other employee of the Company governed by the internal-affairs doctrine
or otherwise related to the Company&rsquo;s internal affairs, in all cases to the fullest extent permitted by law and subject to the
court having personal jurisdiction over the indispensable parties named as defendants. This Section A of Article&nbsp;VII shall not apply
to claims or causes of action brought to enforce a duty or liability created by the Securities Act of 1933, as amended (the &ldquo;<B><I>Securities
Act</I></B>&rdquo;), the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive
jurisdiction.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>B.</B></TD><TD STYLE="text-align: justify">Unless the Company consents in writing to the selection of
an alternative forum, to the fullest extent permitted by law, the federal district courts of the United&nbsp;States of America shall
be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, including all
causes of action asserted against any defendant named in such complaint. For the avoidance of doubt, this provision is intended to benefit
and may be enforced by the Company, its officers and directors, the underwriters for any offering giving rise to such complaint, and
any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified
any part of the documents underlying the offering.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>C.</B></TD><TD STYLE="text-align: justify">Any person or entity holding, owning or otherwise acquiring
any interest in any security of the Company shall be deemed to have notice of and consented to the provisions of this Restated Certificate.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>VIII.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>A.</B></TD><TD STYLE="text-align: justify">The Company reserves the right to amend, alter, change or
repeal any provision contained in this Restated Certificate, in the manner now or hereafter prescribed by statute, except as provided
in Section B of this Article&nbsp;VIII, and all rights conferred upon the stockholders herein are granted subject to this reservation.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>B.</B></TD><TD STYLE="text-align: justify">Notwithstanding any other provisions of this Restated Certificate
or any provision of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders
of any particular class or series of the Company required by law or by this Restated Certificate or any certificate of designation filed
with respect to a series of Preferred Stock that may be designated from time to time, subject to the rights of the holders of any series
of Preferred Stock, (i)&nbsp;the affirmative vote of the holders of at least 66&frac23;%
of the voting power of all of the then-outstanding shares of capital stock of the Company entitled to vote generally in the election
of directors, voting together as a single class, shall be required to waive, alter, amend or repeal (whether by merger, consolidation
or otherwise) Articles V, VI, VII and VIII of this Restated Certificate (for clarification, the holders of Non-Voting Common Stock are
not entitled to vote in the election of directors and should not be included in the calculation of such voting power) (provided that
as of the three-year anniversary of this Restated Certificate, such reference to &ldquo;66&frac23;%&rdquo; shall be deemed to be &ldquo;50%&rdquo;)
and (ii)&nbsp;neither the proviso of paragraph A of Article&nbsp;IV, the final sentence of paragraph A of Article&nbsp;IV, the final
proviso of paragraph C of Article&nbsp;IV, paragraph D of Article&nbsp;IV, the second sentence of paragraph F of Article&nbsp;IV nor
this proviso of Section B of Article&nbsp;VIII shall be waived, altered, amended or repealed (whether by merger, consolidation or otherwise) without the
vote or consent of the holders of a majority of the outstanding shares of Non-Voting Common Stock (which majority must include the vote
or consent of Citadel Multi-Strategy Equities Master Fund Ltd. (or its affiliates) to the extent such entities remain holders of any Non-Voting
Common Stock).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>* * * *</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>FOUR: </B>This Restated Certificate has been
duly adopted and approved by the Board of Directors and by written consent of the stockholders in accordance with Sections&nbsp;228, 242
and 245 of the DGCL and written notice of such action has been given as provided in section 228 of the DGCL.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>IN WITNESS WHEREOF</B>, Amplitude Healthcare Acquisition Corporation has caused this Second Amended and Restated Certificate of Incorporation to be signed by its Chief Financial Officer, Chief Business
Officer and Corporate Secretary this 24<SUP>th</SUP> day of September, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><B>AMPLITUDE HEALTHCARE ACQUISITION CORPORATION</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;/s/ Jeet Mahal</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><B>JEET MAHAL</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer, Chief Business Officer and Corporate Secretary</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>ea147929ex3-2_jasper.htm
<DESCRIPTION>AMENDED AND RESTATED BYLAWS OF JASPER THERAPEUTICS, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 3.2 </P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECOND AMENDED AND RESTATED<BR>
BYLAWS<BR>
OF<BR>
JASPER THERAPEUTICS, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article
I</FONT><BR>
<BR>
OFFICES</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 1.&#9;Registered Office</B>. The registered
office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 2.&#9;Other Offices</B>. The corporation
shall also have and maintain an office or principal place of business at such place as may be fixed by the corporation&rsquo;s Board of
Directors (the &ldquo;<B><I>Board of Directors</I></B>&rdquo;), and may also have offices at such other places, both within and without
the State of Delaware as the Board of Directors may from time to time determine or the business of the corporation may require.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article
II</FONT><BR>
<BR>
CORPORATE SEAL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 3.&#9;Corporate Seal</B>. The Board of
Directors may adopt a corporate seal. The corporate seal shall consist of a die bearing the name of the corporation and the inscription,
&ldquo;Corporate Seal-Delaware.&rdquo; Said seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced
or otherwise.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article
III</FONT><BR>
<BR>
STOCKHOLDERS&rsquo; MEETINGS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 4.&#9;Place of Meetings</B>. Meetings
of the stockholders of the corporation may be held at such place, either within or without the State of Delaware, as may be determined
from time to time by the Board of Directors. The Board of Directors may, in its sole discretion, determine that the meeting shall not
be held at any place, but may instead be held solely by means of remote communication as provided under the Delaware General Corporation
Law (the &ldquo;<B><I>DGCL</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 5.&#9;Annual Meetings</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(a) </B>The
annual meeting of the stockholders of the corporation, for the purpose of election of directors and for such other business as may properly
come before it, shall be held on such date and at such time as may be designated from time to time by the Board of Directors. Nominations
of persons for election to the Board of Directors of the corporation and the proposal of business to be considered by the stockholders
may be made at an annual meeting of stockholders: (i) pursuant to the corporation&rsquo;s notice of meeting of stockholders (with respect
to business other than nominations); (ii) brought specifically by or at the direction of the Board of Directors; or (iii) by any stockholder
of the corporation who was a stockholder of record at the time of giving the stockholder&rsquo;s notice provided for in Section 5(b) of
these Second Amended and Restated Bylaws (the &ldquo;<B><I>Bylaws</I></B>&rdquo;), who is entitled to vote at the meeting and who complied
with the notice procedures set forth in this Section 5. The number of nominees a stockholder may nominate for election at an annual meeting
of stockholders (or in the case of a stockholder giving notice on behalf of a beneficial owner, the number of nominees a stockholder may
nominate for election at the annual meeting on behalf of such beneficial owner) shall not exceed the number of directors to be elected
at such meeting. For the avoidance of doubt, clause&nbsp;(iii) above shall be the exclusive means for a stockholder to make nominations
and submit other business (other than matters properly included in the corporation&rsquo;s notice of meeting of stockholders and proxy
statement under Rule 14a-8 under the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the &ldquo;<B><I>1934
Act</I></B>&rdquo;)) before an annual meeting of stockholders.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(b) </B>At
an annual meeting of the stockholders, only such business shall be conducted as is a proper matter for stockholder action under Delaware
law and as shall have been properly brought before the meeting.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>(i) </B>For
nominations for the election to the Board of Directors to be properly brought before an annual meeting by a stockholder pursuant to clause
(iii) of Section 5(a) of these Bylaws, the stockholder must deliver written notice to the Secretary at the principal executive offices
of the corporation on a timely basis as set forth in Section 5(b)(iii) of these Bylaws and must update and supplement such written notice
on a timely basis as set forth in Section 5(c) of these Bylaws. Such stockholder&rsquo;s notice shall set forth: (A) as to each nominee
such stockholder proposes to nominate at the meeting: (1) the name, age, business address and residence address of such nominee; (2) the
principal occupation or employment of such nominee; (3) the class and number of shares of each class of capital stock of the corporation
which are owned of record and beneficially by such nominee; (4) the date or dates on which such shares were acquired and the investment
intent of such acquisition; (5) with respect to each nominee for election or re-election to the Board of Directors, include a completed
and signed questionnaire, representation and agreement required by Section 5(e) of these Bylaws; and (6) such other information concerning
such nominee as would be required to be disclosed in a proxy statement soliciting proxies for the election of such nominee as a director
in an election contest (even if an election contest is not involved), or that is otherwise required to be disclosed pursuant to Section
14 of the 1934 Act and the rules and regulations promulgated thereunder (including such person&rsquo;s written consent to being named
as a nominee and to serving as a director if elected); and (B) the information required by Section 5(b)(iv) of these Bylaws. The corporation
may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility of such proposed
nominee to serve as an independent director of the corporation or that could be material to a reasonable stockholder&rsquo;s understanding
of the independence, or lack thereof, of such proposed nominee.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>(ii) </B>Other
than proposals sought to be included in the corporation&rsquo;s proxy materials pursuant to Rule 14(a)-8 under the 1934 Act, for business
other than nominations for the election to the Board of Directors to be properly brought before an annual meeting by a stockholder pursuant
to clause (iii) of Section 5(a) of these Bylaws, the stockholder must deliver written notice to the Secretary at the principal executive
offices of the corporation on a timely basis as set forth in Section 5(b)(iii) of these Bylaws, and must update and supplement such written
notice on a timely basis as set forth in Section 5(c) of these Bylaws. Such stockholder&rsquo;s notice shall set forth: (A) as to each
matter such stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting,
the reasons for conducting such business at the meeting, and any material interest (including any anticipated benefit of such business
to any Proponent (as defined below) other than solely as a result of its ownership of the corporation&rsquo;s capital stock, that is material
to any Proponent individually, or to the Proponents in the aggregate) in such business of any Proponent; and (B) the information required
by Section 5(b)(iv) of these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>(iii) </B>To
be timely, the written notice required by Section 5(b)(i) or 5(b)(ii) of these Bylaws must be received by the Secretary at the principal
executive offices of the corporation not later than the close of business on the 90<FONT STYLE="font-size: 10pt">th</FONT> day nor earlier
than the close of business on the 120<FONT STYLE="font-size: 10pt">th</FONT> day prior to the first anniversary of the preceding year&rsquo;s
annual meeting; <I>provided, however,</I> that, subject to the last sentence of this Section 5(b)(iii), in the event that the date of
the annual meeting is advanced more than 30 days prior to or delayed by more than 60 days after the anniversary of the preceding year&rsquo;s
annual meeting, or if no annual meeting was held in the preceding year, notice by the stockholder to be timely must be so received not
earlier than the close of business on the 120<FONT STYLE="font-size: 10pt">th</FONT> day prior to such annual meeting and not later than
the close of business on the later of the 90<FONT STYLE="font-size: 10pt">th</FONT> day prior to such annual meeting and the 10<FONT STYLE="font-size: 10pt">th</FONT>
day following the day on which notice of the date of such annual meeting was mailed or public announcement of the date of such meeting
is first made, whichever first occurs. In no event shall an adjournment or a postponement of an annual meeting for which notice has been
given, or the public announcement thereof has been made, commence a new time period (or extend any time period) for the giving of a stockholder&rsquo;s
notice as described above.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 108pt"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>(iv) </B>The
written notice required by Section 5(b)(i) or 5(b)(ii) of these Bylaws shall also set forth, as of the date of the notice and as to the
stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made (each, a &ldquo;<B><I>Proponent</I></B>&rdquo;
and collectively, the &ldquo;<B><I>Proponents</I></B>&rdquo;): (A)&nbsp;the name and address of each Proponent, as they appear on the
corporation&rsquo;s books; (B) the class, series and number of shares of the corporation that are owned beneficially and of record by
each Proponent; (C) a description of any agreement, arrangement or understanding (whether oral or in writing) with respect to such nomination
or proposal between or among any Proponent and any of its affiliates or associates, and any others (including their names) acting in concert,
or otherwise under the agreement, arrangement or understanding, with any of the foregoing; (D) a representation that the Proponents are
holders of record or beneficial owners, as the case may be, of shares of the corporation entitled to vote at the meeting and intend to
appear in person or by proxy at the meeting to nominate the person or persons specified in the notice (with respect to a notice under
Section 5(b)(i) of these Bylaws) or to propose the business that is specified in the notice (with respect to a notice under Section 5(b)(ii)
of these Bylaws); (E) a representation as to whether the Proponents intend to deliver a proxy statement and form of proxy to holders of
a sufficient number of holders of the corporation&rsquo;s voting shares to elect such nominee or nominees (with respect to a notice under
Section 5(b)(i) of these Bylaws) or to carry such proposal (with respect to a notice under Section 5(b)(ii) of these Bylaws); (F) to the
extent known by any Proponent, the name and address of any other stockholder supporting the proposal on the date of such stockholder&rsquo;s
notice; and (G) a description of all Derivative Transactions (as defined below) by each Proponent during the previous 12-month period,
including the date of the transactions and the class, series and number of securities involved in, and the material economic terms of,
such Derivative Transactions.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">For purposes of Sections 5 and 6 of these Bylaws,
a &ldquo;<B><I>Derivative Transaction</I></B>&rdquo; means any agreement, arrangement, interest or understanding entered into by, or on
behalf or for the benefit of, any Proponent or any of its affiliates or associates, whether record or beneficial:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(w) the
value of which is derived in whole or in part from the value of any class or series of shares or other securities of the corporation;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(x) which
otherwise provides any direct or indirect opportunity to gain or share in any gain derived from a change in the value of securities of
the corporation;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(y) the
effect or intent of which is to mitigate loss, manage risk or benefit from security value or price changes; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(z) which
provides the right to vote or increase or decrease the voting power of, such Proponent, or any of its affiliates or associates, with respect
to any securities of the corporation,</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">which agreement, arrangement, interest or understanding
may include, without limitation, any option, warrant, debt position, note, bond, convertible security, swap, stock appreciation right,
short position, profit interest, hedge, right to dividends, voting agreement, performance-related fee or arrangement to borrow or lend
shares (whether or not subject to payment, settlement, exercise or conversion in any such class or series), and any proportionate interest
of such Proponent in the securities of the corporation held by any general or limited partnership, or any limited liability company, of
which such Proponent is, directly or indirectly, a general partner or managing member.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(c) </B>A
stockholder providing written notice required by Section 5(b)(i) or (ii) of these Bylaws shall update and supplement such notice in writing,
if necessary, so that the information provided or required to be provided in such notice is true and correct in all material respects
as of (i) the record date for the meeting and (ii) the date that is five business days prior to the meeting and, in the event of any adjournment
or postponement thereof, five business days prior to such adjourned or postponed meeting. In the case of an update and supplement pursuant
to clause (i) of this Section 5(c), such update and supplement shall be received by the Secretary at the principal executive offices of
the corporation not later than five business days after the record date for the meeting. In the case of an update and supplement pursuant
to clause (ii) of this Section 5(c), such update and supplement shall be received by the Secretary at the principal executive offices
of the corporation not later than two business days prior to the date for the meeting, and, in the event of any adjournment or postponement
thereof, two business days prior to such adjourned or postponed meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>(d) </B>Notwithstanding
anything in Section 5(b)(iii) of these Bylaws to the contrary, in the event that the number of directors in an Expiring Class (as defined
below) is increased and there is no public announcement of the appointment of a director to such class, or, if no appointment was made,
of the vacancy in such class, made by the corporation at least 10 days before the last day a stockholder may deliver a notice of nomination
in accordance with Section 5(b)(iii) of these Bylaws, a stockholder&rsquo;s notice required by this Section 5 and which complies with
the requirements in Section 5(b)(i) of these Bylaws, other than the timing requirements in Section&nbsp;5(b)(iii) of these Bylaws, shall
also be considered timely, but only with respect to nominees for any new positions in such Expiring Class created by such increase, if
it shall be received by the Secretary at the principal executive offices of the corporation not later than the close of business on the
10th day following the day on which such public announcement is first made by the corporation. For purposes of this Section 5, an &ldquo;<B><I>Expiring
Class</I></B>&rdquo; shall mean a class of directors whose term shall expire at the next annual meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>(e) </B>To
be eligible to be a nominee for election or re-election as a director of the corporation pursuant to a nomination under clause (iii) of
Section 5(a) of these Bylaws, such proposed nominee or a person on such proposed nominee&rsquo;s behalf must deliver (in accordance with
the time periods prescribed for delivery of notice under Section 5(b)(iii) or 5(d) of these Bylaws, as applicable) to the Secretary at
the principal executive offices of the corporation a written questionnaire with respect to the background and qualification of such proposed
nominee and the background of any other person or entity on whose behalf the nomination is being made (which questionnaire shall be provided
by the Secretary upon written request) and a written representation and agreement (in the form provided by the Secretary upon written
request) that such person (i) is not and will not become a party to (A) any agreement, arrangement or understanding with, and has not
given any commitment or assurance to, any person or entity as to how such person, if elected as a director of the corporation, will act
or vote on any issue or question (a &ldquo;<B><I>Voting Commitment</I></B>&rdquo;) that has not been disclosed to the corporation in the
questionnaire or (B) any Voting Commitment that could limit or interfere with such person&rsquo;s ability to comply, if elected as a director
of the corporation, with such person&rsquo;s fiduciary duties under applicable law; (ii) is not and will not become a party to any agreement,
arrangement or understanding with any person or entity other than the corporation with respect to any direct or indirect compensation,
reimbursement or indemnification in connection with service or action as a director of the corporation that has not been disclosed therein;
and (iii) in such person&rsquo;s individual capacity and on behalf of any person or entity on whose behalf the nomination is being made,
would be in compliance, if elected as a director of the corporation, and will comply with, all applicable publicly disclosed corporate
governance, conflict of interest, confidentiality and stock ownership and trading policies and guidelines of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(f) </B>A
person shall not be eligible for election or re-election as a director unless the person is nominated either in accordance with clause
(ii) of Section 5(a) of these Bylaws, or in accordance with clause (iii) of Section 5(a) of these Bylaws. Except as otherwise required
by law, the chairman of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be brought
before the meeting was made, or proposed, as the case may be, in accordance with the procedures set forth in these Bylaws and, if any
proposed nomination or business is not in compliance with these Bylaws, or the Proponent does not act in accordance with the representations
in Sections 5(b)(iv)(D) and 5(b)(iv)(E) of these Bylaws, to declare that such proposal or nomination shall not be presented for stockholder
action at the meeting and shall be disregarded, notwithstanding that proxies in respect of such nominations or such business may have
been solicited or received.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(g) </B>Notwithstanding
the foregoing provisions of this Section 5, in order to include information with respect to a stockholder proposal in the proxy statement
and form of proxy for a stockholders&rsquo; meeting, a stockholder must also comply with all applicable requirements of the 1934 Act and
the rules and regulations thereunder. Nothing in these Bylaws shall be deemed to affect any rights of stockholders to request inclusion
of proposals in the corporation&rsquo;s proxy statement pursuant to Rule 14a-8 under the 1934 Act; <I>provided, however, </I>that any
references in these Bylaws to the 1934 Act or the rules and regulations thereunder are not intended to and shall not limit the requirements
applicable to proposals and/or nominations to be considered pursuant to Section 5(a)(iii) of these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(h) </B>For
purposes of Sections 5 and 6 of these Bylaws,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 108pt"><B>(i) </B>&ldquo;<B><I>public
announcement</I></B>&rdquo; shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable
national news service or in a document publicly filed by the corporation with the Securities and Exchange Commission pursuant to Section
13, 14 or 15(d) of the 1934 Act; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>(ii) </B>&ldquo;<B><I>affiliates</I></B>&rdquo;
and &ldquo;<B><I>associates</I></B>&rdquo; shall have the meanings set forth in Rule 405 under the Securities Act of 1933, as amended
(the &ldquo;<B><I>1933 Act</I></B>&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 6.&#9;Special Meetings</B>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(a) </B>Special
meetings of the stockholders of the corporation may be called, for any purpose as is a proper matter for stockholder action under Delaware
law, by (i) the Chairman of the Board of Directors, (ii) the Chief Executive Officer, or (iii) the Board of Directors pursuant to a resolution
adopted by a majority of the total number of authorized directors (whether or not there exist any vacancies in previously authorized directorships
at the time any such resolution is presented to the Board of Directors for adoption).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(b) </B>The
Board of Directors shall determine the time and place, if any, of such special meeting. Upon determination of the time and place, if any,
of the meeting, the Secretary shall cause a notice of meeting to be given to the stockholders entitled to vote, in accordance with the
provisions of Section 7 of these Bylaws. No business may be transacted at such special meeting otherwise than specified in the notice
of meeting.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(c) </B>Nominations
of persons for election to the Board of Directors may be made at a special meeting of stockholders at which directors are to be elected
(i) by or at the direction of the Board of Directors or (ii)&nbsp;by any stockholder of the corporation who is a stockholder of record
at the time of giving notice provided for in this paragraph, who shall be entitled to vote at the meeting and who delivers written notice
to the Secretary of the corporation setting forth the information required by Section 5(b)(i) of these Bylaws. In the event the corporation
calls a special meeting of stockholders for the purpose of electing one or more directors to the Board of Directors, any such stockholder
of record may nominate a person or persons (as the case may be), for election to such position(s) as specified in the corporation&rsquo;s
notice of meeting, if written notice setting forth the information required by Section 5(b)(i) of these Bylaws shall be received by the
Secretary at the principal executive offices of the corporation not earlier than the 120<SUP>th</SUP> day prior to such special meeting
and not later than the close of business on the later of the 90<FONT STYLE="font-size: 10pt">th</FONT> day prior to such meeting and the
10<FONT STYLE="font-size: 10pt">th</FONT> day following the day on which notice of the date of such special meeting was mailed or public
announcement is first made of the date of the special meeting and of the nominees proposed by the Board of Directors to be elected at
such meeting, whichever first occurs. The stockholder shall also update and supplement such information as required under Section 5(c)
of these Bylaws. The number of nominees a stockholder may nominate for election at a special meeting shall not exceed the number of directors
to be elected at such meeting. In no event shall an adjournment or a postponement of a special meeting for which notice has been given,
or the public announcement thereof has been made, commence a new time period (or extend any time period) for the giving of a stockholder&rsquo;s
notice as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(d) </B>Notwithstanding
the foregoing provisions of this Section 6, a stockholder must also comply with all applicable requirements of the 1934 Act and the rules
and regulations thereunder with respect to matters set forth in this Section 6. Nothing in these Bylaws shall be deemed to affect any
rights of stockholders to request inclusion of proposals in the corporation&rsquo;s proxy statement pursuant to Rule 14a-8 under the 1934
Act; <I>provided, however, </I>that any references in these Bylaws to the 1934 Act or the rules and regulations thereunder are not intended
to and shall not limit the requirements applicable to nominations for the election to the Board of Directors to be considered pursuant
to Section 6(c) of these Bylaws.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 7.&#9;Notice of Meetings</B>. Except
as otherwise provided by law, notice, given in writing or by electronic transmission, of each meeting of stockholders shall be given not
less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting, such notice to
specify the place, if any, date and hour, in the case of special meetings, the purpose or purposes of the meeting, and the means of remote
communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at any such meeting. If
mailed, notice is deemed given when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder&rsquo;s
address as it appears on the records of the corporation. If sent via electronic transmission, notice is deemed given as of the sending
time recorded at the time of transmission. Notice of the time, place, if any, and purpose of any meeting of stockholders may be waived
in writing, signed by the person entitled to notice thereof, or by electronic transmission by such person, either before or after such
meeting, and will be waived by any stockholder by his attendance thereat in person, by remote communication, if applicable, or by proxy,
except when the stockholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction
of any business because the meeting is not lawfully called or convened. Any stockholder so waiving notice of such meeting shall be bound
by the proceedings of any such meeting in all respects as if due notice thereof had been given.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 8.&#9;Quorum</B>. At all meetings of
stockholders, except where otherwise provided by statute or by the corporation&rsquo;s Second Amended and Restated Certificate of Incorporation
(&ldquo;<B><I>Certificate of Incorporation</I></B>&rdquo;), or by these Bylaws, the presence, in person, by remote communication, if applicable,
or by proxy duly authorized, of the holders of a majority of the outstanding shares of stock entitled to vote shall constitute a quorum
for the transaction of business. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time, either by
the chairman of the meeting or by vote of the holders of a majority of the shares represented thereat, but no other business shall be
transacted at such meeting. The stockholders present at a duly called or convened meeting, at which a quorum is present, may continue
to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Except as otherwise
provided by statute or by applicable stock exchange rules, or by the Certificate of Incorporation or these Bylaws, in all matters other
than the election of directors, the affirmative vote of the majority of shares present in person, by remote communication, if applicable,
or represented by proxy at the meeting and entitled to vote generally on the subject matter shall be the act of the stockholders. Except
as otherwise provided by statute, the Certificate of Incorporation or these Bylaws, directors shall be elected by a plurality of the votes
of the shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally
on the election of directors. Where a separate vote by a class or classes or series is required, except where otherwise provided by the
statute or by the Certificate of Incorporation or these Bylaws, a majority of the outstanding shares of such class or classes or series,
present in person, by remote communication, if applicable, or represented by proxy duly authorized, shall constitute a quorum entitled
to take action with respect to that vote on that matter. Except where otherwise provided by statute or by the Certificate of Incorporation
or these Bylaws, the affirmative vote of the majority (plurality, in the case of the election of directors) of shares of such class or
classes or series present in person, by remote communication, if applicable, or represented by proxy at the meeting shall be the act of
such class or classes or series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 9.&#9;Adjournment and Notice of Adjourned
Meetings</B>. Any meeting of stockholders, whether annual or special, may be adjourned from time to time either by the chairman of the
meeting or by the vote of a majority of the shares present in person, by remote communication, if applicable, or represented by proxy
at the meeting. When a meeting is adjourned to another time or place, if any, notice need not be given of the adjourned meeting if the
time and place, if any, thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the corporation
may transact any business which might have been transacted at the original meeting. If the adjournment is for more than 30 days or if
after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder
of record entitled to vote at the meeting.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 10.&#9;Voting Rights</B>. Each stockholder
shall have one vote upon the matter in question for each share of stock entitled to vote held of record by such stockholder and a proportionate
vote for each fractional share so held, unless otherwise provided by law or by the Certificate of Incorporation. For the purpose of determining
those stockholders entitled to vote at any meeting of the stockholders, except as otherwise provided by law, only persons in whose names
shares stand on the stock records of the corporation on the record date, as provided in Section 12 of these Bylaws, shall be entitled
to vote at any meeting of stockholders. Every person entitled to vote shall have the right to do so either in person, by remote communication,
if applicable, or by an agent or agents authorized by a proxy granted in accordance with Delaware law. An agent so appointed need not
be a stockholder. No proxy shall be voted after three years from its date of creation unless the proxy provides for a longer period.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 11.&#9;Joint Owners of Stock</B>. If
shares or other securities having voting power stand of record in the names of two or more persons, whether fiduciaries, members of a
partnership, joint tenants, tenants in common, tenants by the entirety, or otherwise, or if two or more persons have the same fiduciary
relationship respecting the same shares, unless the Secretary is given written notice to the contrary and is furnished with a copy of
the instrument or order appointing them or creating the relationship wherein it is so provided, their acts with respect to voting shall
have the following effect: (a) if only one votes, his act binds all; (b) if more than one votes, the act of the majority so voting binds
all; or (c) if more than one votes, but the vote is evenly split on any particular matter, each faction may vote the securities in question
proportionally, or may apply to the Delaware Court of Chancery for relief as provided in the DGCL, Section 217(b). If the instrument filed
with the Secretary shows that any such tenancy is held in unequal interests, a majority or even-split for the purpose of clause (c) of
this Section 11 shall be a majority or even-split in interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 12.&#9;List of Stockholders</B>. The
Secretary shall prepare and make, at least 10 days before every meeting of stockholders, a complete list of the stockholders entitled
to vote at said meeting (provided, however, if the record date for determining the stockholders entitled to vote is less than 10 days
before the meeting date, the list shall reflect the stockholders entitled to vote as of the tenth day before the meeting), arranged in
alphabetical order, showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such
list shall be open to the examination of any stockholder, for any purpose germane to the meeting for a period of at least 10 days prior
to the meeting, (a) on a reasonably accessible electronic network, provided that the information required to gain access to such list
is provided with the notice of the meeting, or (b) during ordinary business hours, at the principal place of business of the corporation.
In the event that the corporation determines to make the list available on an electronic network, the corporation may take reasonable
steps to ensure that such information is available only to stockholders of the corporation. The list shall be open to examination of any
stockholder during the time of the meeting as provided by&nbsp;law.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 13.&#9;Action Without Meeting</B>. No
action shall be taken by the stockholders except at an annual or special meeting of stockholders called in accordance with these Bylaws,
and no action shall be taken by the stockholders by written consent or electronic transmission.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 14.&#9;Organization</B>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(a) </B>At
every meeting of stockholders, the Chairman of the Board of Directors, or, if a Chairman has not been appointed or is absent, the President,
or, if the President is absent, if applicable, the Lead Independent Director (as defined below), or, if the Lead Independent Director
is absent, a chairman of the meeting chosen by a majority in interest of the stockholders entitled to vote, present in person or by proxy,
shall act as chairman. The Secretary, or, in his or her absence, an Assistant Secretary directed to do so by the President, shall act
as secretary of the meeting.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(b) </B>The
Board of Directors of the corporation shall be entitled to make such rules or regulations for the conduct of meetings of stockholders
as it shall deem necessary, appropriate or convenient. Subject to such rules and regulations of the Board of Directors, if any, the chairman
of the meeting shall have the right and authority to prescribe such rules, regulations and procedures and to do all such acts as, in the
judgment of such chairman, are necessary, appropriate or convenient for the proper conduct of the meeting, including, without limitation,
establishing an agenda or order of business for the meeting, rules and procedures for maintaining order at the meeting and the safety
of those present, limitations on participation in such meeting to stockholders of record of the corporation and their duly authorized
and constituted proxies and such other persons as the chairman shall permit, restrictions on entry to the meeting after the time fixed
for the commencement thereof, limitations on the time allotted to questions or comments by participants and regulation of the opening
and closing of the polls for balloting on matters which are to be voted on by ballot. The date and time of the opening and closing of
the polls for each matter upon which the stockholders will vote at the meeting shall be announced at the meeting. Unless and to the extent
determined by the Board of Directors or the chairman of the meeting, meetings of stockholders shall not be required to be held in accordance
with rules of parliamentary procedure.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article
IV</FONT><BR>
<BR>
DIRECTORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>Section 15.&#9;Number and Term of Office</B>.
The authorized number of directors of the corporation shall be fixed in accordance with the Certificate of Incorporation. Directors need
not be stockholders unless so required by the Certificate of Incorporation. If for any cause, the directors shall not have been elected
at an annual meeting, they may be elected as soon thereafter as convenient at a special meeting of the stockholders called for that purpose
in the manner provided in these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>Section 16.&#9;Powers</B>. The business and affairs
of the corporation shall be managed by or under the direction of the Board of Directors, except as may be otherwise provided by statute
or by the Certificate of Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>Section 17.&#9;Classes of Directors</B>. Subject
to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the directors
shall be divided into three classes designated as Class I, Class II and Class III, respectively. The Board of Directors is authorized
to assign members of the Board of Directors already in office to such classes at the time the classification becomes effective. At the
first annual meeting of stockholders following the initial classification of the Board of Directors, the term of office of the Class I
directors shall expire and Class I directors shall be elected for a full term of three years. At the second annual meeting of stockholders
following such initial classification, the term of office of the Class II directors shall expire and Class II directors shall be elected
for a full term of three years. At the third annual meeting of stockholders following such initial classification, the term of office
of the Class III directors shall expire and Class III directors shall be elected for a full term of three years. At each succeeding annual
meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire
at such annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt">Notwithstanding the foregoing provisions of this
Section 17, each director shall serve until his or her successor is duly elected and qualified or until his or her earlier death, resignation
or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>Section 18.&#9;Vacancies</B>. Unless otherwise
provided in the Certificate of Incorporation, and subject to the rights of the holders of any series of Preferred Stock, any vacancies
on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships
resulting from any increase in the number of directors shall, unless the Board of Directors determines by resolution that any such vacancies
or newly created directorships shall be filled by stockholders, be filled only by the affirmative vote of a majority of the directors
then in office, even though less than a quorum of the Board of Directors, or by a sole remaining director, and not by the stockholders,
<I>provided, however</I>, that whenever the holders of any class or classes of stock or series thereof are entitled to elect one or more
directors by the provisions of the Certificate of Incorporation, vacancies and newly created directorships of such class or classes or
series shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled
by stockholders, be filled by a majority of the directors elected by such class or classes or series thereof then in office, or by a sole
remaining director so elected, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold
office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&rsquo;s
successor shall have been elected and qualified. A vacancy in the Board of Directors shall be deemed to exist under this Bylaw in the
case of the death, removal or resignation of any director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>Section 19.&#9;Resignation</B>. Any director
may resign at any time by delivering his or her notice in writing or by electronic transmission to the Secretary, such resignation to
specify whether it will be effective at a particular time. If no such specification is made, it shall be deemed effective at the time
of delivery to the Secretary. When one or more directors shall resign from the Board of Directors, effective at a future date, a majority
of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon
to take effect when such resignation or resignations shall become effective, and each director so chosen shall hold office for the unexpired
portion of the term of the director whose place shall be vacated and until his successor shall have been duly elected and qualified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>Section 20.&#9;Removal</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>(a) </B>Subject
to the rights of any series of Preferred Stock to elect additional directors under specified circumstances, neither the Board of Directors
nor any individual director may be removed without cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>(b) </B>Subject to any
limitation imposed by law, any individual director or directors may be removed with cause by the affirmative vote of the holders of at
least 66&frac23;% of the voting power of all then outstanding shares of capital stock of the corporation entitled to vote generally
at an election of directors (provided that as of the three-year anniversary of these Bylaws, such reference to &ldquo;66&frac23;&rdquo; shall be deemed to be &ldquo;50%&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>Section 21.&#9;Meetings</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>(a) Regular
Meetings</B>. Unless otherwise restricted by the Certificate of Incorporation, regular meetings of the Board of Directors may be held
at any time or date and at any place within or without the State of Delaware which has been designated by the Board of Directors and publicized
among all directors, either orally or in writing, by telephone, including a voice-messaging system or other system designed to record
and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic means. No further notice shall be required
for regular meetings of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>(b) Special
Meetings</B>. Unless otherwise restricted by the Certificate of Incorporation, special meetings of the Board of Directors may be held
at any time and place within or without the State of Delaware whenever called by the Chairman of the Board, the Chief Executive Officer
or a majority of the authorized number of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>(c) Meetings
by Electronic Communications Equipment</B>. Any member of the Board of Directors, or of any committee thereof, may participate in a meeting
by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear
each other, and participation in a meeting by such means shall constitute presence in person at such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>(d) Notice
of Special Meetings</B>. Notice of the time and place of all special meetings of the Board of Directors shall be given orally or in writing,
by telephone, including a voice messaging system or other system or technology designed to record and communicate messages, facsimile,
telegraph or telex, or by electronic mail or other electronic means, during normal business hours, at least 24 hours before the date and
time of the meeting. If notice is sent by U.S. mail, it shall be sent by first class mail, charges prepaid, at least three days before
the date of the meeting. Notice of any meeting may be waived in writing, or by electronic transmission, at any time before or after the
meeting and will be waived by any director by attendance thereat, except when the director attends the meeting for the express purpose
of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(e) Waiver
of Notice</B>. The transaction of all business at any meeting of the Board of Directors, or any committee thereof, however called or noticed,
or wherever held, shall be as valid as though it had been transacted at a meeting duly held after regular call and notice, if a quorum
be present and if, either before or after the meeting, each of the directors not present who did not receive notice shall sign a written
waiver of notice or shall waive notice by electronic transmission. All such waivers shall be filed with the corporate records or made
a part of the minutes of the meeting.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 22.&#9;Quorum and Voting</B>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(a) </B>Unless
the Certificate of Incorporation requires a greater number, and except with respect to questions related to indemnification arising under
Section 47 of these Bylaws for which a quorum shall be one-third of the exact number of directors fixed from time to time, a quorum of
the Board of Directors shall consist of a majority of the exact number of directors fixed from time to time by the Board of Directors
in accordance with the Certificate of Incorporation; <I>provided, however,</I> at any meeting whether a quorum be present or otherwise,
a majority of the directors present may adjourn from time to time until the time fixed for the next regular meeting of the Board of Directors,
without notice other than by announcement at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(b) </B>At
each meeting of the Board of Directors at which a quorum is present, all questions and business shall be determined by the affirmative
vote of a majority of the directors present, unless a different vote be required by law, the Certificate of Incorporation or these Bylaws.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 23.&#9;Action Without Meeting</B>. Unless
otherwise restricted by the Certificate of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting
of the Board of Directors or of any committee thereof may be taken without a meeting, if all members of the Board of Directors or committee,
as the case may be, consent thereto in writing or by electronic transmission, and such writing or writings or transmission or transmissions
are filed with the minutes of proceedings of the Board of Directors or committee. Such filing shall be in paper form if the minutes are
maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 24.&#9;Fees and Compensation</B>. Directors
shall be entitled to such compensation for their services as may be approved by the Board of Directors, including, if so approved, by
resolution of the Board of Directors, a fixed sum and expenses of attendance, if any, for attendance at each regular or special meeting
of the Board of Directors and at any meeting of a committee of the Board of Directors. Nothing herein contained shall be construed to
preclude any director from serving the corporation in any other capacity as an officer, agent, employee, or otherwise and receiving compensation
therefor.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 25.&#9;Committees</B>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(a) Executive
Committee</B>. The Board of Directors may appoint an Executive Committee to consist of one or more members of the Board of Directors.
The Executive Committee, to the extent permitted by law and provided in the resolution of the Board of Directors shall have and may exercise
all the powers and authority of the Board of Directors in the management of the business and affairs of the corporation, and may authorize
the seal of the corporation to be affixed to all papers which may require it; but no such committee shall have the power or authority
in reference to (i) approving or adopting, or recommending to the stockholders, any action or matter (other than the election or removal
of directors) expressly required by the DGCL to be submitted to stockholders for approval, or (ii) adopting, amending or repealing any
Bylaw of the corporation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(b) Other
Committees</B>. The Board of Directors may, from time to time, appoint such other committees as may be permitted by law. Such other committees
appointed by the Board of Directors shall consist of one or more members of the Board of Directors and shall have such powers and perform
such duties as may be prescribed by the resolution or resolutions creating such committees, but in no event shall any such committee have
the powers denied to the Executive Committee in these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>(c) Term</B>.
The Board of Directors, subject to any requirements of any outstanding series of Preferred Stock and the provisions of subsections (a)
or (b) of this Section 25, may at any time increase or decrease the number of members of a committee or terminate the existence of a committee.
The membership of a committee member shall terminate on the date of his death or voluntary resignation from the committee or from the
Board of Directors. The Board of Directors may at any time for any reason remove any individual committee member and the Board of Directors
may fill any committee vacancy created by death, resignation, removal or increase in the number of members of the committee. The Board
of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member
at any meeting of the committee, and, in addition, in the absence or disqualification of any member of a committee, the member or members
thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint
another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>(d) Meetings</B>.
Unless the Board of Directors shall otherwise provide, regular meetings of the Executive Committee or any other committee appointed pursuant
to this Section 25 shall be held at such times and places as are determined by the Board of Directors, or by any such committee, and when
notice thereof has been given to each member of such committee, no further notice of such regular meetings need be given thereafter. Special
meetings of any such committee may be held at any place which has been determined from time to time by such committee, and may be called
by any director who is a member of such committee, upon notice to the members of such committee of the time and place of such special
meeting given in the manner provided for the giving of notice to members of the Board of Directors of the time and place of special meetings
of the Board of Directors. Notice of any special meeting of any committee may be waived in writing or by electronic transmission at any
time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends such special
meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting
is not lawfully called or convened. Unless otherwise provided by the Board of Directors in the resolutions authorizing the creation of
the committee, a majority of the authorized number of members of any such committee shall constitute a quorum for the transaction of business,
and the act of a majority of those present at any meeting at which a quorum is present shall be the act of such committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>Section 26.&#9;Duties of Chairman of the Board
of Directors</B>. The Chairman of the Board of Directors, when present, shall preside at all meetings of the stockholders and the Board
of Directors. The Chairman of the Board of Directors shall perform other duties commonly incident to the office and shall also perform
such other duties and have such other powers as the Board of Directors shall designate from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>Section 27.&#9;Lead Independent Director</B>.
The Chairman of the Board of Directors, or if the Chairman is not an independent director, one of the independent directors, may be designated
by the Board of Directors as lead independent director (&ldquo;<B><I>Lead Independent Director</I></B>&rdquo;) to serve until replaced
by the Board of Directors. The Lead Independent Director will: with the Chairman of the Board of Directors, establish the agenda for regular
Board meetings and serve as chairman of Board of Directors meetings in the absence of the Chairman of the Board of Directors; establish
the agenda for meetings of the independent directors; coordinate with the committee chairs regarding meeting agendas and informational
requirements; preside over meetings of the independent directors; preside over any portions of meetings of the Board of Directors at which
the evaluation or compensation of the Chief Executive Officer is presented or discussed; preside over any portions of meetings of the
Board of Directors at which the performance of the Board of Directors is presented or discussed; and perform such other duties as may
be established or delegated by the Chairman of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>Section 28.&#9;Organization</B>. At every meeting
of the directors, the Chairman of the Board of Directors, or, if a Chairman has not been appointed or is absent, the Lead Independent
Director, or if the Lead Independent Director is absent, the Chief Executive Officer (if a director), or, if the Chief Executive Officer
is absent, the President (if a director), or if the President is absent, the most senior Vice President (if a director), or, in the absence
of any such person, a chairman of the meeting chosen by a majority of the directors present, shall preside over the meeting. The Secretary,
or in his absence, any Assistant Secretary or other officer or director directed to do so by the Chairman, shall act as secretary of the
meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>Section 29.&#9;Emergency Bylaws</B>. In the event
of any emergency, disaster, catastrophe or other similar emergency condition of a type described in Section 1100(a) of the DGCL (an &ldquo;<B><I>Emergency</I></B>&rdquo;),
notwithstanding any different or conflicting provisions in the Certificate of Incorporation or these Bylaws, during an Emergency:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>(a) Notice</B>.
A meeting of the Board of Directors, the Executive Committee or any other committee appointed pursuant to Section 25 may be called by
any directors, the Chairman of the Board, the Chief Executive Officer, the President or the Secretary by any such means as, in the judgment
of the person calling the meeting, may be feasible at the time, and notice of any such meeting of the Board of Directors, the Executive
Committee or any other committee appointed pursuant to Section 25 may be given, in the judgment of the person calling the meeting, only
to such directors as it may be feasible to reach at the time and by such means as may be feasible at the time. Such notice shall be given
at such time in advance of the meeting as, in the judgement of the person calling the meeting, circumstances permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>(b) Quorum</B>.
The director or directors in attendance at a meeting called in accordance with Section 29(a) shall constitute a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>(c) Liability</B>.
No officer, director or employee acting in accordance with this Section 29 shall be liable except for willful misconduct. No amendment,
repeal or change to this Section 29 shall modify the prior sentence with regard to actions taken prior to the time of such amendment,
repeal or change.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article
V</FONT><BR>
<BR>
OFFICERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>Section 30.&#9;Officers Designated</B>. The officers
of the corporation shall include, if and when designated by the Board of Directors, the Chairman of the Board of Directors, the Chief
Executive Officer, the President, one or more Vice Presidents, the Secretary, the Chief Financial Officer and the Treasurer. The Board
of Directors may also appoint one or more Assistant Secretaries and Assistant Treasurers and such other officers and agents with such
powers and duties as it shall deem necessary. The Board of Directors may assign such additional titles to one or more of the officers
as it shall deem appropriate. Any one person may hold any number of offices of the corporation at any one time unless specifically prohibited
therefrom by law. The salaries and other compensation of the officers of the corporation shall be fixed by or in the manner designated
by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>Section 31.&#9;Tenure and Duties of Officers</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>(a) General</B>.
All officers shall hold office at the pleasure of the Board of Directors and until their successors shall have been duly elected and qualified,
unless sooner removed. Any officer elected or appointed by the Board of Directors may be removed at any time by the Board of Directors.
If the office of any officer becomes vacant for any reason, the vacancy may be filled by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>(b) Duties
of Chief Executive Officer</B>. The Chief Executive Officer shall preside at all meetings of the stockholders and at all meetings of the
Board of Directors, unless the Chairman of the Board of Directors or the Lead Independent Director has been appointed and is present.
Unless an officer has been appointed Chief Executive Officer of the corporation, the President shall be the Chief Executive Officer of
the corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of the business
and officers of the corporation. To the extent that a Chief Executive Officer has been appointed and no President has been appointed,
all references in these Bylaws to the President shall be deemed references to the Chief Executive Officer. The Chief Executive Officer
shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the
Board of Directors shall designate from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(c) Duties
of President</B>. The President shall preside at all meetings of the stockholders and at all meetings of the Board of Directors, unless
the Chairman of the Board of Directors, the Lead Independent Director, or the Chief Executive Officer has been appointed and is present.
Unless another officer has been appointed Chief Executive Officer of the corporation, the President shall be the Chief Executive Officer
of the corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of the
business and officers of the corporation. The President shall perform other duties commonly incident to the office and shall also perform
such other duties and have such other powers as the Board of Directors shall designate from time to time.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(d) Duties
of Vice Presidents</B>. The Vice Presidents may assume and perform the duties of the President in the absence or disability of the President
or whenever the office of President is vacant. The Vice Presidents shall perform other duties commonly incident to their office and shall
also perform such other duties and have such other powers as the Board of Directors or the Chief Executive Officer, or, if the Chief Executive
Officer has not been appointed or is absent, the President shall designate from time to time.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(e) Duties
of Secretary</B>. The Secretary shall attend all meetings of the stockholders and of the Board of Directors and shall record all acts
and proceedings thereof in the minute book of the corporation. The Secretary shall give notice in conformity with these Bylaws of all
meetings of the stockholders and of all meetings of the Board of Directors and any committee thereof requiring notice. The Secretary shall
perform all other duties provided for in these Bylaws and other duties commonly incident to the office and shall also perform such other
duties and have such other powers as the Board of Directors shall designate from time to time. The President may direct any Assistant
Secretary or other officer to assume and perform the duties of the Secretary in the absence or disability of the Secretary, and each Assistant
Secretary shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers
as the Board of Directors or the President shall designate from time to time.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(f) Duties
of Chief Financial Officer</B>. The Chief Financial Officer shall keep or cause to be kept the books of account of the corporation in
a thorough and proper manner and shall render statements of the financial affairs of the corporation in such form and as often as required
by the Board of Directors or the President. The Chief Financial Officer, subject to the order of the Board of Directors, shall have the
custody of all funds and securities of the corporation. The Chief Financial Officer shall perform other duties commonly incident to the
office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate
from time to time. To the extent that a Chief Financial Officer has been appointed and no Treasurer has been appointed, all references
in these Bylaws to the Treasurer shall be deemed references to the Chief Financial Officer. The President may direct the Treasurer, if
any, or any Assistant Treasurer, or the Controller or any Assistant Controller to assume and perform the duties of the Chief Financial
Officer in the absence or disability of the Chief Financial Officer, and each Treasurer and Assistant Treasurer and each Controller and
Assistant Controller shall perform other duties commonly incident to the office and shall also perform such other duties and have such
other powers as the Board of Directors or the President shall designate from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(g) Duties
of Treasurer</B>. Unless another officer has been appointed Chief Financial Officer of the corporation, the Treasurer shall be the chief
financial officer of the corporation and shall keep or cause to be kept the books of account of the corporation in a thorough and proper
manner and shall render statements of the financial affairs of the corporation in such form and as often as required by the Board of Directors
or the President, and, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the corporation.
The Treasurer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other
powers as the Board of Directors or the President shall designate from time to time.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 32.&#9;Delegation of Authority</B>. The
Board of Directors may from time to time delegate the powers or duties of any officer to any other officer or agent, notwithstanding any
provision hereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 33.&#9;Salaries</B>. Officers of the
corporation shall be entitled to such salaries, compensation or reimbursement as shall be fixed or allowed from time to time by the Board
of Directors.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 34.&#9;Resignations</B>. Any officer
may resign at any time by giving notice in writing or by electronic transmission to the Board of Directors or to the President or to the
Secretary. Any such resignation shall be effective when received by the person or persons to whom such notice is given, unless a later
time is specified therein, in which event the resignation shall become effective at such later time. Unless otherwise specified in such
notice, the acceptance of any such resignation shall not be necessary to make it effective. Any resignation shall be without prejudice
to the rights, if any, of the corporation under any contract with the resigning officer.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 35.&#9;Removal</B>. Any officer may be
removed from office at any time, either with or without cause, by the affirmative vote of a majority of the directors in office at the
time, or by the unanimous written consent of the directors in office at the time, or by any committee or by the Chief Executive Officer
or by other superior officers upon whom such power of removal may have been conferred by the Board of Directors.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article
VI</FONT><BR>
<BR>
EXECUTION OF CORPORATE INSTRUMENTS AND VOTING OF SECURITIES OWNED BY THE CORPORATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 36.&#9;Execution of Corporate Instruments</B>.
The Board of Directors may, in its discretion, determine the method and designate the signatory officer or officers, or other person or
persons, to execute on behalf of the corporation any corporate instrument or document, or to sign on behalf of the corporation the corporate
name without limitation, or to enter into contracts on behalf of the corporation, except where otherwise provided by law or these Bylaws,
and such execution or signature shall be binding upon the corporation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">All checks and drafts drawn on banks or other depositaries
on funds to the credit of the corporation or in special accounts of the corporation shall be signed by such person or persons as the Board
of Directors shall authorize so to do.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Unless authorized or ratified by the Board of Directors
or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the corporation by any
contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>Section 37.&#9;Voting of Securities Owned by
the Corporation</B>. All stock and other securities of other corporations owned or held by the corporation for itself, or for other parties
in any capacity, shall be voted, and all proxies with respect thereto shall be executed, by the person authorized so to do by resolution
of the Board of Directors, or, in the absence of such authorization, by the Chairman of the Board of Directors, the Chief Executive Officer,
the President, or any Vice President.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article
VII</FONT><BR>
<BR>
SHARES OF STOCK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 38.&#9;Form and Execution of Certificates</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(a) </B>The
shares of the corporation shall be represented by certificates, or shall be uncertificated if so provided by resolution or resolutions
of the Board of Directors. Certificates for the shares of stock of the corporation, if any, shall be in such form as is consistent with
the Certificate of Incorporation and applicable law. Every holder of stock represented by certificate in the corporation shall be entitled
to have a certificate signed by or in the name of the corporation by the Chairman of the Board of Directors, the Chief Executive Officer,
or the President or any Vice President and by the Chief Financial Officer, Treasurer or Assistant Treasurer or the Secretary or Assistant
Secretary, certifying the number of shares owned by him in the corporation. Any or all of the signatures on the certificate may be facsimiles.
In case any officer, transfer agent, or registrar who has signed or whose facsimile signature has been placed upon a certificate shall
have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it may be issued with the same effect
as if he were such officer, transfer agent, or registrar at the date of issue.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(b) </B>Each
certificate for shares of stock of the corporation that are subject to any restriction on transfer pursuant to the Certificate of Incorporation,
these Bylaws, applicable securities laws or any agreement among any number of stockholders or among such holders and the corporation shall
have conspicuously noted on the face or back of the certificate either the full text of the restriction or a statement of the existence
of such restriction.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(c) </B>If
the corporation shall be authorized to issue more than one class of stock or more than one series of any class, the powers, designations,
preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications,
limitations or restrictions of such preferences and/or rights shall be set forth in full or summarized on the face or back of each certificate
representing shares of such class or series of stock, provided that in lieu of the foregoing requirements there may be set forth on the
face or back of each certificate representing shares of such class or series of stock a statement that the corporation will furnish without
charge to each stockholder who so requests a copy of the full text of the powers, designations, preferences and relative, participating,
optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such
preferences and/or rights.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>Section 39.&#9;Lost Certificates</B>. A new certificate
or certificates shall be issued in place of any certificate or certificates theretofore issued by the corporation alleged to have been
lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen,
or destroyed. The corporation may require, as a condition precedent to the issuance of a new certificate or certificates, the owner of
such lost, stolen, or destroyed certificate or certificates, or the owner&rsquo;s legal representative, to agree to indemnify the corporation
in such manner as it shall require or to give the corporation a surety bond in such form and amount as it may direct as indemnity against
any claim that may be made against the corporation with respect to the certificate alleged to have been lost, stolen, or destroyed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>Section 40.&#9;Transfers</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>(a) </B>Transfers
of record of shares of stock of the corporation shall be made only upon its books by the holders thereof, in person or by attorney duly
authorized, and, in the case of stock represented by certificate, upon the surrender of a properly endorsed certificate or certificates
for a like number of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>(b) </B>The
corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes of stock
of the corporation to restrict the transfer of shares of stock of the corporation of any one or more classes owned by such stockholders
in any manner not prohibited by the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>Section 41.&#9;Fixing Record Dates</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>(a) </B>In
order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment
thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the
record date is adopted by the Board of Directors, and which record date shall, subject to applicable law, not be more than 60 nor less
than 10 days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders
entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which
notice is given, or if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination
of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting;
<I>provided, however,</I> that the Board of Directors may fix a new record date for the adjourned meeting,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"><B>(b) </B>In
order that the corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment
of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the
purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which record date shall not precede the
date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action.
If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the
day on which the Board of Directors adopts the resolution relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>Section 42.&#9;Registered Stockholders</B>. The
corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends,
and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on
the part of any other person whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of
Delaware.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article
VIII</FONT><BR>
<BR>
OTHER SECURITIES OF THE CORPORATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 43.&#9;Execution of Other Securities</B>.
All bonds, debentures and other corporate securities of the corporation, other than stock certificates (covered in Section 38 of these
Bylaws), may be signed by the Chairman of the Board of Directors, the Chief Executive Officer, the President or any Vice President, or
such other person as may be authorized by the Board of Directors, and the corporate seal impressed thereon or a facsimile of such seal
imprinted thereon and attested by the signature of the Secretary or an Assistant Secretary, or the Chief Financial Officer or Treasurer
or an Assistant Treasurer; <I>provided, however,</I> that where any such bond, debenture or other corporate security shall be authenticated
by the manual signature, or where permissible facsimile signature, of a trustee under an indenture pursuant to which such bond, debenture
or other corporate security shall be issued, the signatures of the persons signing and attesting the corporate seal on such bond, debenture
or other corporate security may be the imprinted facsimile of the signatures of such persons. Interest coupons appertaining to any such
bond, debenture or other corporate security, authenticated by a trustee as aforesaid, shall be signed by the Treasurer or an Assistant
Treasurer of the corporation or such other person as may be authorized by the Board of Directors, or bear imprinted thereon the facsimile
signature of such person. In case any officer who shall have signed or attested any bond, debenture or other corporate security, or whose
facsimile signature shall appear thereon or on any such interest coupon, shall have ceased to be such officer before the bond, debenture
or other corporate security so signed or attested shall have been delivered, such bond, debenture or other corporate security nevertheless
may be adopted by the corporation and issued and delivered as though the person who signed the same or whose facsimile signature shall
have been used thereon had not ceased to be such officer of the corporation.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article
IX</FONT><BR>
<BR>
DIVIDENDS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 44.&#9;Declaration of Dividends</B>.
Dividends upon the capital stock of the corporation, subject to the provisions of the Certificate of Incorporation and applicable law,
if any, may be declared by the Board of Directors pursuant to law at any regular or special meeting. Dividends may be paid in cash, in
property, or in shares of the capital stock, subject to the provisions of the Certificate of Incorporation and applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>Section 45.&#9;Dividend Reserve</B>. Before payment
of any dividend, there may be set aside out of any funds of the corporation available for dividends such sum or sums as the Board of Directors
from time to time, in their absolute discretion, think proper as a reserve or reserves to meet contingencies, or for equalizing dividends,
or for repairing or maintaining any property of the corporation, or for such other purpose as the Board of Directors shall think conducive
to the interests of the corporation, and the Board of Directors may modify or abolish any such reserve in the manner in which it was created.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article
X</FONT><BR>
<BR>
FISCAL YEAR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>Section 46.&#9;Fiscal Year</B>. The fiscal year
of the corporation shall be fixed by resolution of the Board of Directors.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article
XI</FONT><BR>
<BR>
INDEMNIFICATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 47.&#9;Indemnification of Directors,
Officers, Employees and Other Agents</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(a) Directors and Officers</B>.
The corporation shall indemnify its directors and officers to the extent not prohibited by the DGCL or any other applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(b) Employees
and Other Agents</B>. The corporation shall have power to indemnify its employees and other agents as set forth in the DGCL or any other
applicable law. The Board of Directors shall have the power to delegate the determination of whether indemnification shall be given to
any such person (except for officers) or other persons as the Board of Directors shall determine.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(c) Expenses</B>.
The corporation shall advance to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed
action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was a director
or officer of the corporation, or is or was serving at the request of the corporation as a director or officer of another corporation,
partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request therefor,
all expenses incurred by any director or officer in connection with such proceeding provided, however, that if the DGCL requires, an advancement
of expenses incurred by a director or officer in his or her capacity as a director or officer (and not in any other capacity in which
service was or is rendered by such indemnitee, including, without limitation, service to an employee benefit plan) shall be made only
upon delivery to the corporation of an undertaking (hereinafter an &ldquo;<B><I>undertaking</I></B>&rdquo;), by or on behalf of such indemnitee,
to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right
to appeal (hereinafter a &ldquo;<B><I>final adjudication</I></B>&rdquo;) that such indemnitee is not entitled to be indemnified for such
expenses under this Section 47 or otherwise.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Notwithstanding the foregoing, unless otherwise
determined pursuant to paragraph (e) of this Section 47, no advance shall be made by the corporation to an officer of the corporation
(except by reason of the fact that such officer is or was a director of the corporation in which event this paragraph shall not apply)
in any action, suit or proceeding, whether civil, criminal, administrative or investigative, if a determination is reasonably and promptly
made (i) by a majority vote of directors who were not parties to the proceeding, even if not a quorum, or (ii) by a committee of such
directors designated by a majority vote of such directors, even though less than a quorum, or (iii)&nbsp;if there are no such directors,
or such directors so direct, by independent legal counsel in a written opinion, that the facts known to the decision-making party at the
time such determination is made demonstrate clearly and convincingly that such person acted in bad faith or in a manner that such person
did not believe to be in or not opposed to the best interests of the corporation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(d) Enforcement</B>.
Without the necessity of entering into an express contract, all rights to indemnification and advances to directors and officers under
this Section 47 shall be deemed to be contractual rights and be effective to the same extent and as if provided for in a contract between
the corporation and the director or officer. If a claim is not paid in full by the Corporation within 60 days after a written claim therefor has been received by the Corporation,
except in the case of a claim for an advancement of expenses, in which case the applicable period shall be 20 days, the Indemnitee may
at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim. To the extent
permitted by law, the claimant in such enforcement action, if successful in whole or in part, shall be entitled to be paid also the expense
of prosecuting the claim. In connection with any claim for indemnification, the corporation shall be entitled to raise as a defense to
any such action that the claimant has not met the standards of conduct that make it permissible under the DGCL or any other applicable
law for the corporation to indemnify the claimant for the amount claimed. In connection with any claim by an officer of the corporation
(except in any action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such officer
is or was a director of the corporation) for advances, the corporation shall be entitled to raise a defense as to any such action clear
and convincing evidence that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to
the best interests of the corporation, or with respect to any criminal action or proceeding that such person acted without reasonable
cause to believe that his conduct was lawful. Neither the failure of the corporation (including its Board of Directors, independent legal
counsel or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant
is proper in the circumstances because the director or officer has met the applicable standard of conduct set forth in the DGCL or any
other applicable law, nor an actual determination by the corporation (including its Board of Directors, independent legal counsel or its
stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption
that claimant has not met the applicable standard of conduct. In any suit brought by a director or officer to enforce a right to indemnification
or to an advancement of expenses hereunder, the burden of proving that the director or officer is not entitled to be indemnified, or to
such advancement of expenses, under this Section 47 or otherwise shall be on the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(e) Non-Exclusivity
of Rights</B>. The rights conferred on any person by this Bylaw shall not be exclusive of any other right which such person may have or
hereafter acquire under any applicable statute, provision of the Certificate of Incorporation, Bylaws, agreement, vote of stockholders
or disinterested directors or otherwise, both as to action in such person&rsquo;s official capacity and as to action in another capacity
while holding office. The corporation is specifically authorized to enter into individual contracts with any or all of its directors,
officers, employees or agents respecting indemnification and advances, to the fullest extent not prohibited by the DGCL, or by any other
applicable law.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(f) Survival
of Rights</B>. The rights conferred on any person by this Bylaw shall continue as to a person who has ceased to be a director or officer,
or, if applicable, employee or other agent, and shall inure to the benefit of the heirs, executors and administrators of such a person.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(g) Insurance</B>.
To the fullest extent permitted by the DGCL or any other applicable law, the corporation, upon approval by the Board of Directors, may
purchase insurance on behalf of any person required or permitted to be indemnified pursuant to this Section 47.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(h) Amendments</B>.
Any repeal or modification of this Section 47 shall only be prospective (except to the extent such amendment or change in applicable law permits the corporation to provide broader indemnification rights to
Indemnitees on a retroactive basis than permitted prior thereto) and shall not affect the rights under this Bylaw in effect
at the time of the alleged occurrence of any action or omission to act that is the cause of any proceeding against any agent of the
corporation in respect of any act or omission occurring prior to such repeal or amendment or adoption of such inconsistent provision; provided however,
that amendments or repeals of this Article XI shall require the affirmative vote of the stockholders holding at least 66.7% of the voting
power of all outstanding shares of capital stock of the corporation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(i) Saving
Clause</B>. If this Bylaw or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the corporation
shall nevertheless indemnify each director and officer to the full extent not prohibited by any applicable portion of this Section 47
that shall not have been invalidated, or by any other applicable law. If this Section 47 shall be invalid due to the application of the
indemnification provisions of another jurisdiction, then the corporation shall indemnify each director and officer to the full extent
under any other applicable law.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(j) Certain
Definitions</B>. For the purposes of this Bylaw, the following definitions shall apply:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>(i) </B>The
term &ldquo;<B><I>proceeding</I></B>&rdquo; shall be broadly construed and shall include, without limitation, the investigation, preparation,
prosecution, defense, settlement, arbitration and appeal of, and the giving of testimony in, any threatened, pending or completed action,
suit or proceeding, whether civil, criminal, administrative or investigative.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>(ii) </B>The term
&ldquo;<B><I>expenses</I></B>&rdquo; shall be broadly construed and shall include, without limitation, court costs, attorneys&rsquo;
fees, witness fees, fines, ERISA excise taxes, penalties, amounts paid in settlement or judgment and any other costs and expenses of
any nature or kind incurred in connection with any proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>(iii) </B>The
term the &ldquo;<B><I>corporation</I></B>&rdquo; shall include, in addition to the resulting corporation, any constituent corporation
(including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would
have had power and authority to indemnify its directors, officers, and employees or agents, so that any person who is or was a director,
officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director,
officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position
under the provisions of this Section 47 with respect to the resulting or surviving corporation as he would have with respect to such constituent
corporation if its separate existence had continued.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>(iv) </B>References
to a &ldquo;<B><I>director</I></B>,&rdquo; &ldquo;<B><I>officer</I></B>,&rdquo; &ldquo;<B><I>employee</I></B>,&rdquo; or &ldquo;<B><I>agent</I></B>&rdquo;
of the corporation shall include, without limitation, situations where such person is serving at the request of the corporation as, respectively,
a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 108pt"><B>(v) </B>References
to &ldquo;<B><I>other enterprises</I></B>&rdquo; shall include employee benefit plans; references to &ldquo;<B><I>fines</I></B>&rdquo;
shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to &ldquo;<B><I>serving at
the request of the corporation</I></B>&rdquo; shall include any service as a director, officer, employee or agent of the corporation which
imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants,
or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants
and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &ldquo;<B><I>not opposed to the best interests
of the corporation</I></B>&rdquo; as referred to in this Section 47.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt"><B>(k)</B> <B>Severability</B>.
If any provision or provisions of this Article XI shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a)
the validity, legality and enforceability of the remaining provisions of this Article XI shall not in any way be affected or impaired
thereby; and (b) to the fullest extent possible, the provisions of this Article XI (including, without limitation, each such portion
of this Article XI containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to give effect
to the intent manifested by the provision held invalid, illegal or unenforceable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article
XII</FONT><BR>
<BR>
NOTICES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 36pt"><B>Section 48.&#9;Notices</B>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(a) Notice
to Stockholders</B>. Written notice to stockholders of stockholder meetings shall be given as provided in Section 7 of these Bylaws. Without
limiting the manner by which notice may otherwise be given effectively to stockholders under any agreement or contract with such stockholder,
and except as otherwise required by law, written notice to stockholders for purposes other than stockholder meetings may be sent by U.S.
mail or nationally recognized overnight courier, or by facsimile, telegraph or telex, or by electronic mail or other electronic means.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(b) Notice
to Directors</B>. Any notice required to be given to any director may be given by the method stated in subsection (a), as otherwise provided
in these Bylaws, or by overnight delivery service, facsimile, telex or telegram, except that such notice other than one which is delivered
personally shall be sent to such address as such director shall have filed in writing with the Secretary, or, in the absence of such filing,
to the last known post office address of such director.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(c) Affidavit
of Mailing</B>. An affidavit of mailing, executed by a duly authorized and competent employee of the corporation or its transfer agent
appointed with respect to the class of stock affected, or other agent, specifying the name and address or the names and addresses of the
stockholder or stockholders, or director or directors, to whom any such notice or notices was or were given, and the time and method of
giving the same, shall in the absence of fraud, be prima facie evidence of the facts therein contained.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(d) Methods
of Notice</B>. It shall not be necessary that the same method of giving notice be employed in respect of all recipients of notice, but
one permissible method may be employed in respect of any one or more, and any other permissible method or methods may be employed in respect
of any other or others.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(e) Notice
to Person With Whom Communication is Unlawful</B>. Whenever notice is required to be given, under any provision of law or of the Certificate
of Incorporation or Bylaws of the corporation, to any person with whom communication is unlawful, the giving of such notice to such person
shall not be required and there shall be no duty to apply to any governmental authority or agency for a license or permit to give such
notice to such person. Any action or meeting which shall be taken or held without notice to any such person with whom communication is
unlawful shall have the same force and effect as if such notice had been duly given. In the event that the action taken by the corporation
is such as to require the filing of a certificate under any provision of the DGCL, the certificate shall state, if such is the fact and
if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is
unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(f) Notice
to Stockholders Sharing an Address</B>. Except as otherwise prohibited under the DGCL, any notice given under the provisions of the DGCL,
the Certificate of Incorporation or the Bylaws shall be effective if given by a single written notice to stockholders who share an address
if consented to by the stockholders at that address to whom such notice is given. Such consent shall have been deemed to have been given
if such stockholder fails to object in writing to the corporation within 60 days of having been given notice by the corporation of its
intention to send the single notice. Any consent shall be revocable by the stockholder by written notice to the corporation.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article
XIII</FONT><BR>
<BR>
AMENDMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 49.&#9;Amendments</B>.
Subject to the limitations set forth in Section 47(h) of these Bylaws or the provisions of the Certificate of Incorporation, the Board
of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the corporation. Any adoption, amendment or repeal of the
Bylaws of the corporation by the Board of Directors shall require the approval of a majority of the authorized number of directors. The
stockholders also shall have power to adopt, amend or repeal the Bylaws of the corporation; <I>provided, however, </I>that, in addition
to any vote of the holders of any class or series of stock of the corporation required by law or by the Certificate of Incorporation,
such action by stockholders shall require the affirmative vote of the holders of at least 66&frac23;% of the voting power of all
of the then-outstanding shares of the capital stock of the corporation entitled to vote generally in the election of directors, voting
together as a single class (provided that as of the three-year anniversary of these Bylaws, such reference to &ldquo;66&frac23;&rdquo; shall be deemed to be &ldquo;50%&rdquo;).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article
XIV</FONT><BR>
<BR>
LOANS TO OFFICERS OR EMPLOYEES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 50.&#9;Loans to Officers or Employees</B>.
Except as otherwise prohibited by applicable law, the corporation may lend money to, or guarantee any obligation of, or otherwise assist
any officer or other employee of the corporation or of its subsidiaries, including any officer or employee who is a director of the corporation
or its subsidiaries, whenever, in the judgment of the Board of Directors, such loan, guarantee or assistance may reasonably be expected
to benefit the corporation. The loan, guarantee or other assistance may be with or without interest and may be unsecured, or secured in
such manner as the Board of Directors shall approve, including, without limitation, a pledge of shares of stock of the corporation. Nothing
in these Bylaws shall be deemed to deny, limit or restrict the powers of guaranty or warranty of the corporation at common law or under
any statute.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article
XV</FONT><BR>
<BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><B>Section 51.&#9;Forum</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(a) </B>Unless
the corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and
only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of
Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware)
and any appellate court therefrom shall be the sole and exclusive forum for the following claims or causes of action under the Delaware
statutory or common law: (i) any derivative claim or cause of action brought on behalf of the corporation; (ii) any claim or cause of
action for breach of a fiduciary duty owed by any current or former director, officer or other employee of the corporation, to the corporation
or the corporation&rsquo;s stockholders; (iii) any claim or cause of action against the corporation or any current or former director,
officer or other employee of the corporation, arising out of or pursuant to any provision of the DGCL, the Certificate of Incorporation
or the Bylaws of the corporation (as each may be amended from time to time); (iv) any claim or cause of action seeking to interpret, apply,
enforce or determine the validity of the Certificate of Incorporation or the Bylaws of the corporation (as each may be amended from time
to time, including any right, obligation, or remedy thereunder); (v) any claim or cause of action as to which the DGCL confers jurisdiction
on the Court of Chancery of the State of Delaware; and (vi) any claim or cause of action against the corporation or any current or former
director, officer or other employee of the corporation, governed by the internal-affairs doctrine or otherwise related to the corporation&rsquo;s
internal affairs, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable
parties named as defendants. This Section 51 of Article XV shall not apply to claims or causes of action brought to enforce a duty or
liability created by the 1933 Act, the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have
exclusive jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(b) </B>Unless
the corporation consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district
courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising
under the 1933 Act, including all causes of action asserted against any defendant named in such complaint. For the avoidance of doubt,
this provision is intended to benefit and may be enforced by the corporation, its officers and directors, the underwriters for any offering
giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or
entity and who has prepared or certified any part of the documents underlying the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"><B>(c) </B>Any
person or entity holding, owning or otherwise acquiring any interest in any security of the corporation shall be deemed to have notice
of and consented to the provisions of these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">20</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 72pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>ea147929ex10-2_jasper.htm
<DESCRIPTION>AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT, DATED SEPTEMBER 24, 2021, BY AND AMONG JASPER THERAPEUTICS, INC. AND THE STOCKHOLDERS PARTY THERETO
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exhibit
10.2</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">AMENDED
AND RESTATED</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">REGISTRATION
RIGHTS AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">THIS
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this &ldquo;<B><I>Agreement</I></B>&rdquo;), dated as of September 24, 2021, is made
and entered into by and among Jasper Therapeutics, Inc. (f/k/a Amplitude Healthcare Acquisition Corporation), a Delaware corporation
(the &ldquo;<B><I>Company</I></B>&rdquo;), Amplitude Healthcare Holdings LLC, a Delaware limited liability company (the &ldquo;<B><I>Sponsor</I></B>&rdquo;),
and certain former stockholders of Jasper Therapeutics, Inc., a Delaware corporation (&ldquo;<B><I>Jasper</I></B>&rdquo;), set forth
in Schedule 1 hereto (such stockholders, the &ldquo;<B><I>Jasper Holders</I></B>&rdquo;, together with the Sponsor and any person or
entity who hereafter becomes a party to this Agreement pursuant to&nbsp;<U>Section&nbsp;6.2</U>&nbsp;of this Agreement, a &ldquo;<B><I>Holder</I></B>&rdquo;
and collectively the &ldquo;<B><I>Holders</I></B>&rdquo;). Capitalized terms used but not otherwise defined in this Agreement shall have
the meanings ascribed to such terms in the Business Combination Agreement (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">RECITALS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B>,
the Company and the Sponsor are party to that certain Registration Rights Agreement, dated as of November 19, 2019 (the &ldquo;<B><I>Original
RRA</I></B>&rdquo;);</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B>,
the Company has entered into that certain Business Combination Agreement, dated as of May 5, 2021 (as may be amended, supplemented or
otherwise modified from time to time, the &ldquo;<B><I>Business Combination Agreement</I></B>&rdquo;), by and among the Company, Ample
Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of the Company (&ldquo;<B><I>Merger Sub</I></B>&rdquo;),
and Jasper, pursuant to which Merger Sub merged with and into Jasper (the &ldquo;<B><I>Merger</I></B>&rdquo;), with Jasper continuing
as the surviving corporation and becoming a direct, wholly owned subsidiary of the Company;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B>,
on the date hereof, pursuant to the Business Combination Agreement, the Jasper Holders received shares of the Company&rsquo;s voting
common stock, par value $0.0001 per share (the &ldquo;<B><I>Voting Common Stock</I></B>&rdquo;) and/or shares of the Company&rsquo;s
non-voting common stock, par value $0.0001 per share (the &ldquo;<B><I>Non-Voting Common Stock</I></B>&rdquo; and together with the Voting
Common Stock, the &ldquo;<B><I>Common Stock</I></B>&rdquo;);</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B>,
on the date hereof, pursuant to the Business Combination Agreement, certain Jasper Holders received Rollover Options, as defined in the
Business Combination Agreement (&ldquo;<B><I>Equity Awards</I></B>&rdquo;);</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B>,
on the date hereof, the Sponsor, certain Jasper Holders and certain investors (such other investors, collectively, the &ldquo;<B><I>Third-Party
Investor Stockholders</I></B>&rdquo;) purchased an aggregate of 10,000,000 shares of Common Stock (the &ldquo;<B><I>Investor Shares</I></B>&rdquo;)
in a transaction (the &ldquo;<B><I>PIPE Financing</I></B>&rdquo;) exempt from registration under the Securities Act pursuant to the respective
Subscription Agreements, each dated as of May 5, 2021, entered into by and between the Company and each of the Sponsor, certain Jasper
Holders and such Third-Party Investor Stockholders (each, a &ldquo;<B><I>Subscription Agreement</I></B>&rdquo; and, collectively, the
&ldquo;<B><I>Subscription Agreements</I></B>&rdquo;);</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B>,
pursuant to Section 5.5 of the Original RRA, the provisions, covenants and conditions set forth therein may be amended or modified upon
the written consent of the Company and the Holders (as defined in the Original RRA) of at least a majority-in-interest of the Registrable
Securities (as defined in the Original RRA) at the time in question, and the Sponsor (as defined in the Original RRA) holds all of the
Registrable Securities as of the date hereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B>,
in connection with the transactions contemplated by the Business Combination Agreement, the Company and the Sponsor desire to amend and
restate the Original RRA in its entirety and enter into this Agreement, pursuant to which the Company shall grant the Holders certain
registration rights with respect to certain securities of the Company, as set forth in this Agreement, and amend and restate in all respects
the Original RRA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOW</B>,<B>&nbsp;THEREFORE</B>,
in consideration of the representations, covenants and agreements contained herein, and certain other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
I<BR>
DEFINITIONS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.1.
<U>Definitions</U>. The terms defined in this<I>&nbsp;</I>ARTICLE I&nbsp;shall, for all purposes of this Agreement, have the respective
meanings set forth below:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Adverse
Disclosure</I></B>&rdquo; shall mean any public disclosure of material&nbsp;non-public&nbsp;information, which disclosure, in the good
faith judgment of the Chief Executive Officer or principal financial officer of the Company, after consultation with counsel to the Company,
(i)&nbsp;would be required to be made in any Registration Statement or Prospectus in order for the applicable Registration Statement
or Prospectus not to contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
contained therein (in the case of any prospectus and any preliminary prospectus, in the light of the circumstances under which they were
made) not&nbsp;misleading, (ii)&nbsp;would not be required to be made at such time if the Registration Statement were not being filed,
declared effective or used, as the case may be, and (iii)&nbsp;the Company has a bona fide business purpose for not making such information
public.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Agreement</I></B>&rdquo;
shall have the meaning given in the Preamble hereto.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Board</I></B>&rdquo;
shall mean the Board of Directors of the Company.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Business
Combination Agreement</I></B>&rdquo; shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Change
in Control</I></B>&rdquo; means any transfer (whether by tender offer, merger, stock purchase, consolidation or other similar transaction),
in one transaction or a series of related transactions, to a person or group of affiliated persons of the Company&rsquo;s voting securities
if, after such transfer, such person or group of affiliated persons would hold more than 50% of outstanding voting securities of the
Company (or surviving entity) or would otherwise have the power to control the board of directors of the Company or to direct the operations
of the Company.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Closing</I></B>&rdquo;
shall have the meaning given in the Business Combination Agreement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Closing
Date</I></B>&rdquo; shall have the meaning given in the Business Combination Agreement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Commission</I></B>&rdquo;
shall mean the Securities and Exchange Commission.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Common
Stock</I></B>&rdquo; shall have the meaning given in the Recitals hereto.&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Company</I></B>&rdquo;
shall have the meaning given in the Preamble hereto and includes the Company&rsquo;s successors by recapitalization, merger, consolidation,
spin-off, reorganization or other similar transaction.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Demanding
Holder</I></B>&rdquo; shall have the meaning given in&nbsp;<U>Section 2.1.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>EDGAR</I></B>&rdquo;
shall have the meaning given in <U>Section 3.1.3<I>.</I></U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Equity
Awards</I></B>&rdquo; shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Exchange
Act</I></B>&rdquo; shall mean the Securities Exchange Act of 1934, as it may be amended from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Filing
Date</I></B>&rdquo; shall have the meaning given in <U>Section 2.1.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Form&nbsp;S-1
Shelf</I></B>&rdquo; shall have the meaning given in&nbsp;<U>Section 2.1.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Form&nbsp;S-3
Shelf</I></B>&rdquo; shall have the meaning given in&nbsp;<U>Section 2.1.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Holder
Information</I></B>&rdquo; shall have the meaning given in <U>Section 4.1.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Holders</I></B>&rdquo;
shall have the meaning given in the Preamble hereto, for so long as such person or entity holds any Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Investor
Shares</I></B>&rdquo; shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&ldquo;<B>Jasper</B></I>&rdquo;
shall have the meaning given in the Preamble hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Jasper
Holder</I></B>&rdquo; shall have the meaning given in the Preamble hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Lock-up</I></B>&rdquo;
shall have the meaning given in <U>Section 5.1.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Lock-up
Parties</I></B>&rdquo; shall mean the Sponsor, the Jasper Holders and their respective Permitted Transferees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Lock-up
Period</I></B>&rdquo; shall mean the period beginning on the Closing Date and ending on the date that is one hundred eighty (180) days
after the Closing Date, or such earlier date specified in <U>Section 5.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Lock-up
Shares</I></B>&rdquo; shall mean the shares of Common Stock and any other equity securities convertible into or exercisable or exchangeable
for shares of Common Stock held by the Jasper Holders immediately following the Closing or shares of Common Stock issued with respect
to or in exchange for Equity Awards on or after the Closing as permitted by this Agreement (other than the Investor Shares or shares
of Common Stock acquired in the public market).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Maximum
Number of Securities</I></B>&rdquo; shall have the meaning given in&nbsp;<U>Section 2.1.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Merger</I></B>&rdquo;
shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Merger
Sub</I></B>&rdquo; shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Minimum
Takedown Threshold</I></B>&rdquo; shall have the meaning given in <U>Section 2.1.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Misstatement</I></B>&rdquo;
shall mean an untrue statement of a material fact or an omission to state a material fact required to be stated in a Registration Statement
or Prospectus, or necessary to make the statements in a Registration Statement or Prospectus (in the case of a Prospectus, in the light
of the circumstances under which they were made) not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Non-Voting
Common Stock</I></B>&rdquo; shall mean shares of the Company&rsquo;s non-voting common stock, par value $0.0001 per share.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Original
RRA</I></B>&rdquo; shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Permitted
Transferees</I></B>&rdquo; shall mean with respect to each Holder and its Permitted Transferees, (a) prior to the expiration of the Lock-up
Period, any person or entity to whom such Holder is permitted to transfer such Registrable Securities prior to the expiration of the
Lock-up&nbsp;Period pursuant to <U>Section 5.1</U> and (b) after the expiration of the Lock-up Period, any person or entity to whom such
Holder is permitted to transfer such Registrable Securities, subject to and in accordance with any applicable agreement between such
Holder and/or its Permitted Transferees and the Company and any transferee thereafter.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Piggyback
Registration</I></B>&rdquo; shall have the meaning given in&nbsp;<U>Section 2.2.1</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Plan
of Distribution</I></B>&rdquo; shall have the meaning given in <U>Section 2.1.1</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Prospectus</I></B>&rdquo;
shall mean the prospectus included in any Registration Statement, as supplemented by any and all prospectus supplements and as amended
by any and all post-effective amendments and including all material incorporated by reference in such prospectus.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Registrable
Security</I></B>&rdquo; shall mean (a)&nbsp;any outstanding shares of Common Stock and any other equity security (including warrants
to purchase shares of Common Stock and shares of Voting Common Stock issued or issuable upon the exercise or conversion of Non-Voting
Common Stock or any other equity security) of the Company held by a Holder immediately following the Closing (including any securities
distributable pursuant to the Business Combination Agreement and any Investor Shares), (b) any outstanding share of Common Stock or any
other equity security (including warrants to purchase shares of Common Stock and shares of Common Stock issued or issuable upon the exercise
or conversion of Non-Voting Common Stock or any other equity security) of the Company acquired by a Holder following the date hereof
to the extent that such securities are &ldquo;restricted securities&rdquo; (as defined in Rule 144) or are otherwise held by an &ldquo;affiliate&rdquo;
(as defined in Rule 144) of the Company, and (c)&nbsp;any other equity security of the Company or any of its Subsidiaries issued or issuable
with respect to any securities reference in clauses (a) or (b) above by way of a stock dividend or stock split or in connection with
a recapitalization, merger, consolidation, spin-off, reorganization or similar transaction; <U>provided</U>,&nbsp;<U>however</U>, that,
as to any particular Registrable Security, such securities shall cease to be Registrable Securities upon the earliest to occur of: (A)&nbsp;a
Registration Statement with respect to the sale of such securities shall have become effective under the Securities Act and such securities
shall have been sold, transferred, disposed of or exchanged in accordance with such Registration Statement by the applicable Holder;
(B)&nbsp;(i) such securities shall have been otherwise transferred (other than to a Permitted Transferee), (ii) new certificates for
such securities not bearing (or book entry position not subject to) a legend restricting further transfer shall have been delivered by
the Company and (iii) subsequent public distribution of such securities shall not require registration under the Securities Act; (C)&nbsp;such
securities shall have ceased to be outstanding; (D)&nbsp;such securities may be sold without registration pursuant to Rule&nbsp;144 or
any successor rule promulgated under the Securities Act (but with no volume or manner of sale or current public information requirement);
(E)&nbsp;such securities have been sold without registration pursuant to Section 4(a)(1) of the Securities Act or Rule 145 promulgated
under the Securities Act or any successor rules promulgated under the Securities Act; and (F) such securities have been sold to, or through,
a broker, dealer or underwriter in a public distribution or other public securities transaction.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Registration</I></B>&rdquo;
shall mean a registration, including any related Shelf Takedown, effected by preparing and filing a registration statement, Prospectus
or similar document in compliance with the requirements of the Securities Act, and the applicable rules&nbsp;and regulations promulgated
thereunder, and such registration statement becoming effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Registration
Expenses</I></B>&rdquo; shall mean the out-of-pocket&nbsp;expenses of a Registration, including, without limitation, the following:</FONT></P>



<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(A)&nbsp;all
registration, listing and filing fees (including fees with respect to filings required to be made with the Financial Industry Regulatory
Authority,&nbsp;Inc.) and any national securities exchange on which the Common Stock is then listed;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(B)&nbsp;fees
and expenses of compliance with securities or blue sky laws (including reasonable fees and disbursements of outside counsel for the Underwriters
in connection with blue sky qualifications of Registrable Securities);</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(C)&nbsp;printing,
messenger, telephone and delivery expenses;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(D)&nbsp;reasonable
fees and disbursements of counsel for the Company;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(E)&nbsp;reasonable
fees and disbursements of all independent registered public accountants of the Company and any other persons, including special experts,
retained by the Company, incurred in connection with such Registration;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(F)&nbsp;all
expenses in connection with the preparation, printing and filing of a Registration Statement, any Prospectus and amendments and supplements
thereto and the mailing and delivering of copies thereof to any Holders, underwriters and dealers and all expenses incidental to delivery
of the Registrable Securities; and</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(G)
in an Underwritten Offering, reasonable fees and expenses of one (1) legal counsel for all holders of Registrable Securities to be registered
for offer and sale in the applicable Registration, selected by a majority-in-interest of the Demanding Holders (not to exceed $50,000
without the consent of the Company).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Registration
Statement</I></B>&rdquo; shall mean any registration statement that covers the Registrable Securities pursuant to the provisions of this
Agreement, including the Prospectus included in such registration statement, amendments (including post-effective amendments) and supplements
to such registration statement, and all exhibits to and all material incorporated by reference in such registration statement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Requesting
Holders</I></B>&rdquo; shall have the meaning given in&nbsp;<U>Section 2.1.5</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Securities
Act</I></B>&rdquo; shall mean the Securities Act of 1933, as amended from time to time.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Shelf</I></B>&rdquo;
shall mean the Form S-1 Shelf, the Form S-3 Shelf or any Subsequent Shelf Registration Statement, as the case may be.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Shelf
Registration</I></B>&rdquo; shall mean a registration of securities pursuant to registration statement filed with the Commission in accordance
with and pursuant to Rule 415 promulgated under the Securities Act (or any successor rule then in effect).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Shelf
Takedown</I></B>&rdquo; shall mean an Underwritten Shelf Takedown or any proposed transfer or sale using a Registration Statement, including
a Piggyback Registration.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Sponsor</I></B>&rdquo;
shall have the meaning given in the Preamble hereto.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Subscription
Agreement</I></B>&rdquo; shall have the meaning given in the Preamble hereto.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Subsequent
Shelf Registration Statement</I></B>&rdquo; shall have the meaning given in <U>Section 2.1.2</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Surveyor</I></B>&rdquo;
means Citadel Multi-Strategy Equities Master Fund Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Third-Party
Investor Stockholders</I></B>&rdquo; shall have the meaning given in the Recitals hereto.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Transfer</I></B>&rdquo;
shall mean the (a) the sale or assignment of, offer to sell, contract or agreement to sell, grant of any option to purchase or otherwise
dispose of or agreement to dispose of, directly or indirectly, or establishment or increase of a put equivalent position or liquidation
with respect to or decrease of a call equivalent position within the meaning of Section 16 of the Exchange Act with respect to, any Lock-up
Share, (b) entry into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences
of ownership of any Lock-up Share, whether any such transaction is to be settled by delivery of such securities, in cash or otherwise,
or (c) public announcement of any intention to effect any transaction specified in clause (a) or (b).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Underwriter</I></B>&rdquo;
shall mean a securities dealer who purchases any Registrable Securities as principal in an Underwritten Offering and not as part of such
dealer&rsquo;s market-making activities.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Underwritten
Offering</I></B>&rdquo; shall mean a Registration in which securities of the Company are sold to an Underwriter in a firm commitment
underwriting for distribution to the public.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Underwritten
Shelf Takedown</I></B>&rdquo; shall have the meaning given in <U>Section 2.1.4</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Withdrawal
Notice</I></B>&rdquo; shall have the meaning given in <U>Section 2.1.6</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
II<BR>
REGISTRATIONS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.1.
<U>Shelf Registration</U></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.1.1
As soon as practicable but no later than thirty (30) calendar days following the Closing Date (the &ldquo;<B><I>Filing Date</I></B>&rdquo;),
the Company shall submit to or file with the Commission a Registration Statement for a Shelf Registration on Form&nbsp;S-3 (the&nbsp;&ldquo;<B><I>Form&nbsp;S-3
Shelf</I></B>&rdquo;)&nbsp;or, if the Company is ineligible to use a Form S-3 Shelf, a Registration Statement for a Shelf Registration
on Form&nbsp;S-1 (the&nbsp;&ldquo;<B><I>Form&nbsp;S-1 Shelf</I></B>&rdquo;), in each case, covering the resale of all the Registrable
Securities (determined as of two (2) business days prior to such filing) on a delayed or continuous basis and shall use its commercially
reasonable efforts to have such Shelf declared effective as soon as practicable after the filing thereof, but no later than the earlier
of (x) ninety (90) calendar days (or 120 calendar days if the Commission notifies the Company that it will &ldquo;review&rdquo; the Shelf
Registration) following the Closing Date and (y)&nbsp;ten (10)&nbsp;business days after the Company is notified (orally or in writing,
whichever is earlier) by the Commission that such Shelf Registration will not be &ldquo;reviewed&rdquo; or will not be subject to further
review. Such Shelf shall provide for the resale of the Registrable Securities included therein pursuant to any method or combination
of methods legally available (the&nbsp;&ldquo;<B><I>Plan of Distribution</I></B>&rdquo;)&nbsp;to, and requested by, any Holder named
therein. The Company shall maintain a Shelf in accordance with the terms hereof, and shall prepare and file with the Commission such
amendments, including post-effective amendments, and supplements as may be necessary to keep a Shelf continuously effective, available
for use to permit the Holders named therein to sell their Registrable Securities included therein and in compliance with the provisions
of the Securities Act until such time as there are no longer any Registrable Securities. In the event the Company files a Form&nbsp;S-1
Shelf, the Company shall use its commercially reasonable efforts to convert the Form&nbsp;S-1 Shelf (and any Subsequent Shelf Registration
Statement) to a Form&nbsp;S-3 Shelf as soon as practicable after the Company is eligible to use a Form&nbsp;S-3 Shelf. The Company&rsquo;s
obligation under this&nbsp;<U>Section&nbsp;2.1.1</U>, shall, for the avoidance of doubt, be subject to&nbsp;<U>Section&nbsp;3.4</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.1.2
<U>Subsequent Shelf Registration</U>. If any Shelf ceases to be effective under the Securities Act for any reason at any time while Registrable
Securities are still outstanding, the Company shall, subject to&nbsp;<U>Section&nbsp;3.4</U>, use its commercially reasonable efforts
to as promptly as is reasonably practicable cause such Shelf to again become effective under the Securities Act (including using its
commercially reasonable efforts to obtain the prompt withdrawal of any order suspending the effectiveness of such Shelf), and shall use
its commercially reasonable efforts to as promptly as is reasonably practicable amend such Shelf in a manner reasonably expected to result
in the withdrawal of any order suspending the effectiveness of such Shelf or file an additional registration statement as a Shelf Registration
(a&nbsp;&ldquo;<B><I>Subsequent Shelf Registration Statement</I></B>&rdquo;)<B><I>&nbsp;</I></B>registering the resale of all Registrable
Securities (determined as of two (2)&nbsp;business days prior to such filing), and pursuant to the Plan of Distribution. If a Subsequent
Shelf Registration Statement is filed, the Company shall use its commercially reasonable efforts to (a)&nbsp;cause such Subsequent Shelf
Registration Statement to become effective under the Securities Act as promptly as is reasonably practicable after the filing thereof
and (b)&nbsp;keep such Subsequent Shelf Registration Statement continuously effective, available for use to permit the Holders named
therein to sell their Registrable Securities included therein and in compliance with the provisions of the Securities Act until such
time as there are no longer any Registrable Securities. Any such Subsequent Shelf Registration Statement shall be on Form&nbsp;S-3 to
the extent that the Company is eligible to use such form. Otherwise, such Subsequent Shelf Registration Statement shall be on another
appropriate form. The Company&rsquo;s obligation under this&nbsp;<U>Section&nbsp;2.1.2</U> shall, for the avoidance of doubt, be subject
to&nbsp;<U>Section&nbsp;3.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.1.3
<U>Additional Registrable Securities</U>. Subject to&nbsp;<U>Section&nbsp;3.4,</U>&nbsp;in the event that any Holder holds Registrable
Securities that are not registered for resale on a delayed or continuous basis, the Company, upon written request of such Holder, shall
promptly use its commercially reasonable efforts to cause the resale of such Registrable Securities to be covered by either, at the Company&rsquo;s
option, any then available Shelf (including by means of a post-effective amendment) or by filing a Subsequent Shelf Registration Statement
and cause the same to become effective as soon as practicable after such filing and such Shelf or Subsequent Shelf Registration Statement
shall be subject to the terms hereof;&nbsp;<U>provided</U>,&nbsp;<U>however,</U>&nbsp;that the Company shall only be required to cause
such additional Registrable Securities to be so covered once per calendar year for each of the Sponsor and the Jasper Holders for an
aggregate of not more than three (3)&nbsp;additional registrations per calendar year.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.1.4
<U>Requests for Underwritten Shelf Takedowns</U>. Subject to&nbsp;<U>Section&nbsp;3.4</U>, at any time and from time to time when an
effective Shelf is on file with the Commission, (a) the Sponsor or (b) Holders of a majority-in-interest of the Registrable Securities
held by the Jasper Holders (any such Holders, the&nbsp;&ldquo;<B><I>Demanding Holders</I></B>&rdquo;)<B><I>&nbsp;</I></B>may request
to sell all or any portion of their Registrable Securities in an Underwritten Offering that is registered pursuant to the Shelf (each,
an&nbsp;&ldquo;<B><I>Underwritten Shelf Takedown</I></B>&rdquo;)<I>;&nbsp;</I><U>provided</U>&nbsp;that the Company shall only be obligated
to effect an Underwritten Shelf Takedown if such offering shall include either (x) Registrable Securities proposed to be sold by the
Demanding Holder, either individually or together with other Demanding Holders, with a total offering price reasonably expected to exceed,
in the aggregate, $30 million (the&nbsp;&ldquo;<B><I>Minimum Takedown Threshold</I></B>&rdquo;)<I>. </I> All requests for Underwritten
Shelf Takedowns shall be made by giving written notice to the Company, which shall specify the approximate number of Registrable Securities
proposed to be sold in the Underwritten Shelf Takedown. The initial Demanding Holder shall have the right to select the Underwriters
for such offering (which shall consist of one or more reputable nationally recognized investment banks), subject to the Company&rsquo;s
prior approval (which shall not be unreasonably withheld, conditioned or delayed). The Sponsor and the Jasper Holders may each demand
not more than three (3)&nbsp;Underwritten Shelf Takedowns, for an aggregate of not more than six (6)&nbsp;Underwritten Shelf Takedowns
pursuant to this Agreement. The Company shall not be required to effect more than one (1) Underwritten Shelf Takedown during any twelve
(12)&nbsp;month period. Notwithstanding anything to the contrary in this Agreement, the Company may effect any Underwritten Offering
pursuant to any then effective Registration Statement, including a Form&nbsp;S-3, that is then available for such offering.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.1.5
<U>Reduction of Underwritten Offering</U>. If the managing Underwriter or Underwriters in an Underwritten Shelf Takedown, in good faith,
advises the Company, the Demanding Holders and the Holders requesting piggy-back rights pursuant to this Agreement with respect to such
Underwritten Shelf Takedown (the&nbsp;&ldquo;<B><I>Requesting Holders</I></B>&rdquo;)<B><I>&nbsp;</I></B>(if any) in writing that the
dollar amount or number of Registrable Securities that the Demanding Holders and the Requesting Holders (if any) desire to sell, taken
together with all other shares of Common Stock or other equity securities that the Company desires to sell and all other shares of Common
Stock or other equity securities, if any, that have been requested to be sold in such Underwritten Offering pursuant to separate written
contractual piggy-back registration rights held by any other stockholders, exceeds the maximum dollar amount or maximum number of equity
securities that can be sold in the Underwritten Offering without adversely affecting the proposed offering price, the timing, the distribution
method, or the probability of success of such offering (such maximum dollar amount or maximum number of such securities, as applicable,
the&nbsp;&ldquo;<B><I>Maximum Number of Securities</I></B>&rdquo;),<B><I>&nbsp;</I></B>then the Company shall include in such Underwritten
Offering, before including any shares of Common Stock or other equity securities proposed to be sold by Company or by other holders of
Common Stock or other equity securities, the Registrable Securities of (a) first, the Demanding Holders that can be sold without exceeding
the Maximum Number of Securities (pro rata based on the respective number of Registrable Securities that each Demanding Holder has requested
be included in such Underwritten Shelf Takedown and the aggregate number of Registrable Securities that all of the Demanding Holders
have requested be included in such Underwritten Shelf Takedown) and (b)&nbsp;second, to the extent that the Maximum Number of Securities
has not been reached under the foregoing clause (i), the Requesting Holders (if any) (pro rata based on the respective number of Registrable
Securities that each Requesting Holder (if any) has requested be included in such Underwritten Shelf Takedown and the aggregate number
of Registrable Securities that all of the Requesting Holders have requested be included in such Underwritten Shelf Takedown) that can
be sold without exceeding the Maximum Number of Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.1.6
<U>Withdrawal</U>. Prior to the filing of the applicable &ldquo;red herring&rdquo; prospectus or prospectus supplement used for marketing
such Underwritten Shelf Takedown, a majority-in-interest of the Demanding Holders initiating an Underwritten Shelf Takedown shall have
the right to withdraw from such Underwritten Shelf Takedown for any or no reason whatsoever upon written notification (a &ldquo;<B><I>Withdrawal
Notice</I></B>&rdquo;)<B><I>&nbsp;</I></B>to the Company and the Underwriter or Underwriters (if any) of their intention to withdraw
from such Underwritten Shelf Takedown;&nbsp;<U>provided</U>&nbsp;that the Requesting Holders may elect to have the Company continue an
Underwritten Shelf Takedown if the Minimum Takedown Threshold would still be satisfied by the Registrable Securities proposed to be sold
in the Underwritten Shelf Takedown by the Sponsor and the Jasper Holders or any of their respective Affiliates, as applicable. If withdrawn,
a demand for an Underwritten Shelf Takedown shall constitute a demand for an Underwritten Shelf Takedown by the withdrawing Demanding
Holder for purposes of <U>Section 2.1.4</U>, unless either (a) such Demanding Holder has not previously withdrawn any Underwritten Shelf
Takedown or (b) such Demanding Holder reimburses the Company for all Registration Expenses with respect to such Underwritten Shelf Takedown
(or, if there is more than one Demanding Holder, a pro rata portion of such Registration Expenses based on the respective number of Registrable
Securities that each Demanding Holder has requested be included in such Underwritten Shelf Takedown); provided that, if the Sponsor or
any Jasper Holder elects to continue an Underwritten Shelf Takedown pursuant to the proviso in the immediately preceding sentence, such
Underwritten Shelf Takedown shall instead count as an Underwritten Shelf Takedown demanded by one of the Sponsor or any Jasper Holders,
as applicable, for purposes of <U>Section 2.1.4</U>. Following the receipt of any Withdrawal Notice, the Company shall promptly forward
such Withdrawal Notice to any other Holders that had elected to participate in such Shelf Takedown. Notwithstanding anything to the contrary
in this Agreement, the Company shall be responsible for the Registration Expenses incurred in connection with a Shelf Takedown prior
to its withdrawal under this&nbsp;<U>Section&nbsp;2.1.6</U>, other than if a Demanding Holder elects to pay such Registration Expenses
pursuant to clause (b) of the second sentence of this <U>Section 2.1.6</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.2.
<U>Piggyback Registration</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.2.1
<U>Piggyback Rights</U>. If the Company proposes to file a Registration Statement under the Securities Act with respect to the Registration
of equity securities, or securities or other obligations exercisable or exchangeable for, or convertible into equity securities, for
its own account or for the account of stockholders of the Company (or by the Company and by the stockholders of the Company including,
without limitation, an Underwritten Shelf Takedown pursuant to&nbsp;<U>Section&nbsp;2.1</U>), other than a Registration Statement (or
any registered offering with respect thereto) (a)&nbsp;filed in connection with any employee stock option or other benefit plan, (b)
for an exchange offer or offering of securities solely to the Company&rsquo;s existing stockholders, (c) pursuant to a Registration Statement
on Form S-4 (or similar form that relates to a transaction subject to Rule 145 under the Securities Act or any successor rule thereto),
(d)&nbsp;for an offering of debt that is convertible into equity securities of the Company or (e)&nbsp;for a dividend reinvestment plan,
then the Company shall give written notice of such proposed offering to all of the Holders of Registrable Securities as soon as practicable
but not less than ten (10)&nbsp;days before the anticipated filing date of such Registration Statement or, in the case of an Underwritten
Offering pursuant to a Shelf Registration, the applicable &ldquo;red herring&rdquo; prospectus or prospectus supplement used for marketing
such offering, which notice shall (i)&nbsp;describe the amount and type of securities to be included in such offering, the intended method(s)&nbsp;of
distribution, and the name of the proposed managing Underwriter or Underwriters, if any, in such offering, and (ii)&nbsp;offer to all
of the Holders of Registrable Securities the opportunity to include in such registered offering such number of Registrable Securities
as such Holders may request in writing within five (5)&nbsp;days after receipt of such written notice (such registered offering, a &ldquo;<B><I>Piggyback
Registration</I></B>&rdquo;). Subject to <U>Section 2.2.2</U>, the Company shall, in good faith, cause such Registrable Securities to
be included in such Piggyback Registration and, if applicable, shall use its commercially reasonable efforts to cause the managing Underwriter
or Underwriters of such Piggyback Registration to permit the Registrable Securities requested by the Holders pursuant to this&nbsp;<U>Section&nbsp;2.2.1
</U>to be included therein on the same terms and conditions as any similar securities of the Company included in such registered offering
and to permit the sale or other disposition of such Registrable Securities in accordance with the intended method(s)&nbsp;of distribution
thereof. The inclusion of any Holder&rsquo;s Registrable Securities in a Piggyback Registration shall be subject to such Holder&rsquo;s
agreement to enter into an underwriting agreement in customary form with the Underwriter(s) selected for such Underwritten Offering by
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.2.2
<U>Reduction of Piggyback Registration</U>. If the managing Underwriter or Underwriters in an Underwritten Offering that is to be a Piggyback
Registration, in good faith, advises the Company and the Holders of Registrable Securities participating in the Piggyback Registration
in writing that the dollar amount or number of shares of Common Stock or other equity securities that the Company desires to sell, taken
together with (i)&nbsp;the shares of Common Stock or other equity securities, if any, as to which Registration or a registered offering
has been demanded pursuant to separate written contractual arrangements with persons or entities other than the Holders of Registrable
Securities hereunder, (ii)&nbsp;the Registrable Securities as to which registration has been requested pursuant to&nbsp;<U>Section&nbsp;2.2
</U>hereof, and (iii)&nbsp;the shares of Common Stock or other equity securities, if any, as to which Registration or registered offering
has been requested pursuant to separate written contractual piggy-back registration rights of persons or entities other than the Holders
of Registrable Securities, exceeds the Maximum Number of Securities, then:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
If the Registration or registered offering is undertaken for the Company&rsquo;s account, the Company shall include in any such Registration
or registered offering (A)&nbsp;first, the shares of Common Stock or other equity securities that the Company desires to sell, which
can be sold without exceeding the Maximum Number of Securities; (B)&nbsp;second, to the extent that the Maximum Number of Securities
has not been reached under the foregoing clause (A), the Registrable Securities of Holders exercising their rights to register their
Registrable Securities pursuant to&nbsp;<U>Section 2.2.1</U> hereof, pro rata, based on the respective number of Registrable Securities
that each Holder has so requested be included in such Underwritten Offering and the aggregate number of Registrable Securities that the
Holders have requested to be included in such Underwritten Offering, which can be sold without exceeding the Maximum Number of Securities;
and (C)&nbsp;third, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (A)&nbsp;and
(B), the shares of Common Stock or other equity securities, if any, as to which Registration or registered offering has been requested
pursuant to separate written contractual piggy-back registration rights of persons or entities other than the Holders of Registrable
Securities, which can be sold without exceeding the Maximum Number of Securities;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
If the Registration or registered offering is pursuant to a demand by persons or entities other than the Holders of Registrable Securities,
then the Company shall include in any such Registration or registered offering (A)&nbsp;first, the shares of Common Stock or other equity
securities, if any, of such requesting persons or entities, other than the Holders of Registrable Securities, which can be sold without
exceeding the Maximum Number of Securities; (B)&nbsp;second, to the extent that the Maximum Number of Securities has not been reached
under the foregoing clause (A), the Registrable Securities of Holders exercising their rights to register their Registrable Securities
pursuant to&nbsp;<U>Section 2.2.1</U>, pro rata, based on the respective number of Registrable Securities that each Holder has requested
be included in such Underwritten Offering and the aggregate number of Registrable Securities that the Holders have requested to be included
in such Underwritten Offering, which can be sold without exceeding the Maximum Number of Securities; (C)&nbsp;third, to the extent that
the Maximum Number of Securities has not been reached under the foregoing clauses (A)&nbsp;and (B), the shares of Common Stock or other
equity securities, if any, as to which Registration or a registered offering has been requested pursuant to the piggy-back registration
rights, if any, of the Third-Party Investor Stockholders set forth in the Subscription Agreements, which can be sold without exceeding
the Maximum Number of Securities; (D) fourth, to the extent that the Maximum Number of Securities has not been reached under the foregoing
clauses (A), (B) and (C), the shares of Common Stock or other equity securities that the Company desires to sell, which can be sold without
exceeding the Maximum Number of Securities; and (E)&nbsp;fifth, to the extent that the Maximum Number of Securities has not been reached
under the foregoing clauses (A), (B), (C)&nbsp;and (D), the shares of Common Stock or other equity securities, if any, as to which Registration
or a registered offering has been requested pursuant to separate written contractual piggy-back registration rights of such persons or
entities other than the Holders of Registrable Securities hereunder or the Third-Party Investor Stockholders, which can be sold without
exceeding the Maximum Number of Securities; and</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
If the Registration or registered offering and Underwritten Shelf Takedown is pursuant to a request by Holder(s) of Registrable Securities
pursuant to <U>Section 2.1</U> hereof, then the Company shall include in any such Registration or registered offering securities in the
priority set forth in <U>Section 2.1.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.2.3
<U>Piggyback Registration Withdrawal</U>. Any Holder of Registrable Securities (other than a Demanding Holder, whose right to withdraw
from an Underwritten Shelf Takedown, and related obligations, shall be governed by <U>Section 2.1.6</U>) shall have the right to withdraw
from a Piggyback Registration for any or no reason whatsoever upon written notification to the Company and the Underwriter or Underwriters
(if any) of his, her or its intention to withdraw from such Piggyback Registration prior to the effectiveness of the Registration Statement
filed with the Commission with respect to such Piggyback Registration or, in the case of a Piggyback Registration pursuant to a Shelf
Registration, the filing of the applicable &ldquo;red herring&rdquo; prospectus or prospectus supplement with respect to such Piggyback
Registration used for marketing such transaction. The Company (whether on its own good faith determination or as the result of a request
for withdrawal by persons pursuant to separate written contractual obligations) may withdraw a Registration Statement filed with the
Commission in connection with a Piggyback Registration (which, in no circumstance, shall include a Shelf) at any time prior to the effectiveness
of such Registration Statement. Notwithstanding anything to the contrary in this Agreement (other than <U>Section 2.1.6</U>), the Company
shall be responsible for the Registration Expenses incurred in connection with the Piggyback Registration prior to its withdrawal under
this&nbsp;<U>Section 2.2.3</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.2.4
<U>Unlimited Piggyback Registration Rights</U>. For purposes of clarity, subject to <U>Section 2.1.6</U>, any Piggyback Registration
effected pursuant to&nbsp;<U>Section&nbsp;2.2</U>&nbsp;hereof shall not be counted as a demand for an Underwritten Shelf Takedown under&nbsp;<U>Section&nbsp;2.1</U>&nbsp;hereof.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.3.
<U>Market Stand-off</U>. In connection with any Underwritten Offering of Common Stock of the Company, if requested by the Underwriters
managing the offering, each Holder that (a) is an executive officer or director of the Company or (b) is a beneficial owner of more than
five percent (5%) of the outstanding shares of Common Stock of the Company participating in such Underwritten Offering as a selling stockholder,
and any other Holder reasonably requested by the managing Underwriter, agrees not to sell, transfer, make any short sale of, loan, pledge,
or otherwise hypothecate or encumber, grant any option for the purpose of, or otherwise dispose of any shares of Common Stock or other
equity securities of the Company (other than those included in such offering pursuant to this Agreement) during the ninety (90) day period
(or such shorter time agreed to by the managing Underwriters) beginning on the date of pricing of such offering, except as expressly
permitted by such lock-up agreement or in the event the managing Underwriters otherwise agree by written consent. Each Holder participating
in such Underwritten Offering as a selling stockholder agrees to execute a customary lock-up agreement in favor of the Underwriters to
such effect (in each case on substantially the same terms and conditions as all such Holders), on terms and conditions consistent with
Section 5.1. With respect to Surveyor, this Section 2.3 shall only apply to each Registrable Security that is a Lock-up Share. This Section
2.3 shall not apply to any Investor Shares acquired by Sponsor through the PIPE Financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
III<BR>
COMPANY PROCEDURES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.
<U>General Procedures</U>. In connection with any Shelf and/or Shelf Takedown, the Company shall use its commercially reasonable efforts
to effect such Registration to permit the sale of such Registrable Securities in accordance with the intended plan of distribution thereof,
and pursuant thereto the Company shall, as expeditiously as possible:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.1
prepare and file with the Commission as soon as practicable a Registration Statement with respect to such Registrable Securities and
use its commercially reasonable efforts to cause such Registration Statement to become effective and remain effective until all Registrable
Securities covered by such Registration Statement have ceased to be Registrable Securities;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.2
prepare and file with the Commission such amendments and post-effective amendments to the Registration Statement, and such supplements
to the Prospectus, as may be reasonably requested by the majority-in-interest of the Holders with Registrable Securities registered on
such Registration Statement or any Underwriter of Registrable Securities or as may be required by the rules, regulations or instructions
applicable to the registration form used by the Company or by the Securities Act or rules&nbsp;and regulations thereunder to keep the
Registration Statement effective until all Registrable Securities covered by such Registration Statement are sold in accordance with
the intended plan of distribution set forth in such Registration Statement or supplement to the Prospectus;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.3
prior to filing a Registration Statement or Prospectus, or any amendment or supplement thereto, furnish without charge to the Underwriters,
if any, and the Holders of Registrable Securities included in such Registration, and such Holders&rsquo; legal counsel, copies of such
Registration Statement as proposed to be filed, each amendment and supplement to such Registration Statement (in each case including
all exhibits thereto and documents incorporated by reference therein), the Prospectus included in such Registration Statement (including
each preliminary Prospectus), and such other documents as the Underwriters and the Holders of Registrable Securities included in such
Registration or the legal counsel for any such Holders may reasonably request in order to facilitate the disposition of the Registrable
Securities owned by such Holders; <U>provided</U>, that the Company shall have no obligation to furnish any documents publicly filed
or furnished with the Commission pursuant to the Electronic Data Gathering Analysis and Retrieval System (&ldquo;<B><I>EDGAR</I></B>&rdquo;);</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.4
prior to any public offering of Registrable Securities, use its commercially reasonable efforts to (a)&nbsp;register or qualify the Registrable
Securities covered by the Registration Statement under such securities or &ldquo;blue sky&rdquo; laws of such jurisdictions in the United
States as the Holders of Registrable Securities included in such Registration Statement (in light of their intended plan of distribution)
may request (or provide evidence satisfactory to such Holders that the Registrable Securities are exempt from such registration or qualification)
and (b)&nbsp;take such action necessary to cause such Registrable Securities covered by the Registration Statement to be registered with
or approved by such other governmental authorities as may be necessary by virtue of the business and operations of the Company and do
any and all other acts and things that may be necessary or advisable to enable the Holders of Registrable Securities included in such
Registration Statement to consummate the disposition of such Registrable Securities in such jurisdictions;&nbsp;<U>provided</U>,&nbsp;<U>however</U>,
that the Company shall not be required to qualify generally to do business in any jurisdiction where it would not otherwise be required
to qualify or take any action to which it would be subject to general service of process or taxation in any such jurisdiction where it
is not then otherwise so subject;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.5
use its commercially reasonable efforts to cause all Registrable Securities included in any Registration to be listed on such exchanges
or otherwise designated for trading in the same manner as similar securities issued by the Company are then listed or designated;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.6
provide a transfer agent or warrant agent, as applicable, and registrar for all such Registrable Securities no later than the effective
date of such Registration Statement;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.7
advise each seller of such Registrable Securities, promptly after it shall receive notice or obtain knowledge thereof, of the issuance
of any stop order by the Commission suspending the effectiveness of such Registration Statement or the initiation or threatening of any
proceeding for such purpose and promptly use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain
its withdrawal if such stop order should be issued;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.8
at least five (5)&nbsp;days prior to the filing of any Registration Statement or Prospectus or any amendment or supplement to such Registration
Statement or Prospectus or any document that is to be incorporated by reference into such Registration Statement or Prospectus (excluding
any exhibits thereto and any filings made under the Exchange Act that is to be incorporated by reference therein), furnish a copy thereof
to each seller of such Registrable Securities or its counsel;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.9
notify the Holders at any time when a Prospectus relating to such Registration Statement is required to be delivered under the Securities
Act, of the happening of any event as a result of which the Prospectus included in such Registration Statement, as then in effect, includes
a Misstatement, and then to correct such Misstatement as set forth in&nbsp;<U>Section&nbsp;3.4</U>&nbsp;hereof;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.10
in the event of an Underwritten Offering, permit a representative of the Holders, the Underwriters, if any, and any attorney or accountant
retained by such Holders, or Underwriter to participate, at each such person&rsquo;s or entity&rsquo;s own expense, in the preparation
of the Registration Statement, and cause the Company&rsquo;s officers, directors and employees to supply all information reasonably requested
by any such representative, Underwriter, financial institution, attorney or accountant in connection with the Registration;&nbsp;<U>provided</U>,&nbsp;<U>however</U>,
that such representative or Underwriters enter into a confidentiality agreement, in form and substance reasonably satisfactory to the
Company, prior to the release or disclosure of any such information;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.11
obtain a &ldquo;cold comfort&rdquo; letter from the Company&rsquo;s independent registered public accountants in the event of an Underwritten
Offering, in customary form and covering such matters of the type customarily covered by &ldquo;cold comfort&rdquo; letters as the managing
Underwriter may reasonably request, and reasonably satisfactory to a&nbsp;majority-in-interest&nbsp;of the participating Holders;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.12
on the date the Registrable Securities are delivered for sale pursuant to such Registration to the extent customary for a transaction
of this type, obtain an opinion, dated such date, of counsel representing the Company for the purposes of such Registration, addressed
to the participating Holders and the Underwriters, if any, covering such legal matters with respect to the Registration in respect of
which such opinion is being given as the participating Holders or Underwriter may reasonably request and as are customarily included
in such opinions and negative assurance letters;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.13
in the event of any Underwritten Offering pursuant to such Registration, enter into and perform its obligations under an underwriting
or other purchase or sales agreement, in usual and customary form, with the managing Underwriter;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.14
make available to its security holders, as soon as reasonably practicable, an earnings statement covering the period of at least twelve
(12)&nbsp;months beginning with the first day of the Company&rsquo;s first full calendar quarter after the effective date of the Registration
Statement which satisfies the provisions of&nbsp;<U>Section&nbsp;11(a)</U>&nbsp;of the Securities Act and Rule&nbsp;158 thereunder (or
any successor rule&nbsp;then in effect);</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.15
with respect to an Underwritten Offering pursuant to <U>Section 2.1.4</U>, use its commercially reasonable efforts to make available
senior executives of the Company to participate in customary &ldquo;road show&rdquo; presentations that may be reasonably requested by
the Underwriter in such Underwritten Offering; and</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.16
otherwise, in good faith, cooperate reasonably with, and take such customary actions as may reasonably be requested by the participating
Holders, consistent with the terms of this Agreement in connection with such Registration.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
the foregoing, the Company shall not be required to provide any documents or information to an Underwriter if such Underwriter has not
been named with respect to the applicable Underwritten Offering or other offering involving a registration as an Underwriter.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.2.
<U>Registration Expenses</U>. Except as otherwise provided herein, the Registration Expenses of all Registrations shall be borne by the
Company. It is acknowledged by the Holders that each Holder shall bear, with respect to such Holder&rsquo;s Registrable Securities being
sold, all Underwriters&rsquo; commissions and discounts, brokerage fees, Underwriter marketing costs and, other than as set forth in
the definition of &ldquo;Registration Expenses,&rdquo; all reasonable fees and expenses of any legal counsel representing the Holders.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.3.
<U>Requirements for Participation in Registration Statement in Offerings</U>. Notwithstanding anything in this Agreement to the contrary,
if any Holder does not provide the Company with its requested Holder Information, the Company may exclude such Holder&rsquo;s Registrable
Securities from the applicable Registration Statement or Prospectus if the Company determines, based on the advice of counsel, that it
is necessary or advisable to include such information in the applicable Registration Statement or Prospectus and such Holder continues
thereafter to withhold such information. In addition, no person or entity may participate in any Underwritten Offering or other offering
for equity securities of the Company pursuant to a Registration initiated by the Company hereunder unless such person or entity (a)&nbsp;agrees
to sell such person&rsquo;s or entity&rsquo;s securities on the basis provided in any underwriting, sales, distribution or placement
arrangements approved by the Company and (b)&nbsp;completes and executes all customary questionnaires, powers of attorney, indemnities,&nbsp;lock-up&nbsp;agreements,
underwriting or other agreements and other customary documents as may be reasonably required under the terms of such underwriting, sales,
distribution or placement arrangements. For the avoidance of doubt, the exclusion of a Holder&rsquo;s Registrable Securities as a result
of this <U>Section 3.3</U> shall not affect the registration of the other Registrable Securities to be included in such Registration.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.4.
<U>Suspension of Sales; Adverse Disclosure; Restrictions on Registration Rights</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.4.1
Upon receipt of written notice from the Company that a Registration Statement or Prospectus contains a Misstatement, each of the Holders
shall forthwith discontinue disposition of Registrable Securities until he, she or it has received copies of a supplemented or amended
Prospectus correcting the Misstatement (it being understood that the Company hereby covenants to prepare and file such supplement or
amendment as soon as reasonably practicable after the time of such notice), or until he, she or it is advised in writing by the Company
that the use of the Prospectus may be resumed.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.4.2
If the filing, initial effectiveness or continued use of a Registration Statement in respect of any Registration at any time would (a)
require the Company to make an Adverse Disclosure, or (b) require the inclusion in such Registration Statement of financial statements
that are unavailable to the Company for reasons beyond the Company&rsquo;s control, the Company may, upon giving prompt written notice
of such action to the Holders, delay the filing or initial effectiveness of, or suspend use of, such Registration Statement for the shortest
period of time (but in no event more than ninety (90) days in any 12 month period) determined in good faith by the Company to be necessary
for such purpose. In the event the Company exercises its rights under this <U>Section 3.4.2</U>, the Holders agree to suspend, immediately
upon their receipt of the notice referred to above, their use of the Prospectus relating to any Registration in connection with any sale
or offer to sell Registrable Securities. The Company shall immediately notify the Holders of the expiration of any period during which
it exercised its rights under this&nbsp;<U>Section&nbsp;3.4</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.5.
<U>Reporting Obligations</U>. As long as any Holder shall own Registrable Securities, the Company, at all times while it shall be a reporting
company under the Exchange Act, covenants to file timely (or obtain extensions in respect thereof and file within the applicable grace
period) all reports required to be filed by the Company after the date hereof pursuant to&nbsp;<U>Sections 13(a)</U>&nbsp;or&nbsp;<U>15(d)</U>&nbsp;of
the Exchange Act and to promptly furnish the Holders with true and complete copies of all such filings; provided that any documents publicly
filed or furnished with the Commission pursuant to EDGAR shall be deemed to have been furnished or delivered to the Holder pursuant to
this <U>Section 3.5</U>. The Company further covenants that it shall take such further action as any Holder may reasonably request, all
to the extent required from time to time to enable such Holder to sell shares of the Common Stock held by such Holder without registration
under the Securities Act within the limitation of the exemptions provided by Rule&nbsp;144 promulgated under the Securities Act (or any
successor rule&nbsp;then in effect).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
IV<BR>
INDEMNIFICATION AND CONTRIBUTION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.1.
<U>Indemnification</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.1.1
The Company agrees to indemnify, to the extent permitted by law, each Holder of Registrable Securities, its officers and directors and
each person or entity who controls such Holder (within the meaning of the Securities Act) against all losses, claims, damages, liabilities
and out-of-pocket expenses (including without limitation reasonable attorneys&rsquo; fees) caused by any untrue or alleged untrue statement
of material fact contained in any Registration Statement, Prospectus or preliminary Prospectus or any amendment thereof or supplement
thereto or any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein
not misleading, except insofar as the same are caused by or contained in any information furnished in writing to the Company by such
Holder expressly for use therein. The Company shall indemnify the Underwriters, their officers and directors and each person who controls
such Underwriters (within the meaning of the Securities Act) to the same extent as provided in the foregoing with respect to the indemnification
of the Holder.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.1.2
In connection with any Registration Statement in which a Holder of Registrable Securities is participating, such Holder shall furnish
to the Company in writing such information and affidavits as the Company reasonably requests for use in connection with any such Registration
Statement or Prospectus (the &ldquo;<B><I>Holder Information</I></B>&rdquo;) and, to the extent permitted by law, shall indemnify the
Company, its directors, officers and agents and each person or entity who controls the Company (within the meaning of the Securities
Act) against any losses, claims, damages, liabilities and out-of-pocket expenses (including without limitation reasonable attorneys&rsquo;
fees) resulting from any untrue or alleged untrue statement of material fact contained or incorporated by reference in the Registration
Statement, Prospectus or preliminary Prospectus or any amendment thereof or supplement thereto or any omission or alleged omission of
a material fact required to be stated therein or necessary to make the statements therein not misleading, but only to the extent that
such untrue or alleged untrue statement or omission is contained in any information or affidavit so furnished in writing by such Holder
expressly for use therein. The Holders of Registrable Securities shall indemnify the Underwriters, their officers, directors and each
person who controls such Underwriters (within the meaning of the Securities Act) to the same extent as provided in the foregoing with
respect to indemnification of the Company. For the avoidance of doubt, the obligation to indemnify under this Section 4.1.2 shall be
several, not joint and several, among the Holders of Registrable Securities, and the total indemnification liability of a Holder under
this Section 4.1.2 shall be in proportion to and limited to the net proceeds received by such Holder from the sale of Registrable Securities
pursuant to such Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.1.3
Any person or entity entitled to indemnification herein shall (a)&nbsp;give prompt written notice to the indemnifying party of any claim
with respect to which it seeks indemnification (provided that the failure to give prompt notice shall not impair any person&rsquo;s or
entity&rsquo;s right to indemnification hereunder to the extent such failure has not materially prejudiced the indemnifying party) and
(b)&nbsp;unless in such indemnified party&rsquo;s reasonable judgment a conflict of interest between such indemnified and indemnifying
parties may exist with respect to such claim, permit such indemnifying party to assume the defense of such claim with counsel reasonably
satisfactory to the indemnified party. If such defense is assumed, the indemnifying party shall not be subject to any liability for any
settlement made by the indemnified party without its consent (but such consent shall not be unreasonably withheld). An indemnifying party
who is not entitled to, or elects not to, assume the defense of a claim shall not be obligated to pay the fees and expenses of more than
one counsel for all parties indemnified by such indemnifying party with respect to such claim, unless in the reasonable judgment of any
indemnified party a conflict of interest may exist between such indemnified party and any other of such indemnified parties with respect
to such claim. No indemnifying party shall, without the consent of the indemnified party, consent to the entry of any judgment or enter
into any settlement which cannot be settled in all respects by the payment of money (and such money is so paid by the indemnifying party
pursuant to the terms of such settlement) or which settlement does not include as an unconditional term thereof the giving by the claimant
or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.1.4
The indemnification provided for under this Agreement shall remain in full force and effect regardless of any investigation made by or
on behalf of the indemnified party or any officer, director or controlling person or entity of such indemnified party and shall survive
the transfer of securities.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.1.5
If the indemnification provided under&nbsp;<U>Section&nbsp;4.1</U>&nbsp;hereof from the indemnifying party is unavailable or insufficient
to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities and expenses referred to herein, then the
indemnifying party, in lieu of indemnifying the indemnified party, shall contribute to the amount paid or payable by the indemnified
party as a result of such losses, claims, damages, liabilities and expenses in such proportion as is appropriate to reflect the relative
fault of the indemnifying party and the indemnified party, as well as any other relevant equitable considerations. The relative fault
of the indemnifying party and indemnified party shall be determined by reference to, among other things, whether any action in question,
including any untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact, was made
by, or relates to information supplied by, such indemnifying party or indemnified party, and the indemnifying party&rsquo;s and indemnified
party&rsquo;s relative intent, knowledge, access to information and opportunity to correct or prevent such action and the benefits received
by such indemnified party or indemnifying party;&nbsp;<U>provided</U>,&nbsp;<U>however</U>, that the liability of any Holder under this&nbsp;<U>Section
4.1.5</U>&nbsp;shall be limited to the amount of the net proceeds received by such Holder in such offering giving rise to such liability.
The amount paid or payable by a party as a result of the losses or other liabilities referred to above shall be deemed to include, subject
to the limitations set forth in&nbsp;<U>Sections 4.1.1</U>,&nbsp;<U>4.1.2</U>&nbsp;and&nbsp;<U>4.1.3</U>&nbsp;above, any legal or other
fees, charges or expenses reasonably incurred by such party in connection with any investigation or proceeding. The parties hereto agree
that it would not be just and equitable if contribution pursuant to this&nbsp;<U>Section 4.1.5</U>&nbsp;were determined by pro rata allocation
or by any other method of allocation, which does not take account of the equitable considerations referred to in this&nbsp;<U>Section
4.1.5</U>. No person or entity guilty of fraudulent misrepresentation (within the meaning of&nbsp;<U>Section&nbsp;11(f)</U>&nbsp;of the
Securities Act) shall be entitled to contribution pursuant to this&nbsp;<U>Section 4.1.5</U>&nbsp;from any person or entity who was not
guilty of such fraudulent misrepresentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
V<BR>
LOCK-UP</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1.
<U>Lock-up</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1.1
Each Lock-up Party agrees that it shall not, without the consent of the Company, Transfer&nbsp;any Lock-up Shares prior to the end of
the Lock-up Period (the&nbsp;&ldquo;<B><I>Lock-up</I></B>&rdquo;), subject to the early release provisions set forth in Section 5.1.5
below. Notwithstanding the foregoing, the provisions of&nbsp;<U>Section&nbsp;5.1&nbsp;</U>shall not apply to: (a) Transfers or distributions
to the Lock-up Party&rsquo;s current or former general or limited partners, managers or members, stockholders, other equityholders or
other direct or indirect affiliates (within the meaning of Rule 405 under the Securities Act) or to any investment fund or other entity
controlling, controlled by, managing or managed by or under common control with the undersigned or affiliates of the Lock-up Party or
who shares a common investment advisor with the Lock-up Party or to the estates of any of the foregoing; (b) transfers by bona fide gift
to a member of the Lock-up Party&rsquo;s immediate family or to a trust, the beneficiary of which is the Lock-up Party or a member of
the Lock-up Party&rsquo;s immediate family for estate planning purposes; (c) by virtue of will, intestate succession or the laws of descent
and distributions upon death of the Lock-up Party; (d) pursuant to a qualified domestic relations order, in each case where such transferee
agrees to be bound by the terms of this Agreement; (e) pursuant to a bona fide third-party tender offer, merger, consolidation, business
combination, stock purchase or other similar transaction or series of related transactions approved by the Board and made to all holders
of the Company&rsquo;s capital stock that would result in a Change in Control; (f) establishment of a trading plan pursuant to Rule 10b-1
under the Exchange Act for the transfer of restricted securities; provided, that such plan does not provide for the transfer of Lock-up
Shares during the Lock-up Period; (g) in the case of an entity, Transfers by virtue of the laws of the state of the entity&rsquo;s organization
and the entity&rsquo;s organizational documents upon dissolution of the entity, (h) transactions and Transfers (including without limitation
any swap, hedge, derivative or other synthetic arrangement) relating to Investor Shares or other securities acquired as part of the PIPE
Financing or issued in exchange for, or on conversion or exercise of, any Investor Shares or securities issued as part of the PIPE Financing,
(i) Transfers and transactions (including without limitation any swap, hedge, derivative or other synthetic arrangement) relating to
Common Stock or other securities convertible into or exercisable or exchangeable for Common Stock acquired in open market or other transactions
after the effective time of the Merger or that otherwise do not involve or relate to Lock-up Shares, (j) transactions in the event of
completion of a liquidation, merger, stock exchange or other similar transaction which results in all of the Company&rsquo;s securityholders
having the right to exchange their shares of Common Stock for cash, securities or other property, (k) transactions to satisfy any U.S.
federal, state, or local income tax obligations of the Lock-up Party (or its direct or indirect owners) arising from a change in the
U.S. Internal Revenue Code of 1986, as amended (the &ldquo;<B><I>Code</I></B>&rdquo;), or the U.S. Treasury Regulations promulgated thereunder
(the &ldquo;<B><I>Regulations</I></B>&rdquo;) after the date on which the Business Combination Agreement was executed by the parties,
and such change prevents the Merger from qualifying as a &ldquo;reorganization&rdquo; pursuant to Section 368 of the Code (and the Merger
does not qualify for similar tax-free treatment pursuant to any successor or other provision of the Code or Regulations taking into account
such changes), in each case solely and to the extent necessary to cover any tax liability as a direct result of the transaction, and
(l) Transfers or conversions of Non-Voting Common Stock into Voting Common Stock.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1.2
If any Transfer of Lock-up Shares prior to the end of the Lock-up Period is made or attempted contrary to the provisions of this Agreement,
such purported Transfer shall be null and void <I>ab initi</I>o, and the Company shall refuse to recognize any such purported transferee
of the Lock-up Shares as one of its equityholders for any purpose. In order to enforce this <U>Section 5.1</U>, the Company may impose
stop-transfer instructions with respect to the Lock-up Shares until the end of the Lock-up Period, except in compliance with the foregoing
restrictions.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1.3
During the Lock-up Period, each certificate evidencing any Lock-up Shares shall be stamped or otherwise imprinted with a legend in substantially
the following form, in addition to any other applicable legends:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;THE
SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER SET FORTH IN AN AMENDED AND RESTATED REGISTRATION
RIGHTS AGREEMENT, DATED AS OF SEPTEMBER 24, 2021, BY AND AMONG THE COMPANY (THE &ldquo;ISSUER&rdquo;), THE ISSUER&rsquo;S STOCKHOLDERS
NAMED THEREIN AND CERTAIN OTHER PARTIES NAMED THEREIN. A COPY OF SUCH AGREEMENT WILL BE FURNISHED WITHOUT CHARGE BY THE ISSUER TO THE
HOLDER HEREOF UPON WRITTEN REQUEST.&rdquo;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Promptly
upon the expiration of the Lock-up Period, the Company will make best efforts to remove such legend from the certificates evidencing
the Lock-up Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1.4
For the avoidance of doubt, each Lock-up Party shall retain all of its rights as a stockholder of the Company during the Lock-up Period
including the right to vote any Lock-up Shares.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1.5
In the event that the Company releases or waives, in full or in part, any Lock-up Party (&ldquo;<B><I>Released Lock-up Party</I></B>&rdquo;)
from the Lock-up, then the same percentage of Lock-up Shares held by the other Lock-up Parties as the percentage of Lock-up Shares held
by such Released Lock-up Party to such other Lock-up Party&rsquo;s aggregate number of Lock-up Shares that are the subject of such waiver
or release shall be automatically, immediately and fully released on the same terms from the Lock-Up; <U>provided</U>, that no such release
shall apply unless the Company releases or waives from the Lock-up, in full or in part, Lock-Up Shares (i) held by any officer or director,
or (ii) held by stockholders which individually or in the aggregate represent more than one percent (1%) of the Company&rsquo;s outstanding
Common Stock (after giving effect to conversion into Common Stock of all outstanding preferred stock of the Company, par value $0.0001
per share). In the event that, as a result of this subsection, any Lock-up Shares owned by Lock-up Parties are to be released from the
restrictions imposed by Lock-up, the Company shall notify the Lock-up Parties in writing at least three (3) business days prior to the
effective date of such release or waiver, which notice shall state the percentage of Lock-up Shares held by the Lock-up Parties to be
released and the effective date of such release.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1.6
The Lock-up Period shall terminate upon the earlier of (i) 180 days after the Closing Date, or (ii) the closing of a merger, liquidation,
stock exchange, reorganization or other similar transaction after the Closing Date that results in all of the public stockholders of
the Company having the right to exchange their shares of Common Stock for cash securities or other property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
VI<BR>
MISCELLANEOUS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1.
<U>Notices</U>. All notices, requests, claims, demands and other communications under this Agreement shall be in writing and shall be
given (and shall be deemed to have been duly given) by delivery in person, by e-mail during normal business hours (and otherwise as of
the immediately following Business Day) (upon confirmation of receipt by the intended recipient, but excluding any automated reply, such
as an out-of-office notification), or by registered or certified mail (postage prepaid, return receipt requested) (upon receipt thereof).
Any notice or communication under this Agreement must be addressed, if to the Company, to: 1177 Avenue of the Americas, Fl 40, New York,
NY 10036,&nbsp;and, if to any Holder, at such Holder&rsquo;s address or contact information as set forth in the Company&rsquo;s books
and records. Any party may change its address for notice at any time and from time to time by written notice to the other parties hereto,
and such change of address shall become effective thirty (30)&nbsp;days after delivery of such notice as provided in this&nbsp;<U>Section&nbsp;6.1</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.2.
<U>Assignment; No Third Party Beneficiaries</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.2.1
Subject to <U>Section 6.2.3</U>, this Agreement and the rights, duties and obligations of the Company and the Holders of Registrable
Securities, as the case may be, hereunder may not be assigned or delegated by the Company or the Holders of Registrable Securities, as
the case may be, in whole or in part.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.2.2
Subject to <U>Section 6.2.4</U> and <U>Section 6.2.5</U>, this Agreement and the rights, duties and obligations of a Holder hereunder
may be assigned in whole or in part to such Holder&rsquo;s Permitted Transferees to which it transfers Registrable Securities; provided
that (1) immediately following such transfer such Registrable Securities remain Registrable Securities, and (2) with respect to the Sponsor
and the Jasper Holders, the rights hereunder that are personal to such Holder may not be assigned or delegated in whole or in part, except
that (i) the Sponsor shall be permitted to transfer its rights hereunder as the Sponsor to one or more affiliates or any direct or indirect
partners, members or equity holders of the Sponsor and (ii) each of the Jasper Holders shall be permitted to transfer its rights hereunder
as the Jasper Holders to one or more affiliates or any direct or indirect partners, members or equity holders of such Jasper Holder (it
being understood that no such transfer shall reduce or modify any rights of such Jasper Holder or such transferee). Prior to the expiration
of the applicable Lock-up Period, no Holder subject to any such Lock-up Period may assign or delegate such Holder&rsquo;s rights, duties
or obligations under this Agreement, in whole or in part, in violation of the applicable Lock-up Period, except in connection with a
transfer of Registrable Securities by such Holder to a Permitted Transferee but only if such Permitted Transferee agrees to become bound
by the transfer restrictions set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.2.3
This Agreement and the provisions hereof shall be binding upon and shall inure to the benefit of each of the parties and its successors
and the permitted assigns of the Holders, which shall include Permitted Transferees.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.2.4
This Agreement shall not confer any rights or benefits on any persons or entities that are not parties hereto, other than as expressly
set forth in this Agreement and&nbsp;<U>Section&nbsp;6.2</U>&nbsp;hereof.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.2.5
No assignment by any party hereto of such party&rsquo;s rights, duties and obligations hereunder shall be binding upon or obligate the
Company unless and until the Company shall have received (a)&nbsp;written notice of such assignment as provided in&nbsp;<U>Section&nbsp;6.1</U>&nbsp;hereof
and (b)&nbsp;the written agreement of the assignee, in a form reasonably satisfactory to the Company, to be bound by the terms and provisions
of this Agreement (which may be accomplished by an addendum or certificate of joinder to this Agreement). Any transfer or assignment
made other than as provided in this&nbsp;<U>Section&nbsp;6.2</U>&nbsp;shall be null and void.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.3.
<U>Counterparts</U>. This Agreement may be executed in multiple counterparts (including facsimile or PDF counterparts), each of which
shall be deemed an original, and all of which together shall constitute the same instrument, but only one of which need be produced.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.4.
<U>Governing Law; Venue</U>. NOTWITHSTANDING THE PLACE WHERE THIS AGREEMENT MAY&nbsp;BE EXECUTED BY ANY OF THE PARTIES HERETO, THE PARTIES
EXPRESSLY AGREE THAT (A)&nbsp;THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED UNDER THE LAWS OF THE STATE OF NEW YORK AS APPLIED TO
AGREEMENTS AMONG NEW YORK RESIDENTS ENTERED INTO AND TO BE PERFORMED ENTIRELY WITHIN NEW YORK, WITHOUT REGARD TO THE CONFLICT OF LAW
PROVISIONS OF SUCH JURISDICTION AND (B) THE VENUE FOR ANY ACTION TAKEN WITH RESPECT TO THIS AGREEMENT SHALL BE ANY STATE OR FEDERAL COURT
IN NEW YORK COUNTY IN THE STATE OF NEW YORK.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">EACH
PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT
ISSUES, AND, THEREFORE, EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW,
ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT TO ANY ACTION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION
WITH OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.5.
<U>Amendments and Modifications</U>. Upon the written consent of the Company and the Holders of a majority-in-interest of the Registrable
Securities at the time in question, compliance with any of the provisions, covenants and conditions set forth in this Agreement may be
waived, or any of such provisions, covenants or conditions may be amended or modified;&nbsp;<U>provided</U>,&nbsp;<U>however</U>, that
notwithstanding the foregoing, (a) any amendment hereto or waiver hereof that adversely affects one Holder or group of affiliated Holders,
solely in his, her or its capacity as a holder of the shares of capital stock of the Company, in a manner that is materially different
from the other Holders (in such capacity) shall require the consent of the Holder so affected, and (b) any amendment hereto or waiver
hereof that adversely affects the rights or increases the obligations of any Holder shall require the consent of such Holder. No course
of dealing between any Holder or the Company and any other party hereto or any failure or delay on the part of a Holder or the Company
in exercising any rights or remedies under this Agreement shall operate as a waiver of any rights or remedies of any Holder or the Company.
No single or partial exercise of any rights or remedies under this Agreement by a party shall operate as a waiver or preclude the exercise
of any other rights or remedies hereunder or thereunder by such party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.6.
<U>Other Registration Rights</U>. Other than the Sponsor and Third-Party Investor Stockholders who each have registration rights with
respect to their Investor Shares pursuant to their respective Subscription Agreements, the Company represents and warrants that no person
or entity, other than a Holder of Registrable Securities, has any right to require the Company to register any securities of the Company
for sale or to include such securities of the Company in any Registration Statement filed by the Company for the sale of securities for
its own account or for the account of any other person. Further, the Company represents and warrants that this Agreement supersedes any
other registration rights agreement or agreement with similar terms and conditions and in the event of a conflict between any such agreement
or agreements and this Agreement, the terms of this Agreement shall prevail. The Company will not grant any person or entity with any
registration rights with respect to the capital stock of the Company that are senior to or in conflict or inconsistent with the rights
of the Holders as set forth in ARTICLE II in any material respect (it being understood that this shall not preclude the grant of additional
demand or piggyback registration rights in and of themselves so long as such rights are not prior in right to the rights under this Agreement).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.7.
<U>Termination of Existing Registration Rights</U>. The registration rights granted under this Agreement shall supersede any registration,
qualification or similar rights of the Holders with respect to any shares or securities of the Company or Jasper granted under any other
agreement, including, but not limited to, the Original RRA and that certain Investors&rsquo; Rights Agreement, dated as of November 21,
2019, by and among Jasper and the other parties thereto, any of such preexisting registration, qualification or similar rights and such
agreements shall be terminated and of no further force and effect.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.8.
<U>Term</U>. This Agreement shall terminate on the earlier of (a) the tenth (10<SUP>th</SUP>) anniversary of the date of this Agreement,
(b) the date as of which all of the Registrable Securities have been sold or disposed of and (c) with respect to any particular Holder,
on the date such Holder no longer holds Registrable Securities. The provisions on <U>Section 3.5</U> and ARTICLE IV shall survive any
termination.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.9.
<U>Holder Information</U>. Each Holder agrees, if requested in writing, to represent to the Company the total number of Registrable Securities
held by such Holder in order for the Company to make determinations hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>[SIGNATURE
PAGES FOLLOW]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF</B>, the undersigned have caused this Agreement to be executed as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>COMPANY:</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">JASPER
    THERAPEUTICS, INC.,</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">a Delaware
    corporation</FONT></P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Bala Venkataraman</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bala Venkataraman</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">AMPLITUDE
    HEALTHCARE</FONT>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">HOLDINGS
    LLC</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">By: Avego
    Healthcare Capital,</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">L.P.,
    its Managing Member</FONT></P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Bala Venkataraman</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bala Venkataraman</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing Member</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[<I>Signature
Page to Amended and Restated Registration Rights Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>HOLDER:</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Judith Shizuru</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Judith Shizuru</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Judith Shizuru</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[<I>Signature
Page to Amended and Restated Registration Rights Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>HOLDER:</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Susan Prohaska</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Susan Prohaska</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">Susan Prohaska</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[<I>Signature
Page to Amended and Restated Registration Rights Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>HOLDER:</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Abingworth Bioventures VII L.P.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ John Heard</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">John Heard</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Partner, General Counsel</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">[<I>Signature
Page to Amended and Restated Registration Rights Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>HOLDER:</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Qiming U.S. Healthcare Fund II, L.P.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Mark McDade</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Mark McDade</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Co-founder and Partner</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">[<I>Signature
Page to Amended and Restated Registration Rights Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>HOLDER:</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Citadel Multi-Strategy Equities Master Fund Ltd.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Michael Weiner</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Michael Weiner</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Authorized Signatory</P></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">[<I>Signature
Page to Amended and Restated Registration Rights Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>HOLDER:</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Roche Finance Ltd</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Felix Kobel</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Felix Kobel</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Authorized Signatory</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Valentin Baltzer</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">Valentin Baltzer</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">Authorized Signatory</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">[<I>Signature
Page to Amended and Restated Registration Rights Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>Schedule
1</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jasper
Holders</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Judith
                                            Shizuru</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Susan
                                            Prohaska</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Abingworth
                                            Bioventures VII L.P.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Qiming
                                            U.S. Healthcare Fund II, L.P.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Citadel Multi-Strategy
                                            Equities Master Fund Ltd.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Roche Finance
                                            Ltd.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">26</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>5
<FILENAME>ea147929ex10-3_jasper.htm
<DESCRIPTION>JASPER THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jasper
Therapeutics, Inc.<BR>
2021 Equity Incentive Plan<BR>
Adopted by the Board of Directors: August 24, 2021<BR>
Approved by the Stockholders: September 22, 2021</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">1.&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General<FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)&nbsp;Plan
Purpose</B>. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide
incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which
such persons may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)&nbsp;Available
Awards</B>. The Plan provides for the grant of the following Awards: (i)&nbsp;Incentive Stock Options; (ii)&nbsp;Nonstatutory Stock Options;
(iii)&nbsp;SARs; (iv)&nbsp;Restricted Stock Awards; (v)&nbsp;RSU Awards; (vi)&nbsp;Performance Awards; and (vii)&nbsp;Other Awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)&nbsp;Adoption
Date; Effective Date</B>. The Plan will come into existence on the Adoption Date, but no Award may be granted prior to the Effective
Date.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">2.&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
Subject to the Plan<FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)&nbsp;Share
Reserve</B>. Subject to adjustment in accordance with Section&nbsp;2(c) and any adjustments as necessary to implement any Capitalization
Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed&nbsp;4,400,000 shares,
plus a number of shares equal to the number of Returning Shares, if any, as such shares become available from time to time. In addition,
subject to any adjustments as necessary to implement any Capitalization Adjustments, such aggregate number of shares of Common Stock
will automatically increase on January&nbsp;1 of each year for a period of ten years commencing on January&nbsp;1, 2022 and ending on
(and including) January&nbsp;1, 2031, in an amount equal to&nbsp;the lesser of (i) 4% of the total number of shares of Common Stock outstanding
on December&nbsp;31 of the preceding year, or (ii) 2,750,000 shares of Common Stock; provided, however, that the Board may act prior
to January&nbsp;1<SUP>st</SUP> of a given year to provide that the increase for such year will be a lesser number of shares of Common
Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)&nbsp;Aggregate
Incentive Stock Option Limit</B>. Notwithstanding anything to the contrary in Section&nbsp;2(a) and subject to any adjustments as necessary
to implement any Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the
exercise of Incentive Stock Options is&nbsp;4,400,000 shares, which such amount shall be increased commencing on January&nbsp;1, 2022
and ending on (and including) January&nbsp;1, 2031, in an amount equal to&nbsp;the lesser of (i) 4% of the total number of shares of
Common Stock outstanding on December&nbsp;31 of the preceding year, (ii) 2,750,000 shares of Common stock, and (iii) such amount as may
be determined by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)&nbsp;Share
Reserve Operation</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)&nbsp;Limit
Applies to Common Stock Issued Pursuant to Awards</B>. For clarity, the Share Reserve is a limit on the number of shares of Common Stock
that may be issued pursuant to Awards and does not limit the granting of Awards, except that the Company will keep available at all times
the number of shares of Common Stock reasonably required to satisfy its obligations to issue shares pursuant to such Awards. Shares may
be issued in connection with a merger or acquisition as permitted by, as applicable, Nasdaq Listing Rule&nbsp;5635(c), NYSE Listed Company
Manual Section&nbsp;303A.08, NYSE American Company Guide Section&nbsp;711 or other applicable rule, and such issuance will not reduce
the number of shares available for issuance under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)&nbsp;Actions
that Do Not Constitute Issuance of Common Stock and Do Not Reduce Share Reserve</B>. The following actions do not result in an issuance
of shares under the Plan and accordingly do not reduce the number of shares subject to the Share Reserve and available for issuance under
the Plan: (1)&nbsp;the expiration or termination of any portion of an Award without the shares covered by such portion of the Award having
been issued, (2)&nbsp;the settlement of any portion of an Award in cash (i.e., the Participant receives cash rather than Common Stock),
(3)&nbsp;the withholding of shares that would otherwise be issued by the Company to satisfy the exercise, strike or purchase price of
an Award; or (4)&nbsp;the withholding of shares that would otherwise be issued by the Company to satisfy a tax withholding obligation
in connection with an Award. For the avoidance of doubt, with respect to a SAR, only shares of Common Stock which are issued upon settlement
of the SAR shall count towards reducing the number of shares available for issuance under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iii)&nbsp;Reversion
of Previously Issued Shares of Common Stock to Share Reserve</B>. The following shares of Common Stock previously issued pursuant to
an Award and accordingly initially deducted from the Share Reserve will be added back to the Share Reserve and again become available
for issuance under the Plan: (1)&nbsp;any shares that are forfeited back to or repurchased by the Company because of a failure to meet
a contingency or condition required for the vesting of such shares; (2)&nbsp;any shares that are reacquired by the Company to satisfy
the exercise, strike or purchase price of an Award; and (3)&nbsp;any shares that are reacquired by the Company to satisfy a tax withholding
obligation in connection with an Award.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">3.&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eligibility
and Limitations<FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)&nbsp;Eligible
Award Recipients</B>. Subject to the terms of the Plan, Employees, Directors and Consultants are eligible to receive Awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)&nbsp;Specific
Award Limitations</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)&nbsp;Limitations
on Incentive Stock Option Recipients</B>. Incentive Stock Options may be granted only to Employees of the Company or a &ldquo;parent
corporation&rdquo; or &ldquo;subsidiary corporation&rdquo; thereof (as such terms are defined in Sections&nbsp;424(e) and (f)&nbsp;of
the Code).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)&nbsp;Incentive
Stock Option $100,000 Limitation</B>. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common
Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under
all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply
with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which
they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary
provision of the applicable Option Agreement(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iii)&nbsp;Limitations
on Incentive Stock Options Granted to Ten Percent Stockholders</B>. A Ten Percent Stockholder may not be granted an Incentive Stock Option
unless (i)&nbsp;the exercise price of such Option is at least&nbsp;110% of the Fair Market Value on the date of grant of such Option
and (ii)&nbsp;the Option is not exercisable after the expiration of five years from the date of grant of such Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iv)&nbsp;Limitations
on Nonstatutory Stock Options and SARs</B>. Nonstatutory Stock Options and SARs may not be granted to Employees, Directors and Consultants
who are providing Continuous Service only to any &ldquo;parent&rdquo; of the Company (as such term is defined in Rule&nbsp;405) unless
the stock underlying such Awards is treated as &ldquo;service recipient stock&rdquo; under Section&nbsp;409A because the Awards are granted
pursuant to a corporate transaction (such as a spin off transaction) or unless such Awards otherwise comply with the distribution requirements
of Section&nbsp;409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)&nbsp;Aggregate
Incentive Stock Option Limit</B>. The aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise
of Incentive Stock Options is the number of shares specified in Section&nbsp;2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)&nbsp;Non-Employee
Director Compensation Limit</B>. The aggregate value of all compensation granted or paid, as applicable, in each case following the Effective
Date, to any individual for service as a Non-Employee Director with respect to any fiscal year, including Awards granted and cash fees
paid by the Company to such Non-Employee Director for his or her service as a Non-Employee Director, will not exceed (i) $750,000 in
total value or (ii)&nbsp;in the event such Non-Employee Director is first appointed or elected to the Board during such fiscal year,
$1,000,000 in total value, in each case calculating the value of any equity awards based on the grant date fair value of such equity
awards for financial reporting purposes.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">4.&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
and Stock Appreciation Rights<FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Option and SAR will have such terms and conditions as determined by the Board. Each Option will be designated in writing as an Incentive
Stock Option or Nonstatutory Stock Option at the time of grant; provided, however, that if an Option is not so designated, then such
Option will be a Nonstatutory Stock Option, and the shares purchased upon exercise of each type of Option will be separately accounted
for. Each SAR will be denominated in shares of Common Stock equivalents. The terms and conditions of separate Options and SARs need not
be identical; provided, however, that each Option Agreement and SAR Agreement will conform&nbsp;(through incorporation of provisions
hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)&nbsp;Term</B>.
Subject to Section&nbsp;3(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of ten years
from the date of grant of such Award or such shorter period specified in the Award Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)&nbsp;Exercise
or Strike Price</B>. Subject to Section&nbsp;3(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or
SAR will not be less than&nbsp;100% of the Fair Market Value on the date of grant of such Award. Notwithstanding the foregoing, an Option
or SAR may be granted with an exercise or strike price lower than&nbsp;100% of the Fair Market Value on the date of grant of such Award
if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate
Transaction and in a manner consistent with the provisions of Sections&nbsp;409A and, if applicable, 424(a) of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)&nbsp;Exercise
Procedure and Payment of Exercise Price for Options</B>. In order to exercise an Option, the Participant must provide notice of exercise
to the Plan Administrator in accordance with the procedures specified in the Option Agreement or otherwise provided by the Company. The
Board has the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability
to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment. The exercise
price of an Option may be paid, to the extent permitted by Applicable Law and as determined by the Board, by one or more of the following
methods of payment to the extent set forth in the Option Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)&nbsp;</B>by
cash or check, bank draft or money order payable to the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)&nbsp;</B>pursuant
to a &ldquo;cashless exercise&rdquo; program developed under Regulation&nbsp;T as promulgated by the U.S.&nbsp;Federal Reserve Board
that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company
or the receipt of irrevocable instructions to pay the exercise price to the Company from the sales proceeds;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iii)&nbsp;</B>by
delivery to the Company (either by actual delivery or attestation) of shares of Common Stock that are already owned by the Participant
free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not
exceed the exercise price, provided that (1)&nbsp;at the time of exercise the Common Stock is publicly traded, (2)&nbsp;any remaining
balance of the exercise price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment, (3)&nbsp;such
delivery would not violate any Applicable Law or agreement restricting the redemption of the Common Stock, (4)&nbsp;any certificated
shares are endorsed or accompanied by an executed assignment separate from certificate and (5)&nbsp;such shares have been held by the
Participant for any minimum period necessary to avoid adverse accounting treatment as a result of such delivery;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iv)&nbsp;</B>if
the Option is a Nonstatutory Stock Option, by a &ldquo;net exercise&rdquo; arrangement pursuant to which the Company will reduce the
number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value on the date of
exercise that does not exceed the exercise price, provided that (1)&nbsp;such shares used to pay the exercise price will not be exercisable
thereafter and (2)&nbsp;any remaining balance of the exercise price not satisfied by such net exercise is paid by the Participant in
cash or other permitted form of payment; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(v)&nbsp;</B>in
any other form of consideration that may be acceptable to the Board and permissible under Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)&nbsp;Exercise
Procedure and Payment of Appreciation Distribution for SARs</B>. In order to exercise any SAR, the Participant must provide notice of
exercise to the Plan Administrator in accordance with the SAR Agreement. The appreciation distribution payable to a Participant upon
the exercise of a SAR will not be greater than an amount equal to the excess of (i)&nbsp;the aggregate Fair Market Value on the date
of exercise of a number of shares of Common Stock equal to the number of Common Stock equivalents that are vested and being exercised
under such SAR, over (ii)&nbsp;the strike price of such SAR. Such appreciation distribution may be paid to the Participant in the form
of Common Stock or cash (or any combination of Common Stock and cash) or in any other form of payment, as determined by the Board and
specified in the SAR Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e)&nbsp;Transferability</B>.
Options and SARs may not be transferred to third-party financial institutions for value. The Board may impose such additional limitations
on the transferability of an Option or SAR as it determines. In the absence of any such determination by the Board, the following restrictions
on the transferability of Options and SARs will apply, provided that except as explicitly provided herein, neither an Option nor a SAR
may be transferred for consideration and provided, further, that if an Option is an Incentive Stock Option, such Option may be deemed
to be a Nonstatutory Stock Option as a result of such transfer:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)&nbsp;Restrictions
on Transfer</B>. An Option or SAR will not be transferable, except by will or by the laws of descent and distribution, and will be exercisable
during the lifetime of the Participant only by the Participant; provided, however, that the Board may permit transfer of an Option or
SAR in a manner that is not prohibited by applicable tax and securities laws upon the Participant&rsquo;s request, including to a trust
if the Participant is considered to be the sole beneficial owner of such trust (as determined under Section&nbsp;671 of the Code and
applicable U.S.&nbsp;state law) while such Option or SAR is held in such trust, provided that the Participant and the trustee enter into
a transfer and other agreements required by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)&nbsp;Domestic
Relations Orders</B>. Notwithstanding the foregoing, subject to the execution of transfer documentation in a format acceptable to the
Company and subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to a domestic
relations order.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(f)&nbsp;Vesting</B>.
The Board may impose such restrictions on or conditions to the vesting and/or exercisability of an Option or SAR as determined by the
Board. Except as otherwise provided in the applicable Award Agreement or other written agreement between a Participant and the Company,
vesting of Options and SARs will cease upon termination of the Participant&rsquo;s Continuous Service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(g)&nbsp;Termination
of Continuous Service for Cause</B>. Except as explicitly otherwise provided in the Award Agreement or other written agreement between
a Participant and the Company, if a Participant&rsquo;s Continuous Service is terminated for Cause, the Participant&rsquo;s Options and
SARs will terminate and be forfeited immediately upon such termination of Continuous Service, and the Participant will be prohibited
from exercising any portion (including any vested portion) of such Awards on and after the date of such termination of Continuous Service
and the Participant will have no further right, title or interest in such forfeited Award, the shares of Common Stock subject to the
forfeited Award, or any consideration in respect of the forfeited Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(h)&nbsp;Post-Termination
Exercise Period Following Termination of Continuous Service for Reasons Other than Cause</B>. Subject to Section&nbsp;4(i), if a Participant&rsquo;s
Continuous Service terminates for any reason other than for Cause, the Participant may exercise his or her Option or SAR to the extent
vested, but only within the following period of time or, if applicable, such other period of time provided in the Award Agreement or
other written agreement between a Participant and the Company; provided, however, that in no event may such Award be exercised after
the expiration of its maximum term (as set forth in Section&nbsp;4(a)):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)&nbsp;</B>three
months following the date of such termination if such termination is a termination without Cause (other than any termination due to the
Participant&rsquo;s Disability or death);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)&nbsp;</B>12&nbsp;months
following the date of such termination if such termination is due to the Participant&rsquo;s Disability;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iii)&nbsp;</B>18&nbsp;months
following the date of such termination if such termination is due to the Participant&rsquo;s death; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iv)&nbsp;</B>18&nbsp;months
following the date of the Participant&rsquo;s death if such death occurs following the date of such termination but during the period
such Award is otherwise exercisable (as provided in (i)&nbsp;or (ii)&nbsp;above).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the date of such termination, to the extent the Participant does not exercise such Award within the applicable Post-Termination Exercise
Period (or, if earlier, prior to the expiration of the maximum term of such Award), such unexercised portion of the Award will terminate,
and the Participant will have no further right, title or interest in terminated Award, the shares of Common Stock subject to the terminated
Award, or any consideration in respect of the terminated Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)&nbsp;Restrictions
on Exercise; Extension of Exercisability</B>. A Participant may not exercise an Option or SAR at any time that the issuance of shares
of Common Stock upon such exercise would violate Applicable Law. Except as otherwise provided in the Award Agreement or other written
agreement between a Participant and the Company, if a Participant&rsquo;s Continuous Service terminates for any reason other than for
Cause and, at any time during the last thirty days of the applicable Post-Termination Exercise Period: (i)&nbsp;the exercise of the Participant&rsquo;s
Option or SAR would be prohibited solely because the issuance of shares of Common Stock upon such exercise would violate Applicable Law,
or (ii)&nbsp;the immediate sale of any shares of Common Stock issued upon such exercise would violate the Company&rsquo;s Trading Policy,
then the applicable Post-Termination Exercise Period will be extended to the last day of the calendar month that commences following
the date the Award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month
to apply if any of the foregoing restrictions apply at any time during such extended exercise period, generally without limitation as
to the maximum permitted number of extensions; provided, however, that in no event may such Award be exercised after the expiration of
its maximum term (as set forth in Section&nbsp;4(a)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(j)&nbsp;Non-Exempt
Employees</B>. No Option or SAR, whether or not vested, granted to an Employee who is a non-exempt employee for purposes of the Fair
Labor Standards Act of&nbsp;1938, as amended, will be first exercisable for any shares of Common Stock until at least six months following
the date of grant of such Award. Notwithstanding the foregoing, in accordance with the provisions of the Worker Economic Opportunity
Act, any vested portion of such Award may be exercised earlier than six months following the date of grant of such Award in the event
of (i)&nbsp;such Participant&rsquo;s death or Disability, (ii)&nbsp;a Corporate Transaction in which such Award is not assumed, continued
or substituted, (iii)&nbsp;a Change in Control, or (iv)&nbsp;such Participant&rsquo;s retirement (as such term may be defined in the
Award Agreement or another applicable agreement or, in the absence of any such definition, in accordance with the Company&rsquo;s then
current employment policies and guidelines). This Section&nbsp;4(j) is intended to operate so that any income derived by a non-exempt
employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(k)&nbsp;Whole
Shares</B>. Options and SARs may be exercised only with respect to whole shares of Common Stock or their equivalents.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">5.&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
Other Than Options and Stock Appreciation Rights<FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)&nbsp;Restricted
Stock Awards and RSU Awards</B>. Each Restricted Stock Award and RSU Award will have such terms and conditions as determined by the Board;
provided, however, that each Restricted Stock Award Agreement and RSU Award Agreement will conform&nbsp;(through incorporation of the
provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)&nbsp;Form
of Award</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(1)&nbsp;</B>RSAs:
To the extent consistent with the Company&rsquo;s Bylaws, at the Board&rsquo;s election, shares of Common Stock subject to a Restricted
Stock Award may be (i)&nbsp;held in book entry form subject to the Company&rsquo;s instructions until such shares become vested or any
other restrictions lapse, or (ii)&nbsp;evidenced by a certificate, which certificate will be held in such form and manner as determined
by the Board. Unless otherwise determined by the Board, a Participant will have voting and other rights as a stockholder of the Company
with respect to any shares subject to a Restricted Stock Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(2)&nbsp;</B>RSUs:
A RSU Award represents a Participant&rsquo;s right to be issued on a future date the number of shares of Common Stock that is equal to
the number of restricted stock units subject to the RSU Award. As a holder of a RSU Award, a Participant is an unsecured creditor of
the Company with respect to the Company&rsquo;s unfunded obligation, if any, to issue shares of Common Stock in settlement of such Award
and nothing contained in the Plan or any RSU Agreement, and no action taken pursuant to its provisions, will create or be construed to
create a trust of any kind or a fiduciary relationship between a Participant and the Company or an Affiliate or any other person. A Participant
will not have voting or any other rights as a stockholder of the Company with respect to any RSU Award (unless and until shares are actually
issued in settlement of a vested RSU Award).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)&nbsp;Consideration</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(1)&nbsp;</B>RSA:
A Restricted Stock Award may be granted in consideration for (A)&nbsp;cash or check, bank draft or money order payable to the Company,
(B)&nbsp;past services to the Company or an Affiliate, or (C)&nbsp;any other form of consideration as the Board may determine and permissible
under Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(2)&nbsp;</B>RSU:
Unless otherwise determined by the Board at the time of grant, a RSU Award will be granted in consideration for the Participant&rsquo;s
services to the Company or an Affiliate, such that the Participant will not be required to make any payment to the Company (other than
such services) with respect to the grant or vesting of the RSU Award, or the issuance of any shares of Common Stock pursuant to the RSU
Award. If, at the time of grant, the Board determines that any consideration must be paid by the Participant (in a form other than the
Participant&rsquo;s services to the Company or an Affiliate) upon the issuance of any shares of Common Stock in settlement of the RSU
Award, such consideration may be paid in any form of consideration as the Board may determine and permissible under Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iii)&nbsp;Vesting</B>.
The Board may impose such restrictions on or conditions to the vesting of a Restricted Stock Award or RSU Award as determined by the
Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate,
vesting of Restricted Stock Awards and RSU Awards will cease upon termination of the Participant&rsquo;s Continuous Service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iv)&nbsp;Termination
of Continuous Service</B>. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the
Company, if a Participant&rsquo;s Continuous Service terminates for any reason, (i)&nbsp;the Company may receive through a forfeiture
condition or a repurchase right any or all of the shares of Common Stock held by the Participant under his or her Restricted Stock Award
that have not vested as of the date of such termination as set forth in the Restricted Stock Award Agreement and (ii)&nbsp;any portion
of his or her RSU Award that has not vested will be forfeited upon such termination and the Participant will have no further right, title
or interest in the RSU Award, the shares of Common Stock issuable pursuant to the RSU Award, or any consideration in respect of the RSU
Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(v)&nbsp;Dividends
and Dividend Equivalents</B>. Dividends or dividend equivalents may be paid or credited, as applicable, with respect to any shares of
Common Stock subject to a Restricted Stock Award or RSU Award, as determined by the Board and specified in the Award Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(vi)&nbsp;Settlement
of RSU Awards</B>. A RSU Award may be settled by the issuance of shares of Common Stock or cash (or any combination thereof) or in any
other form of payment, as determined by the Board and specified in the RSU Award Agreement. At the time of grant, the Board may determine
to impose such restrictions or conditions that delay such delivery to a date following the vesting of the RSU Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)&nbsp;Performance
Awards</B>. With respect to any Performance Award, the length of any Performance Period, the Performance Goals to be achieved during
the Performance Period, the other terms and conditions of such Award, and the measure of whether and to what degree such Performance
Goals have been attained will be determined by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)&nbsp;Other
Awards</B>. Other Awards may be granted either alone or in addition to Awards provided for under Section&nbsp;4 and the preceding provisions
of this Section&nbsp;5. Subject to the provisions of the Plan, the Board will have sole and complete discretion to determine the persons
to whom and the time or times at which such Other Awards will be granted, the number of shares of Common Stock (or the cash equivalent
thereof) to be granted pursuant to such Other Awards and all other terms and conditions of such Other Awards.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">6.&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
Upon Changes in Common Stock; Other Corporate Events<FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)&nbsp;Capitalization
Adjustments</B>. In the event of a Capitalization Adjustment, the Board shall appropriately and proportionately adjust: (i)&nbsp;the
class(es) and maximum number of shares of Common Stock subject to the Plan and the maximum number of shares by which the Share Reserve
may annually increase pursuant to Section 2(a), (ii)&nbsp;the class(es) and maximum number of shares that may be issued pursuant to the
exercise of Incentive Stock Options pursuant to Section&nbsp;2(b), and (iii)&nbsp;the class(es) and number of securities and exercise
price, strike price or purchase price of Common Stock subject to outstanding Awards. The Board shall make such adjustments, and its determination
shall be final, binding and conclusive. Notwithstanding the foregoing, no fractional shares or rights for fractional shares of Common
Stock shall be created in order to implement any Capitalization Adjustment. The Board shall determine an appropriate equivalent benefit,
if any, for any fractional shares or rights to fractional shares that might be created by the adjustments referred to in the preceding
provisions of this Section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)&nbsp;Dissolution
or Liquidation</B>. Except as otherwise provided in the Award Agreement, in the event of a dissolution or liquidation of the Company,
all outstanding Awards (other than Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition
or the Company&rsquo;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and
the shares of Common Stock subject to the Company&rsquo;s repurchase rights or subject to a forfeiture condition may be repurchased or
reacquired by the Company notwithstanding the fact that the holder of such Award is providing Continuous Service, provided, however,
that the Board may determine to cause some or all Awards to become fully vested, exercisable and/or no longer subject to repurchase or
forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but
contingent on its completion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)&nbsp;Corporate
Transaction</B>. The following provisions will apply to Awards in the event of a Corporate Transaction except as set forth in Section&nbsp;11,
and unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate
and the Participant or unless otherwise expressly provided by the Board at the time of grant of an Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)&nbsp;Awards
May Be Assumed</B>. In the event of a Corporate Transaction, any surviving corporation or acquiring corporation (or the surviving or
acquiring corporation&rsquo;s parent company) may assume or continue any or all Awards outstanding under the Plan or may substitute similar
awards for Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders
of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common
Stock issued pursuant to Awards may be assigned by the Company to the successor of the Company (or the successor&rsquo;s parent company,
if any), in connection with such Corporate Transaction. A surviving corporation or acquiring corporation (or its parent) may choose to
assume or continue only a portion of an Award or substitute a similar award for only a portion of an Award, or may choose to assume or
continue the Awards held by some, but not all Participants. The terms of any assumption, continuation or substitution will be set by
the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)&nbsp;Awards
Held by Current Participants</B>. In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation
(or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards,
then with respect to Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service
has not terminated prior to the effective time of the Corporate Transaction (referred to as the &ldquo;<B>Current Participants</B>&rdquo;),
the vesting of such Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Awards may be exercised) will
be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the
Corporate Transaction) as the Board determines (or, if the Board does not determine such a date, to the date that is five days prior
to the effective time of the Corporate Transaction), and such Awards will terminate if not exercised (if applicable) at or prior to the
effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Awards
will lapse (contingent upon the effectiveness of the Corporate Transaction). With respect to the vesting of Performance Awards that will
accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection&nbsp;(ii) and that have multiple vesting levels
depending on the level of performance, unless otherwise provided in the Award Agreement, the vesting of such Performance Awards will
accelerate at&nbsp;100% of the target level upon the occurrence of the Corporate Transaction. With respect to the vesting of Awards that
will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection&nbsp;(ii) and are settled in the form of a
cash payment, such cash payment will be made no later than&nbsp;30&nbsp;days following the occurrence of the Corporate Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iii)&nbsp;Awards
Held by Persons other than Current Participants</B>. In the event of a Corporate Transaction in which the surviving corporation or acquiring
corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding
Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by persons other than Current
Participants, such Awards will terminate if not exercised (if applicable) prior to the occurrence of the Corporate Transaction; provided,
however, that any reacquisition or repurchase rights held by the Company with respect to such Awards will not terminate and may continue
to be exercised notwithstanding the Corporate Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iv)&nbsp;Payment
for Awards in Lieu of Exercise</B>. Notwithstanding the foregoing, in the event an Award will terminate if not exercised prior to the
effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Award may not exercise
such Award but will receive a payment, in such form as may be determined by the Board, equal in value, at the effective time, to the
excess, if any, of (1)&nbsp;the value of the property the Participant would have received upon the exercise of the Award (including,
at the discretion of the Board, any unvested portion of such Award), over (2)&nbsp;any exercise price payable by such holder in connection
with such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)&nbsp;Appointment
of Stockholder Representative</B>. As a condition to the receipt of an Award under this Plan, a Participant will be deemed to have agreed
that the Award will be subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without
limitation, a provision for the appointment of a stockholder representative that is authorized to act on the Participant&rsquo;s behalf
with respect to any escrow, indemnities and any contingent consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e)&nbsp;No
Restriction on Right to Undertake Transactions</B>. The grant of any Award under the Plan and the issuance of shares pursuant to any
Award does not affect or restrict in any way the right or power of the Company or the stockholders of the Company to make or authorize
any adjustment, recapitalization, reorganization or other change in the Company&rsquo;s capital structure or its business, any merger
or consolidation of the Company, any issue of stock or of options, rights or options to purchase stock or of bonds, debentures, preferred
or prior preference stocks whose rights are superior to or affect the Common Stock or the rights thereof or which are convertible into
or exchangeable for Common Stock, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its
assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">7.&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administration<FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)&nbsp;Administration
by Board</B>. The Board will administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees,
as provided in subsection&nbsp;(c) below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)&nbsp;Powers
of Board</B>. The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)&nbsp;</B>To
determine from time to time: (1)&nbsp;which of the persons eligible under the Plan will be granted Awards; (2)&nbsp;when and how each
Award will be granted; (3)&nbsp;what type or combination of types of Award will be granted; (4)&nbsp;the provisions of each Award granted
(which need not be identical), including the time or times when a person will be permitted to receive an issuance of Common Stock or
other payment pursuant to an Award; (5)&nbsp;the number of shares of Common Stock or cash equivalent with respect to which an Award will
be granted to each such person; (6)&nbsp;the Fair Market Value applicable to an Award; and (7)&nbsp;the terms of any Performance Award
that is not valued in whole or in part by reference to, or otherwise based on, the Common Stock, including the amount of cash payment
or other property that may be earned and the timing of payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)&nbsp;</B>To
construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration.
The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in
a manner and to the extent it deems necessary or expedient to make the Plan or Award fully effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iii)&nbsp;</B>To
settle all controversies regarding the Plan and Awards granted under it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iv)&nbsp;</B>To
accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest, notwithstanding
the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(v)&nbsp;</B>To
prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to&nbsp;30&nbsp;days prior to the consummation
of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than
normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock or the share price
of the Common Stock including any Corporate Transaction, for reasons of administrative convenience.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(vi)&nbsp;</B>To
suspend or terminate the Plan at any time. Suspension or termination of the Plan will not Materially Impair rights and obligations under
any Award granted while the Plan is in effect except with the written consent of the affected Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(vii)&nbsp;</B>To
amend the Plan in any respect the Board deems necessary or advisable; provided, however, that stockholder approval will be required for
any amendment to the extent required by Applicable Law. Except as provided above, rights under any Award granted before amendment of
the Plan will not be Materially Impaired by any amendment of the Plan unless (1)&nbsp;the Company requests the consent of the affected
Participant, and (2)&nbsp;such Participant consents in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(viii)&nbsp;</B>To
submit any amendment to the Plan for stockholder approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ix)&nbsp;</B>To
approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited
to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified
limits in the Plan that are not subject to Board discretion; provided however, that, (1) the Board shall not, without stockholder approval,
reduce the exercise or strike price of an Option or SAR (other than in connection with a Capitalization Adjustment) and, at any time
when the exercise or strike price of an Option or SAR is above the Fair Market Value of a share of Common Stock, the Board shall not,
without stockholder approval, cancel and re-grant or exchange such Option or SAR for a new Award with a lower (or no) purchase price
or for cash, and (2) a Participant&rsquo;s rights under any Award will not be Materially Impaired by any such amendment unless (A)&nbsp;the
Company requests the consent of the affected Participant, and (B)&nbsp;such Participant consents in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(x)&nbsp;</B>Generally,
to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company
and that are not in conflict with the provisions of the Plan or Awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(xi)&nbsp;</B>To
adopt such procedures and sub-plans as are necessary or appropriate to permit and facilitate participation in the Plan by, or take advantage
of specific tax treatment for Awards granted to, Employees, Directors or Consultants who are non-U.S.&nbsp;nationals or employed outside
the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement
to ensure or facilitate compliance with the laws of the relevant non-U.S.&nbsp;jurisdiction).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)&nbsp;Delegation
to Committee</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)&nbsp;General</B>.
The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated
to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board
that have been delegated to the Committee, including the power to delegate to another Committee or a subcommittee of the Committee any
of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to
the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted
from time to time by the Board. Each Committee may retain the authority to concurrently administer the Plan with the Committee or subcommittee
to which it has delegated its authority hereunder and may, at any time, revest in such Committee some or all of the powers previously
delegated. The Board may retain the authority to concurrently administer the Plan with any Committee and may, at any time, revest in
the Board some or all of the powers previously delegated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)&nbsp;Rule&nbsp;16b-3
Compliance</B>. To the extent an Award is intended to qualify for the exemption from Section&nbsp;16(b) of the Exchange Act that is available
under Rule&nbsp;16b-3 of the Exchange Act, the Award will be granted by the Board or a Committee that consists solely of two or more
Non-Employee Directors, as determined under Rule&nbsp;16b-3(b)(3) of the Exchange Act, and, thereafter, any action establishing or modifying
the terms of the Award will be approved by the Board or a Committee meeting such requirements to the extent necessary for such exemption
to remain available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)&nbsp;Effect
of Board&rsquo;s Decision</B>. All determinations, interpretations and constructions made by the Board or any Committee in good faith
will not be subject to review by any person and will be final, binding and conclusive on all persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e)&nbsp;Delegation
to an Officer</B>. The Board or any Committee may delegate to one or more Officers the authority to do one or both of the following (i)&nbsp;designate
Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by Applicable Law, other types of Awards)
and, to the extent permitted by Applicable Law, the terms thereof, and (ii)&nbsp;determine the number of shares of Common Stock to be
subject to such Awards granted to such Employees; provided, however, that the resolutions or charter adopted by the Board or any Committee
evidencing such delegation will specify the total number of shares of Common Stock that may be subject to the Awards granted by such
Officer and that such Officer may not grant an Award to himself or herself. Any such Awards will be granted on the applicable form of
Award Agreement most recently approved for use by the Board or the Committee, unless otherwise provided in the resolutions approving
the delegation authority. Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate to an Officer
who is acting solely in the capacity of an Officer (and not also as a Director) the authority to determine the Fair Market Value.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">8.&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
Withholding</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)&nbsp;Withholding
Authorization</B>. As a condition to acceptance of any Award under the Plan, a Participant authorizes withholding from payroll and any
other amounts payable to such Participant, and otherwise agrees to make adequate provision for (including), any sums required to satisfy
any U.S.&nbsp;and/or non-U.S.&nbsp;federal, state, or local tax or social insurance contribution withholding obligations of the Company
or an Affiliate, if any, which arise in connection with the exercise, vesting or settlement of such Award, as applicable. Accordingly,
a Participant may not be able to exercise an Award even though the Award is vested, and the Company shall have no obligation to issue
shares of Common Stock subject to an Award, unless and until such obligations are satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)&nbsp;Satisfaction
of Withholding Obligation</B>. To the extent permitted by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy
any U.S.&nbsp;and/or non-U.S.&nbsp;federal, state or local tax or social insurance withholding obligation relating to an Award by any
of the following means or by a combination of such means: (i)&nbsp;causing the Participant to tender a cash payment; (ii)&nbsp;withholding
shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award;
(iii)&nbsp;withholding cash from an Award settled in cash; (iv)&nbsp;withholding payment from any amounts otherwise payable to the Participant;
(v)&nbsp;by allowing a Participant to effectuate a &ldquo;cashless exercise&rdquo; pursuant to a program developed under Regulation&nbsp;T
as promulgated by the U.S.&nbsp;Federal Reserve Board or (vi)&nbsp;by such other method as may be set forth in the Award Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)&nbsp;No
Obligation to Notify or Minimize Taxes; No Liability to Claims</B>. Except as required by Applicable Law, the Company has no duty or
obligation to any Participant to advise such holder as to the time or manner of exercising such Award. Furthermore, the Company has no
duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in
which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder
of such Award and will not be liable to any holder of an Award for any adverse tax consequences to such holder in connection with an
Award. As a condition to accepting an Award under the Plan, each Participant (i)&nbsp;agrees to not make any claim against the Company,
or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from such Award or other Company compensation
and (ii)&nbsp;acknowledges that such Participant was advised to consult with his or her own personal tax, financial and other legal advisors
regarding the tax consequences of the Award and has either done so or knowingly and voluntarily declined to do so. Additionally, each
Participant acknowledges any Option or SAR granted under the Plan is exempt from Section&nbsp;409A only if the exercise or strike price
is at least equal to the &ldquo;fair market value&rdquo; of the Common Stock on the date of grant as determined by the Internal Revenue
Service and there is no other impermissible deferral of compensation associated with the Award. Additionally, as a condition to accepting
an Option or SAR granted under the Plan, each Participant agrees not make any claim against the Company, or any of its Officers, Directors,
Employees or Affiliates in the event that the U.S.&nbsp;Internal Revenue Service asserts that such exercise price or strike price is
less than the &ldquo;fair market value&rdquo; of the Common Stock on the date of grant as subsequently determined by the U.S.&nbsp;Internal
Revenue Service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)&nbsp;Withholding
Indemnification</B>. As a condition to accepting an Award under the Plan, in the event that the amount of the Company&rsquo;s and/or
its Affiliate&rsquo;s withholding obligation in connection with such Award was greater than the amount actually withheld by the Company
and/or its Affiliates, each Participant agrees to indemnify and hold the Company and/or its Affiliates harmless from any failure by the
Company and/or its Affiliates to withhold the proper amount.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">9.&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous<FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)&nbsp;Source
of Shares</B>. The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares
repurchased by the Company on the open market or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)&nbsp;Use
of Proceeds from Sales of Common Stock</B>. Proceeds from the sale of shares of Common Stock pursuant to Awards will constitute general
funds of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)&nbsp;Corporate
Action Constituting Grant of Awards</B>. Corporate action constituting a grant by the Company of an Award to any Participant will be
deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument,
certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that
the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action approving the grant contain terms
(e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant
documents as a result of a clerical error in the Award Agreement or related grant documents, the corporate records will control and the
Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)&nbsp;Stockholder
Rights</B>. No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of
Common Stock subject to such Award unless and until (i)&nbsp;such Participant has satisfied all requirements for exercise of the Award
pursuant to its terms, if applicable, and (ii)&nbsp;the issuance of the Common Stock subject to such Award is reflected in the records
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e)&nbsp;No
Employment or Other Service Rights</B>. Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection
with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in
the capacity in effect at the time the Award was granted or affect the right of the Company or an Affiliate to terminate at will and
without regard to any future vesting opportunity that a Participant may have with respect to any Award (i)&nbsp;the employment of an
Employee with or without notice and with or without cause, (ii)&nbsp;the service of a Consultant pursuant to the terms of such Consultant&rsquo;s
agreement with the Company or an Affiliate or (iii)&nbsp;the service of a Director pursuant to the Bylaws of the Company or an Affiliate,
and any applicable provisions of the corporate law of the U.S.&nbsp;state or non-U.S.&nbsp;jurisdiction in which the Company or the Affiliate
is incorporated, as the case may be. Further, nothing in the Plan, any Award Agreement or any other instrument executed thereunder or
in connection with any Award will constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of
future positions, future work assignments, future compensation or any other term or condition of employment or service or confer any
right or benefit under the Award or the Plan unless such right or benefit has specifically accrued under the terms of the Award Agreement
and/or Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(f)&nbsp;Change
in Time Commitment</B>. In the event a Participant&rsquo;s regular level of time commitment in the performance of his or her services
for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company
and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after
the date of grant of any Award to the Participant, the Board may determine, to the extent permitted by Applicable Law, to (i)&nbsp;make
a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become
payable after the date of such change in time commitment, and (ii)&nbsp;in lieu of or in combination with such a reduction, extend the
vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect
to any portion of the Award that is so reduced or extended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(g)&nbsp;Execution
of Additional Documents</B>. As a condition to accepting an Award under the Plan, the Participant agrees to execute any additional documents
or instruments necessary or desirable, as determined in the Plan Administrator&rsquo;s sole discretion, to carry out the purposes or
intent of the Award, or facilitate compliance with securities and/or other regulatory requirements, in each case at the Plan Administrator&rsquo;s
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(h)&nbsp;Electronic
Delivery and Participation</B>. Any reference herein or in an Award Agreement to a &ldquo;written&rdquo; agreement or document will include
any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the
Company&rsquo;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access). By accepting
any Award the Participant consents to receive documents by electronic delivery and to participate in the Plan through any on-line electronic
system established and maintained by the Plan Administrator or another third party selected by the Plan Administrator. The form of delivery
of any Common Stock (e.g., a stock certificate or electronic entry evidencing such shares) shall be determined by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)&nbsp;Clawback/Recovery</B>.
All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to
adopt pursuant to the listing standards of any national securities exchange or association on which the Company&rsquo;s securities are
listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law and any clawback
policy that the Company otherwise adopts, to the extent applicable and permissible under Applicable Law. In addition, the Board may impose
such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including
but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the
occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a Participant&rsquo;s right
to voluntarily terminate employment upon a &ldquo;resignation for good reason,&rdquo; or for a &ldquo;constructive termination&rdquo;
or any similar term under any plan of or agreement with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(j)&nbsp;Securities
Law Compliance</B>. A Participant will not be issued any shares in respect of an Award unless either (i)&nbsp;the shares are registered
under the Securities Act; or (ii)&nbsp;the Company has determined that such issuance would be exempt from the registration requirements
of the Securities Act. Each Award also must comply with other Applicable Law governing the Award, and a Participant will not receive
such shares if the Company determines that such receipt would not be in material compliance with Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(k)&nbsp;Transfer
or Assignment of Awards; Issued Shares</B>. Except as expressly provided in the Plan or the form of Award Agreement, Awards granted under
the Plan may not be transferred or assigned by the Participant. After the vested shares subject to an Award have been issued, or in the
case of Restricted Stock and similar awards, after the issued shares have vested, the holder of such shares is free to assign, hypothecate,
donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions
herein, the terms of the Trading Policy and Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(l)&nbsp;Effect
on Other Employee Benefit Plans</B>. The value of any Award granted under the Plan, as determined upon grant, vesting or settlement,
shall not be included as compensation, earnings, salaries, or other similar terms used when calculating any Participant&rsquo;s benefits
under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company
expressly reserves its rights to amend, modify, or terminate any of the Company&rsquo;s or any Affiliate&rsquo;s employee benefit plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(m)&nbsp;Deferrals</B>.
To the extent permitted by Applicable Law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the
payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs
and procedures for deferral elections to be made by Participants. Deferrals will be made in accordance with the requirements of Section&nbsp;409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(n)&nbsp;Section&nbsp;409A</B>.
Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent
possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section&nbsp;409A, and, to the extent not so exempt,
in compliance with the requirements of Section&nbsp;409A. If the Board determines that any Award granted hereunder is not exempt from
and is therefore subject to Section&nbsp;409A, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary
to avoid the consequences specified in Section&nbsp;409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary
for compliance, such terms are hereby incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in
this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if
a Participant holding an Award that constitutes &ldquo;deferred compensation&rdquo; under Section&nbsp;409A is a &ldquo;specified employee&rdquo;
for purposes of Section&nbsp;409A, no distribution or payment of any amount that is due because of a &ldquo;separation from service&rdquo;
(as defined in Section&nbsp;409A without regard to alternative definitions thereunder) will be issued or paid before the date that is
six months and one day following the date of such Participant&rsquo;s &ldquo;separation from service&rdquo; or, if earlier, the date
of the Participant&rsquo;s death, unless such distribution or payment can be made in a manner that complies with Section&nbsp;409A, and
any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on
the original schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(o)&nbsp;Choice
of Law</B>. This Plan and any controversy arising out of or relating to this Plan shall be governed by, and construed in accordance with,
the internal laws of the State of Delaware, without regard to conflict of law principles that would result in any application of any
law other than the law of the State of Delaware.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">10.&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covenants
of the Company<FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)&nbsp;Compliance
with Law</B>. The Company will seek to obtain from each regulatory commission or agency, as may be deemed necessary, having jurisdiction
over the Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise or vesting
of the Awards; provided, however, that this undertaking will not require the Company to register under the Securities Act the Plan, any
Award or any Common Stock issued or issuable pursuant to any such Award. If, after reasonable efforts and at a reasonable cost, the Company
is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary or advisable
for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue
and sell Common Stock upon exercise or vesting of such Awards unless and until such authority is obtained. A Participant is not eligible
for the grant of an Award or the subsequent issuance of Common Stock pursuant to the Award if such grant or issuance would be in violation
of any Applicable Law.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">11.&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
Rules for Awards Subject to Section&nbsp;409A<FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)&nbsp;Application</B>.
Unless the provisions of this Section of the Plan are expressly superseded by the provisions in the form of Award Agreement, the provisions
of this Section shall apply and shall supersede anything to the contrary set forth in the Award Agreement for a Non-Exempt Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)&nbsp;Non-Exempt
Awards Subject to Non-Exempt Severance Arrangements</B>. To the extent a Non-Exempt Award is subject to Section&nbsp;409A due to application
of a Non-Exempt Severance Arrangement, the following provisions of this subsection&nbsp;(b) apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)&nbsp;</B>If
the Non-Exempt Award vests in the ordinary course during the Participant&rsquo;s Continuous Service in accordance with the vesting schedule
set forth in the Award Agreement, and does not accelerate vesting under the terms of a Non-Exempt Severance Arrangement, in no event
will the shares be issued in respect of such Non-Exempt Award any later than the later of: (i)&nbsp;December&nbsp;31<SUP>st</SUP> of
the calendar year that includes the applicable vesting date, or (ii)&nbsp;the&nbsp;60<SUP>th</SUP> day that follows the applicable vesting
date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)&nbsp;</B>If
vesting of the Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with the Participant&rsquo;s
Separation from Service, and such vesting acceleration provisions were in effect as of the date of grant of the Non-Exempt Award and,
therefore, are part of the terms of such Non-Exempt Award as of the date of grant, then the shares will be earlier issued in settlement
of such Non-Exempt Award upon the Participant&rsquo;s Separation from Service in accordance with the terms of the Non-Exempt Severance
Arrangement, but in no event later than the&nbsp;60<SUP>th</SUP> day that follows the date of the Participant&rsquo;s Separation from
Service. However, if at the time the shares would otherwise be issued the Participant is subject to the distribution limitations contained
in Section&nbsp;409A applicable to &ldquo;specified employees,&rdquo; as defined in Section&nbsp;409A(a)(2)(B)(i) of the Code, such shares
shall not be issued before the date that is six months following the date of such Participant&rsquo;s Separation from Service, or, if
earlier, the date of the Participant&rsquo;s death that occurs within such six month period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iii)&nbsp;</B>If
vesting of a Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with a Participant&rsquo;s
Separation from Service, and such vesting acceleration provisions were not in effect as of the date of grant of the Non-Exempt Award
and, therefore, are not a part of the terms of such Non-Exempt Award on the date of grant, then such acceleration of vesting of the Non-Exempt
Award shall not accelerate the issuance date of the shares, but the shares shall instead be issued on the same schedule as set forth
in the Grant Notice as if they had vested in the ordinary course during the Participant&rsquo;s Continuous Service, notwithstanding the
vesting acceleration of the Non-Exempt Award. Such issuance schedule is intended to satisfy the requirements of payment on a specified
date or pursuant to a fixed schedule, as provided under Treasury Regulations&nbsp;Section&nbsp;1.409A-3(a)(4).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)&nbsp;Treatment
of Non-Exempt Awards Upon a Corporate Transaction for Employees and Consultants</B>. The provisions of this subsection&nbsp;(c) shall
apply and shall supersede anything to the contrary set forth in the Plan with respect to the permitted treatment of any Non-Exempt Award
in connection with a Corporate Transaction if the Participant was either an Employee or Consultant upon the applicable date of grant
of the Non-Exempt Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)&nbsp;Vested
Non-Exempt Awards</B>. The following provisions shall apply to any Vested Non-Exempt Award in connection with a Corporate Transaction:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(1)&nbsp;</B>If
the Corporate Transaction is also a Section&nbsp;409A Change in Control then the Acquiring Entity may not assume, continue or substitute
the Vested Non-Exempt Award. Upon the Section&nbsp;409A Change in Control the settlement of the Vested Non-Exempt Award will automatically
be accelerated and the shares will be immediately issued in respect of the Vested Non-Exempt Award. Alternatively, the Company may instead
provide that the Participant will receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued
to the Participant upon the Section&nbsp;409A Change in Control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(2)&nbsp;</B>If
the Corporate Transaction is not also a Section&nbsp;409A Change in Control, then the Acquiring Entity must either assume, continue or
substitute each Vested Non-Exempt Award. The shares to be issued in respect of the Vested Non-Exempt Award shall be issued to the Participant
by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had
not occurred. In the Acquiring Entity&rsquo;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute
a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant
on such issuance dates, with the determination of the Fair Market Value of the shares made on the date of the Corporate Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)&nbsp;Unvested
Non-Exempt Awards</B>. The following provisions shall apply to any Unvested Non-Exempt Award unless otherwise determined by the Board
pursuant to subsection&nbsp;(e) of this Section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(1)&nbsp;</B>In
the event of a Corporate Transaction, the Acquiring Entity shall assume, continue or substitute any Unvested Non-Exempt Award. Unless
otherwise determined by the Board, any Unvested Non-Exempt Award will remain subject to the same vesting and forfeiture restrictions
that were applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of any Unvested Non-Exempt Award
shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant
if the Corporate Transaction had not occurred. In the Acquiring Entity&rsquo;s discretion, in lieu of an issuance of shares, the Acquiring
Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would
otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value of the shares made on the
date of the Corporate Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(2)&nbsp;</B>If
the Acquiring Entity will not assume, substitute or continue any Unvested Non-Exempt Award in connection with a Corporate Transaction,
then such Award shall automatically terminate and be forfeited upon the Corporate Transaction with no consideration payable to any Participant
in respect of such forfeited Unvested Non-Exempt Award. Notwithstanding the foregoing, to the extent permitted and in compliance with
the requirements of Section&nbsp;409A, the Board may in its discretion determine to elect to accelerate the vesting and settlement of
the Unvested Non-Exempt Award upon the Corporate Transaction, or instead substitute a cash payment equal to the Fair Market Value of
such shares that would otherwise be issued to the Participant, as further provided in subsection&nbsp;(e)(ii) below. In the absence of
such discretionary election by the Board, any Unvested Non-Exempt Award shall be forfeited without payment of any consideration to the
affected Participants if the Acquiring Entity will not assume, substitute or continue the Unvested Non-Exempt Awards in connection with
the Corporate Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(3)&nbsp;</B>The
foregoing treatment shall apply with respect to all Unvested Non-Exempt Awards upon any Corporate Transaction, and regardless of whether
or not such Corporate Transaction is also a Section&nbsp;409A Change in Control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)&nbsp;Treatment
of Non-Exempt Awards Upon a Corporate Transaction for Non-Employee Directors</B>. The following provisions of this subsection&nbsp;(d)
shall apply and shall supersede anything to the contrary that may be set forth in the Plan with respect to the permitted treatment of
a Non-Exempt Director Award in connection with a Corporate Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)&nbsp;</B>If
the Corporate Transaction is also a Section&nbsp;409A Change in Control then the Acquiring Entity may not assume, continue or substitute
the Non-Exempt Director Award. Upon the Section&nbsp;409A Change in Control the vesting and settlement of any Non-Exempt Director Award
will automatically be accelerated and the shares will be immediately issued to the Participant in respect of the Non-Exempt Director
Award. Alternatively, the Company may provide that the Participant will instead receive a cash settlement equal to the Fair Market Value
of the shares that would otherwise be issued to the Participant upon the Section&nbsp;409A Change in Control pursuant to the preceding
provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)&nbsp;</B>If
the Corporate Transaction is not also a Section&nbsp;409A Change in Control, then the Acquiring Entity must either assume, continue or
substitute the Non-Exempt Director Award. Unless otherwise determined by the Board, the Non-Exempt Director Award will remain subject
to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction. The shares to be
issued in respect of the Non-Exempt Director Award shall be issued to the Participant by the Acquiring Entity on the same schedule that
the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&rsquo;s discretion,
in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal
to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination
of Fair Market Value made on the date of the Corporate Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e)&nbsp;</B>If
the RSU Award is a Non-Exempt Award, then the provisions in this Section&nbsp;11(e) shall apply and supersede anything to the contrary
that may be set forth in the Plan or the Award Agreement with respect to the permitted treatment of such Non-Exempt Award:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)&nbsp;</B>Any
exercise by the Board of discretion to accelerate the vesting of a Non-Exempt Award shall not result in any acceleration of the scheduled
issuance dates for the shares in respect of the Non-Exempt Award unless earlier issuance of the shares upon the applicable vesting dates
would be in compliance with the requirements of Section&nbsp;409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)&nbsp;</B>The
Company explicitly reserves the right to earlier settle any Non-Exempt Award to the extent permitted and in compliance with the requirements
of Section&nbsp;409A, including pursuant to any of the exemptions available in Treasury Regulations&nbsp;Section&nbsp;1.409A-3(j)(4)(ix).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iii)&nbsp;</B>To
the extent the terms of any Non-Exempt Award provide that it will be settled upon a Change in Control or Corporate Transaction, to the
extent it is required for compliance with the requirements of Section&nbsp;409A, the Change in Control or Corporate Transaction event
triggering settlement must also constitute a Section&nbsp;409A Change in Control. To the extent the terms of a Non-Exempt Award provide
that it will be settled upon a termination of employment or termination of Continuous Service, to the extent it is required for compliance
with the requirements of Section&nbsp;409A, the termination event triggering settlement must also constitute a Separation From Service.
However, if at the time the shares would otherwise be issued to a Participant in connection with a &ldquo;separation from service&rdquo;
such Participant is subject to the distribution limitations contained in Section&nbsp;409A applicable to &ldquo;specified employees,&rdquo;
as defined in Section&nbsp;409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following
the date of the Participant&rsquo;s Separation From Service, or, if earlier, the date of the Participant&rsquo;s death that occurs within
such six month period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iv)&nbsp;</B>The
provisions in this subsection&nbsp;(e) for delivery of the shares in respect of the settlement of a RSU Award that is a Non-Exempt Award
are intended to comply with the requirements of Section&nbsp;409A so that the delivery of the shares to the Participant in respect of
such Non-Exempt Award will not trigger the additional tax imposed under Section&nbsp;409A, and any ambiguities herein will be so interpreted.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">12.&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability<FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
all or any part of the Plan or any Award Agreement is declared by any court or governmental authority to be unlawful or invalid, such
unlawfulness or invalidity shall not invalidate any portion of the Plan or such Award Agreement not declared to be unlawful or invalid.
Any Section of the Plan or any Award Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible,
be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while
remaining lawful and valid.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">13.&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
of the Plan<FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board may suspend or terminate the Plan at any time. No Incentive Stock Options may be granted after the tenth anniversary of the earlier
of: (i)&nbsp;the Adoption Date, or (ii)&nbsp;the date the Plan is approved by the Company&rsquo;s stockholders. No Awards may be granted
under the Plan while the Plan is suspended or after it is terminated.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">14.&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions<FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in the Plan, the following definitions apply to the capitalized terms indicated below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)&nbsp;</B>&ldquo;<B><I>Acquiring
Entity</I></B>&rdquo; means the surviving or acquiring corporation (or its parent company) in connection with a Corporate Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)&nbsp;</B>&ldquo;<B><I>Adoption
Date</I></B>&rdquo; means the date the Plan is first approved by the Board or Compensation Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)&nbsp;</B>&ldquo;<B><I>Affiliate</I></B>&rdquo;
means, at the time of determination, any &ldquo;parent&rdquo; or &ldquo;subsidiary&rdquo; of the Company as such terms are defined in
Rule&nbsp;405 promulgated under the Securities Act. The Board may determine the time or times at which &ldquo;parent&rdquo; or &ldquo;subsidiary&rdquo;
status is determined within the foregoing definition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)&nbsp;</B>&ldquo;<B><I>Applicable
Law</I></B>&rdquo; means shall mean the Code and any applicable U.S.&nbsp;or non-U.S.&nbsp;securities, federal, state, material local
or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing
rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect
by or under the authority of any Governmental Body (including under the authority of any applicable self-regulating organization such
as the Nasdaq Stock Market, New York Stock Exchange or the Financial Industry Regulatory Authority).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e)&nbsp;</B>&ldquo;<B><I>Award</I></B>&rdquo;
means any right to receive Common Stock, cash or other property granted under the Plan (including an Incentive Stock Option, a Nonstatutory
Stock Option, a Restricted Stock Award, a RSU Award, a SAR, a Performance Award or any Other Award).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(f)&nbsp;</B>&ldquo;<B><I>Award
Agreement</I></B>&rdquo; means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award.
The Award Agreement generally consists of the Grant Notice and the agreement containing the written summary of the general terms and
conditions applicable to the Award and which is provided to a Participant along with the Grant Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(g)&nbsp;</B>&ldquo;<B><I>Board</I></B>&rdquo;
means the board of directors of the Company (or its designee). Any decision or determination made by the Board shall be a decision or
determination that is made in the sole discretion of the Board (or its designee), and such decision or determination shall be final and
binding on all Participants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(h)&nbsp;</B><I>&ldquo;<B>Capitalization
Adjustment</B></I>&rdquo; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the
Plan or subject to any Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation,
reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend,
stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any
similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards
Codification Topic&nbsp;718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of
the Company will not be treated as a Capitalization Adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)&nbsp;</B>&ldquo;<B><I>Cause</I></B>&rdquo;
has the meaning ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the
absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i)&nbsp;the
Participant&rsquo;s theft, dishonesty, willful misconduct, breach of fiduciary duty for personal profit, or intentional falsification
of any Company or Affiliate documents or records; (ii)&nbsp;the Participant&rsquo;s material failure to abide by the Company&rsquo;s
Code of Conduct or other policies (including, without limitation, policies relating to confidentiality and reasonable workplace conduct
and policies of any Affiliate, as applicable); (iii)&nbsp;the Participant&rsquo;s unauthorized use, misappropriation, destruction or
diversion of any tangible or intangible asset or corporate opportunity of the Company or any of its Affiliates (including, without limitation,
the Participant&rsquo;s improper use or disclosure of Company or Affiliate confidential or proprietary information); (iv)&nbsp;any intentional
act by the Participant which has a material detrimental effect on the Company&rsquo;s or its Affiliate&rsquo;s reputation or business;
(v)&nbsp;the Participant&rsquo;s repeated failure or inability to perform any reasonable assigned duties after written notice from the
Company (or its Affiliate, as applicable) of, and a reasonable opportunity to cure, such failure or inability; (vi)&nbsp;any material
breach by the Participant of any employment or service agreement between the Participant and the Company (or its Affiliate, as applicable),
which breach is not cured pursuant to the terms of such agreement; or (vii)&nbsp;the Participant&rsquo;s conviction (including any plea
of guilty or <I>nolo contendere</I>) of any criminal act involving fraud, dishonesty, misappropriation or moral turpitude, or which impairs
the Participant&rsquo;s ability to perform his or her duties with the Company (or its Affiliate, as applicable). The determination that
a termination of the Participant&rsquo;s Continuous Service is either for Cause or without Cause will be made by the Board with respect
to Participants who are executive officers of the Company and by the Company&rsquo;s Chief Executive Officer or his or her designee with
respect to Participants who are not executive officers of the Company. Any determination by the Company that the Continuous Service of
a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect
upon any determination of the rights or obligations of the Company or such Participant for any other purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(j)&nbsp;</B>&ldquo;<B><I>Change
in Control</I></B>&rdquo; or &ldquo;<B><I>Change of Control</I></B>&rdquo; means the occurrence, in a single transaction or in a series
of related transactions, of any one or more of the following events; provided, however, to the extent necessary to avoid adverse personal
income tax consequences to the Participant in connection with an Award, also constitutes a Section&nbsp;409A Change in Control:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)&nbsp;</B>any
Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than&nbsp;50% of the combined
voting power of the Company&rsquo;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction.
Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A)&nbsp;on account of the acquisition of securities
of the Company directly from the Company, (B)&nbsp;on account of the acquisition of securities of the Company by an investor, any affiliate
thereof or any other Exchange Act Person that acquires the Company&rsquo;s securities in a transaction or series of related transactions
the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, or (C)&nbsp;solely because
the level of Ownership held by any Exchange Act Person (the &ldquo;<B><I>Subject Person</I></B>&rdquo;) exceeds the designated percentage
threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing
the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result
of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any
additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then
outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be
deemed to occur;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)&nbsp;</B>there
is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the
consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own,
directly or indirectly, either (A)&nbsp;outstanding voting securities representing more than&nbsp;50% of the combined outstanding voting
power of the surviving Entity in such merger, consolidation or similar transaction or (B)&nbsp;more than&nbsp;50% of the combined outstanding
voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially
the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iii)&nbsp;</B>the
stockholders of the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a complete
dissolution or liquidation of the Company shall otherwise occur, except for a liquidation into a parent corporation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iv)&nbsp;</B>there
is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company
and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of
the Company and its Subsidiaries to an Entity, more than&nbsp;50% of the combined voting power of the voting securities of which are
Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of
the Company immediately prior to such sale, lease, license or other disposition; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(v)&nbsp;</B>individuals
who, on the date the Plan is adopted by the Board, are members of the Board (the &ldquo;<B><I>Incumbent Board</I></B>&rdquo;) cease for
any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or
nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board
then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing or any other provision of this Plan, (A)&nbsp;the term Change in Control shall not include a sale of assets, merger or
other transaction effected exclusively for the purpose of changing the domicile of the Company, and (B)&nbsp;the definition of Change
in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall
supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change
in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(k)&nbsp;</B>&ldquo;<B><I>Code</I></B>&rdquo;
means the U.S.&nbsp;Internal Revenue Code of&nbsp;1986, as amended, including any applicable regulations and guidance thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(l)&nbsp;</B>&ldquo;<B><I>Committee</I></B>&rdquo;
means the Compensation Committee and any other committee of one or more Directors to whom authority has been delegated by the Board or
Compensation Committee in accordance with the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(m)&nbsp;</B>&ldquo;<B><I>Common
Stock</I></B>&rdquo; means the common stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(n)&nbsp;</B>&ldquo;<B><I>Company</I></B>&rdquo;
means Jasper Therapeutics, Inc., a Delaware corporation, and any successor corporation thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(o)&nbsp;</B>&ldquo;<B><I>Compensation
Committee</I></B>&rdquo; means the Compensation Committee of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(p)&nbsp;</B>&ldquo;<B><I>Consultant</I></B>&rdquo;
means any person, including an advisor, who is (i)&nbsp;engaged by the Company or an Affiliate to render consulting or advisory services
and is compensated for such services, or (ii)&nbsp;serving as a member of the board of directors of an Affiliate and is compensated for
such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered
a &ldquo;Consultant&rdquo; for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan
only if a Form&nbsp;S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the
Company&rsquo;s securities to such person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(q)&nbsp;</B>&ldquo;<B><I>Continuous
Service</I></B>&rdquo; means that the Participant&rsquo;s service with the Company or an Affiliate, whether as an Employee, Director
or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or
an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided
that there is no interruption or termination of the Participant&rsquo;s service with the Company or an Affiliate, will not terminate
a Participant&rsquo;s Continuous Service; provided, however, that if the Entity for which a Participant is rendering services ceases
to qualify as an Affiliate, as determined by the Board, such Participant&rsquo;s Continuous Service will be considered to have terminated
on the date such Entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the Company to a Consultant
of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board
or the chief executive officer of the Company, in that party&rsquo;s sole discretion, may determine whether Continuous Service will be
considered interrupted in the case of (i)&nbsp;any leave of absence approved by the Board or chief executive officer, including sick
leave, military leave or any other personal leave, or (ii)&nbsp;transfers between the Company, an Affiliate, or their successors. Notwithstanding
the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may
be provided in the Company&rsquo;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable
to the Participant, or as otherwise required by law. In addition, to the extent required for exemption from or compliance with Section&nbsp;409A,
the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner
that is consistent with the definition of &ldquo;separation from service&rdquo; as defined under U.S.&nbsp;Treasury Regulation&nbsp;Section&nbsp;1.409A-1(h)
(without regard to any alternative definition thereunder).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(r)&nbsp;</B>&ldquo;<B><I>Corporate
Transaction</I></B>&rdquo; means the consummation, in a single transaction or in a series of related transactions, of any one or more
of the following events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)&nbsp;</B>a
sale or other disposition of all or substantially all, as determined by the Board, of the consolidated assets of the Company and its
Subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)&nbsp;</B>a
sale or other disposition of at least&nbsp;50% of the outstanding securities of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iii)&nbsp;</B>a
merger, consolidation or similar transaction following which the Company is not the surviving corporation; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iv)&nbsp;</B>a
merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock
outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger,
consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(s)&nbsp;</B>&ldquo;<B><I>Director</I></B>&rdquo;
means a member of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(t)&nbsp;</B>&ldquo;<B><I>determine</I></B>&rdquo;
<B><I>or </I></B>&ldquo;<B><I>determined</I></B>&rdquo; means as determined by the Board or the Committee (or its designee) in its sole
discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(u)&nbsp;</B>&ldquo;<B><I>Disability</I></B>&rdquo;
means, with respect to a Participant, such Participant is unable to engage in any substantial gainful activity by reason of any medically
determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for
a continuous period of not less than&nbsp;12&nbsp;months, as provided in Section&nbsp;22(e)(3) of the Code, and will be determined by
the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(v)&nbsp;</B>&ldquo;<B><I>Effective
Date</I></B>&rdquo;&nbsp;means the later of (i) the date on which the Plan is approved by the stockholders of the Company in accordance
with Section&nbsp;13, and (ii) the day that is one day prior to the date of the closing of the transactions contemplated by that certain
Business Combination Agreement, dated as of May 5, 2021, by and among the Company and the other parties thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(w)&nbsp;</B>&ldquo;<B><I>Employee</I></B>&rdquo;
means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services,
will not cause a Director to be considered an &ldquo;Employee&rdquo; for purposes of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(x)&nbsp;</B>&ldquo;<B><I>Employer</I></B>&rdquo;
means the Company or the Affiliate that employs the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(y)&nbsp;</B>&ldquo;<B><I>Entity</I></B>&rdquo;
means a corporation, partnership, limited liability company or other entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(z)&nbsp;</B>&ldquo;<B><I>Exchange
Act</I></B>&rdquo; means the U.S.&nbsp;Securities Exchange Act of&nbsp;1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(aa)&nbsp;</B>&ldquo;<B><I>Exchange
Act Person</I></B>&rdquo; means any natural person, Entity or &ldquo;group&rdquo; (within the meaning of Section&nbsp;13(d) or&nbsp;14(d)
of the Exchange Act), except that &ldquo;Exchange Act Person&rdquo; will not include (i)&nbsp;the Company or any Subsidiary of the Company,
(ii)&nbsp;any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities
under an employee benefit plan of the Company or any Subsidiary of the Company, (iii)&nbsp;an underwriter temporarily holding securities
pursuant to a registered public offering of such securities, (iv)&nbsp;an Entity Owned, directly or indirectly, by the stockholders of
the Company in substantially the same proportions as their Ownership of stock of the Company; or (v)&nbsp;any natural person, Entity
or &ldquo;group&rdquo; (within the meaning of Section&nbsp;13(d) or&nbsp;14(d) of the Exchange Act) that, as of the Effective Date, is
the Owner, directly or indirectly, of securities of the Company representing more than&nbsp;50% of the combined voting power of the Company&rsquo;s
then outstanding securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(bb)&nbsp;</B>&ldquo;<B><I>Fair
Market Value</I></B>&rdquo; means, as of any date, unless otherwise determined by the Board, the value of the Common Stock (as determined
on a per share or aggregate basis, as applicable) determined as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)&nbsp;</B>If
the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value will be the closing
sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the
Common Stock) on the date of determination, as reported in a source the Board deems reliable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)&nbsp;</B>If
there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling
price on the last preceding date for which such quotation exists.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iii)&nbsp;</B>In
the absence of such markets for the Common Stock, or if otherwise determined by the Board, the Fair Market Value will be determined by
the Board in good faith and in a manner that complies with Sections&nbsp;409A and&nbsp;422 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(cc)&nbsp;</B>&ldquo;<B><I>Governmental
Body</I></B>&rdquo; means any: (a)&nbsp;nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction
of any nature; (b)&nbsp;U.S.&nbsp;or non-U.S.&nbsp;federal, state, local, municipal, or other government; (c)&nbsp;governmental or regulatory
body, or quasi-governmental body of any nature (including any governmental division, department, administrative agency or bureau, commission,
authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal,
and for the avoidance of doubt, any tax authority) or other body exercising similar powers or authority; or (d)&nbsp;self-regulatory
organization (including the Nasdaq Stock Market, New York Stock Exchange, and the Financial Industry Regulatory Authority).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(dd)&nbsp;</B>&ldquo;<B><I>Grant
Notice</I></B>&rdquo; means the notice provided to a Participant that he or she has been granted an Award under the Plan and which includes
the name of the Participant, the type of Award, the date of grant of the Award, number of shares of Common Stock subject to the Award
or potential cash payment right, (if any), the vesting schedule for the Award (if any) and other key terms applicable to the Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ee)&nbsp;&#8239;</B>&ldquo;<B><I>Incentive
Stock Option</I></B>&rdquo; means an option granted pursuant to Section&nbsp;4 of the Plan that is intended to be, and qualifies as,
an &ldquo;incentive stock option&rdquo; within the meaning of Section&nbsp;422 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ff)&nbsp;</B>&ldquo;<B><I>Materially
Impair</I></B>&rdquo; means any amendment to the terms of the Award that materially adversely affects the Participant&rsquo;s rights
under the Award. A Participant&rsquo;s rights under an Award will not be deemed to have been Materially Impaired by any such amendment
if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant&rsquo;s
rights. For example, the following types of amendments to the terms of an Award do not Materially Impair the Participant&rsquo;s rights
under the Award: (i)&nbsp;imposition of reasonable restrictions on the minimum number of shares subject to an Option that may be exercised,
(ii)&nbsp;to maintain the qualified status of the Award as an Incentive Stock Option under Section&nbsp;422 of the Code; (iii)&nbsp;to
change the terms of an Incentive Stock Option in a manner that disqualifies, impairs or otherwise affects the qualified status of the
Award as an Incentive Stock Option under Section&nbsp;422 of the Code; (iv)&nbsp;to clarify the manner of exemption from, or to bring
the Award into compliance with or qualify it for an exemption from, Section&nbsp;409A; or (v)&nbsp;to comply with other Applicable Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(gg)&nbsp;</B>&ldquo;<B><I>Non-Employee
Director</I></B>&rdquo; means a Director who either (i)&nbsp;is not a current employee or officer of the Company or an Affiliate, does
not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in
any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item&nbsp;404(a) of Regulation&nbsp;S-K
promulgated pursuant to the Securities Act (&ldquo;<B><I>Regulation&nbsp;S-K</I></B>&rdquo;)), does not possess an interest in any other
transaction for which disclosure would be required under Item&nbsp;404(a) of Regulation&nbsp;S-K, and is not engaged in a business relationship
for which disclosure would be required pursuant to Item&nbsp;404(b) of Regulation&nbsp;S-K; or (ii)&nbsp;is otherwise considered a &ldquo;non-employee
director&rdquo; for purposes of Rule&nbsp;16b-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(hh)&nbsp;</B>&ldquo;<B><I>Non-Exempt
Award</I></B>&rdquo; means any Award that is subject to, and not exempt from, Section&nbsp;409A, including as the result of (i)&nbsp;a
deferral of the issuance of the shares subject to the Award which is elected by the Participant or imposed by the Company or (ii)&nbsp;the
terms of any Non-Exempt Severance Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)&nbsp;</B>&ldquo;<B><I>Non-Exempt
Director Award</I></B>&rdquo; means a Non-Exempt Award granted to a Participant who was a Director but not an Employee on the applicable
grant date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(jj)&nbsp;<I>&ldquo;Non-Exempt
Severance Arrangement</I></B>&rdquo; means a severance arrangement or other agreement between the Participant and the Company that provides
for acceleration of vesting of an Award and issuance of the shares in respect of such Award upon the Participant&rsquo;s termination
of employment or separation from service (as such term is defined in Section&nbsp;409A(a)(2)(A)(i) of the Code (and without regard to
any alternative definition thereunder) (&ldquo;<B><I>Separation from Service</I></B>&rdquo;) and such severance benefit does not satisfy
the requirements for an exemption from application of Section&nbsp;409A provided under Treasury Regulations&nbsp;Section&nbsp;1.409A-1(b)(4),
1.409A-1(b)(9) or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(kk)&nbsp;</B>&ldquo;<B><I>Nonstatutory
Stock Option</I></B>&rdquo; means any option granted pursuant to Section&nbsp;4 of the Plan that does not qualify as an Incentive Stock
Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ll)&nbsp;</B>&ldquo;<B><I>Officer</I></B>&rdquo;
means a person who is an officer of the Company within the meaning of Section&nbsp;16 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(mm)&nbsp;</B>&ldquo;<B><I>Option</I></B>&rdquo;
means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(nn)&nbsp;</B>&ldquo;<B><I>Option
Agreement</I></B>&rdquo; means a written agreement between the Company and the Optionholder evidencing the terms and conditions of the
Option grant. The Option Agreement includes the Grant Notice for the Option and the agreement containing the written summary of the general
terms and conditions applicable to the Option and which is provided to a Participant along with the Grant Notice. Each Option Agreement
will be subject to the terms and conditions of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(oo)&nbsp;</B>&ldquo;<B><I>Optionholder</I></B>&rdquo;
means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(pp)&nbsp;</B>&ldquo;<B><I>Other
Award</I></B>&rdquo; means an award valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation
in value thereof (e.g., options or stock rights with an exercise price or strike price less than&nbsp;100% of the Fair Market Value at
the time of grant) that is not an Incentive Stock Options, Nonstatutory Stock Option, SAR, Restricted Stock Award, RSU Award or Performance
Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(qq)&nbsp;</B>&ldquo;<B><I>Other
Award Agreement</I></B>&rdquo; means a written agreement between the Company and a holder of an Other Award evidencing the terms and
conditions of an Other Award grant. Each Other Award Agreement will be subject to the terms and conditions of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(rr)&nbsp;</B>&ldquo;<B><I>Own,</I></B>&rdquo;
&ldquo;<B><I>Owned,</I></B>&rdquo; &ldquo;<B><I>Owner,</I></B>&rdquo; &ldquo;<B><I>Ownership</I></B>&rdquo; means that a person or Entity
will be deemed to &ldquo;Own,&rdquo; to have &ldquo;Owned,&rdquo; to be the &ldquo;Owner&rdquo; of or to have acquired &ldquo;Ownership&rdquo;
of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise,
has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ss)&nbsp;</B>&ldquo;<B><I>Participant</I></B>&rdquo;
means an Employee, Director or Consultant to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds
an outstanding Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(tt)&nbsp;</B>&ldquo;<B><I>Performance
Award</I></B>&rdquo; means an Award that may vest or may be exercised or a cash award that may vest or become earned and paid contingent
upon the attainment during a Performance Period of certain Performance Goals and which is granted under the terms and conditions of Section&nbsp;5(b)
pursuant to such terms as are approved by the Board. In addition, to the extent permitted by Applicable Law and set forth in the applicable
Award Agreement, the Board may determine that cash or other property may be used in payment of Performance Awards. Performance Awards
that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on,
the Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(uu)&nbsp;</B>&ldquo;<B><I>Performance
Criteria</I></B>&rdquo; means the one or more criteria that the Board will select for purposes of establishing the Performance Goals
for a Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on any one of,
or combination of, the following as determined by the Board: earnings (including earnings per share and net earnings); earnings before
interest, taxes and depreciation; earnings before interest, taxes, depreciation and amortization; total stockholder return; return on
equity or average stockholder&rsquo;s equity; return on assets, investment, or capital employed; stock price; margin (including gross
margin); income (before or after taxes); operating income; operating income after taxes; pre-tax profit; operating cash flow; sales or
revenue targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement in or attainment of working
capital levels; economic value added (or an equivalent metric); market share; cash flow; cash flow per share; share price performance;
debt reduction; customer satisfaction; stockholders&rsquo; equity; capital expenditures; debt levels; operating profit or net operating
profit; workforce diversity; growth of net income or operating income; billings; pre-clinical development related compound goals; financing;
regulatory milestones, including approval of a compound; stockholder liquidity; corporate governance and compliance; product commercialization;
intellectual property; personnel matters; progress of internal research or clinical programs; progress of partnered programs; partner
satisfaction; budget management; clinical achievements; completing phases of a clinical study (including the treatment phase); announcing
or presenting preliminary or final data from clinical studies; in each case, whether on particular timelines or generally; timely completion
of clinical trials; submission of INDs and NDAs and other regulatory achievements; partner or collaborator achievements; internal controls,
including those related to the Sarbanes-Oxley Act of&nbsp;2002; research progress, including the development of programs; investor relations,
analysts and communication; manufacturing achievements (including obtaining particular yields from manufacturing runs and other measurable
objectives related to process development activities); strategic partnerships or transactions (including in-licensing and out-licensing
of intellectual property; establishing relationships with commercial entities with respect to the marketing, distribution and sale of
the Company&rsquo;s products (including with group purchasing organizations, distributors and other vendors); supply chain achievements
(including establishing relationships with manufacturers or suppliers of active pharmaceutical ingredients and other component materials
and manufacturers of the Company&rsquo;s products); co-development, co-marketing, profit sharing, joint venture or other similar arrangements;
individual performance goals; corporate development and planning goals; and other measures of performance selected by the Board or Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(vv)&nbsp;</B>&ldquo;<B><I>Performance
Goals</I></B>&rdquo; means, for a Performance Period, the one or more goals established by the Board for the Performance Period based
upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions,
Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or
the performance of one or more relevant indices. Unless specified otherwise by the Board (i)&nbsp;in the Award Agreement at the time
the Award is granted or (ii)&nbsp;in such other document setting forth the Performance Goals at the time the Performance Goals are established,
the Board will appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period
as follows: (1)&nbsp;to exclude restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects; (3)&nbsp;to
exclude the effects of changes to generally accepted accounting principles; (4)&nbsp;to exclude the effects of any statutory adjustments
to corporate tax rates; (5)&nbsp;to exclude the effects of items that are &ldquo;unusual&rdquo; in nature or occur &ldquo;infrequently&rdquo;
as determined under generally accepted accounting principles; (6)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures;
(7)&nbsp;to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of
a Performance Period following such divestiture; (8)&nbsp;to exclude the effect of any change in the outstanding shares of Common Stock
of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off,
combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash
dividends; (9)&nbsp;to exclude the effects of stock based compensation and the award of bonuses under the Company&rsquo;s bonus plans;
(10)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to expensed under generally
accepted accounting principles; and (11)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be
recorded under generally accepted accounting principles. In addition, the Board retains the discretion to reduce or eliminate the compensation
or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects
to use for such Performance Period. Partial achievement of the specified criteria may result in the payment or vesting corresponding
to the degree of achievement as specified in the Award Agreement or the written terms of a Performance Cash Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ww)&nbsp;</B>&ldquo;<B><I>Performance
Period</I></B>&rdquo; means the period of time selected by the Board over which the attainment of one or more Performance Goals will
be measured for the purpose of determining a Participant&rsquo;s right to vesting or exercise of an Award. Performance Periods may be
of varying and overlapping duration, at the sole discretion of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(xx)&nbsp;</B>&ldquo;<B><I>Plan</I></B>&rdquo;
means this Jasper Therapeutics, Inc. 2021 Equity Incentive Plan, as amended from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(yy)&nbsp;</B>&ldquo;<B><I>Plan
Administrator</I></B>&rdquo; means the person, persons, and/or third-party administrator designated by the Company to administer the
day-to-day operations of the Plan and the Company&rsquo;s other equity incentive programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(zz)&nbsp;</B>&ldquo;<B><I>Post-Termination
Exercise Period</I></B>&rdquo; means the period following termination of a Participant&rsquo;s Continuous Service within which an Option
or SAR is exercisable, as specified in Section&nbsp;4(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(aaa)&nbsp;</B>&ldquo;<B><I>Restricted
Stock Award</I></B>&rdquo; or &ldquo;<B><I>RSA</I></B>&rdquo; means an Award of shares of Common Stock granted pursuant to the terms
and conditions of Section&nbsp;5(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(bbb)&nbsp;</B>&ldquo;<B><I>Restricted
Stock Award Agreement</I></B>&rdquo; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing
the terms and conditions of a Restricted Stock Award grant. The Restricted Stock Award Agreement includes the Grant Notice for the Restricted
Stock Award and the agreement containing the written summary of the general terms and conditions applicable to the Restricted Stock Award
and which is provided to a Participant along with the Grant Notice. Each Restricted Stock Award Agreement will be subject to the terms
and conditions of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ccc)&nbsp;</B>&ldquo;<B><I>Returning
Shares</I></B>&rdquo; means shares of Common Stock subject to outstanding stock awards granted under the Company&rsquo;s 2019 Equity
Incentive Plan and that following the Effective Date: (i) are not issued because such stock award or any portion thereof expires or otherwise
terminates without all of the shares covered by such stock award having been issued; (ii) are withheld or reacquired to satisfy the exercise,
strike or purchase price; or (iii) are withheld or reacquired to satisfy a tax withholding obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ddd)&nbsp;</B>&ldquo;<B><I>RSU
Award</I></B>&rdquo; or &ldquo;<B><I>RSU</I></B>&rdquo; means an Award of restricted stock units representing the right to receive an
issuance of shares of Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;5(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(eee)&nbsp;</B>&ldquo;<B><I>RSU
Award Agreement</I></B>&rdquo; means a written agreement between the Company and a holder of a RSU Award evidencing the terms and conditions
of a RSU Award. The RSU Award Agreement includes the Grant Notice for the RSU Award and the agreement containing the written summary
of the general terms and conditions applicable to the RSU Award and which is provided to a Participant along with the Grant Notice. Each
RSU Award Agreement will be subject to the terms and conditions of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(fff)&nbsp;</B>&ldquo;<B><I>Rule&nbsp;16b-3</I></B>&rdquo;
means Rule&nbsp;16b-3 promulgated under the Exchange Act or any successor to Rule&nbsp;16b-3, as in effect from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ggg)&nbsp;</B>&ldquo;<B><I>Rule&nbsp;405</I></B>&rdquo;
means Rule&nbsp;405 promulgated under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(hhh)&nbsp;</B>&ldquo;<B><I>Section&nbsp;409A</I></B>&rdquo;
means Section&nbsp;409A of the Code and the regulations and other guidance thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iii)&nbsp;</B>&ldquo;<B><I>Section&nbsp;409A
Change in Control</I></B>&rdquo; means a change in the ownership or effective control of the Company, or in the ownership of a substantial
portion of the Company&rsquo;s assets, as provided in Section&nbsp;409A(a)(2)(A)(v) of the Code and Treasury Regulations&nbsp;Section&nbsp;1.409A-3(i)(5)
(without regard to any alternative definition thereunder).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(jjj)&nbsp;</B>&ldquo;<B><I>Securities
Act</I></B>&rdquo; means the U.S.&nbsp;Securities Act of&nbsp;1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(kkk)&nbsp;</B>&ldquo;<B><I>Share
Reserve</I></B>&rdquo; means the number of shares available for issuance under the Plan as set forth in Section&nbsp;2(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(lll)&nbsp;</B>&ldquo;<B><I>Stock
Appreciation Right</I></B>&rdquo; or &ldquo;<B><I>SAR</I></B>&rdquo; means a right to receive the appreciation on Common Stock that is
granted pursuant to the terms and conditions of Section&nbsp;4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(mmm)&nbsp;</B>&ldquo;<B><I>SAR
Agreement</I></B>&rdquo; means a written agreement between the Company and a holder of a SAR evidencing the terms and conditions of a
SAR grant. The SAR Agreement includes the Grant Notice for the SAR and the agreement containing the written summary of the general terms
and conditions applicable to the SAR and which is provided to a Participant along with the Grant Notice. Each SAR Agreement will be subject
to the terms and conditions of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(nnn)&nbsp;</B>&ldquo;<B><I>Subsidiary</I></B>&rdquo;
means, with respect to the Company, (i)&nbsp;any corporation of which more than&nbsp;50% of the outstanding Common Stock having ordinary
voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other
class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time,
directly or indirectly, Owned by the Company, and (ii)&nbsp;any partnership, limited liability company or other entity in which the Company
has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than&nbsp;50%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ooo)&nbsp;</B>&ldquo;<B><I>Ten
Percent Stockholder</I></B>&rdquo; means a person who Owns (or is deemed to Own pursuant to Section&nbsp;424(d) of the Code) stock possessing
more than&nbsp;10% of the total combined voting power of all classes of stock of the Company or any Affiliate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ppp)&nbsp;</B>&ldquo;<B><I>Trading
Policy</I></B>&rdquo; means the Company&rsquo;s policy permitting certain individuals to sell Company shares only during certain &ldquo;window&rdquo;
periods and/or otherwise restricts the ability of certain individuals to transfer or encumber Company shares, as in effect from time
to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(qqq)&nbsp;</B>&ldquo;<B><I>Unvested
Non-Exempt Award</I></B>&rdquo; means the portion of any Non-Exempt Award that had not vested in accordance with its terms upon or prior
to the date of any Corporate Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(rrr)&nbsp;</B>&ldquo;<B><I>Vested
Non-Exempt Award</I></B>&rdquo; means the portion of any Non-Exempt Award that had vested in accordance with its terms upon or prior
to the date of a Corporate Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 24; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>6
<FILENAME>ea147929ex10-4_jasper.htm
<DESCRIPTION>JASPER THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN FORM OF STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt; font-variant: small-caps">Jasper
Therapeutics, Inc.<BR>
Stock Option Grant Notice<BR>
</FONT><FONT STYLE="font-variant: small-caps">(2021 Equity Incentive Plan)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jasper Therapeutics, Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;),
pursuant to its&nbsp;2021 Equity Incentive Plan (the &ldquo;<B><I>Plan</I></B>&rdquo;), has granted to you (&ldquo;<B><I>Optionholder</I></B>&rdquo;)
an option to purchase the number of shares of the Common Stock set forth below (the &ldquo;<B><I>Option</I></B>&rdquo;). Your Option is
subject to all of the terms and conditions as set forth herein and in the Plan and the Stock Option Agreement, all of which are attached
hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein, but defined in the Plan or the Stock
Option Agreement, shall have the meanings set forth in the Plan or the Stock Option Agreement, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: justify">Optionholder:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; text-align: justify"></TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Date of Grant:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Vesting Commencement Date:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Number of Shares of Common Stock Subject to Option:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Exercise Price (Per Share):</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Total Exercise Price:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Expiration Date:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.2in; text-align: left; text-indent: -1.2in"><B>Type of
Grant</B>: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Incentive Stock Option] <U>OR</U> [Nonstatutory Stock Option]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.2in; text-align: justify; text-indent: -1.2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.2in; text-align: justify; text-indent: -1.2in"><B>Exercise and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.2in; text-align: justify; text-indent: -1.2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.2in; text-align: left; text-indent: -1.2in"><B>Vesting
Schedule</B>: Subject to the Optionholder&rsquo;s Continuous Service through each applicable vesting date, the Option will vest as
follows:<BR> <BR> [__________]. Notwithstanding the foregoing, vesting shall terminate upon the Participant&rsquo;s termination of
Continuous Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.2in; text-align: left; text-indent: -1.2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Optionholder Acknowledgements</B>: By your
signature below, or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Option is governed by this Stock Option Grant Notice, and the provisions of the Plan and the Stock
Option Agreement, all of which are made a part of this document. Unless otherwise provided in the Plan, this Grant Notice and the Stock
Option Agreement (together, the &ldquo;<B><I>Option Agreement</I></B>&rdquo;) may not be modified, amended or revised, except in a writing
signed by you and a duly authorized officer of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">If the Option is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options granted
to you) cannot be first <I>exercisable</I> for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess
over $100,000 is a Nonstatutory Stock Option.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">You consent to receive this Grant Notice, the Stock Option Agreement, the Plan, the Prospectus and any
other Plan-related documents by electronic delivery and to participate in the Plan through an on-line or electronic system established
and maintained by the Company or another third party designated by the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">You have read and are familiar with the provisions of the Plan, the Stock Option Agreement, and the Prospectus.
In the event of any conflict between the provisions in this Grant Notice, the Option Agreement, or the Prospectus and the terms of the
Plan, the terms of the Plan shall control.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Option Agreement sets forth the entire understanding between you and the Company regarding the acquisition
of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject, with the exception
of other equity awards previously granted to you and any</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">written employment agreement, offer letter, severance agreement, written severance plan or policy, or
other written agreement between the Company and you in each case that specifies the terms that should govern this Option.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature
complying with the U.S.&nbsp;federal ESIGN Act of&nbsp;2000, Uniform&nbsp;Electronic Transactions Act or other applicable law) or other
transmission method, and any counterpart so delivered, will be deemed to have been duly and validly delivered and be valid and effective
for all purposes.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-variant: small-caps"><B>Jasper Therapeutics, Inc.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-variant: small-caps"><B>Optionholder: </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Signature</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Signature</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Date:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Date:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Jasper
Therapeutics, Inc.<BR>
2021 Equity Incentive Plan<BR>
<BR>
Stock Option Agreement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As reflected by your Stock
Option Grant Notice (&ldquo;<B><I>Grant Notice</I></B>&rdquo;) Jasper Therapeutics, Inc., (the &ldquo;<B><I>Company</I></B>&rdquo;) has
granted you an option under its&nbsp;2021 Equity Incentive Plan (the &ldquo;<B><I>Plan</I></B>&rdquo;) to purchase a number of shares
of Common Stock at the exercise price indicated in your Grant Notice (the &ldquo;<B><I>Option</I></B>&rdquo;). Capitalized terms not explicitly
defined in this Agreement, but defined in the Grant Notice or the Plan, shall have the meanings set forth in the Grant Notice or Plan,
as applicable. The terms of your Option as specified in the Grant Notice and this Stock Option Agreement constitute your Option Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The general terms and conditions
applicable to your Option are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Governing Plan Document</FONT></B>. Your Option is subject to all the provisions of the
Plan. Your Option is further subject to all interpretations, amendments, rules and regulations, which may, from time to time, be promulgated
and adopted pursuant to the Plan. In the event of any conflict between the Option Agreement and the provisions of the Plan, the provisions
of the Plan shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Exercise</FONT></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>You may generally exercise the vested portion of your Option for whole shares of Common Stock at any time during its term by
delivery of payment of the exercise price and applicable withholding taxes and other required documentation to the Plan Administrator
in accordance with the exercise procedures established by the Plan Administrator, which may include an electronic submission. Please review
the Plan, which may restrict or prohibit your ability to exercise your Option during certain periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>To the extent permitted by Applicable Law, you may pay your Option exercise price as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>cash, check, bank draft or money order;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>subject to Company and/or Committee consent at the time of exercise, pursuant to a &ldquo;cashless exercise&rdquo; program
as further described in the Plan, if at the time of exercise the Common Stock is publicly traded;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>subject to Company and/or Committee consent at the time of exercise, by delivery of previously owned shares of Common Stock
as further described in the Plan; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>subject to Company and/or Committee consent at the time of exercise, if the Option is a Nonstatutory Stock Option, by a &ldquo;net
exercise&rdquo; arrangement as further described in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Term</FONT></B>. You may not exercise your Option before the commencement of its term or
after its term expires. The term of your option commences on the Date of Grant and expires upon the earliest of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>immediately upon the termination of your Continuous Service for Cause;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>three months after the termination of your Continuous Service for any reason other than Cause, Disability or death;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>12&nbsp;months after the termination of your Continuous Service due to your Disability;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>18&nbsp;months after your death if you die during your Continuous Service;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>immediately upon a Corporate Transaction if the Board has determined that the Option will terminate in connection with a Corporate
Transaction,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>the Expiration Date indicated in your Grant Notice; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>the day before the&nbsp;10th anniversary of the Date of Grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
if you die during the period provided in Section&nbsp;3(b) or&nbsp;3(c) above, the term of your Option shall not expire until the earlier
of (i)&nbsp;18 months after your death, (ii)&nbsp;upon any termination of the Option in connection with a Corporate Transaction, (iii)&nbsp;the
Expiration Date indicated in your Grant Notice, or (iv)&nbsp;the day before the 10th anniversary of the Date of Grant. Additionally, the
Post-Termination Exercise Period of your Option may be extended as provided in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To obtain the federal income
tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the date of grant of your Option,
and ending on the day three months before the date of your Option&rsquo;s exercise, you must be an employee of the Company or an Affiliate,
except in the event of your death or Disability. If the Company provides for the extended exercisability of your Option under certain
circumstances for your benefit, your Option will not necessarily be treated as an Incentive Stock Option if you exercise your Option more
than three months after the date your employment terminates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Withholding Obligations</FONT></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>Regardless of any action taken by the Company or, if different, the Affiliate to which you provide Continuous Service (the
&ldquo;<B><I>Service Recipient</I></B>&rdquo;) with respect to any income tax, social insurance, payroll tax, fringe benefits tax, payment
on account, or other tax-related items associated with the grant, vesting or exercise of the Option or sale of the underlying Common Stock
or other tax-related items related to your participation in the Plan and legally applicable to you (the &ldquo;<B><I>Tax Liability</I></B>&rdquo;),
you hereby acknowledge and agree that the Tax Liability is your ultimate responsibility and may exceed the amount, if any, actually withheld
by the Company or the Service Recipient. You further acknowledge that the Company and the Service Recipient (i)&nbsp;make no representations
or undertakings regarding any Tax Liability in connection with any aspect of this Option, including, but not limited to, the grant, vesting
or exercise of the Option, the issuance of Common Stock pursuant to such exercise, the subsequent sale of shares of Common Stock, and
the payment of any dividends on the shares; and (ii)&nbsp;do not commit to, and are under no obligation to structure the terms of the
grant or any aspect of the Option to reduce or eliminate your Tax Liability or achieve a particular tax result. Further, if you are subject
to Tax Liability in more than one jurisdiction, you acknowledge that the Company and/or the Service Recipient (or former service recipient,
as applicable) may be required to withhold or account for Tax Liability in more than one jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>Prior to any relevant taxable or tax withholding event, as applicable, you agree to make adequate arrangements satisfactory
to the Company and/or the Service Recipient to satisfy all Tax Liability. As further provided in Section&nbsp;8 of the Plan, you hereby
authorize the Company and any applicable Service Recipient to satisfy any applicable withholding obligations with regard to the Tax Liability
by one or a combination of the following methods: (i)&nbsp;causing you to pay any portion of the Tax Liability in cash or cash equivalent
in a form acceptable to the Company; (ii)&nbsp;withholding from any compensation otherwise payable to you by the Company or the Service
Recipient; (iii)&nbsp;withholding from the proceeds of the sale of shares of Common Stock issued upon exercise of the Option (including
by means of a &ldquo;cashless exercise&rdquo; pursuant to a program developed under Regulation&nbsp;T as promulgated by the Federal Reserve
Board to the extent permitted by the Company, or by means of the Company acting as your agent to sell sufficient shares of Common Stock
for the proceeds to settle such withholding requirements, on your behalf pursuant to this authorization without further consent); (iv)&nbsp;withholding
shares of Common Stock otherwise issuable to you upon the exercise of the Option, provided that to the extent necessary to qualify for
an exemption from application of Section&nbsp;16(b) of the Exchange Act, if applicable, such share withholding procedure will be subject
to the express prior approval of the Board or the Company&rsquo;s Compensation Committee; and/or (v)&nbsp;any other method determined
by the Company to be in compliance with Applicable Law. Furthermore, you agree to pay the Company or the Service Recipient any amount
the Company or the Service Recipient may be required to withhold, collect or pay as a result of your participation in the Plan or that
cannot be satisfied by the means previously described. In the event it is determined that the amount of the Tax Liability was greater
than the amount withheld by the Company or the Service Recipient, you agree to indemnify and hold the Company and/or the Service Recipient
(as applicable) harmless from any failure by the Company or the applicable Service Recipient to withhold the proper amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>The Company may withhold or account for your Tax Liability by considering statutory withholding amounts or other withholding
rates applicable in your jurisdiction(s), including (i)&nbsp;maximum applicable rates in your jurisdiction(s), in which case you may receive
a refund of any over-withheld amount in cash (whether from applicable tax authorities or the Company) and you will have no entitlement
to the equivalent amount in Common Stock or (ii)&nbsp;minimum or such other applicable rates in your jurisdiction(s), in which case, you
may be solely responsible for paying any additional Tax Liability to the applicable tax authorities or to the Company and/or the Service
Recipient. If the Tax Liability withholding obligation is satisfied by withholding shares of Common Stock, for tax purposes, you are deemed
to have been issued the full number of shares of Common Stock subject to the exercised portion of the Option, notwithstanding that a number
of the shares of Common Stock is held back solely for the purpose of paying such Tax Liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>You acknowledge that you may not be able to exercise your Option, even though the Option is vested, and that the Company shall
have no obligation to issue shares of Common Stock, in each case, unless, and until you have fully satisfied any applicable Tax Liability,
as determined by the Company. Unless any withholding obligation for the Tax Liability is satisfied, the Company shall have no obligation
to deliver to you any Common Stock in respect of the Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Incentive Stock Option Disposition Requirement</FONT></B>. If your option is an Incentive
Stock Option, you must notify the Company in writing within&nbsp;15&nbsp;days after the date of any disposition of any of the shares of
the Common Stock issued upon exercise of your option that occurs within two years after the date of your option grant or within one year
after such shares of Common Stock are transferred upon exercise of your option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Transferability</FONT></B>. Except as otherwise provided in the Plan, your Option is not
transferable, except by will or by the applicable laws of descent and distribution, and is exercisable during your life only by you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Corporate Transaction</FONT></B>. Your Option is subject to the terms of any agreement governing
a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative
that is authorized to act on your behalf with respect to any escrow, indemnities and any contingent consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">No Liability for Taxes</FONT></B>. As a condition to accepting the Option, you hereby (a)&nbsp;agree
to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising
from the Option or other Company compensation and (b)&nbsp;acknowledge that you were advised to consult with your own personal tax, financial
and other legal advisors regarding the tax consequences of the Option, and have either done so, or knowingly and voluntarily declined
to do so. Additionally, you acknowledge that the Option is exempt from Section&nbsp;409A, only if the exercise price is at least equal
to the &ldquo;fair market value&rdquo; of the Common Stock on the date of grant as determined by the Internal Revenue Service, and there
is no other impermissible deferral of compensation associated with the Option. Additionally, as a condition to accepting the Option, you
agree not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal
Revenue Service asserts that such exercise is less than the &ldquo;fair market value&rdquo; of the Common Stock on the date of grant as
subsequently determined by the Internal Revenue Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Obligations; Recoupment</FONT></B>. You hereby acknowledge that the grant of your Option
is additional consideration for any obligations (whether during or after employment) that you have to the Company not to compete, not
to solicit its customers, clients or employees, not to disclose or misuse confidential information or similar obligations. Accordingly,
if the Company reasonably determines that you breached such obligations, in addition to any other available remedy, the Company may, to
the extent permitted by Applicable Law, recoup any income realized by you with respect to the exercise of your Option within two years
of such breach. In addition, to the extent permitted by Applicable Law, this right to recoupment by the Company applies in the event that
your employment is terminated for Cause, or if the Company reasonably determines that circumstances existed that it could have terminated
your employment for Cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Severability</FONT></B>. If any part of this Option Agreement or the Plan is declared by
any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this
Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Option Agreement (or part of such a Section)
so declared to be unlawful or invalid, will, if possible, be construed in a manner which will give effect to the terms of such Section
or part of a Section to the fullest extent possible, while remaining lawful and valid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Indebtedness to the Company</FONT></B>. In the event that you have any loans, draws, advances
or any other indebtedness owing to the Company at the time of exercise of all or a portion of the Option, the Company may deduct and not
deliver that number of shares of Common Stock with a Fair Market Value subject to the Option equal to such indebtedness to satisfy all
or a portion of such indebtedness, to the extent permitted by law and in a manner consistent with Section&nbsp;409A of the Code, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Other Documents</FONT></B>. You hereby acknowledge receipt of, or the right to receive a
document providing the information required by Rule&nbsp;428(b)(1) promulgated under the Securities Act, which includes the Prospectus.
In addition, you acknowledge receipt of the Company&rsquo;s Trading Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><FONT STYLE="font-variant: small-caps">Questions</FONT></B>. If you have questions regarding these or any other terms and conditions
applicable to your Option, including a summary of the applicable federal income tax consequences, please see the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">* * * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>7
<FILENAME>ea147929ex10-5_jasper.htm
<DESCRIPTION>JASPER THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN FORM OF RSU AWARD GRANT NOTICE AND AWARD AGREEMENT (RSU AWARD)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.5</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Jasper
Therapeutics, Inc.<BR>
RSU Award Grant Notice<BR>
(2021 Equity Incentive Plan)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jasper Therapeutics, Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;)
has awarded to you (the &ldquo;<B><I>Participant</I></B>&rdquo;) the number of restricted stock units specified and on the terms set forth
below in consideration of your services (the &ldquo;<B><I>RSU Award</I></B>&rdquo;). Your RSU Award is subject to all of the terms and
conditions as set forth herein and in the Company&rsquo;s&nbsp;2021 Equity Incentive Plan (the &ldquo;<B><I>Plan</I></B>&rdquo;) and the
Award Agreement (the &ldquo;<B><I>Agreement</I></B>&rdquo;), which are incorporated herein in their entirety. Capitalized terms not explicitly
defined herein but defined in the Plan or the Agreement shall have the meanings set forth in the Plan or the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 35%">Participant:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 45%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Date of Grant:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Vesting Commencement Date:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Number of Restricted Stock Units:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; text-align: left"><B>Vesting Schedule</B>:</TD>
    <TD STYLE="width: 0%">[</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 85%"></TD>
    <TD STYLE="width: 0%; text-align: left">].</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Notwithstanding the foregoing, vesting shall terminate upon the Participant&rsquo;s termination of Continuous Service.</TD>
    <TD STYLE="text-align: justify"> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><B>Issuance Schedule</B>:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">One share of Common Stock will be issued for each restricted stock unit, which vests at the time set forth in Section 5 of the Agreement.</TD>
    <TD STYLE="text-align: justify"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Participant Acknowledgements</B>: By your signature
below or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;<FONT STYLE="font-family: Symbol"></FONT></TD><TD STYLE="text-align: justify">The RSU Award is governed by this RSU Award Grant Notice (the &ldquo;<B><I>Grant Notice</I></B>&rdquo;),
and the provisions of the Plan and the Agreement, all of which are made a part of this document. Unless otherwise provided in the Plan,
this Grant Notice and the Agreement (together, the &ldquo;<B><I>RSU Award Agreement</I></B>&rdquo;) may not be modified, amended or revised
except in a writing signed by you and a duly authorized officer of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;<FONT STYLE="font-family: Symbol"></FONT></TD><TD STYLE="text-align: justify">You have read and are familiar with the provisions of the Plan, the RSU Award Agreement and the Prospectus.
In the event of any conflict between the provisions in the RSU Award Agreement, or the Prospectus and the terms of the Plan, the terms
of the Plan shall control.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">The RSU Award Agreement sets forth the entire understanding between you and the Company regarding the
acquisition of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with
the exception of: (i)&nbsp;other equity awards previously granted to you, and (ii)&nbsp;any written employment agreement, offer letter,
severance agreement, written severance plan or policy, or other written agreement between the Company and you in each case that specifies
the terms that should govern this RSU Award.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 40%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Jasper Therapeutics,
Inc.</B></FONT></P></TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Participant:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">Signature</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">Signature</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"></TD>
    <TD>&nbsp;</TD>
    <TD>Date:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Date:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps">Jasper
Therapeutics, Inc.</FONT><BR>
2021 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps">Equity Incentive Plan<BR>
Award Agreement (RSU Award)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As reflected by your Restricted
Stock Unit Grant Notice (&ldquo;<B><I>Grant Notice</I></B>&rdquo;), Jasper Therapeutics, Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;)
has granted you a RSU Award under its&nbsp;2021 Equity Incentive Plan (the &ldquo;<B><I>Plan</I></B>&rdquo;) for the number of restricted
stock units as indicated in your Grant Notice (the &ldquo;<B><I>RSU Award</I></B>&rdquo;). The terms of your RSU Award as specified in
this Award Agreement for your RSU Award (the &ldquo;<B><I>Agreement</I></B>&rdquo;) and the Grant Notice constitute your &ldquo;<B><I>RSU
Award Agreement</I></B>&rdquo;. Defined terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall
have the same definitions as in the Grant Notice or Plan, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The general terms applicable
to your RSU Award are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.   <FONT STYLE="font-variant: small-caps">Governing
Plan Document</FONT></B>. Your RSU Award is subject to all the provisions of the Plan. Your RSU Award is further subject to all interpretations,
amendments, rules and regulations, which may, from time to time, be promulgated and adopted pursuant to the Plan. In the event of any
conflict between the RSU Award Agreement and the provisions of the Plan, the provisions of the Plan shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.   <FONT STYLE="font-variant: small-caps">Grant
of the RSU Award</FONT></B>. This RSU Award represents your right to be issued on a future date the number of shares of the Company&rsquo;s
Common Stock that is equal to the number of restricted stock units indicated in the Grant Notice subject to your satisfaction of the vesting
conditions set forth therein (the &ldquo;<B><I>Restricted Stock Units</I></B>&rdquo;). Any additional Restricted Stock Units that become
subject to the RSU Award pursuant to Capitalization Adjustments as set forth in the Plan and the provisions of Section&nbsp;3 below, if
any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and
time and manner of delivery as applicable to the other Restricted Stock Units covered by your RSU Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.   <FONT STYLE="font-variant: small-caps">Dividends</FONT></B>.
You shall receive no benefit or adjustment to your RSU Award with respect to any cash dividend, stock dividend or other distribution that
does not result from a Capitalization Adjustment as provided in the Plan; provided, however, that this sentence shall not apply with respect
to any shares of Common Stock that are delivered to you in connection with your RSU Award after such shares have been delivered to you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.   <FONT STYLE="font-variant: small-caps">Withholding
Obligations</FONT></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)   </B>Regardless
of any action taken by the Company or, if different, the Affiliate to which you provide Continuous Service (the &ldquo;<B><I>Service Recipient</I></B>&rdquo;)
with respect to any income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items associated
with the grant or vesting of the RSU Award or sale of the underlying Common Stock or other tax-related items related to your participation
in the Plan and legally applicable to you (the &ldquo;<B><I>Tax Liability</I></B>&rdquo;), you hereby acknowledge and agree that the Tax
Liability is your ultimate responsibility and may exceed the amount, if any, actually withheld by the Company or the Service Recipient.
You further acknowledge that the Company and the Service Recipient (i)&nbsp;make no representations or undertakings regarding any Tax
Liability in connection with any aspect of this RSU Award, including, but not limited to, the grant or vesting of the RSU Award, the issuance
of Common Stock pursuant to such vesting, the subsequent sale of shares of Common Stock, and the payment of any dividends on the Common
Stock; and (ii)&nbsp;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the RSU Award to
reduce or eliminate your Tax Liability or achieve a particular tax result. Further, if you are subject to Tax Liability in more than one
jurisdiction, you acknowledge that the Company and/or the Service Recipient (or former service recipient, as applicable) may be required
to withhold or account for Tax Liability in more than one jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)   </B>Prior
to any relevant taxable or tax withholding event, as applicable, you agree to make adequate arrangements satisfactory to the Company and/or
the Service Recipient to satisfy all Tax Liability. As further provided in Section&nbsp;8 of the Plan, you hereby authorize the Company
and any applicable Service Recipient to satisfy any applicable withholding obligations with regard to the Tax Liability by any of the
following means or by a combination of such means: (i)&nbsp;causing you to pay any portion of the Tax Liability in cash or cash equivalent
in a form acceptable to the Company; (ii)&nbsp;withholding from any compensation otherwise payable to you by the Company or the Service
Recipient; (iii)&nbsp;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to you in connection
with the Award; <I>provided</I>, however, that to the extent necessary to qualify for an exemption from application of Section&nbsp;16(b)
of the Exchange Act, if applicable, such share withholding procedure will be subject to the express prior approval of the Board or the
Company&rsquo;s Compensation Committee; (iv)&nbsp;permitting or requiring you to enter into a &ldquo;same day sale&rdquo; commitment,
if applicable, with a broker-dealer that is a member of the Financial Industry Regulatory Authority (a &ldquo;<B><I>FINRA Dealer</I></B>&rdquo;),
pursuant to this authorization and without further consent, whereby you irrevocably elect to sell a portion of the shares of Common Stock
to be delivered in connection with your Restricted Stock Units to satisfy the Tax Liability and whereby the FINRA Dealer irrevocably commits
to forward the proceeds necessary to satisfy the Tax Liability directly to the Company or the Service Recipient; and/or (v)&nbsp;any other
method determined by the Company to be in compliance with Applicable Law. Furthermore, you agree to pay the Company or the Service Recipient
any amount the Company or the Service Recipient may be required to withhold, collect, or pay as a result of your participation in the
Plan or that cannot be satisfied by the means previously described. In the event it is determined that the amount of the Tax Liability
was greater than the amount withheld by the Company and/or the Service Recipient (as applicable), you agree to indemnify and hold the
Company and/or the Service Recipient (as applicable) harmless from any failure by the Company or the applicable Service Recipient to withhold
the proper amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)   </B>The
Company may withhold or account for your Tax Liability by considering statutory withholding amounts or other withholding rates applicable
in your jurisdiction(s), including (i)&nbsp;maximum applicable rates in your jurisdiction(s), in which case you may receive a refund of
any over-withheld amount in cash (whether from applicable tax authorities or the Company) and you will have no entitlement to the equivalent
amount in Common Stock or (ii)&nbsp;minimum or such other applicable rates in your jurisdiction(s), in which case you may be solely responsible
for paying any additional Tax Liability to the applicable tax authorities or to the Company and/or the Service Recipient. If the Tax Liability
withholding obligation is satisfied by withholding shares of Common Stock, for tax purposes, you are deemed to have been issued the full
number of shares of Common Stock subject to the vested portion of the RSU Award, notwithstanding that a number of the shares of Common
Stock is held back solely for the purpose of paying such Tax Liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)   </B>You
acknowledge that you may not participate in the Plan and the Company shall have no obligation to deliver shares of Common Stock until
you have fully satisfied the Tax Liability, as determined by the Company. Unless any withholding obligation for the Tax Liability is satisfied,
the Company shall have no obligation to deliver to you any Common Stock in respect of the RSU Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.   <FONT STYLE="font-variant: small-caps">Date
of Issuance</FONT></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)   </B>The
issuance of shares in respect of the Restricted Stock Units is intended to comply with U.S.&nbsp;Treasury Regulations&nbsp;Section&nbsp;1.409A-3(a)
and will be construed and administered in such a manner. Subject to the satisfaction of the Tax Liability withholding obligation, if any,
in the event one or more Restricted Stock Units vests, the Company shall issue to you one (1)&nbsp;share of Common Stock for each vested
Restricted Stock Unit. Each issuance date determined by this paragraph is referred to as an &ldquo;<B><I>Original Issuance Date</I></B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)   </B>If
the Original Issuance Date falls on a date that is not a business day, delivery shall instead occur on the next following business day.
In addition, if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(i)   </B>the
Original Issuance Date does not occur (1)&nbsp;during an &ldquo;open window period&rdquo; applicable to you, as determined by the Company
in accordance with the Company&rsquo;s then-effective policy on trading in Company securities, or (2)&nbsp;on a date when you are otherwise
permitted to sell shares of Common Stock on an established stock exchange or stock market (including but not limited to under a previously
established written trading plan that meets the requirements of Rule&nbsp;10b5-1 under the Exchange Act and was entered into in compliance
with the Company&rsquo;s policies (a &ldquo;<B><I>10b5-1 Arrangement</I></B>&rdquo;)), <I>and</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(ii)   </B>either
(1)&nbsp;a Tax Liability withholding obligation does not apply, or (2)&nbsp;the Company decides, prior to the Original Issuance Date,
(A)&nbsp;not to satisfy the Tax Liability withholding obligation by withholding shares of Common Stock from the shares otherwise due,
on the Original Issuance Date, to you under this Award, and (B)&nbsp;not to permit you to enter into a &ldquo;same day sale&rdquo; commitment
with a broker-dealer (including, but not limited to, a commitment under a&nbsp;10b5-1 Arrangement) and (C)&nbsp;not to permit you to pay
your Tax Liability in cash, <U>then</U> the shares that would otherwise be issued to you on the Original Issuance Date will not be delivered
on such Original Issuance Date and will instead be delivered on the first business day when you are not prohibited from selling shares
of the Common Stock in the open public market, but in no event later than December&nbsp;31 of the calendar year in which the Original
Issuance Date occurs (that is, the last day of your taxable year in which the Original Issuance Date occurs), or, <U>if and only if</U>
permitted in a manner that complies with U.S.&nbsp;Treasury Regulations&nbsp;Section&nbsp;1.409A-1(b)(4), no later than the date that
is the&nbsp;15th day of the third calendar month of the applicable year following the year in which the shares of Common Stock under this
Award are no longer subject to a &ldquo;substantial risk of forfeiture&rdquo; within the meaning of U.S.&nbsp;Treasury Regulations&nbsp;Section&nbsp;1.409A-1(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.   <FONT STYLE="font-variant: small-caps">Transferability</FONT></B>.
Except as otherwise provided in the Plan, your RSU Award is not transferable, except by will or by the applicable laws of descent and
distribution</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.   <FONT STYLE="font-variant: small-caps">Corporate
Transaction</FONT></B>. Your RSU Award is subject to the terms of any agreement governing a Corporate Transaction involving the Company,
including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf
with respect to any escrow, indemnities and any contingent consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.   <FONT STYLE="font-variant: small-caps">No
Liability for Taxes</FONT></B>. As a condition to accepting the RSU Award, you hereby (a)&nbsp;agree to not make any claim against the
Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from the RSU Award or other Company
compensation and (b)&nbsp;acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors
regarding the tax consequences of the RSU Award and have either done so or knowingly and voluntarily declined to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.   <FONT STYLE="font-variant: small-caps">Severability</FONT></B>.
If any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness
or invalidity will not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid. Any Section of this
Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give
effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.   <FONT STYLE="font-variant: small-caps">Other
Documents</FONT></B>. You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule&nbsp;428(b)(1)
promulgated under the Securities Act, which includes the Prospectus. In addition, you acknowledge receipt of the Company&rsquo;s Trading
Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.   <FONT STYLE="font-variant: small-caps">Questions</FONT></B>.
If you have questions regarding these or any other terms and conditions applicable to your RSU Award, including a summary of the applicable
federal income tax consequences please see the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>8
<FILENAME>ea147929ex10-6_jasper.htm
<DESCRIPTION>JASPER THERAPEUTICS, INC., 2021 EMPLOYEE STOCK PURCHASE PLAN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 10.6</B></FONT></P>
<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jasper
Therapeutics, Inc.<BR>
<BR>
2021 Employee Stock Purchase Plan<BR>
Adopted by the Board Of Directors: August 24, 2021<BR>
Approved by the Stockholders: September 22, 2021<BR>
<BR></FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General; Purpose.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity
to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an
Employee Stock Purchase Plan. In addition, the Plan permits the Company to grant a series of Purchase Rights to Eligible Employees that
do not meet the requirements of an Employee Stock Purchase Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>The Plan includes two components: a&nbsp;423 Component and a Non-423 Component. The Company intends (but makes no undertaking or
representation to maintain) the&nbsp;423 Component to qualify as an Employee Stock Purchase Plan. The provisions of the&nbsp;423 Component,
accordingly, will be construed in a manner that is consistent with the requirements of Section&nbsp;423 of the Code. Except as otherwise
provided in the Plan or determined by the Board, the Non-423 Component will operate and be administered in the same manner as the&nbsp;423
Component.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)
</B>The Company, by means of the Plan, seeks to retain the services of such Employees, to secure and retain the services of new Employees
and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administration.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>The Board or the Committee will administer the Plan. References herein to the Board shall be deemed to refer to the Committee except
where context dictates otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)
</B>To determine how and when Purchase Rights will be granted and the provisions of each Offering (which need not be identical).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)
</B>To designate from time to time (A)&nbsp;which Related Corporations will be eligible to participate in the Plan as Designated&nbsp;423
Corporations, (B)&nbsp;which Related Corporations or Affiliates will be eligible to participate in the Plan as Designated Non-423 Corporations,
or (C)&nbsp;which Designated Companies will participate in each separate Offering (to the extent that the Company makes separate Offerings).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iii)
</B>To construe and interpret the Plan and Purchase Rights, and to establish, amend and revoke rules and regulations for its administration.
The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent
it deems necessary or expedient to make the Plan fully effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"> &nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iv)
</B>To settle all controversies regarding the Plan and Purchase Rights granted under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(v)
</B>To suspend or terminate the Plan at any time as provided in Section&nbsp;12.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(vi)
</B>To amend the Plan at any time as provided in Section&nbsp;12.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(vii)
</B>Generally, to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of the
Company and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan with respect
to the&nbsp;423 Component.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(viii)
</B>To adopt such rules, procedures and sub-plans as are necessary or appropriate to permit or facilitate participation in the Plan by
Employees who are foreign nationals or employed or located outside the United States. Without limiting the generality of, and consistent
with, the foregoing, the Board specifically is authorized to adopt rules, procedures, and sub-plans regarding, without limitation, eligibility
to participate in the Plan, the definition of eligible &ldquo;earnings,&rdquo; handling and making of Contributions, establishment of
bank or trust accounts to hold Contributions, payment of interest, conversion of local currency, obligations to pay payroll tax, determination
of beneficiary designation requirements, withholding procedures and handling of share issuances, any of which may vary according to applicable
requirements, and which, if applicable to a Designated Non-423 Corporation, do not have to comply with the requirements of Section&nbsp;423
of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)
</B>The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration is delegated
to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board
that have been delegated to the Committee, including the power to delegate to a subcommittee any of the administrative powers the Committee
is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject, however,
to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. Further, to
the extent not prohibited by Applicable Law, the Board or Committee may, from time to time, delegate some or all of its authority under
the Plan to one or more officers of the Company or other persons or groups of persons as it deems necessary, appropriate or advisable
under conditions or limitations that it may set at or after the time of the delegation. The Board may retain the authority to concurrently
administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. Whether
or not the Board has delegated administration of the Plan to a Committee, the Board will have the final power to determine all questions
of policy and expediency that may arise in the administration of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)
</B>All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person
and will be final, binding and conclusive on all persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">3.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of Common Stock Subject to the Plan.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>Subject to the provisions of Section&nbsp;11(a) relating to Capitalization Adjustments, the maximum number of shares of Common Stock
that may be issued under the Plan will not exceed&nbsp;550,000 shares of Common Stock, plus the number of shares of Common Stock that
are automatically added on January&nbsp;1<SUP>st</SUP> of each year for a period of up to ten years, commencing on the first January&nbsp;1
following the year in which the Effective Date occurs and ending on (and including) January&nbsp;1, 2031, in an amount equal to the lesser
of (i) 1% of the total number of shares of Common Stock outstanding on December&nbsp;31<SUP>st</SUP> of the preceding calendar year,
and (ii) 550,000 shares of Common Stock. Notwithstanding the foregoing, the Board may act prior to the first day of any calendar year
to provide that there will be no January&nbsp;1<SUP>st </SUP>increase in the share reserve for such calendar year or that the increase
in the share reserve for such calendar year will be a lesser number of shares of Common Stock than would otherwise occur pursuant to
the preceding sentence. For the avoidance of doubt, up to the maximum number of shares of Common Stock reserved under this Section&nbsp;3(a)
may be used to satisfy purchases of Common Stock under the&nbsp;423 Component and any remaining portion of such maximum number of shares
may be used to satisfy purchases of Common Stock under the Non-423 Component.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>If any Purchase Right granted under the Plan terminates without having been exercised in full, the shares of Common Stock not purchased
under such Purchase Right will again become available for issuance under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)
</B>The stock purchasable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased
by the Company on the open market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">4.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant of Purchase Rights; Offering.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>The Board may, from time to time, grant or provide for the grant of Purchase Rights to Eligible Employees under an Offering (consisting
of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering will be in such form and
will contain such terms and conditions as the Board will deem appropriate, and, with respect to the&nbsp;423 Component, will comply with
the requirement of Section&nbsp;423(b)(5) of the Code that all Employees granted Purchase Rights will have the same rights and privileges.
The terms and conditions of an Offering shall be incorporated by reference into the Plan and treated as part of the Plan. The provisions
of separate Offerings need not be identical, but each Offering will include (through incorporation of the provisions of this Plan by
reference in the document comprising the Offering or otherwise) the period during which the Offering will be effective, which period
will not exceed&nbsp;27&nbsp;months beginning with the Offering Date, and the substance of the provisions contained in Sections&nbsp;5
through&nbsp;8, inclusive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>If a Participant has more than one Purchase Right outstanding under the Plan, unless he or she otherwise indicates in forms delivered
to the Company or a third party designated by the Company (each, a &ldquo;<B><I>Company Designee</I></B>&rdquo;): (i)&nbsp;each form
will apply to all of his or her Purchase Rights under the Plan, and (ii)&nbsp;a Purchase Right with a lower exercise price (or an earlier-granted
Purchase Right, if different Purchase Rights have identical exercise prices) will be exercised to the fullest possible extent before
a Purchase Right with a higher exercise price (or a later-granted Purchase Right if different Purchase Rights have identical exercise
prices) will be exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)
</B>The Board will have the discretion to structure an Offering so that if the Fair Market Value of a share of Common Stock on the first
Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a share of Common Stock on
the Offering Date for that Offering, then (i)&nbsp;that Offering will terminate immediately as of that first Trading Day, and (ii)&nbsp;the
Participants in such terminated Offering will be automatically enrolled in a new Offering beginning on the first Trading Day of such
new Purchase Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">5.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eligibility.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>Purchase Rights may be granted only to Employees of the Company or, as the Board may designate in accordance with Section&nbsp;2(b),
to Employees of a Related Corporation or an Affiliate. Except as provided in Section&nbsp;5(b) or as required by Applicable Law, an Employee
will not be eligible to be granted Purchase Rights unless, on the Offering Date, the Employee has been in the employ of the Company or
the Related Corporation or an Affiliate, as the case may be, for such continuous period preceding such Offering Date as the Board may
require, but in no event will the required period of continuous employment be equal to or greater than two years. In addition, the Board
may (unless prohibited by Applicable Law) provide that no Employee will be eligible to be granted Purchase Rights under the Plan unless,
on the Offering Date, such Employee&rsquo;s customary employment with the Company, the Related Corporation, or the Affiliate is more
than&nbsp;20 hours per week and more than five months per calendar year or such other criteria as the Board may determine consistent
with Section&nbsp;423 of the Code with respect to the&nbsp;423 Component. The Board may also exclude from participation in the Plan or
any Offering Employees who are &ldquo;highly compensated employees&rdquo; (within the meaning of Section&nbsp;423(b)(4)(D) of the Code)
of the Company or a Related Corporation or a subset of such highly compensated employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>The Board may provide that each person who, during the course of an Offering, first becomes an Eligible Employee will, on a date
or dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs thereafter,
receive a Purchase Right under that Offering, which Purchase Right will thereafter be deemed to be a part of that Offering. Such Purchase
Right will have the same characteristics as any Purchase Rights originally granted under that Offering, as described herein, except that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)
</B>the date on which such Purchase Right is granted will be the &ldquo;Offering Date&rdquo; of such Purchase Right for all purposes,
including determination of the exercise price of such Purchase Right;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)
</B>the period of the Offering with respect to such Purchase Right will begin on its Offering Date and end coincident with the end of
such Offering; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iii)
</B>the Board may provide that if such person first becomes an Eligible Employee within a specified period of time before the end of
the Offering, he or she will not receive any Purchase Right under that Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)
</B>No Employee will be eligible for the grant of any Purchase Rights if, immediately after any such Purchase Rights are granted, such
Employee owns stock possessing 5% or more of the total combined voting power or value of all classes of stock of the Company or of any
Related Corporation. For purposes of this Section&nbsp;5(c), the rules of Section&nbsp;424(d) of the Code will apply in determining the
stock ownership of any Employee, and stock that such Employee may purchase under all outstanding Purchase Rights and options will be
treated as stock owned by such Employee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)
</B>As specified by Section&nbsp;423(b)(8) of the Code, an Eligible Employee may be granted Purchase Rights only if such Purchase Rights,
together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit
such Eligible Employee&rsquo;s rights to purchase stock of the Company or any Related Corporation to accrue at a rate which, when aggregated,
exceeds US $25,000 of Fair Market Value of such stock (determined at the time such rights are granted, and which, with respect to the
Plan, will be determined as of their respective Offering Dates) for each calendar year in which such rights are outstanding at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e)
</B>Officers of the Company and any Designated Company, if they are otherwise Eligible Employees, will be eligible to participate in
Offerings under the Plan. Notwithstanding the foregoing, the Board may (unless prohibited by Applicable Law) provide in an Offering that
Employees who are highly compensated Employees within the meaning of Section&nbsp;423(b)(4)(D) of the Code will not be eligible to participate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(f)
</B>Notwithstanding anything in this Section&nbsp;5 to the contrary, in the case of an Offering under the Non-423 Component, an Eligible
Employee (or group of Eligible Employees) may be excluded from participation in the Plan or an Offering if the Board has determined,
in its sole discretion, that participation of such Eligible Employee(s) is not advisable or practical for any reason.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">6.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase Rights; Purchase Price.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>On each Offering Date, each Eligible Employee, pursuant to an Offering made under the Plan, will be granted a Purchase Right to purchase
up to that number of shares of Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by the
Board, but in either case not exceeding&nbsp;15% of such Employee&rsquo;s earnings (as defined by the Board in each Offering) during
the period that begins on the Offering Date (or such later date as the Board determines for a particular Offering) and ends on the date
stated in the Offering, which date will be no later than the end of the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>The Board will establish one or more Purchase Dates during an Offering on which Purchase Rights granted for that Offering will be
exercised and shares of Common Stock will be purchased in accordance with such Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)
</B>In connection with each Offering made under the Plan, each Eligible Employee may purchase up to 4,000 shares of Common Stock (or
such lesser number of shares determined by the Board prior to the commencement of the Offering) and the Board may specify (i)&nbsp;a
maximum number of shares of Common Stock that may be purchased by any Participant on any Purchase Date during such Offering, (ii)&nbsp;a
maximum aggregate number of shares of Common Stock that may be purchased by all Participants pursuant to such Offering and/or (iii)&nbsp;a
maximum aggregate number of shares of Common Stock that may be purchased by all Participants on any Purchase Date under the Offering.
If the aggregate purchase of shares of Common Stock issuable upon exercise of Purchase Rights granted under the Offering would exceed
any such maximum aggregate number, then, in the absence of any Board action otherwise, a pro rata (based on each Participant&rsquo;s
accumulated Contributions) allocation of the shares of Common Stock (rounded down to the nearest whole share) available will be made
in as nearly a uniform manner as will be practicable and equitable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)
</B>The purchase price of shares of Common Stock acquired pursuant to Purchase Rights will be not less than the lesser of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)
</B>an amount equal to&nbsp;85% of the Fair Market Value of the shares of Common Stock on the Offering Date; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)
</B>an amount equal to&nbsp;85% of the Fair Market Value of the shares of Common Stock on the applicable Purchase Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">7.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participation; Withdrawal; Termination.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>An Eligible Employee may elect to participate in an Offering and authorize payroll deductions as the means of making Contributions
by completing and delivering to the Company or a Company Designee, within the time specified in the Offering, an enrollment form provided
by the Company or Company Designee. The enrollment form will specify the amount of Contributions not to exceed the maximum amount specified
by the Board. Each Participant&rsquo;s Contributions will be credited to a bookkeeping account for such Participant under the Plan and
will be deposited with the general funds of the Company except where Applicable Law requires that Contributions be deposited with a third
party. If permitted in the Offering, a Participant may begin such Contributions with the first payroll occurring on or after the Offering
Date (or, in the case of a payroll date that occurs after the end of the prior Offering but before the Offering Date of the next new
Offering, Contributions from such payroll will be included in the new Offering). If permitted in the Offering, a Participant may thereafter
reduce (including to zero) or increase his or her Contributions. If required under Applicable Law or if specifically provided in the
Offering, in addition to or instead of making Contributions by payroll deductions, a Participant may make Contributions through payment
by cash, check or wire transfer prior to a Purchase Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>During an Offering, a Participant may cease making Contributions and withdraw from the Offering by delivering to the Company or a
Company Designee a withdrawal form provided by the Company. The Company may impose a deadline before a Purchase Date for withdrawing.
Upon such withdrawal, such Participant&rsquo;s Purchase Right in that Offering will immediately terminate and the Company will distribute
as soon as practicable to such Participant all of his or her accumulated but unused Contributions and such Participant&rsquo;s Purchase
Right in that Offering shall thereupon terminate. A Participant&rsquo;s withdrawal from that Offering will have no effect upon his or
her eligibility to participate in any other Offerings under the Plan, but such Participant will be required to deliver a new enrollment
form to participate in subsequent Offerings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)
</B>Unless otherwise required by Applicable Law, Purchase Rights granted pursuant to any Offering under the Plan will terminate immediately
if the Participant either (i)&nbsp;is no longer an Employee for any reason or for no reason (subject to any post-employment participation
period required by Applicable Law) or (ii)&nbsp;is otherwise no longer eligible to participate. The Company will distribute as soon as
practicable to such individual all of his or her accumulated but unused Contributions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)
</B>Unless otherwise determined by the Board, a Participant whose employment transfers or whose employment terminates with an immediate
rehire (with no break in service) by or between the Company and a Designated Company or between Designated Companies will not be treated
as having terminated employment for purposes of participating in the Plan or an Offering; however, if a Participant transfers from an
Offering under the&nbsp;423 Component to an Offering under the Non-423 Component, the exercise of the Participant&rsquo;s Purchase Right
will be qualified under the&nbsp;423 Component only to the extent such exercise complies with Section&nbsp;423 of the Code. If a Participant
transfers from an Offering under the Non-423 Component to an Offering under the&nbsp;423 Component, the exercise of the Purchase Right
will remain non-qualified under the Non-423 Component. The Board may establish different and additional rules governing transfers between
separate Offerings within the&nbsp;423 Component and between Offerings under the&nbsp;423 Component and Offerings under the Non-423 Component.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e)
</B>During a Participant&rsquo;s lifetime, Purchase Rights will be exercisable only by such Participant. Purchase Rights are not transferable
by a Participant, except by will, by the laws of descent and distribution, or, if permitted by the Company, by a beneficiary designation
as described in Section&nbsp;10.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(f)
</B>Unless otherwise specified in the Offering or as required by Applicable Law, the Company will have no obligation to pay interest
on Contributions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">8.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of Purchase Rights.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>On each Purchase Date, each Participant&rsquo;s accumulated Contributions will be applied to the purchase of shares of Common Stock,
up to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified
in the Offering. No fractional shares will be issued unless specifically provided for in the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>Unless otherwise provided in the Offering, if any amount of accumulated Contributions remains in a Participant&rsquo;s account after
the purchase of shares of Common Stock on the final Purchase Date of an Offering, then such remaining amount will not roll over to the
next Offering and will instead be distributed in full to such Participant after the final Purchase Date of such Offering without interest
(unless otherwise required by Applicable Law).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)
</B>No Purchase Rights may be exercised to any extent unless the shares of Common Stock to be issued upon such exercise under the Plan
are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable
U.S.&nbsp;federal and state, foreign and other securities, exchange control and other laws applicable to the Plan. If on a Purchase Date
the shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights will be exercised on such
Purchase Date, and the Purchase Date will be delayed until the shares of Common Stock are subject to such an effective registration statement
and the Plan is in material compliance, except that the Purchase Date will in no event be more than&nbsp;27&nbsp;months from the Offering
Date. If, on the Purchase Date, as delayed to the maximum extent permissible, the shares of Common Stock are not registered and the Plan
is not in material compliance with all Applicable Laws, as determined by the Company in its sole discretion, no Purchase Rights will
be exercised and all accumulated but unused Contributions will be distributed to the Participants without interest (unless the payment
of interest is otherwise required by Applicable Law).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">9.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covenants of the Company.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will seek to obtain from each U.S.&nbsp;federal or state, foreign or other regulatory commission, agency or other Governmental
Body having jurisdiction over the Plan such authority as may be required to grant Purchase Rights and issue and sell shares of Common
Stock thereunder unless the Company determines, in its sole discretion, that doing so is not practical or would cause the Company to
incur costs that are unreasonable. If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel
for the Company deems necessary for the grant of Purchase Rights or the lawful issuance and sale of Common Stock under the Plan, and
at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and/or to issue
and sell Common Stock upon exercise of such Purchase Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">10.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designation of Beneficiary.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>The Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who will receive any shares
of Common Stock and/or Contributions from the Participant&rsquo;s account under the Plan if the Participant dies before such shares and/or
Contributions are delivered to the Participant. The Company may, but is not obligated to, permit the Participant to change such designation
of beneficiary. Any such designation and/or change must be on a form approved by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>If a Participant dies, and in the absence of a valid beneficiary designation, the Company will deliver any shares of Common Stock
and/or Contributions to the executor or administrator of the estate of the Participant. If no executor or administrator has been appointed
(to the knowledge of the Company), the Company, in its sole discretion, may deliver such shares of Common Stock and/or Contributions,
without interest (unless the payment of interest is otherwise required by Applicable Law), to the Participant&rsquo;s spouse, dependents
or relatives, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">11.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments Upon Changes in Common Stock; Corporate
Transactions.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i)&nbsp;the class(es) and
maximum number of securities subject to the Plan pursuant to Section&nbsp;3(a), (ii)&nbsp;the class(es) and maximum number of securities
by which the share reserve is to increase automatically each year pursuant to Section&nbsp;3(a), (iii)&nbsp;the class(es) and number
of securities subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights and (iv)&nbsp;the class(es)
and number of securities that are the subject of the purchase limits under each ongoing Offering. The Board will make these adjustments,
and its determination will be final, binding and conclusive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>In the event of a Corporate Transaction, then: (i)&nbsp;any surviving corporation or acquiring corporation (or the surviving or acquiring
corporation&rsquo;s parent company) may assume or continue outstanding Purchase Rights or may substitute similar rights (including a
right to acquire the same consideration paid to the stockholders in the Corporate Transaction) for outstanding Purchase Rights, or (ii)&nbsp;if
any surviving or acquiring corporation (or its parent company) does not assume or continue such Purchase Rights or does not substitute
similar rights for such Purchase Rights, then (A) the Participants&rsquo; accumulated Contributions will be used to purchase shares of
Common Stock (rounded down to the nearest whole share) within ten business days (or such other period specified by the Board) prior to
the Corporate Transaction under the outstanding Purchase Rights, and the Purchase Rights will terminate immediately after such purchase,
or (B) the Board, in its discretion, may terminate any outstanding Offerings, cancel the outstanding Purchase Rights and refund the Participants&rsquo;
accumulated Contributions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">12.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment, Termination or Suspension of the Plan.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>The Board may amend the Plan at any time in any respect the Board deems necessary or advisable. However, except as provided in Section&nbsp;11(a)
relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval
is required by Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>The Board may suspend or terminate the Plan at any time. No Purchase Rights may be granted under the Plan while the Plan is suspended
or after it is terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
benefits, privileges, entitlements and obligations under any outstanding Purchase Rights granted before an amendment, suspension or termination
of the Plan will not be materially impaired by any such amendment, suspension or termination except (i)&nbsp;with the consent of the
person to whom such Purchase Rights were granted, (ii)&nbsp;as necessary to facilitate compliance with any laws, listing requirements,
or governmental regulations&nbsp;(including, without limitation, the provisions of Section&nbsp;423 of the Code and the regulations and
other interpretive guidance issued thereunder relating to Employee Stock Purchase Plans) including without limitation any such regulations
or other guidance that may be issued or amended after the date the Plan is adopted by the Board, or (iii)&nbsp;as necessary to obtain
or maintain favorable tax, listing, or regulatory treatment. To be clear, the Board may amend outstanding Purchase Rights without a Participant&rsquo;s
consent if such amendment is necessary to ensure that the Purchase Right and/or the Plan complies with the requirements of Section&nbsp;423
of the Code with respect to the&nbsp;423 Component or with respect to other Applicable Laws. Notwithstanding anything in the Plan or
any Offering Document to the contrary, the Board will be entitled to: (i)&nbsp;establish the exchange ratio applicable to amounts withheld
in a currency other than U.S.&nbsp;dollars; (ii)&nbsp;permit Contributions in excess of the amount designated by a Participant in order
to adjust for mistakes in the Company&rsquo;s processing of properly completed Contribution elections; (iii)&nbsp;establish reasonable
waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common
Stock for each Participant properly correspond with amounts withheld from the Participant&rsquo;s Contributions; (iv)&nbsp;amend any
outstanding Purchase Rights or clarify any ambiguities regarding the terms of any Offering to enable the Purchase Rights to qualify under
and/or comply with Section&nbsp;423 of the Code with respect to the&nbsp;423 Component; and (v)&nbsp;establish other limitations or procedures
as the Board determines in its sole discretion advisable that are consistent with the Plan. The actions of the Board pursuant to this
paragraph will not be considered to alter or impair any Purchase Rights granted under an Offering as they are part of the initial terms
of each Offering and the Purchase Rights granted under each Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">13.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Qualification; Tax Withholding.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>Although the Company may endeavor to (i)&nbsp;qualify a Purchase Right for special tax treatment under the laws of the United States
or jurisdictions outside of the United States or (ii)&nbsp;avoid adverse tax treatment, the Company makes no representation to that effect
and expressly disavows any covenant to maintain special or to avoid unfavorable tax treatment, notwithstanding anything to the contrary
in this Plan. The Company will be unconstrained in its corporate activities without regard to the potential negative tax impact on Participants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>Each Participant will make arrangements, satisfactory to the Company and any applicable Related Corporation, to enable the Company
or the Related Corporation to fulfill any withholding obligation for Tax-Related Items. Without limitation to the foregoing, in the Company&rsquo;s
sole discretion and subject to Applicable Law, such withholding obligation may be satisfied in whole or in part by (i)&nbsp;withholding
from the Participant&rsquo;s salary or any other cash payment due to the Participant from the Company or a Related Corporation; (ii)&nbsp;withholding
from the proceeds of the sale of shares of Common Stock acquired under the Plan, either through a voluntary sale or a mandatory sale
arranged by the Company; or (iii)&nbsp;any other method deemed acceptable by the Board. The Company shall not be required to issue any
shares of Common Stock under the Plan until such obligations are satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">14.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective Date of Plan.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Plan will become effective upon the Effective Date. No Purchase Rights will be exercised unless and until the Plan has been approved
by the stockholders of the Company, which approval must be within&nbsp;12&nbsp;months before or after the date the Plan is adopted (or
if required under Section&nbsp;12(a) above, materially amended) by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">15.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous Provisions.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights will constitute general funds of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>A Participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of Common
Stock subject to Purchase Rights unless and until the Participant&rsquo;s shares of Common Stock acquired upon exercise of Purchase Rights
are recorded in the books of the Company (or its transfer agent).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)
</B>The Plan and Offering do not constitute an employment contract. Nothing in the Plan or in the Offering will in any way alter the
at will nature of a Participant&rsquo;s employment or amend a Participant&rsquo;s employment contract, if applicable, or be deemed to
create in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or a Related Corporation
or an Affiliate, or on the part of the Company, a Related Corporation or an Affiliate to continue the employment of a Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)
</B>The provisions of the Plan will be governed by the laws of the State of Delaware without resort to that state&rsquo;s conflicts of
laws rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e)
</B>If any particular provision of the Plan is found to be invalid or otherwise unenforceable, such provision will not affect the other
provisions of the Plan, but the Plan will be construed in all respects as if such invalid provision were omitted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(f)
</B>If any provision of the Plan does not comply with Applicable Law, such provision shall be construed in such a manner as to comply
with Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">16.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in the Plan, the following definitions will apply to the capitalized terms indicated below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>&ldquo;<B><I>423 Component</I></B>&rdquo; means the part of the Plan, which excludes the Non-423 Component, pursuant to which Purchase
Rights that satisfy the requirements for an Employee Stock Purchase Plan may be granted to Eligible Employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>&ldquo;<B><I>Affiliate</I></B>&rdquo; means any entity, other than a Related Corporation, whether now or subsequently established,
which is at the time of determination, a &ldquo;parent&rdquo; or &ldquo;subsidiary&rdquo; of the Company as such terms are defined in
Rule&nbsp;405 promulgated under the Securities Act. The Board may determine the time or times at which &ldquo;parent&rdquo; or &ldquo;subsidiary&rdquo;
status is determined within the foregoing definition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)
</B>&ldquo;<B><I>Applicable Law</I></B>&rdquo; means the Code and any applicable securities, federal, state, foreign, material local
or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing
rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect
by or under the authority of any Governmental Body (or under the authority of the NASDAQ Stock Market or the Financial Industry Regulatory
Authority).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)
</B>&ldquo;<B><I>Board</I></B>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e)
</B>&ldquo;<B><I>Capitalization Adjustment</I></B>&rdquo; means any change that is made in, or other events that occur with respect to,
the Common Stock subject to the Plan or subject to any Purchase Right after the date the Plan is adopted by the Board without the receipt
of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend
in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of
shares, change in corporate structure or other similar equity restructuring transaction, as that term is used in Financial Accounting
Standards Board Accounting Standards Codification Topic&nbsp;718 (or any successor thereto). Notwithstanding the foregoing, the conversion
of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(f)
</B>&ldquo;<B><I>Code</I></B>&rdquo; means the U.S.&nbsp;Internal Revenue Code of&nbsp;1986, as amended, including any applicable regulations
and guidance thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(g)
</B>&ldquo;<B><I>Committee</I></B>&rdquo; means a committee of one or more members of the Board to whom authority has been delegated
by the Board in accordance with Section&nbsp;2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(h)
</B>&ldquo;<B><I>Common Stock</I></B>&rdquo; means the common stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)
</B>&ldquo;<B><I>Company</I></B>&rdquo; means Jasper Therapeutics, Inc., a Delaware corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(j)
</B>&ldquo;<B><I>Contributions</I></B>&rdquo; means the payroll deductions and other additional payments specifically provided for in
the Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make additional payments into
his or her account if specifically provided for in the Offering, and then only if the Participant has not already had the maximum permitted
amount withheld during the Offering through payroll deductions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(k)
</B>&ldquo;<B><I>Corporate Transaction</I></B>&rdquo; means the consummation, in a single transaction or in a series of related transactions,
of any one or more of the following events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)
</B>a sale or other disposition of all or substantially all, as determined by the Board in its sole discretion, of the consolidated assets
of the Company and its subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)
</B>a sale or other disposition of more than&nbsp;50% of the outstanding securities of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iii)
</B>a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(iv)
</B>a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common
Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the
merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(l)
</B>&ldquo;<B><I>Designated&nbsp;423 Corporation</I></B>&rdquo; means any Related Corporation selected by the Board to participate in
the&nbsp;423 Component.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(m)
</B>&ldquo;<B><I>Designated Company</I></B>&rdquo; means any Designated Non-423 Corporation or Designated&nbsp;423 Corporation, provided,
however, that at any given time, a Related Corporation participating in the&nbsp;423 Component shall not be a Related Corporation participating
in the Non-423 Component.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(n)
</B>&ldquo;<B><I>Designated Non-423 Corporation</I></B>&rdquo; means any Related Corporation or Affiliate selected by the Board to participate
in the Non-423 Component.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(o)
</B>&ldquo;<B><I>Director</I></B>&rdquo; means a member of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(p)
</B>&ldquo;<B><I>Effective Date</I></B>&rdquo;&nbsp;means the date as of which the Plan is adopted by the Board and approved by the stockholders
of the Company in accordance with Section&nbsp;14.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(q)
</B>&ldquo;<B><I>Eligible Employee</I></B>&rdquo; means an Employee who meets the requirements set forth in the document(s) governing
the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility
to participate set forth in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(r)
</B>&ldquo;<B><I>Employee</I></B>&rdquo; means any person, including an Officer or Director, who is &ldquo;employed&rdquo; for purposes
of Section&nbsp;423(b)(4) of the Code by the Company or a Related Corporation, or solely with respect to the Non-423 Component, an Affiliate.
However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &ldquo;Employee&rdquo;
for purposes of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(s)
</B>&ldquo;<B><I>Employee Stock Purchase Plan</I></B>&rdquo; means a plan that grants Purchase Rights intended to be options issued under
an &ldquo;employee stock purchase plan,&rdquo; as that term is defined in Section&nbsp;423(b) of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(t)
</B>&ldquo;<B><I>Exchange Act</I></B>&rdquo; means the U.S.&nbsp;Securities Exchange Act of&nbsp;1934, as amended and the rules and regulations
promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(u)
</B>&ldquo;<B><I>Fair Market Value</I></B>&rdquo; means, as of any date, the value of the Common Stock determined as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)
</B>If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share
of Common Stock will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the
greatest volume of trading in the Common Stock) on the date of determination, as reported in such source as the Board deems reliable.
Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the
Fair Market Value will be the closing sales price on the last preceding date for which such quotation exists.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)
</B>In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith in compliance
with Applicable Laws and regulations and, to the extent applicable as determined in the sole discretion of the Board, in a manner that
complies with Sections&nbsp;409A of the Code</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(v)
</B>&ldquo;<B><I>Governmental Body</I></B>&rdquo; means any: (a)&nbsp;nation, state, commonwealth, province, territory, county, municipality,
district or other jurisdiction of any nature; (b)&nbsp;federal, state, local, municipal, foreign or other government; (c)&nbsp;governmental
or regulatory body, or quasi-governmental body of any nature (including any governmental division, department, administrative agency
or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or entity and
any court or other tribunal, and for the avoidance of doubt, any tax authority) or other body exercising similar powers or authority;
or (d)&nbsp;self-regulatory organization (including the NASDAQ Stock Market and the Financial Industry Regulatory Authority).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(w)
</B>&ldquo;<B><I>Non-423 Component</I></B>&rdquo; means the part of the Plan, which excludes the&nbsp;423 Component, pursuant to which
Purchase Rights that are not intended to satisfy the requirements for an Employee Stock Purchase Plan may be granted to Eligible Employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(x)
</B>&ldquo;<B><I>Offering</I></B>&rdquo; means the grant to Eligible Employees of Purchase Rights, with the exercise of those Purchase
Rights automatically occurring at the end of one or more Purchase Periods. The terms and conditions of an Offering will generally be
set forth in the &ldquo;<B><I>Offering Document</I></B>&rdquo; approved by the Board for that Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(y)
</B>&ldquo;<B><I>Offering Date</I></B>&rdquo; means a date selected by the Board for an Offering to commence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(z)
</B>&ldquo;<B><I>Officer</I></B>&rdquo; means a person who is an officer of the Company or a Related Corporation within the meaning of
Section&nbsp;16 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(aa)
</B>&ldquo;<B><I>Participant</I></B>&rdquo; means an Eligible Employee who holds an outstanding Purchase Right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(bb)
</B>&ldquo;<B><I>Plan</I></B>&rdquo; means this Jasper Therapeutics, Inc. 2021 Employee Stock Purchase Plan, as amended from time to
time, including both the&nbsp;423 Component and the Non-423 Component.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(cc)
</B>&ldquo;<B><I>Purchase Date</I></B>&rdquo; means one or more dates during an Offering selected by the Board on which Purchase Rights
will be exercised and on which purchases of shares of Common Stock will be carried out in accordance with such Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(dd)
</B>&ldquo;<B><I>Purchase Period</I></B>&rdquo; means a period of time specified within an Offering, generally beginning on the Offering
Date or on the first Trading Day following a Purchase Date, and ending on a Purchase Date. An Offering may consist of one or more Purchase
Periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ee)
</B>&ldquo;<B><I>Purchase Right</I></B>&rdquo; means an option to purchase shares of Common Stock granted pursuant to the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ff)
</B>&ldquo;<B><I>Related Corporation</I></B>&rdquo; means any &ldquo;parent corporation&rdquo; or &ldquo;subsidiary corporation&rdquo;
of the Company whether now or subsequently established, as those terms are defined in Sections&nbsp;424(e) and (f), respectively, of
the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(gg)
</B>&ldquo;<B><I>Securities Act</I></B>&rdquo; means the U.S.&nbsp;Securities Act of&nbsp;1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(hh)
</B>&ldquo;<B><I>Tax-Related Items</I></B>&rdquo; means any income tax, social insurance, payroll tax, fringe benefit tax, payment on
account or other tax-related items arising out of or in relation to a Participant&rsquo;s participation in the Plan, including, but not
limited to, the exercise of a Purchase Right and the receipt of shares of Common Stock or the sale or other disposition of shares of
Common Stock acquired under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)
</B>&ldquo;<B><I>Trading Day</I></B>&rdquo; means any day on which the exchange(s) or market(s) on which shares of Common Stock are listed,
including but not limited to the NYSE, Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors
thereto, is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>9
<FILENAME>ea147929ex10-7_jasper.htm
<DESCRIPTION>EMPLOYMENT AGREEMENT, DATED AS OF SEPTEMBER 24, 2021, BY AND BETWEEN JASPER THERAPEUTICS, INC. AND WILLIAM LIS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.7</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>EMPLOYMENT AGREEMENT</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><B>THIS EMPLOYMENT AGREEMENT</B> (this &ldquo;<U>Agreement</U>&rdquo;)
is made and entered into as of September 24, 2021 by and between Jasper Therapeutics, Inc., a Delaware corporation (the &ldquo;<U>Corporation</U>&rdquo;),
and William Lis (the &ldquo;<U>Executive</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RECITALS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THE PARTIES ENTER THIS AGREEMENT</B> on the
basis of the following facts, understandings and intentions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>A.   </B>The
Corporation desires that the Executive be employed by the Corporation to carry out the duties and responsibilities described below, all
on the terms and conditions hereinafter set forth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>B.   </B>The
Executive desires to accept such employment on such terms and conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in consideration of the
above recitals incorporated herein and the mutual covenants and promises contained herein and other good and valuable consideration, the
receipt and sufficiency of which are hereby expressly acknowledged, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Employment and Duties</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Employment</U></B>. The Corporation does hereby hire, engage and employ the Executive on an at-will basis, subject to the terms
and conditions expressly set forth in this Agreement, including, but not limited to, Sections 5 and 6 of this Agreement. The Executive
does hereby accept and agree to such hiring, engagement and employment on the terms and conditions expressly set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Duties</U></B>. The Executive shall serve the Corporation as its Executive Chairman and Chief Executive Officer and shall perform
and have the responsibilities, duties, status and authority customary for a position in an organization of the size and nature of the
Corporation, subject to the corporate policies of the Corporation as in effect from time to time (including, without limitation, the Corporation&rsquo;s
business conduct and ethics policies, as they may be amended from time to time). In this position, the Executive shall report to the Corporation&rsquo;s
Board of Directors (the &ldquo;<U>Board</U>&rdquo;) and shall render such administrative, financial, and other executive and managerial
services to the Corporation and its affiliates as the Board may from time to time direct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Other Employment; Time Commitment</U></B>. For so long as the Executive is employed with the Corporation, the Executive shall
both (i) devote the Executive&rsquo;s full business time, energy and skill to the performance of the Executive&rsquo;s duties for the
Corporation and (ii) hold no other employment. Notwithstanding the foregoing, the Executive may serve on managing or advisory boards of
non-profit entities and up to three (3) managing or advisory boards of for-profit companies, so long as such service does not interfere
with the Executive&rsquo;s duties to, or otherwise create a conflict of interest with respect to, the Corporation. The Board shall have
the right to require the Executive to resign from any board or similar body on which the Executive may then serve if the Board determines
that such activity interferes with the effective discharge of the Executive&rsquo;s duties and responsibilities to the Corporation or
that any business related to such service is then in competition with any business of the Corporation or any of its affiliates, successors
or assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Breach of Contract</U></B>. The Executive hereby represents to the Corporation: (i)&nbsp;that the execution and delivery
of this Agreement by the Executive and the Corporation and the performance by the Executive of the Executive&rsquo;s duties hereunder
shall not constitute a breach of, or otherwise contravene, the terms of any other agreement or policy to which the Executive is a party
or otherwise bound; (ii)&nbsp;that the Executive has no information (including, without limitation, confidential information and trade
secrets) relating to any other person or entity which would prevent, or be violated by, the Executive entering into this Agreement or
carrying out the Executive&rsquo;s duties hereunder; and (iii)&nbsp;that the Executive is not bound by any confidentiality, trade secret
or similar agreement with any other person or entity which would prevent, or be violated by, the Executive (x)&nbsp;entering into this
Agreement or (y)&nbsp;carrying out the Executive&rsquo;s duties hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Location</U></B>. The Executive&rsquo;s principal place of employment initially shall be the offices of the Corporation&rsquo;s
headquarters, currently located in Northern California. The Executive acknowledges that business travel may be required from time to time
in the course of performing the Executive&rsquo;s duties for the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Term</U></B>. The Executive&rsquo;s employment under this Agreement shall commence on the date of this Agreement,
which such date of commencement of employment will be hereinafter referred to as the &ldquo;<U>Effective Date</U>.&rdquo; The period from
the Effective Date until the termination of the Executive&rsquo;s employment under this Agreement is hereinafter referred to as &ldquo;the
term of this Agreement&rdquo; or &ldquo;the term hereof.&rdquo; Until the occurrence of the Effective Date, this Agreement shall be null
and void and without force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Compensation</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Base Salary</U></B>. During the term hereof, the Executive&rsquo;s base salary (the &ldquo;<U>Base Salary</U>&rdquo;) shall
be paid in accordance with the Corporation&rsquo;s regular payroll practices in effect from time to time, but not less frequently than
in monthly installments. As of the Effective Date, the Executive&rsquo;s Base Salary shall be at an annualized rate of $530,000. During
the term hereof, the Corporation may review and adjust the Executive&rsquo;s rate of Base Salary from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Incentive Bonus</U></B>. During the term hereof, in addition to the Base Salary, the Executive shall be eligible to receive
an annual incentive bonus (&ldquo;<U>Incentive Bonus</U>&rdquo;) for each fiscal year with a target amount of 50% of Base Salary. The
actual amount of any Incentive Bonus earned by the Executive each year shall be determined in good faith by the Compensation Committee
of the Board (the &ldquo;<U>Compensation Committee</U>&rdquo;) in its reasonable discretion, based on the achievement of performance objectives
established for that particular fiscal year by the Board or the Compensation Committee. The Incentive Bonus earned for each fiscal year
(if any) shall be paid as soon as practicable following the Board&rsquo;s certification of financial results for the applicable calendar
year, subject to the Executive&rsquo;s continued employment by the Corporation or its affiliates through the applicable payment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Equity Compensation</U></B>. The Corporation acknowledges that certain August 10, 2021 letter agreement by and between the Executive
and Jasper Corporation, a wholly-owned subsidiary of the Corporation (the &ldquo;<U>Letter Agreement</U>&rdquo;), which such Letter Agreement
is hereby incorporated herein by this reference. The Corporation hereby agrees to assume the obligations of Jasper Corporation pursuant
to the Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Benefits</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Retirement, Welfare and Fringe Benefits</U></B>. During the term hereof, the Executive shall be eligible to participate in all
employee retirement and welfare benefit plans and programs, and fringe benefit plans and programs, made available by the Corporation to
the Corporation&rsquo;s executive employees generally, in accordance with the terms of such plans and as such plans or programs may be
in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Reimbursement of Expenses</U></B>. During the term hereof, the Executive shall be authorized to incur reasonable expenses to
facilitate performance of his duties under this Agreement. The Executive shall be eligible for reimbursement of such expenses, subject
to the Corporation&rsquo;s expense reimbursement policies and the discretion of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Vacation and Other Leave</U></B>. During the term hereof, the Executive shall accrue paid time off and other leave in accordance
with the applicable policies of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in"><B>4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Indemnification</U></B>. The Executive shall be provided indemnification, and coverage under the Corporation&rsquo;s D&amp;O
liability insurance policies, to the same extent as other executive officers of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Termination of Employment</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Generally</U></B>. The Executive&rsquo;s employment by the Corporation, and the term hereof, may be terminated at any time (i)
by the Corporation with or without Cause (as defined in Section 5.4), (ii) by the Corporation in the event that the Executive has incurred
a Disability (as defined in Section 5.4), (iii) by the Executive for any reason, or (iv) due to the Executive&rsquo;s death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Notice of Termination</U>. </B> Any termination of the Executive&rsquo;s employment under this Agreement (other than because
of the Executive&rsquo;s death) shall be communicated by written notice of termination from the terminating party to the other party,
which termination shall be effective (i) no less than thirty (30) days following delivery of such notice in the event of a termination
by the Executive for any reason or (ii) immediately in the event of a termination by the Corporation. The notice of termination shall
indicate the specific provision(s) of this Agreement relied upon in effecting the termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Benefits Upon Termination</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Upon any termination of the Executive&rsquo;s employment with the Corporation (the date of termination, the &ldquo;<U>Severance
Date</U>&rdquo;), the Corporation shall pay to the Executive (or the Executive&rsquo;s estate, if applicable) (i) any Base Salary that
had accrued but had not been paid (including accrued and unpaid vacation time) on or before the Severance Date; (ii) any reimbursement
due to the Executive pursuant to Section 4.2 for expenses incurred by the Executive on or before the Severance Date; and (iii) any other
amounts required under applicable law. The treatment (including, without limitation, the cancellation or vesting thereof and/or the entitlement
of the Executive thereto) of any outstanding equity awards then held by the Executive as of the Severance Date shall be subject to the
applicable terms of the Equity Plan and the applicable award agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>In addition to amounts payable under the immediately preceding clause (a), in the event of certain terminations the Executive shall
be eligible for payments and benefits under the Corporation&rsquo;s Employee Severance Plan for Vice Presidents and Executive Committee
Members (as may be amended or restated from time to time, the &ldquo;<U>Severance Plan</U>&rdquo;), subject to the Executive meeting the
eligibility criteria set forth in the Severance Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Certain Defined Terms</U></B>. In the event of a conflicting definition between this Agreement and any other agreement between
the Corporation and the Executive, the definitions of Cause and Good Reason contained in this Agreement shall govern unless such other
agreement states otherwise by specifically making reference to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>As used herein, &ldquo;<U>Cause</U>&rdquo; shall have the meaning ascribed to such term in the Severance Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>As used herein, &ldquo;<U>Disability</U>&rdquo; shall mean a disability that qualifies the Executive for benefits under the Corporation&rsquo;s
long-term disability plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>As used herein, &ldquo;<U>Good Reason</U>&rdquo; shall have the meaning ascribed to such term in the Severance Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>5.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Resignation from Directorships and Officerships</U></B>. The termination of the Executive&rsquo;s employment with the Corporation
for any reason shall be treated as the Executive&rsquo;s resignation from (i) any director, officer or employee position the Executive
has with the Corporation and any of its respective affiliates, and (ii) all fiduciary positions (including as a trustee) the Executive
holds with respect to any employee benefit plans or trusts established by the Corporation or any of its affiliates, in each case unless
otherwise determined by the Board or one of its committees. The Executive agrees that this Agreement shall serve as written notice of
resignation in this circumstance. Furthermore, the Executive agrees to execute any documents evidencing such resignations that the Corporation
reasonably requests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Non-Disparagement</U></B>. The Executive agrees that at no time during employment with the Corporation or thereafter
shall the Executive make, or cause or assist any other person to make, any statement or other communication to any third party which impugns
or attacks, or is otherwise critical of, the reputation, business or character of the Corporation, any Corporation affiliate, or any of
their respective directors, officers, representatives, agents or employees. Notwithstanding anything in this Section to the contrary,
in no event shall any party be prohibited from providing truthful testimony in connection with a legal proceeding or governmental investigation.
In addition, nothing in this Agreement shall prohibit the Executive from reporting a suspected violation of law to the appropriate governmental
agency or authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Defense of Claims</U></B>. The Executive agrees that, during the term hereof and following the termination of
the Executive&rsquo;s employment, upon request from the Corporation, the Executive will cooperate with the Corporation in the defense
of any claims or actions that may be made by or against the Corporation that affect the Executive&rsquo;s prior areas of responsibility,
except if the Executive&rsquo;s reasonable interests are adverse to the Corporation in such claim or action. The Corporation agrees that
it shall reimburse the reasonable out of pocket costs and attorney fees the Executive actually incurs in connection with the Executive
providing such assistance or cooperation to the Corporation, in accordance with the Corporation&rsquo;s standard policies and procedures
as in effect from time to time, <U>provided</U> that the Executive shall have obtained prior written approval from the Corporation for
any travel or legal fees and expenses incurred by the Executive in connection with the Executive&rsquo;s obligations under this Section
7. In addition, if the Executive no longer is providing services to the Corporation, the Corporation shall reimburse the Executive for
time spent providing such assistance at an hourly rate equal to the Executive&rsquo;s most recent annual Base Salary divided by 2080,
rounded down to the nearest whole dollar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Source of Payments</U></B>. All payments provided under this Agreement, other than payments made pursuant to a
plan which provides otherwise, shall be paid in cash from the general funds of the Corporation, and no special or separate fund shall
be established, and no other segregation of assets shall be made, to assure payment. The Executive shall have no right, title or interest
whatsoever in or to any investments which the Corporation may make to aid the Corporation in meeting its obligations hereunder. Any payments
provided under this Agreement shall be treated as amounts owed to an unsecured creditor of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Withholding</U></B>. Notwithstanding anything else herein to the contrary, the Corporation may withhold (or cause
there to be withheld, as the case may be) from any amounts otherwise due or payable under or pursuant to this Agreement such federal,
state and local income, employment, or other taxes or other amounts as may be required to be withheld pursuant to any applicable law or
regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Assignment; Binding Effect</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>By the Executive</U>. This Agreement and any and all rights, duties, obligations or interests hereunder shall not be assignable
or delegable by the Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>By the Corporation</U>. This Agreement and all of the Corporation&rsquo;s rights and obligations hereunder shall not be assignable
by the Corporation except as incident to a reorganization, merger or consolidation, or transfer of all or substantially all of the Corporation&rsquo;s
assets. Notwithstanding the foregoing, or any contrary provision herein, concurrently with the occurrence of the Effective Date, references
to the Corporation herein shall mean the entity formerly known as Amplitude Healthcare Acquisition Corporation which, as of the Effective
Date, has changed its name to Jasper Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Binding Effect</U>. This Agreement shall be binding upon, and inure to the benefit of, the parties hereto, any successors to
or assigns of the Corporation and the Executive&rsquo;s heirs and the personal representatives of the Executive&rsquo;s estate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Number and Gender</U></B>. Where the context requires, the singular shall include the plural, the plural shall
include the singular, and any gender shall include all other genders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Section Headings</U></B>. The section headings of, and titles of paragraphs and subparagraphs contained in, this
Agreement are for the purpose of convenience only, and they neither form a part of this Agreement nor are they to be used in the construction
or interpretation thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Governing Law</U></B>. This Agreement, and all questions relating to its validity, interpretation, performance
and enforcement, as well as the legal relations hereby created between the parties hereto, shall be governed by and construed under, and
interpreted and enforced in accordance with, the laws of the State of California applicable to contracts executed solely in California
and to be performed entirely within that State.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Survival of Certain Provisions</U></B>. Sections 5, 6, 7, 8, 9, 13, 14, 16, 17, 18, 19 and 20 shall survive any
termination or expiration of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Entire Agreement</U></B>. This Agreement embodies the entire agreement of the parties hereto respecting the matters
within its scope. As of the date hereof, this Agreement supersedes all prior and contemporaneous agreements of the parties hereto that
directly or indirectly bear upon the subject matter hereof. Any prior negotiations, correspondence, agreements, proposals or understandings
relating to the subject matter hereof shall be deemed to be of no force or effect, and the parties to any such other negotiations, commitments,
agreements or writings shall have no further rights or obligations thereunder. There are no representations, warranties, or agreements,
whether express or implied, or oral or written, with respect to the subject matter hereof, except as expressly set forth herein. For the
avoidance of doubt, this Agreement does not supersede or replace the Severance Plan or the Side Letter and shall be interpreted to be
consistent with the Severance Plan and the Side Letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Modifications, Waivers</U></B>. This Agreement may not be amended, modified or changed (in whole or in part),
except by an instrument in writing signed by both parties hereto. The waiver by either party of compliance with any provision of this
Agreement by the other party shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent
breach by such party of a provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Arbitration</U></B>. The Executive and the Corporation agree that to the extent permitted by law, any dispute
or controversy arising out of, relating to, or in connection with this Agreement, or the interpretation, validity, construction, performance,
breach, or termination thereof, or the Executive&rsquo;s employment by the Corporation or any termination thereof, will be settled by
arbitration to be held at a location in San Francisco, California in accordance with then applicable rules of the American Arbitration
Association specifically designed for the resolution of employment disputes. The Executive acknowledges that a copy of such rules in effect
as of the date hereof has been provided to the Executive. The arbitrator may grant injunctions or other relief in such dispute or controversy.
The decision of the arbitrator will be final, conclusive and binding on the parties to the arbitration. Judgment may be entered on the
arbitrator&rsquo;s decision in any court having jurisdiction. The Corporation shall pay the costs associated with arbitration (arbitration
fee and location fee, if any); provided, however, that each party shall bear its own legal fees and expenses. Notwithstanding the foregoing,
the arbitrator shall be permitted to award costs associated with arbitration in the event the arbitrator determines a claim is frivolous.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>18.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Notices</U></B>. All notices, requests, demands and other communications required or permitted under this Agreement
shall be in writing (including in electronic formats) and shall be deemed to have been duly given and made if (i) delivered by hand, (ii)
otherwise delivered against receipt therefor, (iii) sent to an email address of record, or (iv) sent by registered or certified mail,
postage prepaid, return receipt requested. Any notice shall be duly addressed to the parties as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">if to the Corporation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">Jasper Therapeutics, Inc.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">2200 Bridge Parkway Suite #102</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">Redwood City, CA 94065<BR>
Attention: Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">if to the Executive, to the address (or e-mail address) most recently
on file in the personnel records of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>19.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Code Section 409A</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>This Agreement is intended to meet the requirements of Section 409A of the Code, and shall be interpreted and construed consistent
with that intent. Each payment provided hereunder, whether part of a severance benefit or otherwise, is intended to be a separate payment
for purposes of Section 409A of the Code, including Treasury Regulation 1.409A-2(b)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Notwithstanding any other provision of this Agreement, to the extent that the right to any payment (including the provision of
benefits) hereunder or under any other plan or agreement of the Corporation or any Corporation affiliate covering Executive, provides
for the &ldquo;deferral of compensation&rdquo; within the meaning of Section 409A(d)(1) of the Code, the payment shall be paid (or provided)
in accordance with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>If the Executive is a &ldquo;Specified Employee&rdquo; within the meaning of Section 409A(a)(2)(B)(i) of the Code on the date of
the Executive&rsquo;s Separation from Service (within the meaning of Section 409A of the Code) (the &ldquo;<U>Separation Date</U>&rdquo;),
then no payment of non-qualified deferred compensation (within the meaning of Section 409A of the Code) otherwise to be made as a result
of the Executive&rsquo;s Separation from Service shall be made or commence during the period beginning on the Separation Date and ending
on the date that is six months following the Separation Date or, if earlier, on the date of the Executive&rsquo;s death. The amount of
any payment that would otherwise be paid to the Executive during this period shall instead be paid to the Executive on the first day of
the first calendar month following the end of such six-month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Payments with respect to reimbursements of expenses or benefits or provision of fringe or other in-kind benefits shall be made
on or before the last day of the calendar year following the calendar year in which the relevant expense or benefit is incurred. The amount
of expenses or benefits eligible for reimbursement, payment or provision during a calendar year shall not affect the expenses or benefits
eligible for reimbursement, payment or provision in any other calendar year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>20.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>&ldquo;Blue-Pencil&rdquo;</U></B>. If any provision of this Agreement shall be invalid or unenforceable, in whole
or in part, or as applied to any circumstances, under the laws of any jurisdiction which may govern for such purpose, then such provision
shall be deemed, to the extent allowed by the laws of such jurisdiction, to be modified or restricted to the extent and in the manner
necessary to render the same valid and enforceable, either generally or as applied to such circumstance, or shall be deemed excised from
this Agreement, as the case may require, and this Agreement shall be construed and enforced to the maximum extent permitted by law, as
if such provision had been originally incorporated herein as so modified or restricted, or as if such provision had not been originally
incorporated herein, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>21.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Counterparts</U></B>. This Agreement may be executed in any number of counterparts, each of which shall be deemed
an original as against any party whose signature appears thereon, and all of which together shall constitute one and the same instrument.
This Agreement shall become binding when one or more counterparts hereof, individually or taken together, shall bear the signatures of
all of the parties reflected hereon as the signatories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>22.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Legal Counsel</U></B>. Each party recognizes that this is a legally binding contract and acknowledges and agrees
that they have had the opportunity to consult with legal counsel of their choice. The Executive agrees and acknowledges that he has read
and understands this Agreement, is entering into it freely and voluntarily, and has been advised to seek counsel prior to entering into
this Agreement and has had ample opportunity to do so. This Agreement has resulted from negotiations and discussions between the parties
and no one party shall be treated as drafting this Agreement for purposes of interpreting any provision hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">[<I>The remainder of this page
has intentionally been left blank</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the Corporation and
the Executive have executed this Agreement as of the date set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>&ldquo;CORPORATION&rdquo;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">/s/ Anna French, Ph.D.</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;&nbsp;</TD>
    <TD>Anna French, Ph.D.</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: justify">Director; Chairperson of the Compensation Committee of the Board of Directors</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>&ldquo;EXECUTIVE&rdquo;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ William Lis</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">/s/ William Lis</TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>10
<FILENAME>ea147929ex10-8_jasper.htm
<DESCRIPTION>EMPLOYMENT AGREEMENT, DATED AS OF SEPTEMBER 24, 2021, BY AND BETWEEN JASPER THERAPEUTICS, INC. AND JEET MAHAL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 10.8</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>EMPLOYMENT AGREEMENT</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>THIS EMPLOYMENT AGREEMENT</B> (this &ldquo;<U>Agreement</U>&rdquo;)
is made and entered into as of September 24, 2021 by and between Jasper Therapeutics, Inc., a Delaware corporation (the &ldquo;<U>Corporation</U>&rdquo;),
and Jeetinder Mahal (the &ldquo;<U>Executive</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RECITALS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>THE PARTIES ENTER THIS AGREEMENT</B> on the
basis of the following facts, understandings and intentions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>A. </B>The
Corporation desires that the Executive be employed by the Corporation to carry out the duties and responsibilities described below, all
on the terms and conditions hereinafter set forth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>B.      </B>The
Executive desires to accept such employment on such terms and conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in consideration of the
above recitals incorporated herein and the mutual covenants and promises contained herein and other good and valuable consideration, the
receipt and sufficiency of which are hereby expressly acknowledged, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Employment and Duties</U></B>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Employment</U></B>. The Corporation does hereby hire, engage and employ the Executive on an at-will basis, subject to the terms
and conditions expressly set forth in this Agreement, including, but not limited to, Sections 5 and 6 of this Agreement. The Executive
does hereby accept and agree to such hiring, engagement and employment on the terms and conditions expressly set forth in this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Duties</U></B>. The Executive shall serve the Corporation as its Chief Financial Officer and Business Officer and shall perform
and have the responsibilities, duties, status and authority customary for a position in an organization of the size and nature of the
Corporation, subject to the corporate policies of the Corporation as in effect from time to time (including, without limitation, the Corporation&rsquo;s
business conduct and ethics policies, as they may be amended from time to time). In this position, the Executive shall report to the Corporation&rsquo;s
Chief Executive Officer (&ldquo;<U>CEO</U>&rdquo;) and shall render such administrative, financial, and other executive and managerial
services to the Corporation and its affiliates as the CEO and the Corporation&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo;)
may from time to time direct.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Other Employment; Time Commitment</U></B>. For so long as the Executive is employed with the Corporation, the Executive shall
both (i) devote the Executive&rsquo;s full business time, energy and skill to the performance of the Executive&rsquo;s duties for the
Corporation and (ii) hold no other employment. Notwithstanding the foregoing, the Executive may serve on managing or advisory boards of
non-profit entities and up to two (2) managing or advisory boards of for-profit companies, so long as such service does not interfere
with the Executive&rsquo;s duties to, or otherwise create a conflict of interest with respect to, the Corporation. The Board shall have
the right to require the Executive to resign from any board or similar body on which the Executive may then serve if the Board determines
that such activity interferes with the effective discharge of the Executive&rsquo;s duties and responsibilities to the Corporation or
that any business related to such service is then in competition with any business of the Corporation or any of its affiliates, successors
or assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Breach of Contract</U></B>. The Executive hereby represents to the Corporation: (i)&nbsp;that the execution and delivery
of this Agreement by the Executive and the Corporation and the performance by the Executive of the Executive&rsquo;s duties hereunder
shall not constitute a breach of, or otherwise contravene, the terms of any other agreement or policy to which the Executive is a party
or otherwise bound; (ii)&nbsp;that the Executive has no information (including, without limitation, confidential information and trade
secrets) relating to any other person or entity which would prevent, or be violated by, the Executive entering into this Agreement or
carrying out the Executive&rsquo;s duties hereunder; and (iii)&nbsp;that the Executive is not bound by any confidentiality, trade secret
or similar agreement with any other person or entity which would prevent, or be violated by, the Executive (x)&nbsp;entering into this
Agreement or (y)&nbsp;carrying out the Executive&rsquo;s duties hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Location</U></B>. The Executive&rsquo;s principal place of employment initially shall be the offices of the Corporation&rsquo;s
headquarters, currently located in Northern California. The Executive acknowledges that business travel may be required from time to time
in the course of performing the Executive&rsquo;s duties for the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Term</U></B>. The Executive&rsquo;s employment under this Agreement shall commence on the date of this Agreement,
which such date of commencement of employment will be hereinafter referred to as the &ldquo;<U>Effective Date</U>.&rdquo; The period from
the Effective Date until the termination of the Executive&rsquo;s employment under this Agreement is hereinafter referred to as &ldquo;the
term of this Agreement&rdquo; or &ldquo;the term hereof.&rdquo; Until the occurrence of the Effective Date, this Agreement shall be null
and void and without force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Compensation</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Base Salary</U></B>. During the term hereof, the Executive&rsquo;s base salary (the &ldquo;<U>Base Salary</U>&rdquo;) shall
be paid in accordance with the Corporation&rsquo;s regular payroll practices in effect from time to time, but not less frequently than
in monthly installments. As of the Effective Date, the Executive&rsquo;s Base Salary shall be at an annualized rate of $400,000. During
the term hereof, the Corporation may review and adjust the Executive&rsquo;s rate of Base Salary from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Incentive Bonus</U></B>. During the term hereof, in addition to the Base Salary, the Executive shall be eligible to receive
an annual incentive bonus (&ldquo;<U>Incentive Bonus</U>&rdquo;) for each fiscal year with a target amount of 40% of Base Salary. The
actual amount of any Incentive Bonus earned by the Executive each year shall be determined in good faith by the Compensation Committee
of the Board (the &ldquo;<U>Compensation Committee</U>&rdquo;) in its reasonable discretion, based on the achievement of performance objectives
established for that particular fiscal year by the Board or the Compensation Committee. The Incentive Bonus earned for each fiscal year
(if any) shall be paid as soon as practicable following the Board&rsquo;s certification of financial results for the applicable calendar
year, subject to the Executive&rsquo;s continued employment by the Corporation or its affiliates through the applicable payment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Equity Compensation</U></B>. As soon as practicable after the Effective Date, the Executive shall be provided additional equity
compensation, in such form and on such terms consistent with Executive&rsquo;s current equity holdings (including derivative holdings),
such that the Executive&rsquo;s equity ownership in the Corporation is not less than 0.75% of the Corporation&rsquo;s outstanding shares
of common stock as of the date of grant (after giving effect to such grant) (the &ldquo;<U>Initial Grant</U>&rdquo;); <I>provided that</I>
any shares of common stock of the Corporation transferred by Executive at any time after the Effective Date and prior to the Initial Grant
shall be deemed owned by Executive for purposes of this calculation. In addition, no later than March 31, 2022, the Executive shall be
provided additional equity compensation, on such terms and in such form as will be approved by the Corporation&rsquo;s Executive Chairman,
such that the Executive&rsquo;s equity ownership in the Corporation is not less than 1.0% of the Corporation&rsquo;s outstanding shares
of common stock as of the date of grant (after giving effect to such grant) (the &ldquo;<U>Additional Grant</U>&rdquo;); <I>provided that</I>
any shares of common stock of the Corporation transferred by Executive at any time after the Effective Date and prior to the Additional
Grant shall be deemed owned by Executive for purposes of this calculation. For the avoidance of doubt, and notwithstanding any contrary
provision herein, any stock options shall have an exercise price of no less than fair market value of the covered shares on the date of
grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Benefits</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Retirement, Welfare and Fringe Benefits</U></B>. During the term hereof, the Executive shall be eligible to participate in all
employee retirement and welfare benefit plans and programs, and fringe benefit plans and programs, made available by the Corporation to
the Corporation&rsquo;s executive employees generally, in accordance with the terms of such plans and as such plans or programs may be
in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Reimbursement of Expenses</U></B>. During the term hereof, the Executive shall be authorized to incur reasonable expenses to
facilitate performance of his duties under this Agreement. The Executive shall be eligible for reimbursement of such expenses, subject
to the Corporation&rsquo;s expense reimbursement policies and the discretion of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Vacation and Other Leave</U></B>. During the term hereof, the Executive shall accrue paid time off and other leave in accordance
with the applicable policies of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Indemnification</U></B>. The Executive shall be provided indemnification, and coverage under the Corporation&rsquo;s D&amp;O
liability insurance policies, to the same extent as other executive officers of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Termination of Employment</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Generally</U></B>. The Executive&rsquo;s employment by the Corporation, and the term hereof, may be terminated at any time (i)
by the Corporation with or without Cause (as defined in Section 5.4), (ii) by the Corporation in the event that the Executive has incurred
a Disability (as defined in Section 5.4), (iii) by the Executive for any reason, or (iv) due to the Executive&rsquo;s death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Notice of Termination</U>. </B> Any termination of the Executive&rsquo;s employment under this Agreement (other than because
of the Executive&rsquo;s death) shall be communicated by written notice of termination from the terminating party to the other party,
which termination shall be effective (i) no less than thirty (30) days following delivery of such notice in the event of a termination
by the Executive for any reason or (ii) immediately in the event of a termination by the Corporation. The notice of termination shall
indicate the specific provision(s) of this Agreement relied upon in effecting the termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Benefits Upon Termination</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Upon any termination of the Executive&rsquo;s employment with the Corporation (the date of termination, the &ldquo;<U>Severance
Date</U>&rdquo;), the Corporation shall pay to the Executive (or the Executive&rsquo;s estate, if applicable) (i) any Base Salary that
had accrued but had not been paid (including accrued and unpaid vacation time) on or before the Severance Date; (ii) any reimbursement
due to the Executive pursuant to Section 4.2 for expenses incurred by the Executive on or before the Severance Date; and (iii) any other
amounts required under applicable law. The treatment (including, without limitation, the cancellation or vesting thereof and/or the entitlement
of the Executive thereto) of any outstanding equity awards then held by the Executive as of the Severance Date shall be subject to the
applicable terms of the Equity Plan and the applicable award agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>In addition to amounts payable under the immediately preceding clause (a), in the event of certain terminations the Executive shall
be eligible for payments and benefits under the Corporation&rsquo;s Employee Severance Plan for Vice Presidents and Executive Committee
Members (as may be amended or restated from time to time, the &ldquo;<U>Severance Plan</U>&rdquo;), subject to the Executive meeting the
eligibility criteria set forth in the Severance Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Certain Defined Terms</U></B>. In the event of a conflicting definition between this Agreement and any other agreement between
the Corporation and the Executive, the definitions of Cause and Good Reason contained in this Agreement shall govern unless such other
agreement states otherwise by specifically making reference to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>As used herein, &ldquo;<U>Cause</U>&rdquo; shall have the meaning ascribed to such term in the Severance Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>As used herein, &ldquo;<U>Disability</U>&rdquo; shall mean a disability that qualifies the Executive for benefits under the Corporation&rsquo;s
long-term disability plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>As used herein, &ldquo;<U>Good Reason</U>&rdquo; shall have the meaning ascribed to such term in the Severance Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>5.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Resignation from Directorships and Officerships</U></B>. The termination of the Executive&rsquo;s employment with the Corporation
for any reason shall be treated as the Executive&rsquo;s resignation from (i) any director, officer or employee position the Executive
has with the Corporation and any of its respective affiliates, and (ii) all fiduciary positions (including as a trustee) the Executive
holds with respect to any employee benefit plans or trusts established by the Corporation or any of its affiliates, in each case unless
otherwise determined by the Board or one of its committees. The Executive agrees that this Agreement shall serve as written notice of
resignation in this circumstance. Furthermore, the Executive agrees to execute any documents evidencing such resignations that the Corporation
reasonably requests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Non-Disparagement</U></B>. The Executive agrees that at no time during employment with the Corporation or thereafter
shall the Executive make, or cause or assist any other person to make, any statement or other communication to any third party which impugns
or attacks, or is otherwise critical of, the reputation, business or character of the Corporation, any Corporation affiliate, or any of
their respective directors, officers, representatives, agents or employees. Notwithstanding anything in this Section to the contrary,
in no event shall any party be prohibited from providing truthful testimony in connection with a legal proceeding or governmental investigation.
In addition, nothing in this Agreement shall prohibit the Executive from reporting a suspected violation of law to the appropriate governmental
agency or authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Defense of Claims</U></B>. The Executive agrees that, during the term hereof and following the termination of
the Executive&rsquo;s employment, upon request from the Corporation, the Executive will cooperate with the Corporation in the defense
of any claims or actions that may be made by or against the Corporation that affect the Executive&rsquo;s prior areas of responsibility,
except if the Executive&rsquo;s reasonable interests are adverse to the Corporation in such claim or action. The Corporation agrees that
it shall reimburse the reasonable out of pocket costs and attorney fees the Executive actually incurs in connection with the Executive
providing such assistance or cooperation to the Corporation, in accordance with the Corporation&rsquo;s standard policies and procedures
as in effect from time to time, <U>provided</U> that the Executive shall have obtained prior written approval from the Corporation for
any travel or legal fees and expenses incurred by the Executive in connection with the Executive&rsquo;s obligations under this Section
7. In addition, if the Executive no longer is providing services to the Corporation, the Corporation shall reimburse the Executive for
time spent providing such assistance at an hourly rate equal to the Executive&rsquo;s most recent annual Base Salary divided by 2080,
rounded down to the nearest whole dollar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Source of Payments</U></B>. All payments provided under this Agreement, other than payments made pursuant to a
plan which provides otherwise, shall be paid in cash from the general funds of the Corporation, and no special or separate fund shall
be established, and no other segregation of assets shall be made, to assure payment. The Executive shall have no right, title or interest
whatsoever in or to any investments which the Corporation may make to aid the Corporation in meeting its obligations hereunder. Any payments
provided under this Agreement shall be treated as amounts owed to an unsecured creditor of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Withholding</U></B>. Notwithstanding anything else herein to the contrary, the Corporation may withhold (or cause
there to be withheld, as the case may be) from any amounts otherwise due or payable under or pursuant to this Agreement such federal,
state and local income, employment, or other taxes or other amounts as may be required to be withheld pursuant to any applicable law or
regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Assignment; Binding Effect</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>By the Executive</U>. This Agreement and any and all rights, duties, obligations or interests hereunder shall not be assignable
or delegable by the Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>By the Corporation</U>. This Agreement and all of the Corporation&rsquo;s rights and obligations hereunder shall not be assignable
by the Corporation except as incident to a reorganization, merger or consolidation, or transfer of all or substantially all of the Corporation&rsquo;s
assets. Notwithstanding the foregoing, or any contrary provision herein, concurrently with the occurrence of the Effective Date, references
to the Corporation herein shall mean the entity formerly known as Amplitude Healthcare Acquisition Corporation which, as of the Effective
Date, has changed its name to Jasper Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Binding Effect</U>. This Agreement shall be binding upon, and inure to the benefit of, the parties hereto, any successors to
or assigns of the Corporation and the Executive&rsquo;s heirs and the personal representatives of the Executive&rsquo;s estate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Number and Gender</U></B>. Where the context requires, the singular shall include the plural, the plural shall
include the singular, and any gender shall include all other genders.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Section Headings</U></B>. The section headings of, and titles of paragraphs and subparagraphs contained in, this
Agreement are for the purpose of convenience only, and they neither form a part of this Agreement nor are they to be used in the construction
or interpretation thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Governing Law</U></B>. This Agreement, and all questions relating to its validity, interpretation, performance
and enforcement, as well as the legal relations hereby created between the parties hereto, shall be governed by and construed under, and
interpreted and enforced in accordance with, the laws of the State of California applicable to contracts executed solely in California
and to be performed entirely within that State.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Survival of Certain Provisions</U></B>. Sections 5, 6, 7, 8, 9, 13, 14, 16, 17, 18, 19 and 20 shall survive any
termination or expiration of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Entire Agreement</U></B>. This Agreement embodies the entire agreement of the parties hereto respecting the matters
within its scope. As of the date hereof, this Agreement supersedes all prior and contemporaneous agreements of the parties hereto that
directly or indirectly bear upon the subject matter hereof. Any prior negotiations, correspondence, agreements, proposals or understandings
relating to the subject matter hereof shall be deemed to be of no force or effect, and the parties to any such other negotiations, commitments,
agreements or writings shall have no further rights or obligations thereunder. There are no representations, warranties, or agreements,
whether express or implied, or oral or written, with respect to the subject matter hereof, except as expressly set forth herein. For the
avoidance of doubt, this Agreement does not supersede or replace the Severance Plan and shall be interpreted to be consistent with the
Severance Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Modifications, Waivers</U></B>. This Agreement may not be amended, modified or changed (in whole or in part),
except by an instrument in writing signed by both parties hereto. The waiver by either party of compliance with any provision of this
Agreement by the other party shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent
breach by such party of a provision of this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Arbitration</U></B>. The Executive and the Corporation agree that to the extent permitted by law, any dispute
or controversy arising out of, relating to, or in connection with this Agreement, or the interpretation, validity, construction, performance,
breach, or termination thereof, or the Executive&rsquo;s employment by the Corporation or any termination thereof, will be settled by
arbitration to be held at a location in San Francisco, California in accordance with then applicable rules of the American Arbitration
Association specifically designed for the resolution of employment disputes. The Executive acknowledges that a copy of such rules in effect
as of the date hereof has been provided to the Executive. The arbitrator may grant injunctions or other relief in such dispute or controversy.
The decision of the arbitrator will be final, conclusive and binding on the parties to the arbitration. Judgment may be entered on the
arbitrator&rsquo;s decision in any court having jurisdiction. The Corporation shall pay the costs associated with arbitration (arbitration
fee and location fee, if any); provided, however, that each party shall bear its own legal fees and expenses. Notwithstanding the foregoing,
the arbitrator shall be permitted to award costs associated with arbitration in the event the arbitrator determines a claim is frivolous.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>18.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Notices</U></B>. All notices, requests, demands and other communications required or permitted under this Agreement
shall be in writing (including in electronic formats) and shall be deemed to have been duly given and made if (i) delivered by hand, (ii)
otherwise delivered against receipt therefor, (iii) sent to an email address of record, or (iv) sent by registered or certified mail,
postage prepaid, return receipt requested. Any notice shall be duly addressed to the parties as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">if to the Corporation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">Jasper Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">2200 Bridge Parkway Suite #102</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">Redwood City, CA 94065<BR>
Attention: Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0.5in">if to the Executive, to the address (or e-mail address) most recently
on file in the personnel records of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>19.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Code Section 409A</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>This Agreement is intended to meet the requirements of Section 409A of the Code, and shall be interpreted and construed consistent
with that intent. Each payment provided hereunder, whether part of a severance benefit or otherwise, is intended to be a separate payment
for purposes of Section 409A of the Code, including Treasury Regulation 1.409A-2(b)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Notwithstanding any other provision of this Agreement, to the extent that the right to any payment (including the provision of
benefits) hereunder or under any other plan or agreement of the Corporation or any Corporation affiliate covering Executive, provides
for the &ldquo;deferral of compensation&rdquo; within the meaning of Section 409A(d)(1) of the Code, the payment shall be paid (or provided)
in accordance with the following:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>If the Executive is a &ldquo;Specified Employee&rdquo; within the meaning of Section 409A(a)(2)(B)(i) of the Code on the date of
the Executive&rsquo;s Separation from Service (within the meaning of Section 409A of the Code) (the &ldquo;<U>Separation Date</U>&rdquo;),
then no payment of non-qualified deferred compensation (within the meaning of Section 409A of the Code) otherwise to be made as a result
of the Executive&rsquo;s Separation from Service shall be made or commence during the period beginning on the Separation Date and ending
on the date that is six months following the Separation Date or, if earlier, on the date of the Executive&rsquo;s death. The amount of
any payment that would otherwise be paid to the Executive during this period shall instead be paid to the Executive on the first day of
the first calendar month following the end of such six-month period.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">            &nbsp;
</FONT>Payments with respect to reimbursements of expenses or benefits or provision of fringe or other in-kind benefits shall be made
on or before the last day of the calendar year following the calendar year in which the relevant expense or benefit is incurred. The amount
of expenses or benefits eligible for reimbursement, payment or provision during a calendar year shall not affect the expenses or benefits
eligible for reimbursement, payment or provision in any other calendar year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>20.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>&ldquo;Blue-Pencil&rdquo;</U></B>. If any provision of this Agreement shall be invalid or unenforceable, in whole
or in part, or as applied to any circumstances, under the laws of any jurisdiction which may govern for such purpose, then such provision
shall be deemed, to the extent allowed by the laws of such jurisdiction, to be modified or restricted to the extent and in the manner
necessary to render the same valid and enforceable, either generally or as applied to such circumstance, or shall be deemed excised from
this Agreement, as the case may require, and this Agreement shall be construed and enforced to the maximum extent permitted by law, as
if such provision had been originally incorporated herein as so modified or restricted, or as if such provision had not been originally
incorporated herein, as the case may be.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>21.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Counterparts</U></B>. This Agreement may be executed in any number of counterparts, each of which shall be deemed
an original as against any party whose signature appears thereon, and all of which together shall constitute one and the same instrument.
This Agreement shall become binding when one or more counterparts hereof, individually or taken together, shall bear the signatures of
all of the parties reflected hereon as the signatories.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>22.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B></FONT><B><U>Legal Counsel</U></B>. Each party recognizes that this is a legally binding contract and acknowledges and agrees
that they have had the opportunity to consult with legal counsel of their choice. The Executive agrees and acknowledges that he has read
and understands this Agreement, is entering into it freely and voluntarily, and has been advised to seek counsel prior to entering into
this Agreement and has had ample opportunity to do so. This Agreement has resulted from negotiations and discussions between the parties
and no one party shall be treated as drafting this Agreement for purposes of interpreting any provision hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>The remainder of this page
has intentionally been left blank</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the Corporation and
the Executive have executed this Agreement as of the date set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>&ldquo;CORPORATION&rdquo;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ William Lis</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>William Lis</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Executive Chairperson &amp; CEO</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>&ldquo;EXECUTIVE&rdquo;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Jeetinder Mahal</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Jeetinder Mahal</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">[SIGNATURE
PAGE TO EMPLOYMENT AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>11
<FILENAME>ea147929ex10-9_jasper.htm
<DESCRIPTION>EMPLOYMENT AGREEMENT, DATED AS OF SEPTEMBER 24, 2021, BY AND BETWEEN JASPER THERAPEUTICS, INC. AND KEVIN HELLER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 10.9</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>EMPLOYMENT
AGREEMENT</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
EMPLOYMENT AGREEMENT</B> (this &ldquo;<U>Agreement</U>&rdquo;) is made and entered into as of September 24, 2021 by and between Jasper
Therapeutics, Inc., a Delaware corporation (the &ldquo;<U>Corporation</U>&rdquo;), and Kevin Heller (the &ldquo;<U>Executive</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RECITALS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
PARTIES ENTER THIS AGREEMENT</B> on the basis of the following facts, understandings and intentions:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A.   </B>The
Corporation desires that the Executive be employed by the Corporation to carry out the duties and responsibilities described below, all
on the terms and conditions hereinafter set forth.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>B.   </B>The
Executive desires to accept such employment on such terms and conditions.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B>, in consideration of the above recitals incorporated herein and the mutual covenants and promises contained herein and
other good and valuable consideration, the receipt and sufficiency of which are hereby expressly acknowledged, the parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>1.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Employment
and Duties</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.1   <U>Employment</U></B>.
The Corporation does hereby hire, engage and employ the Executive on an at-will basis, subject to the terms and conditions expressly
set forth in this Agreement, including, but not limited to, Sections 5 and 6 of this Agreement. The Executive does hereby accept and
agree to such hiring, engagement and employment on the terms and conditions expressly set forth in this Agreement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.2   <U>Duties</U></B>.
The Executive shall serve the Corporation as its Executive Vice President, Research and Development, and shall perform and have the responsibilities,
duties, status and authority customary for a position in an organization of the size and nature of the Corporation, subject to the corporate
policies of the Corporation as in effect from time to time (including, without limitation, the Corporation&rsquo;s business conduct and
ethics policies, as they may be amended from time to time). In this position, the Executive shall report to the Corporation&rsquo;s Chief
Executive Officer (&ldquo;<U>CEO</U>&rdquo;) and shall render such administrative, financial, and other executive and managerial services
to the Corporation and its affiliates as the CEO and the Corporation&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo;) may
from time to time direct.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.3   <U>No
Other Employment; Time Commitment</U></B>. For so long as the Executive is employed with the Corporation, the Executive shall both (i)
devote the Executive&rsquo;s full business time, energy and skill to the performance of the Executive&rsquo;s duties for the Corporation
and (ii) hold no other employment. Notwithstanding the foregoing, the Executive may serve on managing or advisory boards of non-profit
entities and up to two (2) managing or advisory boards of for-profit companies, so long as such service does not interfere with the Executive&rsquo;s
duties to, or otherwise create a conflict of interest with respect to, the Corporation. The Board shall have the right to require the
Executive to resign from any board or similar body on which the Executive may then serve if the Board determines that such activity interferes
with the effective discharge of the Executive&rsquo;s duties and responsibilities to the Corporation or that any business related to
such service is then in competition with any business of the Corporation or any of its affiliates, successors or assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.4   <U>No
Breach of Contract</U></B>. The Executive hereby represents to the Corporation: (i)&nbsp;that the execution and delivery of this Agreement
by the Executive and the Corporation and the performance by the Executive of the Executive&rsquo;s duties hereunder shall not constitute
a breach of, or otherwise contravene, the terms of any other agreement or policy to which the Executive is a party or otherwise bound;
(ii)&nbsp;that the Executive has no information (including, without limitation, confidential information and trade secrets) relating
to any other person or entity which would prevent, or be violated by, the Executive entering into this Agreement or carrying out the
Executive&rsquo;s duties hereunder; and (iii)&nbsp;that the Executive is not bound by any confidentiality, trade secret or similar agreement
with any other person or entity which would prevent, or be violated by, the Executive (x)&nbsp;entering into this Agreement or (y)&nbsp;carrying
out the Executive&rsquo;s duties hereunder.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.5   <U>Location</U></B>.
The Executive&rsquo;s principal place of employment initially shall be the offices of the Corporation&rsquo;s headquarters, currently
located in Northern California. The Executive acknowledges that business travel may be required from time to time in the course of performing
the Executive&rsquo;s duties for the Corporation.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>2.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Term</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.
The Executive&rsquo;s employment under this Agreement shall commence on the date of this Agreement<SUP></SUP>, which such date of
commencement of employment will be hereinafter referred to as the &ldquo;<U>Effective Date</U>.&rdquo; The period from the Effective
Date until the termination of the Executive&rsquo;s employment under this Agreement is hereinafter referred to as &ldquo;the term of
this Agreement&rdquo; or &ldquo;the term hereof.&rdquo; Until the occurrence of the Effective Date, this Agreement shall be null and
void and without force or effect.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>3.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compensation</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.1   <U>Base
Salary</U></B>. During the term hereof, the Executive&rsquo;s base salary (the &ldquo;<U>Base Salary</U>&rdquo;) shall be paid in accordance
with the Corporation&rsquo;s regular payroll practices in effect from time to time, but not less frequently than in monthly installments.
As of the Effective Date, the Executive&rsquo;s Base Salary shall be at an annualized rate of $455,274.59. During the term hereof, the
Corporation may review and adjust the Executive&rsquo;s rate of Base Salary from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.2   <U>Incentive
Bonus</U></B>. During the term hereof, in addition to the Base Salary, the Executive shall be eligible to receive an annual incentive
bonus (&ldquo;<U>Incentive Bonus</U>&rdquo;) for each fiscal year with a target amount of 40% of Base Salary. The actual amount of any
Incentive Bonus earned by the Executive each year shall be determined in good faith by the Compensation Committee of the Board (the &ldquo;<U>Compensation
Committee</U>&rdquo;) in its reasonable discretion, based on the achievement of performance objectives established for that particular
fiscal year by the Board or the Compensation Committee. The Incentive Bonus earned for each fiscal year (if any) shall be paid as soon
as practicable following the Board&rsquo;s certification of financial results for the applicable calendar year, subject to the Executive&rsquo;s
continued employment by the Corporation or its affiliates through the applicable payment date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>4.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Benefits</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.1   <U>Retirement,
Welfare and Fringe Benefits</U></B>. During the term hereof, the Executive shall be eligible to participate in all employee retirement
and welfare benefit plans and programs, and fringe benefit plans and programs, made available by the Corporation to the Corporation&rsquo;s
executive employees generally, in accordance with the terms of such plans and as such plans or programs may be in effect from time to
time.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.2   <U>Reimbursement
of Expenses</U></B>. During the term hereof, the Executive shall be authorized to incur reasonable expenses to facilitate performance
of his duties under this Agreement. The Executive shall be eligible for reimbursement of such expenses, subject to the Corporation&rsquo;s
expense reimbursement policies and the discretion of the Board.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.3   <U>Vacation
and Other Leave</U></B>. During the term hereof, the Executive shall accrue paid time off and other leave in accordance with the applicable
policies of the Corporation.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.4   <U>Indemnification</U></B>.
The Executive shall be provided indemnification, and coverage under the Corporation&rsquo;s D&amp;O liability insurance policies, to
the same extent as other executive officers of the Corporation.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>5.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Termination
of Employment</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1   <U>Generally</U></B>.
The Executive&rsquo;s employment by the Corporation, and the term hereof, may be terminated at any time (i) by the Corporation with or
without Cause (as defined in Section 5.4), (ii) by the Corporation in the event that the Executive has incurred a Disability (as defined
in Section 5.4), (iii) by the Executive for any reason, or (iv) due to the Executive&rsquo;s death.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2   <U>Notice
of Termination</U>. </B> Any termination of the Executive&rsquo;s employment under this Agreement (other than because of the Executive&rsquo;s
death) shall be communicated by written notice of termination from the terminating party to the other party, which termination shall
be effective (i) no less than thirty (30) days following delivery of such notice in the event of a termination by the Executive for any
reason or (ii) immediately in the event of a termination by the Corporation. The notice of termination shall indicate the specific provision(s)
of this Agreement relied upon in effecting the termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.3   <U>Benefits
Upon Termination</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)   Upon
any termination of the Executive&rsquo;s employment with the Corporation (the date of termination, the &ldquo;<U>Severance Date</U>&rdquo;),
the Corporation shall pay to the Executive (or the Executive&rsquo;s estate, if applicable) (i) any Base Salary that had accrued but
had not been paid (including accrued and unpaid vacation time) on or before the Severance Date; (ii) any reimbursement due to the Executive
pursuant to Section 4.2 for expenses incurred by the Executive on or before the Severance Date; and (iii) any other amounts required
under applicable law. The treatment (including, without limitation, the cancellation or vesting thereof and/or the entitlement of the
Executive thereto) of any outstanding equity awards then held by the Executive as of the Severance Date shall be subject to the applicable
terms of the Equity Plan and the applicable award agreements.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)   In
addition to amounts payable under the immediately preceding clause (a), in the event of certain terminations the Executive shall be eligible
for payments and benefits under the Corporation&rsquo;s Employee Severance Plan for Vice Presidents and Executive Committee Members (as
may be amended or restated from time to time, the &ldquo;<U>Severance Plan</U>&rdquo;), subject to the Executive meeting the eligibility
criteria set forth in the Severance Plan.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.4   <U>Certain
Defined Terms</U></B>. In the event of a conflicting definition between this Agreement and any other agreement between the Corporation
and the Executive, the definitions of Cause and Good Reason contained in this Agreement shall govern unless such other agreement states
otherwise by specifically making reference to this Agreement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)   As
used herein, &ldquo;<U>Cause</U>&rdquo; shall have the meaning ascribed to such term in the Severance Plan.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)   As
used herein, &ldquo;<U>Disability</U>&rdquo; shall mean a disability that qualifies the Executive for benefits under the Corporation&rsquo;s
long-term disability plan.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)   As
used herein, &ldquo;<U>Good Reason</U>&rdquo; shall have the meaning ascribed to such term in the Severance Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.5   <U>Resignation
from Directorships and Officerships</U></B>. The termination of the Executive&rsquo;s employment with the Corporation for any reason
shall be treated as the Executive&rsquo;s resignation from (i) any director, officer or employee position the Executive has with the
Corporation and any of its respective affiliates, and (ii) all fiduciary positions (including as a trustee) the Executive holds with
respect to any employee benefit plans or trusts established by the Corporation or any of its affiliates, in each case unless otherwise
determined by the Board or one of its committees. The Executive agrees that this Agreement shall serve as written notice of resignation
in this circumstance. Furthermore, the Executive agrees to execute any documents evidencing such resignations that the Corporation reasonably
requests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>6.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Non-Disparagement</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.
The Executive agrees that at no time during employment with the Corporation or thereafter shall the Executive make, or cause or assist
any other person to make, any statement or other communication to any third party which impugns or attacks, or is otherwise critical
of, the reputation, business or character of the Corporation, any Corporation affiliate, or any of their respective directors, officers,
representatives, agents or employees. Notwithstanding anything in this Section to the contrary, in no event shall any party be prohibited
from providing truthful testimony in connection with a legal proceeding or governmental investigation. In addition, nothing in this Agreement
shall prohibit the Executive from reporting a suspected violation of law to the appropriate governmental agency or authority.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>7.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Defense
of Claims</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. The Executive agrees that, during the term hereof and
following the termination of the Executive&rsquo;s employment, upon request from the Corporation, the Executive will cooperate with the
Corporation in the defense of any claims or actions that may be made by or against the Corporation that affect the Executive&rsquo;s
prior areas of responsibility, except if the Executive&rsquo;s reasonable interests are adverse to the Corporation in such claim or action.
The Corporation agrees that it shall reimburse the reasonable out of pocket costs and attorney fees the Executive actually incurs in
connection with the Executive providing such assistance or cooperation to the Corporation, in accordance with the Corporation&rsquo;s
standard policies and procedures as in effect from time to time, <U>provided</U> that the Executive shall have obtained prior written
approval from the Corporation for any travel or legal fees and expenses incurred by the Executive in connection with the Executive&rsquo;s
obligations under this Section 7. In addition, if the Executive no longer is providing services to the Corporation, the Corporation shall
reimburse the Executive for time spent providing such assistance at an hourly rate equal to the Executive&rsquo;s most recent annual
Base Salary divided by 2080, rounded down to the nearest whole dollar.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>8.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Source
of Payments</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. All payments provided under this Agreement, other
than payments made pursuant to a plan which provides otherwise, shall be paid in cash from the general funds of the Corporation, and
no special or separate fund shall be established, and no other segregation of assets shall be made, to assure payment. The Executive
shall have no right, title or interest whatsoever in or to any investments which the Corporation may make to aid the Corporation in meeting
its obligations hereunder. Any payments provided under this Agreement shall be treated as amounts owed to an unsecured creditor of the
Corporation.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>9.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Withholding</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.
Notwithstanding anything else herein to the contrary, the Corporation may withhold (or cause there to be withheld, as the case may be)
from any amounts otherwise due or payable under or pursuant to this Agreement such federal, state and local income, employment, or other
taxes or other amounts as may be required to be withheld pursuant to any applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>10.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Assignment;
Binding Effect</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)   <U>By
the Executive</U>. This Agreement and any and all rights, duties, obligations or interests hereunder shall not be assignable or delegable
by the Executive.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)   <U>By
the Corporation</U>. This Agreement and all of the Corporation&rsquo;s rights and obligations hereunder shall not be assignable by the
Corporation except as incident to a reorganization, merger or consolidation, or transfer of all or substantially all of the Corporation&rsquo;s
assets. Notwithstanding the foregoing, or any contrary provision herein, concurrently with the occurrence of the Effective Date, references
to the Corporation herein shall mean the entity formerly known as Amplitude Healthcare Acquisition Corporation which, as of the Effective
Date, has changed its name to Jasper Therapeutics, Inc.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)   <U>Binding
Effect</U>. This Agreement shall be binding upon, and inure to the benefit of, the parties hereto, any successors to or assigns of the
Corporation and the Executive&rsquo;s heirs and the personal representatives of the Executive&rsquo;s estate.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>11.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Number
and Gender</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. Where the context requires, the singular shall include
the plural, the plural shall include the singular, and any gender shall include all other genders.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>12.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
Headings</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. The section headings of, and titles of paragraphs and
subparagraphs contained in, this Agreement are for the purpose of convenience only, and they neither form a part of this Agreement nor
are they to be used in the construction or interpretation thereof.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>13.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Governing
Law</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. This Agreement, and all questions relating to its validity,
interpretation, performance and enforcement, as well as the legal relations hereby created between the parties hereto, shall be governed
by and construed under, and interpreted and enforced in accordance with, the laws of the State of California applicable to contracts
executed solely in California and to be performed entirely within that State.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>14.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Survival
of Certain Provisions</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. Sections 5, 6, 7, 8, 9, 13, 14, 16, 17,
18, 19 and 20 shall survive any termination or expiration of this Agreement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>15.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Entire
Agreement</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. This Agreement embodies the entire agreement of the
parties hereto respecting the matters within its scope. As of the date hereof, this Agreement supersedes all prior and contemporaneous
agreements of the parties hereto that directly or indirectly bear upon the subject matter hereof. Any prior negotiations, correspondence,
agreements, proposals or understandings relating to the subject matter hereof shall be deemed to be of no force or effect, and the parties
to any such other negotiations, commitments, agreements or writings shall have no further rights or obligations thereunder. There are
no representations, warranties, or agreements, whether express or implied, or oral or written, with respect to the subject matter hereof,
except as expressly set forth herein. For the avoidance of doubt, this Agreement does not supersede or replace the Severance Plan and
shall be interpreted to be consistent with the Severance Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>16.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Modifications,
Waivers</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. This Agreement may not be amended, modified or changed
(in whole or in part), except by an instrument in writing signed by both parties hereto. The waiver by either party of compliance with
any provision of this Agreement by the other party shall not operate or be construed as a waiver of any other provision of this Agreement,
or of any subsequent breach by such party of a provision of this Agreement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>17.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Arbitration</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.
The Executive and the Corporation agree that to the extent permitted by law, any dispute or controversy arising out of, relating to,
or in connection with this Agreement, or the interpretation, validity, construction, performance, breach, or termination thereof, or
the Executive&rsquo;s employment by the Corporation or any termination thereof, will be settled by arbitration to be held at a location
in San Francisco, California in accordance with then applicable rules of the American Arbitration Association specifically designed for
the resolution of employment disputes. The Executive acknowledges that a copy of such rules in effect as of the date hereof has been
provided to the Executive. The arbitrator may grant injunctions or other relief in such dispute or controversy. The decision of the arbitrator
will be final, conclusive and binding on the parties to the arbitration. Judgment may be entered on the arbitrator&rsquo;s decision in
any court having jurisdiction. The Corporation shall pay the costs associated with arbitration (arbitration fee and location fee, if
any); provided, however, that each party shall bear its own legal fees and expenses. Notwithstanding the foregoing, the arbitrator shall
be permitted to award costs associated with arbitration in the event the arbitrator determines a claim is frivolous.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>18.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notices</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.
All notices, requests, demands and other communications required or permitted under this Agreement shall be in writing (including in
electronic formats) and shall be deemed to have been duly given and made if (i) delivered by hand, (ii) otherwise delivered against receipt
therefor, (iii) sent to an email address of record, or (iv) sent by registered or certified mail, postage prepaid, return receipt requested.
Any notice shall be duly addressed to the parties as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
to the Corporation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jasper
Therapeutics, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2200
Bridge Parkway Suite #102</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redwood
City, CA 94065<BR>
Attention: Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
to the Executive, to the address (or e-mail address) most recently on file in the personnel records of the Corporation.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>19.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Code
Section 409A</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)   This
Agreement is intended to meet the requirements of Section 409A of the Code, and shall be interpreted and construed consistent with that
intent. Each payment provided hereunder, whether part of a severance benefit or otherwise, is intended to be a separate payment for purposes
of Section 409A of the Code, including Treasury Regulation 1.409A-2(b)(2).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)   Notwithstanding
any other provision of this Agreement, to the extent that the right to any payment (including the provision of benefits) hereunder or
under any other plan or agreement of the Corporation or any Corporation affiliate covering Executive, provides for the &ldquo;deferral
of compensation&rdquo; within the meaning of Section 409A(d)(1) of the Code, the payment shall be paid (or provided) in accordance with
the following:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)   If
the Executive is a &ldquo;Specified Employee&rdquo; within the meaning of Section 409A(a)(2)(B)(i) of the Code on the date of the Executive&rsquo;s
Separation from Service (within the meaning of Section 409A of the Code) (the &ldquo;<U>Separation Date</U>&rdquo;), then no payment
of non-qualified deferred compensation (within the meaning of Section 409A of the Code) otherwise to be made as a result of the Executive&rsquo;s
Separation from Service shall be made or commence during the period beginning on the Separation Date and ending on the date that is six
months following the Separation Date or, if earlier, on the date of the Executive&rsquo;s death. The amount of any payment that would
otherwise be paid to the Executive during this period shall instead be paid to the Executive on the first day of the first calendar month
following the end of such six-month period.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)   Payments
with respect to reimbursements of expenses or benefits or provision of fringe or other in-kind benefits shall be made on or before the
last day of the calendar year following the calendar year in which the relevant expense or benefit is incurred. The amount of expenses
or benefits eligible for reimbursement, payment or provision during a calendar year shall not affect the expenses or benefits eligible
for reimbursement, payment or provision in any other calendar year.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>20.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>&ldquo;Blue-Pencil&rdquo;</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.
If any provision of this Agreement shall be invalid or unenforceable, in whole or in part, or as applied to any circumstances, under
the laws of any jurisdiction which may govern for such purpose, then such provision shall be deemed, to the extent allowed by the laws
of such jurisdiction, to be modified or restricted to the extent and in the manner necessary to render the same valid and enforceable,
either generally or as applied to such circumstance, or shall be deemed excised from this Agreement, as the case may require, and this
Agreement shall be construed and enforced to the maximum extent permitted by law, as if such provision had been originally incorporated
herein as so modified or restricted, or as if such provision had not been originally incorporated herein, as the case may be.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>21.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Counterparts</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.
This Agreement may be executed in any number of counterparts, each of which shall be deemed an original as against any party whose signature
appears thereon, and all of which together shall constitute one and the same instrument. This Agreement shall become binding when one
or more counterparts hereof, individually or taken together, shall bear the signatures of all of the parties reflected hereon as the
signatories.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>22.   </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Legal
Counsel</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. Each party recognizes that this is a legally binding contract
and acknowledges and agrees that they have had the opportunity to consult with legal counsel of their choice. The Executive agrees and
acknowledges that he has read and understands this Agreement, is entering into it freely and voluntarily, and has been advised to seek
counsel prior to entering into this Agreement and has had ample opportunity to do so. This Agreement has resulted from negotiations and
discussions between the parties and no one party shall be treated as drafting this Agreement for purposes of interpreting any provision
hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>The
remainder of this page has intentionally been left blank</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF</B>, the Corporation and the Executive have executed this Agreement as of the date set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>&ldquo;CORPORATION&rdquo;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ William Lis</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>William Lis</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Executive Chairperson &amp; CEO</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><B>&ldquo;EXECUTIVE&rdquo;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Kevin Heller</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Kevin Heller</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">[SIGNATURE PAGE TO EMPLOYMENT AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>12
<FILENAME>ea147929ex10-14_jasper.htm
<DESCRIPTION>AMENDMENT TO SPONSOR SUPPORT AGREEMENT, DATED AS OF SEPTEMBER 24, 2021, BY AND AMONG AMPLITUDE HEALTHCARE ACQUISITION CORPORATION, AMPLITUDE HEALTHCARE HOLDINGS LLC AND JASPER THERAPEUTICS, INC.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 10.14</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">AMENDMENT TO SPONSOR SUPPORT AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS AMENDMENT TO SPONSOR
SUPPORT AGREEMENT, dated as of September&nbsp;24, 2021 (this &ldquo;<U>Amendment</U>&rdquo;) is entered into by and among Amplitude Healthcare
Holdings LLC, a Delaware limited liability company (&ldquo;<B>Sponsor</B>&rdquo;), Amplitude Healthcare Acquisition Corporation, a Delaware
corporation (&ldquo;<B>AMHC</B>&rdquo;), and Jasper Therapeutics, Inc. a Delaware corporation (&ldquo;<B>Jasper</B>&rdquo; and, together
with Sponsor and AMHC, the &ldquo;<U>Parties</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A. The
Parties entered into that certain Sponsor Support Agreement, dated as of May&nbsp;5, 2021 (the &ldquo;<B>Sponsor Support Agreement</B>&rdquo;)
(unless otherwise defined herein, capitalized terms used herein shall have the meanings assigned to them in the Sponsor Support Agreement);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B. Pursuant
to Section&nbsp;25(a) of the Sponsor Support Agreement, the Sponsor Support Agreement may be amended by a writing signed by the Parties;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C. The Parties have agreed
to amend certain terms and conditions of the Sponsor Support Agreement, as fully set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In consideration of the foregoing
and the mutual covenants and agreements herein contained, and intending to be legally bound hereby, the Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1. <U>Amendment
Sponsor Support Agreement</U>. The following sections and subsections of the Sponsor Support Agreement are amended as set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The
first sentence of Section&nbsp;6 shall be amended and restated as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify">&ldquo;The Sponsor agrees that,
as of immediately following the Closing, 1,050,000 AMHC Class&nbsp;B Shares beneficially owned by the Sponsor as of immediately prior
to the Closing (which, for clarity, shall be automatically converted into AMHC Class&nbsp;A Shares pursuant to Section&nbsp;4.3(b) of
the AMHC CoI prior to the Closing of the Merger and the Business Combination Agreement) (collectively, the &ldquo;<B>Sponsor Earn-Out
Shares</B>&rdquo;) shall be subject to the escrow, vesting and forfeiture provisions set forth in this Section&nbsp;6.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Section&nbsp;6(b)(i)
and Section&nbsp;6(b)(ii) are hereby amended and restated as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) (A)
If, during the period from and after the Closing until the third anniversary of the Closing (the &ldquo;<B>Earnout Period</B>&rdquo;),
over any twenty (20)&nbsp;Trading Days (as defined below) within any thirty (30)&nbsp;consecutive Trading Day period the VWAP (as defined
below) of the AMHC Shares is greater than or equal to $11.50 (the &ldquo;<B>First Milestone</B>&rdquo;), then 250,000 Sponsor Earn-Out
Shares shall vest and be released to the Sponsor (such&nbsp;250,000 Sponsor Earn-Out Shares, the &ldquo;<B>First Milestone Earnout</B>&rdquo;).
(B)&nbsp;If, during the Earnout Period, over any twenty (20)&nbsp;Trading Days within any thirty (30)&nbsp;consecutive Trading Day period
the VWAP of the AMHC Shares is greater than or equal to $15.00 (the &ldquo;<B>Second Milestone</B>&rdquo;), then 500,000 Sponsor Earn-Out
Shares shall vest and be released to the Sponsor (such 500,000 Sponsor Earn-Out Shares, the &ldquo;<B>Second Milestone Earnout</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii) If,
during the Earnout Period, over any twenty (20)&nbsp;Trading Days within any thirty (30)&nbsp;consecutive Trading Day period the VWAP
of the AMHC Shares is greater than or equal to $18.00 (the &ldquo;<B>Third Milestone</B>&rdquo; and together with the First Milestone
and the Second Milestone, the &ldquo;<B>Earnout Milestones</B>&rdquo;), then 300,000 Sponsor Earn-Out Shares shall vest and be released
to the Sponsor (such 300,000 Sponsor Earn-Out Shares, the &ldquo;<B>Third Milestone Earnout</B>&rdquo; and together with the First Milestone
Earnout and the Second Milestone Earnout, the &ldquo;<B>Earnout Consideration</B>&rdquo;). For the avoidance of doubt, the Earnout Consideration
in respect of each Earnout Milestone shall be vested and released only once and the Earnout Consideration shall in no event exceed the
total amount of Sponsor Earn-Out Shares, in the aggregate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) A
new Section&nbsp;6(d) shall be added, which shall read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&ldquo;(d) <U>Forfeiture of Certain
Sponsor Shares</U>. Effective as of immediately prior to the Closing, 200,000 AMHC Class&nbsp;B shares beneficially owned by the Sponsor
shall be forfeited and AMHC shall direct AMHC&rsquo;s transfer agent to transfer such forfeited shares to AMHC for cancellation, without
any consideration for such transfer.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 2. <U>Effectiveness</U>.
This Amendment will be effective upon its execution by the Parties and as of the date specified above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 3. <U>No Other
Modification; Reference to Agreement</U>. The Sponsor Support Agreement shall not be modified by this Amendment in any respect except
as expressly set forth in this Amendment, and except as expressly set forth in this Amendment, all terms and conditions of the Sponsor
Support Agreement shall continue in full force and effect. On and after the effective date of this Amendment, each reference in the Agreement
to &ldquo;the Agreement,&rdquo; &ldquo;this Agreement,&rdquo; &ldquo;hereunder&rdquo; and &ldquo;hereof&rdquo; or words of like import
shall refer to the Agreement as amended by this Amendment. The Agreement, as amended by this Amendment, is and shall continue to be in
full force and effect and is hereby in all respects ratified and confirmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4. <U>Miscellaneous</U>.
This Amendment shall be subject to the terms and conditions of <U>Section&nbsp;12</U> of the Sponsor Support Agreement, <I>mutatis mutandis</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5. <U>Counterparts</U>.
This Amendment may be executed in two or more counterparts (including by facsimile or by an electronic scan delivered by electronic mail),
each of which shall be deemed an original but all of which together shall be considered one and the same agreement and shall become effective
when counterparts have been signed by each of the parties and delivered to the other parties, it being understood that all parties need
not sign the same counterpart. This Amendment may be executed and delivered by facsimile or by an electronic scan delivered by electronic
mail.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Signature Page Follows]</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Parties
have caused this Amendment to be executed as of the date first written above by their respective officers thereunto duly authorized.</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">AMPLITUDE HEALTHCARE HOLDINGS LLC</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; width: 60%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; width: 5%">By:</TD>
    <TD STYLE="font-weight: bold; width: 35%">Avego Healthcare Capital, L.P., its<BR>
 Managing Member</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Bala Venkataraman</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD>Bala Venkataraman</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Managing Member</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">AMPLITUDE HEALTHCARE ACQUISITION<BR>
 CORPORATION</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 5%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 35%; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By: </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Bala Venkataraman<FONT STYLE="font-style: normal; font-weight: normal"></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD>Bala Venkataraman</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">JASPER THERAPEUTICS, INC.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; width: 60%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; width: 5%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Jeet Mahal</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Jeet Mahal</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Financial and Business Officer</TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-14.1
<SEQUENCE>13
<FILENAME>ea147929ex14-1_jasper.htm
<DESCRIPTION>CODE OF BUSINESS CONDUCT AND ETHICS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 14.1</B></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Jasper
Therapeutics, Inc.<BR>
<BR>
Code of Business Conduct and Ethics<BR>
</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Introduction</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Jasper Therapeutics, Inc.
(the &ldquo;<B><I>Company</I></B>,&rdquo; &ldquo;<B><I>us</I></B>,&rdquo; &ldquo;<B><I>we</I></B>,&rdquo; &ldquo;<B><I>our</I></B>&rdquo;)
is committed to maintaining the highest standards of business conduct and ethics. This Code of Business Conduct and Ethics (this &ldquo;<B><I>Code</I></B>&rdquo;)
reflects the business practices and principles of behavior that support this commitment. We expect every employee, officer and director
to read and understand this Code and its application to the performance of his or her business responsibilities. References in this Code
to employees are intended to cover officers and, as applicable, directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Officers, managers and other
supervisors are expected to develop in employees a sense of commitment to the spirit, as well as the letter, of this Code. Supervisors
are also expected to ensure that all agents and contractors conform to Code standards when working for or on behalf of the Company. The
compliance environment within each supervisor&rsquo;s assigned area of responsibility will be an important factor in evaluating the quality
of that individual&rsquo;s performance. In addition, any employee who makes an exemplary effort to implement and uphold our legal and
ethical standards may be recognized for that effort in his or her performance review. Nothing in this Code alters the at-will employment
policy of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Code addresses conduct
that is particularly important to proper dealings with the people and entities with whom we interact, but reflects only a part of our
commitment. We may adopt additional policies and procedures with which our employees, officers and directors are expected to comply, if
applicable to them. However, it is the responsibility of each employee to apply common sense, together with his or her own highest personal
ethical standards, in making business decisions where there is no stated guideline in this Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Action by members of your
immediate family, significant others or other persons who live in your household (referred to in this Code as &ldquo;<B><I>family members</I></B>&rdquo;)
may also potentially result in ethical issues to the extent that they involve the Company&rsquo;s business. For example, acceptance of
inappropriate gifts by a family member from one of our partners or suppliers could create a conflict of interest and result in a Code
violation attributable to you. Consequently, in complying with this Code, you should consider not only your own conduct, but also that
of your immediate family members, significant others and other persons who live in your household.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should not hesitate to
ask questions about whether any conduct may violate this Code, voice concerns or clarify gray areas. Section&nbsp;19 below details the
compliance resources available to you. In addition, you should be alert to possible violations of this Code by others and report suspected
violations, without fear of any form of retaliation, as further described in Section&nbsp;19. Violations of this Code will not be tolerated.
Any employee who violates the standards in this Code may be subject to disciplinary action, which, depending on the nature of the violation
and the history of the employee, may range from a warning or reprimand to and including termination of employment and, in appropriate
cases, civil legal action or referral for regulatory or criminal prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After carefully reviewing
this Code, you must sign the acknowledgment attached as <FONT STYLE="font-variant: small-caps"><B>Exhibit&nbsp;A</B></FONT> hereto, indicating
that you have received, read, understand and agree to comply with this Code. The acknowledgment must be returned either electronically
in a manner provided for by the Company or to the person designated as the Compliance Officer (as further described in Section&nbsp;19)
or such Compliance Officer&rsquo;s designee within ten business days of your receipt of this Code and on an annual basis as the Company
may require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is committed to
providing a work environment free of any form of unlawful harassment or discrimination. The Company is committed to maintaining a respectful,
courteous work environment that respects the dignity and worth of each employee. Inappropriate workplace behavior and unlawful harassment
are wholly inconsistent with this commitment. No employee, contract worker, customer, vendor or other person who does business with this
organization is exempt from the prohibitions within this policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1. Honest and Ethical
Conduct</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is the policy of the Company
to promote high standards of integrity by conducting our affairs in an honest and ethical manner. The integrity and reputation of the
Company depends on the honesty, fairness and integrity brought to the job by each person associated with us. Unyielding personal integrity
is the foundation of corporate integrity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Legal Compliance</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Obeying the law, both in letter
and in spirit, is the foundation of this Code. Our success depends upon each employee&rsquo;s operating within legal guidelines and cooperating
with local, regional and national authorities (as further described in Section&nbsp;4). We expect employees to understand the legal and
regulatory requirements applicable to their business units and areas of responsibility. We hold periodic training sessions to ensure that
all employees comply with the relevant laws, rules and regulations associated with their employment, including laws prohibiting insider
trading (which are discussed in further detail in Section&nbsp;3 below). While we do not expect you to memorize every detail of these
laws, rules and regulations, we want you to be able to determine when to seek advice from others. If you do have a question in the area
of legal compliance, it is important that you not hesitate to seek answers from your supervisor or a Compliance Officer (as further described
in Section&nbsp;19).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disregard of the law will
not be tolerated. Violation of laws, rules and regulations may subject an individual, as well as the Company, to civil and/or criminal
penalties. You should be aware that conduct and records, including emails, are subject to internal and external audits and to discovery
by third parties in the event of a government investigation or civil litigation. It is in everyone&rsquo;s best interests to know and
comply with our legal obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3. Insider Trading</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Employees who have access
to confidential (or &ldquo;nonpublic&rdquo;) information are not permitted to use or share that information for stock trading purposes
or for any other purpose except to conduct our business. All nonpublic information about the Company or about companies with which we
do business is considered confidential information. To use material, nonpublic information in connection with buying or selling securities,
including &ldquo;tipping&rdquo; others who might make an investment decision based on this information, is both unethical and illegal.
Employees must exercise the utmost care when handling material nonpublic information. Please refer to the Company&rsquo;s Insider Trading
Policy for more detailed information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While not part of this Code,
the Company&rsquo;s other policies that apply to the Company&rsquo;s employees, which may differ by business area and jurisdiction, are
developed to support and reinforce the principles set forth in this Code. These various separate policies and standards can be accessed
electronically through the Company&rsquo;s intranet site, or by request to the Compliance Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4. Regulating International
Business Activity</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our employees are expected
to comply with the applicable laws in all countries to which they travel, in which they operate and where we otherwise do business, including
laws prohibiting bribery, corruption or the conduct of business with specified individuals, companies or countries. The fact that in some
countries certain laws are not enforced or that violation of those laws is not subject to public criticism will not be accepted as an
excuse for noncompliance. In addition, we expect employees to comply with U.S.&nbsp;laws, rules and regulations governing the conduct
of business by its citizens and corporations outside the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These U.S.&nbsp;laws, rules
and regulations, which extend to all our activities outside the United States, include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Foreign Corrupt Practices Act, which prohibits directly or indirectly giving anything of
                                            value to a government official to obtain or retain business or favorable treatment and requires
                                            the maintenance of accurate books of account, with all company transactions being properly
                                            recorded;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.&nbsp;Sanctions,
                                            which generally prohibit U.S.&nbsp;companies, their subsidiaries and their employees from
                                            doing business with or traveling to countries subject to sanctions imposed by the U.S.&nbsp;government
                                            (currently Crimea Region of Ukraine, Cuba, Iran, North Korea and Syria), as well as specific
                                            companies and individuals identified on lists published by the U.S.&nbsp;Treasury Department;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
                                            Export Controls, which restrict exports from the United States and re-exports from other
                                            countries of goods, software and technology to many countries, and prohibits transfers of
                                            U.S.-origin items to denied persons and entities; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Antiboycott
                                            Regulations, which prohibit U.S.&nbsp;companies from taking any action that has the effect
                                            of furthering or supporting a restrictive trade practice or boycott imposed by a foreign
                                            country against a country friendly to the United States or against any U.S.&nbsp;person.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you have any questions
as to whether an activity is restricted or prohibited, seek assistance before taking any action, including giving any verbal assurances
that might be regulated by laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Antitrust</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Antitrust laws are designed
to promote competition. These laws are based on the premise that the public interest is best served by vigorous competition and will suffer
from illegal agreements or collusion among competitors. Antitrust laws generally prohibit:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">agreements,
                                            formal or informal, with competitors that harm competition or customers, including price
                                            fixing and allocations of customers, territories or contracts;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">agreements,
                                            formal or informal, that establish or fix the price at which a customer may resell a product;
                                            and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            acquisition or maintenance of a monopoly or attempted monop</FONT>oly through anti- competitive
                                            conduct.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain kinds of information,
such as pricing, production, inventory, business plans, strategies, budgets, projections, forecasts, financial and operating information,
methods and development plans, should not be exchanged with competitors, regardless of how innocent or casual the exchange may be and
regardless of the setting, whether business or social.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Antitrust laws impose severe
penalties for certain types of violations, including criminal penalties and potential fines and damages of millions of dollars, which
may be tripled under certain circumstances. Understanding the requirements of antitrust and unfair competition laws of the various jurisdictions
where we do business can be difficult, and you are urged to seek assistance from your supervisor or the Compliance Officer whenever you
have a question relating to these laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6. Environmental Compliance</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Federal law imposes criminal
liability on any person or company that contaminates the environment with any hazardous substance that could cause injury to the community
or environment. Violation of environmental laws can involve monetary fines and imprisonment. We expect employees to comply with all applicable
environmental laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is our policy to conduct
our business in an environmentally responsible way that minimizes environmental impacts. We are committed to minimizing and, if practicable,
eliminating the use of any substance or material that may cause environmental damage, reducing waste generation and disposing of all waste
through safe and responsible methods, minimizing environmental risks by employing safe technologies and operating procedures, and being
prepared to respond appropriately to accidents and emergencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Conflicts of Interest</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We respect the rights of our
employees to manage their personal affairs and investments and do not wish to intrude upon their personal lives. At the same time, employees
should avoid conflicts of interest that occur when their personal interests may interfere in any way with the performance of their duties
or the best interests of the Company. A conflicting personal interest could result from an expectation of personal gain now or in the
future or from a need to satisfy a prior or concurrent personal obligation. We expect our employees to be free from influences that conflict
with the best interests of the Company or might deprive the Company of their undivided loyalty in business dealings. Even the appearance
of a conflict of interest where none actually exists can be damaging and should be avoided. Whether or not a conflict of interest exists
or will exist can be unclear. Conflicts of interest are prohibited unless specifically authorized as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you have any questions
about a potential conflict or if you become aware of an actual or potential conflict, and you are not an officer or director of the Company,
you should discuss the matter with your supervisor or the Compliance Officer (as further described in Section&nbsp;19). Supervisors may
not authorize conflict of interest matters or make determinations as to whether a problematic conflict of interest exists without first
seeking the approval of the Compliance Officer and providing the Compliance Officer with a written description of the activity. If the
supervisor is involved in the potential or actual conflict, you should discuss the matter directly with the Compliance Officer. Officers
and directors may seek authorizations and determinations from the Nominating and Corporate Governance Committee (the &ldquo;<B><I>Nominating
Committee</I></B>&rdquo;) of the Company&rsquo;s Board of Directors (the &ldquo;<B><I>Board of Directors</I></B>&rdquo;). Factors that
may be considered in evaluating a potential conflict of interest are, among others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                            it may interfere with the employee&rsquo;s job performance, responsibilities or morale;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                            the employee has access to confidential information;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                            it may interfere with the job performance, responsibilities or morale of others within the
                                            organization;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            potential adverse or beneficial impact on our business;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            potential adverse or beneficial impact on our relationships with our customers or suppliers
                                            or other service providers;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                            it would enhance or support a competitor&rsquo;s position;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            extent to which it would result in financial or other benefit (direct or indirect) to the
                                            employee;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            extent to which it would result in financial or other benefit (direct or indirect) to one
                                            of our customers, suppliers or other service providers; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            extent to which it would appear improper to an outside observ</FONT>er.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although no list can include
every possible situation in which a conflict of interest could arise, the following are examples of situations that may, depending on
the facts and circumstances, involve problematic conflicts of interests:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employment
                                            by (including consulting for) or service on the board of a competitor, collaborator, partner,
                                            customer or supplier or other service provider. </B>Activity that enhances or supports the
                                            position of a competitor to the detriment of the Company is prohibited, including employment
                                            by or service on the board of a competitor. Employment by or service on the board of a collaborator,
                                            partner, customer or supplier or other service provider is generally discouraged and you
                                            must seek authorization in advance if you plan to take such a position.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Owning,
                                            directly or indirectly, a significant financial interest in any entity that does business,
                                            seeks to do business or competes with us. </B>In addition to the factors described above,
                                            persons evaluating ownership in other entities for conflicts of interest will consider the
                                            size and nature of the investment; the nature of the relationship between the other entity
                                            and the Company; the employee&rsquo;s access to confidential information and the employee&rsquo;s
                                            ability to influence Company decisions. If you would like to acquire a financial interest
                                            of that kind, you must seek approval in advance.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Soliciting
                                            or accepting gifts, favors, loans or preferential treatment from any person or entity that
                                            does business or seeks to do business with us. </B>See Section&nbsp;11 for further discussion
                                            of the issues involved in this type of conflict.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Soliciting
                                            contributions to any charity or for any political candidate from any person or entity that
                                            does business or seeks to do business with us</B>.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Taking
                                            personal advantage of corporate opportunities. </B>See Section&nbsp;8 for further discussion
                                            of the issues involved in this type of conflict.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Moonlighting
                                            without permission.</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conducting
                                            our business transactions with your family member or a business in which you have a significant
                                            financial interest. </B>Material related-party transactions approved by the Audit Committee
                                            of the Board (the &ldquo;<B><I>Audit Committee</I></B>&rdquo;) and involving any executive
                                            officer or director will be publicly disclosed as required by applicable law s and regulations
                                            in keeping with the Company&rsquo;s Policy and Procedures with Respect to Related Person
                                            Transactions.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercising
                                            supervisory or other authority on behalf of the Company over a co-worker who is also a family
                                            member</B>. The employee&rsquo;s supervisor and/or the Compliance Officer will consult with
                                            the Human Resources department to assess the advisability of reassignment.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Maintaining
                                            a financial relationship with a member of the Board or an employee of the Company, which
                                            could influence the independent judgment of the director or the employee.</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Loans
to, or guarantees of obligations of, employees or their family members by the Company could constitute an improper personal benefit to
the recipients of these loans or guarantees, depending on the facts and circumstances. Some loans are expressly prohibited by law and
applicable law requires that our Board of Directors approve all loans and guarantees to employees. As a result, all loans and guarantees
by the Company must be approved in advance by the Board of Directors or the Nominating Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">8.
Corporate Opportunities</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">You
may not take personal advantage of opportunities for the Company that are presented to you or discovered by you as a result of your position
with the Company or through your use of corporate property or information, unless authorized by your supervisor, the Compliance Officer
or the Nominating Committee, as described in Section&nbsp;7 above. Even opportunities that are acquired privately by you may be questionable
if they are related to our existing or proposed lines of business. Significant participation in an investment or outside business opportunity
that is directly related to our lines of business must be pre- approved. You may not use your position with the Company or corporate
property or information for improper personal gain, nor should you compete with the Company in any way.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">9.
Maintenance of Corporate Books, Records, Documents and Accounts; Financial Integrity; Public Reporting</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
integrity of our records and public disclosure depends upon the validity, accuracy and completeness of the information supporting the
entries to our books of account. Therefore, our corporate and business records should be completed accurately and honestly. The making
of false or misleading entries, whether they relate to financial results or test results, is strictly prohibited. Our records serve as
a basis for managing our business and are important in meeting our obligations to customers, suppliers, creditors, employees and others
with whom we do business. As a result, it is important that our books, records and accounts accurately and fairly reflect, in reasonable
detail, our assets, liabilities, revenues, costs and expenses, as well as all transactions and changes in assets and liabilities. We
require that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">no
                                            entry be made in our books and records that intentionally hides or disguises the nature of
                                            any transaction or of any of our liabilities or misclassifies any transactions as to accounts
                                            or accounting periods;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">transactions
                                            be supported by appropriate documentation;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the
                                            terms of sales and other commercial transactions be reflected accurately in the documentation
                                            for those transactions and all such documentation be reflected accurately in our books and
                                            records;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">employees
                                            comply with our system of internal controls; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">no
                                            cash or other assets be maintained for any purpose in any unrecorded or &ldquo;off-the-books&rdquo;
                                            fund.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Our
accounting records are also relied upon to produce reports for our management, stockholders and creditors, as well as for governmental
agencies. In particular, we rely upon our accounting and other business and corporate records in preparing the periodic and current reports
that we file with the Securities and Exchange Commission (the &ldquo;<B><I>SEC</I></B>&rdquo;). Securities laws require that these reports
provide full, fair, accurate, timely and understandable disclosure and fairly present our financial condition and results of operations.
Employees who collect, provide or analyze information for or otherwise contribute in any way in preparing or verifying these reports
should strive to ensure that our financial disclosure is accurate and transparent and that our reports contain all of the information
about the Company that would be important to enable stockholders and potential investors to assess the soundness and risks of our business
and finances and the quality and integrity of our accounting and disclosures. In addition:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">no
                                            employee may take or authorize any action that would cause our financial records or financial
                                            disclosure to fail to comply with generally accepted accounting principles, the rules and
                                            regulations of the SEC or other applicable laws, rules and regulations;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">all
                                            employees must cooperate fully with our Finance and Accounting Personnel, as well as our
                                            independent public accountants and counsel, respond to their questions with candor and provide
                                            them with complete and accurate information to help ensure that our books and records, as
                                            well as our reports filed with the SEC, are accurate and complete;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">no
                                            employee, director or person acting under their direction, may coerce, manipulate, mislead
                                            or fraudulently influence our Finance and Accounting Personnel, our independent public accountants
                                            or counsel; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">no
                                            employee should knowingly make (or cause or encourage any other person to make) any false
                                            or misleading statement in any of our reports filed with the SEC or knowingly omit (or cause
                                            or encourage any other person to omit) any information necessary to make the disclosure in
                                            any of our reports accurate in all material respects.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Any
employee who becomes aware of any departure from these standards has a responsibility to report his or her knowledge promptly to a supervisor,
the Compliance Officer, the Audit Committee or one of the other compliance resources described in Section&nbsp;19 or in accordance with
the provisions of the Company&rsquo;s Open Door Policy for Reporting Violations and Complaints (the &ldquo;<B><I>Open Door Policy</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">10.
Fair Dealing</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
strive to outperform our competition fairly and honestly. Advantages over our competitors are to be obtained through superior performance
of our products and services, not through unethical or illegal business practices. Acquiring proprietary information from others through
improper means, possessing trade secret information that was improperly obtained, or inducing improper disclosure of confidential information
from past or present employees of other companies is prohibited, even if motivated by an intention to advance our interests. If information
is obtained by mistake that may constitute a trade secret or other confidential information of another business, or if you have any questions
about the legality of proposed information gathering, you must consult your supervisor or the Compliance Officer, as further described
in Section&nbsp;19.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">You
are expected to deal fairly with our customers, suppliers, employees and anyone else with whom you have contact in the course of performing
your job. Be aware that the Federal Trade Commission Act provides that &ldquo;unfair methods of competition in commerce, and unfair or
deceptive acts or practices in commerce, are declared unlawful.&rdquo; It is a violation of the Federal Trade Commission Act to engage
in deceptive, unfair or unethical practices and to make misrepresentations in connection with sales activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Employees
involved in procurement have a special responsibility to adhere to principles of fair competition in the purchase of products and services
by selecting suppliers based exclusively on normal commercial considerations, such as quality, cost, availability, service and reputation,
and not on the receipt of special favors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.
Gifts and Entertainment</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Business
gifts and entertainment are meant to create goodwill and sound working relationships and not to gain improper advantage with customers
or facilitate approvals from government officials. The exchange, as a normal business courtesy, of meals or entertainment (such as tickets
to a game or the theatre or a round of golf) is a common and acceptable practice as long as it is not extravagant. Unless express permission
is received from a supervisor, the Compliance Officer or the Nominating Committee, gifts and entertainment cannot be offered, provided
or accepted by any employee unless consistent with customary business practices and not (a)&nbsp;of more than token or nominal monetary
value, (b)&nbsp;in cash, (c)&nbsp;susceptible of being construed as a bribe or kickback, (d)&nbsp;made or received on a regular or frequent
basis or (e)&nbsp;in violation of any laws. This principle applies to our transactions everywhere in the world, even where the practice
is widely considered &ldquo;a way of doing business.&rdquo; Employees should not accept gifts or entertainment that may reasonably be
deemed to affect their judgment or actions in the performance of their duties. Our customers, suppliers and the public at large should
know that our employees&rsquo; judgment is not for sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Under
some statutes, such as the U.S.&nbsp;Foreign Corrupt Practices Act (further described in Section&nbsp;4 above), giving anything of value
to a government official to obtain or retain business or favorable treatment is a criminal act subject to prosecution and conviction.
Discuss with your supervisor or the Compliance Officer any proposed entertainment or gifts if you are uncertain about their appropriateness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">12.
Protection and Proper Use of Company Assets</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">All
employees are expected to protect our assets and ensure their efficient use. Theft, carelessness and waste have a direct impact on our
financial condition and results of operations. Our property, such as office supplies, computer equipment, laboratory or manufacturing
supplies, and office, laboratory or manufacturing space are expected to be used only for legitimate business purposes, although incidental
personal use may be permitted. You may not, however, use the Company&rsquo;s corporate name, any brand name or trademark owned or associated
with the Company or any letterhead stationery for any personal purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">You
may not, while acting on behalf of the Company or while using our computing or communications equipment or facilities, either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">access
                                            the internal computer system (also known as &ldquo;hacking&rdquo;) or other resource of another
                                            entity without express written authorization from the entity responsible for operating that
                                            resource; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">commit
                                            any unlawful or illegal act, including harassment, libel, fraud, sending of unsolicited bulk
                                            email (also known as &ldquo;spam&rdquo;) or material of objectionable content in violation
                                            of applicable law, trafficking in contraband of any kind or any kind of espionage.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">If
you receive authorization to access another entity&rsquo;s internal computer system or other resource, you must make a permanent record
of that authorization so that it may be retrieved for future reference, and you may not exceed the scope of that authorization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Unsolicited
bulk email is regulated by law in a number of jurisdictions. If you intend to send unsolicited bulk email to persons outside of the Company,
either while acting on our behalf or using our computing or communications equipment or facilities, you should contact your supervisor
or the Compliance Officer for prior approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">All
data residing on or transmitted through our computing and communications facilities, including email and word processing documents, is
the property of the Company and subject to inspection, retention and review by the Company, with or without an employee&rsquo;s or third
party&rsquo;s knowledge, consent or approval, in accordance with applicable law. Any misuse or suspected misuse of our assets must be
immediately reported to your supervisor or the Compliance Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.
Confidentiality</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">One
of our most important assets is our confidential information. As an employee of the Company, you may learn of information about the Company
that is confidential and proprietary. You also may learn of information before that information is released to the general public. Employees
who have received or have access to confidential information should take care to keep this information confidential. Confidential information
includes non-public information that might be of use to competitors or harmful to the Company or its customers if disclosed, such as
business plans, scientific and technical strategies, financial information, information related to the Company&rsquo;s research, testing
platforms and sequencing methods, data and results, designs, ideas, inventions and new developments and methods, works of authorship,
trade secrets, processes, protocols, conceptions, formulas, patents, patent applications, licenses, suppliers, manufacturers, raw material
and product specifications customers, market data, personnel data, personally identifiable information pertaining to our employees, customers
or other individuals (including, for example, names, addresses, telephone numbers and social security numbers), and similar types of
information provided to the Company by our customers, suppliers and partners. This information may be protected by patent, trademark,
copyright and trade secret laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
addition, because we interact with other companies and organizations, there may be times when you learn confidential information about
other companies before that information has been made available to the public. You must treat this information in the same manner as
you are required to treat our confidential and proprietary information. There may even be times when you must treat as confidential the
fact that we have an interest in, or are involved with, another company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">You
are expected to keep confidential and proprietary information confidential unless and until that information is released to the public
through approved channels (usually through a press release, an SEC filing or a formal communication from a member of senior management,
as further described in Section&nbsp;14). Every employee has a duty to refrain from disclosing to any person confidential or proprietary
information about the Company or any other company learned in the course of employment here, until that information is disclosed to the
public through approved channels. This policy requires you to refrain from discussing confidential or proprietary information with outsiders
and even with other employees of the Company, unless those fellow employees have a legitimate need to know the information in order to
perform their job duties. Unauthorized use or distribution of this information could also be illegal and result in civil liability and/or
criminal penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">You
should also take care not to inadvertently disclose confidential information. Materials that contain confidential information, such as
memos, notebooks, mobile devices, thumb drives or other data storage devices, and laptop computers, should be stored securely. Unauthorized
posting or discussion of any information concerning our business, information or prospects on the Internet is prohibited. You may not
discuss our business, information or prospects in any &ldquo;chat room,&rdquo; regardless of whether you use your own name or a pseudonym.
Be cautious when discussing sensitive information in public places like elevators, airports, restaurants and &ldquo;quasi-public&rdquo;
areas in and around our place of business. All Company emails, voicemails and other communications are presumed confidential and should
not be forwarded or otherwise disseminated outside of the Company except where required for legitimate business purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
addition to the above responsibilities, if you are handling information protected by any privacy policy published by us, such as our
website privacy policy, then you must handle that information in accordance with the applicable policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">14.
Media/Public Discussions</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">It
is our policy to disclose material information concerning the Company to the public only through specific limited channels to avoid inappropriate
publicity and to ensure that all those with an interest in the company will have equal access to information. All inquiries or calls
from the press and financial analysts should be referred to the Company&rsquo;s Chief Executive Officer (the &ldquo;<B><I>CEO</I></B>&rdquo;)
or Chief Financial Officer (the &ldquo;<B><I>CFO</I></B>&rdquo;). We have designated our CEO and CFO as our official spokespersons for
financial, scientific, clinical, technical and other related information. Unless a specific exception has been made by the CEO or CFO,
these designees are the only people who may communicate with the press on behalf of the Company. You also may not provide any information
to the media about the Company off the record, for background, confidentially or secretly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Board of Directors should not speak for the Company. Individual directors (other than the CEO or CFO, if applicable) wishing to communicate
with the media, current or potential future investors in the Company or any other constituency of the Company in any manner relating
to the Company must first seek approval for such communication from the chairperson of the Board of Directors or CEO and otherwise comply
with any corporate disclosure or communication policy that may be adopted by the Company (except in those rare cases when a member of
a committee of the Board of Directors may be required to communicate with a third party without the knowledge of any of such persons,
as may be advised by counsel).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Please
also refer to the Company&rsquo;s Disclosure and Regulation FD Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">15.
Political Activities and Contributions</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
encourage our team members, officers, and directors to contribute to the community and to fully participate in local, national, and international
political processes. However, business contributions to political campaigns are strictly regulated by federal, state, local, and foreign
law in the United States and other jurisdictions. Accordingly, there are certain ethical guidelines for doing so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">As
a private citizen, you are free to make contributions to causes, candidates, or political parties of your choice. If you express a personal
view in a public forum (such as social media posts), do not use the Company&rsquo;s letterhead or Company e-mail. Team members should
avoid activities such as campaigning for an elected official while on duty. All lobbying activities, including the retention of outside
lobbyists, must be pre-cleared through the Compliance Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company will comply with all relevant laws regulating its participation in political affairs, including political contributions. All
political contributions proposed to be made with the Company&rsquo;s funds must be coordinated through and approved by the Compliance
Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">16.
Charitable Contributions</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company supports community development throughout the world. Company team members may contribute to these efforts, or may choose to contribute
to organizations of their own choice. However, as with political activities, you may not use Company resources to personally support
charitable or other non-profit institutions not specifically sanctioned or supported by the Company. You should consult with the Compliance
Officer if you have questions about permissible use of Company resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">17.
Human Rights</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company is committed to upholding fundamental human rights and believe that all human beings around the world should be treated with
dignity, fairness, and respect. The Company will only engage suppliers and direct contractors who demonstrate a serious commitment to
the health and safety of their workers, and operate in compliance with human rights laws. The Company does not use or condone the use
of slave labor or human trafficking, denounces any degrading treatment of individuals or unsafe working condition and supports our products
being free of conflict minerals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">18.
Waivers</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Any
waiver of this Code for executive officers (including, where required by applicable laws, our principal executive officer, principal
financial officer, principal accounting officer or controller (or persons performing similar functions)) or directors may be authorized
only by our Board of Directors or, to the extent permitted by the rules of The Nasdaq Stock Market LLC (&ldquo;<B><I>Nasdaq</I></B>&rdquo;)
and our Corporate Governance Guidelines, a committee of the Board of Directors, and will be disclosed as required by applicable laws,
rules and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">19.
Compliance Standards and Procedures</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">Compliance Resources</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">To
facilitate compliance with this Code, we have implemented a program of Code awareness, training and review. We have appointed our Chief
Financial Officer to the position of Compliance Officer to oversee this program. In the future, we may appoint another senior officer
as the Compliance Officer. The Compliance Officer can be reached at jmahal@jaspertherapeutics.com. The Compliance Officer is a person
to whom you can address any questions or concerns. In addition to fielding questions or concerns with respect to potential violations
of this Code, the Compliance Officer is responsible for:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">investigating
                                            possible violations of this Code;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">training
                                            new employees in Code policies;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">conducting
                                            training sessions to refresh employees&rsquo; familiarity with this Code;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">distributing
                                            copies of this Code from time to time via email and the Company&rsquo;s secure internal human
                                            resources website to each employee with a reminder that each employee is responsible for
                                            reading, understanding and complying with this Code;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">updating
                                            this Code as needed and alerting employees to any updates, with appropriate approval of the
                                            Board of Directors or Nominating Committee, as appropriate, to reflect changes in the law,
                                            Company operations and recognized best practices, and to reflect the Company&rsquo;s experience;
                                            and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">otherwise
                                            promoting an atmosphere of responsible and ethical conduct.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Your
most immediate resource for any matter related to this Code is your supervisor. He or she may have the information you need or may be
able to refer the question to another appropriate source. There may, however, be times when you prefer not to go to your supervisor.
In these instances, you should feel free to discuss your concern with the Compliance Officer. If you are uncomfortable speaking with
the Compliance Officer because he or she works in your department or is one of your supervisors, please contact the CFO. Of course, if
your concern involves potential misconduct by another person and relates to questionable accounting or auditing matters under the Company&rsquo;s
Open Door Policy, you may report that violation as set forth in such policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
Company established a toll-free hotline at&nbsp;1-866-561-0928 and a website address at
https://www.whistleblowerservices.com/jaspertherapeutics for those who wish to ask questions about Company policy, seek guidance on
specific situations or report violations of this Code. You may call the toll-free number or submit reports through the website
anonymously, although if you do so, the Compliance Officer will be unable to obtain follow-up details from you that may be necessary
to investigate the matter. Whether you identify yourself or remain anonymous, your telephonic or email contact with the Compliance
Officer will be kept strictly confidential to the extent reasonably possible within the objectives of this Code, and subject to
applicable law, regulations or legal proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Clarifying Questions and Concerns;
Reporting Possible Violations</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">If
you encounter a situation or are considering a course of action and its appropriateness is unclear, discuss the matter promptly with
your supervisor or the Compliance Officer; even the appearance of impropriety can be very damaging and should be avoided.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">If
you are aware of a suspected or actual violation of Code standards by others, you have a responsibility to report it. You are expected
to promptly provide a compliance resource with a specific description of the violation that you believe has occurred, including any information
you have about the persons involved and the time of the violation. Whether you choose to speak with your supervisor or the Compliance
Officer, you should do so without fear of any form of retaliation. We will take prompt disciplinary action against any employee who retaliates
against you, including termination of employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Supervisors
must promptly report any complaints or observations of Code violations to the Compliance Officer. If you believe your supervisor has
not taken appropriate action, you should contact the Compliance Officer directly. The Compliance Officer will investigate all reported
possible Code violations promptly and with the highest degree of confidentiality that is possible under the specific circumstances. Neither
you nor your supervisor may conduct any preliminary investigation, unless authorized to do so by the Compliance Officer. Your cooperation
in the investigation will be expected. As needed, the Compliance Officer will consult with legal counsel, the Human Resources department
and/or Nominating Committee. It is our policy to employ a fair process by which to determine violations of this Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">With
respect to any complaints or observations of violations that may involve accounting, internal accounting controls and auditing concerns,
under the Company&rsquo;s Open Door Policy, the Compliance Officer shall promptly inform the Audit Committee, and the Audit Committee
shall be responsible for supervising and overseeing the inquiry and any investigation that is undertaken. If a potential violation is
reported via the confidential hotline or email address as provided under the Open Door Policy, the Audit Committee will be notified automatically
and directly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">If
any investigation indicates that a violation of this Code has probably occurred, we will take such action as we believe to be appropriate
under the circumstances. If we determine that an employee is responsible for a Code violation, he or she will be subject to disciplinary
action up to, and including, termination of employment and, in appropriate cases, civil action or referral for criminal prosecution.
Appropriate action may also be taken to deter any future Code violations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.
No Rights Created</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
Code is a statement of certain fundamental principles, policies and procedures that is intended to govern the conduct of the Company&rsquo;s
business. It is not intended to and does not create any rights in any employee, customer, client, visitor, supplier, competitor, stockholder
or any other person or entity. Nothing in this Code creates or implies an employment contract or term of employment, or limits either
the Company&rsquo;s or employee&rsquo;s right to terminate employment at any time for any reason. No employee of the Company except the
Chief Executive Officer has any authority to enter into any agreement for employment for a specified period of time or to make any agreement
or representation contrary to the Company&rsquo;s policy of at-will employment, and any such agreement or representation must be in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">21.
Changes; Review</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company is committed to continuously reviewing and updating its policies and procedures. Subject to applicable rules and regulations
of the SEC and Nasdaq, the Company reserves the right to amend or terminate this Code at any time and for any reason. Any changes to
this Code will be effective upon approval by the Board of Directors. The Nominating Committee will review and reassess the adequacy of
this Code from time to time, and recommend to the Board of Directors any changes the Nominating Committee determines are appropriate.
All changes must be promptly disclosed as required by law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">22.
Website Disclosure</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
Code, as may be amended from time to time, shall be posted on the Company&rsquo;s website. The Company shall state in its annual meeting
of stockholders proxy statement that this Code is available on the Company&rsquo;s website and provide the website address as required
by law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.45pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Adopted
on September 24, 2021</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I>Effective on September 24, 2021</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Exhibit A</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">JASPER THERAPEUTICS,
INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">CODE OF BUSINESS
CONDUCT AND ETHICS ACKNOWLEDGMENT<BR>
&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">I
hereby acknowledge that I have received, read, understand and will comply with Jasper Therapeutics, Inc.&rsquo;s Code of Business Conduct
and Ethics (the &ldquo;<B><I>Code</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">I
will seek guidance from and raise concerns about possible violations of this Code with my supervisor, management and Jasper Therapeutics,
Inc.&rsquo;s Compliance Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">I
understand that my agreement to comply with this Code does not constitute a contract of employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please sign
    here:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"></TD>
    <TD STYLE="width: 39%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt"><B>This signed and completed
form must be returned to Jasper Therapeutics, Inc.&rsquo;s Compliance Officer within ten business days of receiving this Code.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A-1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-16.1
<SEQUENCE>14
<FILENAME>ea147929ex16-1_jasper.htm
<DESCRIPTION>LETTERTO SEC FROM WITHUMSMITH+BROWN, PC
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exhibit 16.1</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 29, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Office of the Chief Accountant</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 F Street, NE Washington, D.C. 20549</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have read Jasper Therapeutics, Inc.&rsquo;s (formerly known as Amplitude Healthcare Acquisition Corporation) statements included under Item 4.01 of its Form 8-K dated
September 29, 2021. We agree with the statements concerning our Firm under Item 4.01, in which we were informed of our dismissal on
September 24, 2021. We are not in a position to agree or disagree with other statements contained therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ WithumSmith+Brown, PC</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>15
<FILENAME>ea147929ex21-1_jasper.htm
<DESCRIPTION>LIST OF SUBSIDIARIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21.1&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>List
of Subsidiaries</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jasper
Tx Corp., a Delaware corporation</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>16
<FILENAME>ea147929ex99-1_jasper.htm
<DESCRIPTION>PRESS RELEASE, DATED SEPTEMBER 24, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0in 0in"><IMG SRC="ex99-1_001.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jasper
Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated
to Enabling Cures Through Hematopoietic Stem Cell Therapy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
24, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Combined
company expected to begin trading on the Nasdaq Global Select Market under &ldquo;JSPR&rdquo; and &ldquo;JSPRW&rdquo; on or about September
27, 2021 </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REDWOOD
CITY, Calif.--(BUSINESS WIRE)--Jasper Therapeutics, Inc., a biotechnology company focused
on hematopoietic cell transplant therapies, today announced the completion of its business combination with Amplitude Healthcare Acquisition
Corporation (Nasdaq:AMHC), a special purpose acquisition company sponsored by affiliates of Avego Management, LLC and Metalmark Capital.
The business combination closed on September 24, 2021. Following the closing, the combined company will operate as Jasper Therapeutics,
Inc. and, on or about September 27, 2021, its shares of voting common stock and warrants are expected to begin trading on the Nasdaq
Global Select Market under the ticker symbol &ldquo;JSPR&rdquo; and &ldquo;JSPRW,&rdquo; respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The
completion of our merger and companion PIPE transaction allows Jasper to debut as a public company with greater than $100 million in
new capital proceeds to advance the clinical development of JSP191, our first-in-class anti-CD117 monoclonal antibody in development
as a targeted, non-toxic conditioning agent, and our novel mRNA engineered hematopoietic stem cell platform through significant milestones
in 2022 and into 2023,&rdquo; said Mr. Jeet Mahal, Chief Financial Officer of Jasper. &ldquo;Allogeneic hematopoietic stem cell transplant
and autologous stem cell gene therapies can cure patients with a number of life-threatening diseases but the limitations of current transplant
technologies include the use of toxic agents for conditioning that are needed prior to transplant and the failure of stem cells to survive
when engrafted. We believe that JSP191 and our mRNA engineered stem cell platform are well positioned to address these limitations, and
to transform and expand the use of lifesaving, and potentially curative hematopoietic stem cell transplants.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Jasper
continues to make strong progress advancing the development of JSP191 through its internal and partnered programs,&rdquo; said Vishal
Kapoor, President of Amplitude. &ldquo;We believe Jasper is uniquely positioned with both JSP191 and its mRNA engineered stem cell platform,
which have great potential individually and in combination.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
business combination was approved by Amplitude&rsquo;s stockholders at its special shareholder&rsquo;s meeting on September 22, 2021,
along with all other proposals presented at the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Advisors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
Suisse acted as lead PIPE placement agent and as capital markets advisor to Jasper Therapeutics, William Blair acted as co-placement
agent and financial advisor, and Cantor Fitzgerald acted as co-placement agent. Paul Hastings LLP served as legal counsel to Jasper Therapeutics.
BMO Capital Markets and Oppenheimer &amp; Co. Inc. acted as capital markets advisors to Amplitude. Wilmer Cutler Pickering Hale and Dorr
LLP served as legal counsel to Amplitude.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Jasper Therapeutics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jasper
Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic
stem cell. The company is advancing two potentially groundbreaking programs. JSP191, an anti-CD117 monoclonal antibody, is in clinical
development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell
transplantation. It is designed to enable safer and more effective curative allogeneic hematopoietic cell transplants and gene therapies.
In parallel, Jasper Therapeutics is advancing its preclinical mRNA engineered hematopoietic stem cell (eHSC) platform, which is designed
to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Both innovative programs have the potential to
transform the field and expand hematopoietic stem cell therapy cures to a greater number of patients with life-threatening cancers, genetic
diseases and autoimmune diseases than is possible today. For more information, please visit us at jaspertherapeutics.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor
provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied
by words such as &ldquo;believe,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;intend,&rdquo; &ldquo;expect,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;plan,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential,&rdquo;
&ldquo;seem,&rdquo; &ldquo;seek,&rdquo; &ldquo;future,&rdquo; &ldquo;outlook&rdquo; and similar expressions that predict or indicate
future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited
to, statements the proposed business combination between AMHC and Jasper Therapeutics, the estimated or anticipated future results and
benefits of the combined company following the business combination, including Jasper Therapeutics&rsquo; business strategy, expected
cash resources of the combined company and the expected uses thereof, current and prospective product candidates, planned clinical trials
and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and
the related market opportunity. These statements are based on various assumptions, whether or not identified in this press release, and
on the current expectations of the respective management teams of Jasper Therapeutics and AMHC and are not predictions of actual performance.
These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied
on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances
are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control
of Jasper Therapeutics and AMHC. These forward-looking statements are subject to a number of risks and uncertainties, including general
economic, political and business conditions the outcome of any legal proceedings that may be instituted against the parties regarding
the Business Combination; the risk that the potential product candidates that Jasper Therapeutics develops may not progress through clinical
development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the
regulatory pathway for Jasper Therapeutics&rsquo; product candidates; the risk that clinical trials may not confirm any safety, potency
or other product characteristics described or assumed in this press release; the risk that Jasper Therapeutics will be unable to successfully
market or gain market acceptance of its product candidates; the risk that Jasper Therapeutics&rsquo; product candidates may not be beneficial
to patients or successfully commercialized; the risk that Jasper Therapeutics has overestimated the size of the target patient population,
their willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on
Jasper Therapeutics&rsquo; business; the risk that third parties on which Jasper Therapeutics depends for laboratory, clinical development,
manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper Therapeutics&rsquo; business, operations,
clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics, including
the ongoing COVID-19 pandemic; the risk that Jasper Therapeutics will be unable to obtain and maintain sufficient intellectual property
protection for its investigational products or will infringe the intellectual property protection of others; the potential inability
of the parties to successfully or timely consummate the proposed transaction; the risk of failure to realize the anticipated benefits
of the proposed transaction and other risks and uncertainties indicated from time to time in AMHC&rsquo;s public filings, including its
most recent Annual Report on Form 10-K for the year ended December 31, 2020 and the proxy statement/prospectus relating to the proposed
transaction, including those under &ldquo;Risk Factors&rdquo; therein, and in AMHC&rsquo;s other filings with the SEC. If any of these
risks materialize or AMHC&rsquo;s and Jasper Therapeutics&rsquo; assumptions prove incorrect, actual results could differ materially
from the results implied by these forward-looking statements. There may be additional risks that neither AMHC nor Jasper Therapeutics
presently know, or that AMHC or Jasper Therapeutics currently believe are immaterial, that could also cause actual results to differ
from those contained in the forward-looking statements. In addition, forward-looking statements reflect AMHC&rsquo;s and Jasper Therapeutics&rsquo;
expectations, plans or forecasts of future events and views as of the date of this press release. AMHC and Jasper Therapeutics anticipate
that subsequent events and developments will cause AMHC&rsquo;s and Jasper Therapeutics&rsquo; assessments to change. However, while
AMHC and Jasper Therapeutics may elect to update these forward-looking statements at some point in the future, AMHC and Jasper Therapeutics
specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing AMHC&rsquo;s
and Jasper Therapeutics&rsquo; assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should
not be placed upon the forward-looking statements.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
Mullaly (investors)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeSci
Advisors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">617-429-3548</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jmullaly@lifesciadvisors.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lily
Eng (media)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Real
Chemistry</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">206-661-8627</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">leng@realchemistry.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeet
Mahal (investors)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jasper
Therapeutics</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">650-549-1403</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jmahal@jaspertherapeutics.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>17
<FILENAME>ea147929ex99-2_jasper.htm
<DESCRIPTION>UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION OF THE COMPANY AS OF AND FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND FOR THE YEAR DECEMBER 31, 2020
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
99.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>UNAUDITED
PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Defined
terms used but not defined in this Exhibit 99.2 shall have the meanings ascribed to them in the Current Report on Form 8-K (the &ldquo;<U>Form
8-K</U>&rdquo;) to which this Exhibit 99.2 is filed as an exhibit and, if not defined in the Form 8-K, the Definitive Proxy Statement.</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following unaudited pro forma condensed combined financial information has been prepared in accordance with Regulation S-X Article 11,
Pro Forma Financial Information, as amended by the final rule, Release No. 33-10786, and presents the combination of the historical financial
information of AMHC and Jasper adjusted to give effect to the Business Combination and the other events contemplated by the Business
Combination Agreement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
unaudited pro forma condensed combined balance sheet as of June 30, 2021 combines the historical unaudited condensed balance sheet of
AMHC as of June 30, 2021 and the historical unaudited condensed balance sheet of Jasper as of June 30, 2021 on a pro forma basis as if
the Business Combination and the other events contemplated by the Business Combination Agreement, summarized below, had been consummated
on June 30, 2021.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
unaudited pro forma condensed combined statement of operations for the six months ended June 30, 2021 combines the historical unaudited
condensed statement of operations of AMHC for the six months ended June 30, 2021 and the historical unaudited condensed statement of
operations of Jasper for the six months ended June 30, 2021. The unaudited pro forma condensed combined statement of operations for the
year ended December 31, 2020 combines the historical audited statement of operations of AMHC for the year ended December 31, 2020, as
restated, and historical audited statement of operations of Jasper for the year ended December 31, 2020 on a pro forma basis as if the
Business Combination and the other events contemplated by the Business Combination Agreement, as summarized below, had been consummated
on January 1, 2020.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
unaudited pro forma condensed combined financial statements have been derived from and should be read in conjunction with:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            accompanying notes to the unaudited pro forma condensed combined financial statements;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            (a) historical audited financial statements of AMHC as of and for the year ended December
                                            31, 2020, as restated, and (b) historical unaudited condensed financial statements of AMHC
                                            as of and for the six months ended June 30, 2021;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            (a) historical audited financial statements of Jasper as of and for the year ended December
                                            31, 2020 and (b) historical unaudited condensed financial statements of Jasper as of and
                                            for the six months ended June 30, 2021; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">other
                                            information relating to AMHC and Jasper included in the Form 8-K or the Definitive Proxy
                                            Statement, including the Business Combination Agreement and the description of certain terms
                                            thereof set forth under the sections of the Definitive Proxy Statement entitled <I>&ldquo;Business
                                            Combination Proposal&rdquo;</I>, &ldquo;<I>AMHC&rsquo;s Management&rsquo;s Discussion and
                                            Analysis of Financial Condition and Results of Operations&rdquo; </I>and <I>&ldquo;Jasper&rsquo;s
                                            Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</I>&rdquo;
                                            beginning on pages 102, 184 and 219 of the Definitive Proxy Statement, respectively.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
unaudited pro forma condensed combined financial statements also reflect the closing of the $100.0 million PIPE Investment and the redemption
of an aggregate of 9,262,099 shares of AMHC Class A Common Stock for aggregate payments of $92.7 million.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">AMHC
and Jasper are collectively referred to herein as the &ldquo;Companies,&rdquo; and the Companies, subsequent to the Business Combination
and the other events contemplated by the Business Combination Agreement, are referred to herein as New Jasper.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
unaudited pro forma condensed combined financial statements are provided for illustrative purposes only and are not necessarily indicative
of what the actual results of operations and financial position would have been had the Business Combination and the other events taken
place on the dates indicated, nor are they indicative of the future results of operations or financial position of New Jasper. The actual
financial position and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of
factors. The unaudited pro forma adjustments represent management&rsquo;s estimates based on information available as of the date of
these unaudited pro forma combined financial statements and are subject to change as additional information becomes available and analyses
are performed.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
September 24, 2021, New Jasper consummated the previously announced Business Combination pursuant to Business Combination Agreement,
under the terms of which a wholly-owned subsidiary of AMHC merged with and into Jasper, with Jasper becoming a wholly-owned subsidiary
of AMHC, referred to herein as New Jasper, which became a publicly-listed entity. As a result of the Business Combination, New Jasper
owns, directly or indirectly, all of the issued and outstanding equity interests of Jasper and the former Jasper equity holders hold
a portion of the New Jasper Common Stock.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>UNAUDITED
PRO FORMA CONDENSED COMBINED BALANCE SHEET<BR>
AS OF JUNE 30, 2021<BR>
(in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">AMHC<BR>
 (Historical)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Jasper<BR>
 (Historical)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Transaction<BR>
 Accounting<BR>
 Adjustments<BR>
 (Business<BR>
 Combination)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Notes</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Pro&nbsp;Forma<BR>
 Combined</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 53%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">310</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">16,757</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">100,126</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 6%; font-weight: bold; text-align: center">A</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">108,416</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,377</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">B</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(329</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">C</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,925</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">D</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,444</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">E</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(92,702</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">F</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">I</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Prepaid income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">103</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,216</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,319</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">423</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,973</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,349</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">109,745</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Marketable securities held in Trust Account</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,126</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(100,126</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">A</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,832</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,832</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating lease right-of-use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,215</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,215</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">345</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">345</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other non-current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,726</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,726</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">E</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total Assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100,549</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">26,091</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(12,503</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">114,137</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">329</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,612</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(329</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">C</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,943</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,669</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">E</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current portion of operating lease liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">424</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">424</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Accrued expenses and other current liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,117</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(388</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">E</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,729</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">329</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,153</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,386</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,096</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred underwriting fee payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,500</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">D</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Non-current portion of operating lease liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,642</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,642</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,430</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,680</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">J</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Earnout liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,599</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">K</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,599</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other non-current liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">648</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">648</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,259</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,443</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,967</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,735</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">AMHC Class A common stock subject to possible redemption, 8,129,010 shares as of June 30, 2021 (at $10.00 per share)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81,290</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(81,290</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">F</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Jasper redeemable convertible preferred stock: $0.001 par value &mdash; 69,136,757 shares authorized and 69,136,742 shares issued and outstanding as of June 30, 2021, liquidation value $51,915 as of June 30, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,249</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(66,249</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">G</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Stockholder&rsquo;s Equity (Deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">AMHC Preferred stock, $0.0001 par value; 1,000,000 shares authorized, none issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">New Jasper Preferred stock, $0.0001 par value; 10,000,000 shares authorized, none issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">New Jasper Common Stock - Voting: $0.0001 par value - 490,000,000 shares authorized and 36,520,288 shares to be issued and outstanding as of June 30, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">I</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">L</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">M</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">New Jasper Common Stock - Nonvoting: $0.0001 par value - 2,000,000 shares authorized and 1,296,022 shares to be issued and outstanding as of June 30, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">L</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Jasper Common Stock: $0.001 par value &mdash; 177,841,414 shares authorized and 10,160,967 shares issued and outstanding as of June 30, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">G</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(79</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">L</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">AMHC Class A common stock, $0.0001 par value; 100,000,000 shares authorized; 1,870,990 issued and outstanding as of June 30, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;F</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;H</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;M</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">AMHC Class B common stock, $0.0001 par value; 10,000,000 shares authorized; 2,500,000 issued and outstanding as of June 30, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">H</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,148</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,370</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,377</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">B</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">145,379</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">D</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,113</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">E</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,412</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">F</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,180</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">G</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99,999</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">I</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,680</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">J</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,599</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">K</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">L</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,148</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">N</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,148</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(54,981</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,148</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">N</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(54,981</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total stockholders&rsquo; Equity (Deficit)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(52,601</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">138,003</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">90,402</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total liabilities, Class A common stock subject to redemption, redeemable convertible preferred stock and stockholders&rsquo; equity (deficit)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100,549</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">26,091</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(12,503</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">114,137</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>UNAUDITED
PRO FORMA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CONDENSED
COMBINED STATEMENTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FOR
THE SIX MONTHS ENDED JUNE 30, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(in
thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">AMHC<BR> (Historical)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Jasper<BR>
 (Historical)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Transaction<BR> Accounting<BR> Adjustments (Business<BR>
 Combination)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Notes</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Pro Forma<BR>
 Combined</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 53%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">9,576</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: center">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">9,576</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">776</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,096</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,872</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">776</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,672</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,448</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(776</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14,672</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,448</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest and other (expense) income, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest earned on marketable securities held in Trust Account</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">AA</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Change in fair value of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,200</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">CC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Change in fair value of derivative liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,501</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,501</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">DD</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total other income (expense), net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,705</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,496</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,296</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,505</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Provision for income taxes</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss and comprehensive loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,929</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(18,168</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,296</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(13,943</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss per share attributable to common stockholders, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2.51</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.39</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Weighted average shares outstanding of Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,235,862</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,154,492</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Earnings Allocable to Redeemable Class A Common Stock (Redeemable Net Earnings)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average shares outstanding of Class A Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Basic and diluted net loss per share- Class A</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net (Loss) Income minus Redeemable Net Earnings (Non-Redeemable Net Loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,929</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average shares outstanding of Class B Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Basic and diluted net loss per share- Class B</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.77</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>UNAUDITED
PRO FORMA </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CONDENSED
COMBINED STATEMENT OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FOR
THE YEAR ENDED DECEMBER 31, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(in
thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">AMHC<BR> (Historical) <BR> (as Restated)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Jasper<BR>
 (Historical)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Transaction<BR> Accounting<BR> Adjustments (Business Combination)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Notes</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma<BR>
 Combined</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; width: 53%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">15,883</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: center">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">15,883</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">935</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,800</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,735</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">935</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,683</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,618</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(935</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,683</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(21,618</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Interest and other (expense) income, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(111</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(111</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Interest earned on marketable securities held in Trust Account</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">383</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(383</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">AA</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Change in fair value of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,890</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,640</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">CC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,250</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Change in fair value of derivative liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,875</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,875</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">DD</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Total other income (expense), net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,507</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,986</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13,132</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,361</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">(Loss) income before provision for income taxes</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,442</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(31,669</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13,132</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(24,979</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Provision for income taxes</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(39</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">39</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">BB</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Net loss and comprehensive loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(6,481</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(31,669</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">13,171</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(24,979</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss per share attributable to common stockholders,<BR> &nbsp;&nbsp;&nbsp;basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(5.17</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.69</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">Weighted average shares outstanding of Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,125,897</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,154,492</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Earnings Allocable to Redeemable Class A Common Stock
    (Redeemable Net Earnings)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">145</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">Weighted average shares outstanding of Class A Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Basic and diluted net loss per share- Class A</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.01</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net (Loss) Income minus Redeemable Net Earnings (Non-Redeemable Net Loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(6,625</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">Weighted average shares outstanding of Class B Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Basic and diluted net loss per share- Class B</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2.65</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Note 1
&mdash; Description of the Business Combination</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
September 24, 2021, New Jasper consummated the previously announced Business Combination pursuant to the Business Combination Agreement.
Pursuant to the Business Combination Agreement, Merger Sub, a wholly owned subsidiary of AMHC, merged with and into Jasper, with Jasper
being the surviving entity. Jasper became a wholly owned subsidiary of AMHC and AMHC was immediately renamed to &ldquo;Jasper Therapeutics,
Inc.&rdquo;. The Business Combination consideration received by former stockholders of Jasper at the Closing of the Business Combination
pursuant to the Business Combination Agreement had an agreed upon value of $275.0 million (the &ldquo;Equity Value&rdquo;). Pursuant
to the Business Combination Agreement, Transaction Share Consideration means a number of AMHC Shares equal to (a) Jasper&rsquo;s Equity
Value, divided by (b) the AMHC Share Value, or $10.00. New Jasper Common Stock is comprised of New Jasper Voting Common Stock and New
Jasper Non-Voting Common Stock. The former stockholders of Jasper, including holders of common stock, founders&rsquo; unvested restricted
common stock, preferred stock and stock options, received a deemed value of $10.00 per share after giving effect to the Exchange Ratio
of 0.2823780 at the Closing. </FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Business Combination occurred in the following steps as contemplated by the Business Combination Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            conversion of all outstanding shares of Jasper Series A-1 redeemable convertible preferred
                                            stock into shares of Jasper Class A Common Stock at the one-to-one conversion ratio, pursuant
                                            to the consent of the majority of Jasper Series A-1 Stockholders, immediately prior to the
                                            Closing of the Business Combination;</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            cancellation of each issued and outstanding share of Jasper Class A Common Stock (including
                                            shares of Jasper Class A Common Stock resulting from the conversion of Jasper&rsquo;s Series
                                            A-1 redeemable convertible preferred stock) and the conversion into the right to receive
                                            a number of shares New Jasper Voting Common Stock or New Jasper Non-Voting Common Stock at
                                            the Exchange Ratio as set forth in the Allocation Schedule;</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            conversion of all outstanding shares of Jasper Series A-2 redeemable convertible preferred
                                            stock into shares of New Jasper Voting Common stock, which was calculated as 8% of the Equity
                                            Value divided by $10.00 per share or 2,200,000 shares of New Jasper Voting Common Stock;</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            conversion of all outstanding Jasper Class A Common Stock options into options exercisable
                                            for shares of New Jasper Voting Common Stock with the same terms except for the number of
                                            shares exercisable and the exercise price, each of which will be adjusted at the Exchange
                                            Ratio as set forth in the Allocation Schedule. The conversion of Jasper options did not have
                                            an impact on the pro-forma condensed combined unaudited financial statements;</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            conversion of all outstanding shares of Jasper&rsquo;s founders&rsquo; unvested Jasper Class
                                            A Common Stock into restricted common stock shares of New Jasper Voting Common Stock based
                                            on the Exchange Ratio as set forth in the Allocation Schedule, which shares continue to be
                                            governed by the same terms and conditions (including vesting and repurchase terms) effective
                                            immediately prior to the Closing of the Business Combination;</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            redemption of an aggregate of 9,262,099 shares of AMHC Class A Common Stock at a price of
                                            $10.0088193 per share for aggregate payments of $92.7 million prior to the Closing and the
                                            conversion of 737,901 remaining outstanding shares of AMHC Class A Common Stock shares into
                                            New Jasper Voting Common Stock</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            conversion of all outstanding shares of AMHC Class A Common Stock and AMHC Public Warrants
                                            into New Jasper Voting Common Stock and New Jasper Public Voting Common Stock Warrants and
                                            the cancellation of the outstanding AMHC Private Placement Warrants;</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            forfeiture of 200,000 shares of AMHC Class B Common Stock by the Sponsor immediately prior
                                            to the Closing and the conversion of 2,300,000 outstanding shares of AMHC Class B Common
                                            Stock held by the Sponsor into 2,300,000 shares of AMHC Class A Common Stock, which were
                                            then converted into New Jasper Voting Common Stock, and the placement of 1,050,000 of these
                                            shares of New Jasper Voting Common Stock in escrow pursuant to the Sponsor Support Agreement,
                                            as a amended, of which:</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">250,000
                                            shares placed in escrow are restricted subject to certain vesting conditions and will be
                                            released if, during the period from and after the Closing until the third anniversary of
                                            the Closing (the &ldquo;Earnout Period&rdquo;), over 20 trading days within any 30 day consecutive
                                            trading day period, the volume-weighted average purchase price of the New Jasper Voting Common
                                            Stock (the &ldquo;Applicable VWAP&rdquo;) is greater than or equal to $11.50;</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">500,000
                                            shares placed in escrow are restricted subject to certain vesting conditions and will be
                                            released if, during the Earnout Period, over 20 trading days within any 30 day consecutive
                                            trading day period, the Applicable VWAP is greater than or equal to $15.00 and</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">300,000
                                            shares placed in escrow are restricted subject to certain vesting conditions and will be
                                            released if, during the Earnout Period, over 20 trading days within any 30 day consecutive
                                            trading day period, the Applicable VWAP is greater than or equal to $18.00.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Other
Events in Connection with the Business Combination</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
connection with the Business Combination, AMHC issued and sold to the PIPE Investors an aggregate of 10,000,000 shares of AMHC Class
A Common Stock at a price of $10.00 per share, for aggregate gross proceeds of $100,000,000. The 10,000,000 shares of AMHC Class A Common
Stock were subsequently converted into 10,000,000 shares of New Jasper Voting Common Stock at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Accounting
for the Business Combination</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
the legal form of the Business Combination, pursuant to the Business Combination Agreement, the Business Combination will be accounted
for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, AMHC will be treated as the acquired company
and Jasper will be treated as the acquirer for financial reporting purposes. Accordingly, for accounting purposes, the financial statements
of New Jasper will represent a continuation of the financial statements of Jasper, with the Business Combination treated as the equivalent
of Jasper issuing stock for the net assets of AMHC, accompanied by a recapitalization. The net assets of AMHC will be stated at historical
cost, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination will be those of Jasper.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jasper
has been determined to be the accounting acquirer based on an evaluation of the following facts and circumstances:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jasper&rsquo;s
                                            existing stockholders have a majority of the voting power in New Jasper;</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            New Jasper Board consists of six directors, five of whom were designated by Jasper and one
                                            of whom was designated by AMHC;</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jasper&rsquo;s
                                            existing senior management team comprises the senior management of New Jasper; and</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jasper&rsquo;s
                                            operations prior to the Business Combination comprise the ongoing operations of New Jasper.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following summarizes the number of shares of New Jasper Common Stock outstanding following the consummation of the Business Combination
and the PIPE Investment:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Shareholder<BR> (shares outstanding as of September 24, 2021):</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Former AMHC Class A shareholders (1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">737,901</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2.0</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">PIPE Investors (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26.4</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">AMHC Sponsor Promote (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,300,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.1</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Former Jasper Stockholder (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,296,022</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.4</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Former Jasper Stockholders (5)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">23,482,387</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">62.1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">37,816,310</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount
                                            excludes warrants to purchase 5,000,000 shares of New Jasper Voting Common Stock that are
                                            outstanding post-Closing of the Business Combination.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount
                                            includes 2,715,000 shares of New Jasper Voting Common Stock purchased by former stockholders
                                            of Jasper and 2,835,000 shares of New Jasper Voting Common Stock purchased by the Sponsor
                                            and certain of AMHC&rsquo;s officers and directors.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective
                                            as of immediately prior to the Closing, the Sponsor forfeited 200,000 shares of Class B Common
                                            Stock. All of the shares of AMHC Class B Common Stock were then converted into shares of
                                            the AMHC Class A Common Stock and then into 2,300,000 shares of New Jasper Voting Common
                                            Stock at the Closing. Amount includes 250,000 shares of New Jasper Voting Common Stock subject
                                            to forfeiture if the Applicable VWAP per share of New Jasper Voting Common Stock does not
                                            achieve $11.50 for twenty trading days within any thirty consecutive trading day period during
                                            the Earnout Period, 500,000 shares of New Jasper Voting Common Stock subject to forfeiture
                                            if the Applicable VWAP per share of New Jasper Voting Common Stock does not achieve $15.00
                                            for twenty trading days within any thirty consecutive trading day period during the Earnout
                                            Period and an additional 300,000 shares of New Jasper Voting Common Stock subject to forfeiture
                                            if the Applicable VWAP per share of New Jasper Voting Common Stock does not achieve $18.00
                                            for twenty trading days within any thirty consecutive trading day period during the Earnout
                                            Period.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount
                                            represents 1,296,022 shares of New Jasper Non-Voting Common Stock issued to one of Jasper&rsquo;s
                                            former stockholders.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount
                                            includes 611,818 shares of New Jasper Voting Common Stock subject to repurchase related to
                                            the conversion of all outstanding shares of Jasper&rsquo;s founders&rsquo; unvested common
                                            stock; 2,200,000 shares of New Jasper Voting Common Stock issued to Jasper&rsquo;s Series
                                            A-2 Stockholder; and excludes New Jasper options to purchase 2,721,557 shares of New Jasper
                                            Voting Common Stock.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table illustrates the conversion of Jasper Common Stock, Jasper Series A-1 Preferred Stock and Jasper Series A-2 Preferred
Stock into New Jasper Common Stock. Immediately prior to the Closing of the Business Combination, all outstanding shares of Jasper Series
A-1 Preferred Stock were converted into Jasper Common Stock at a one-to-one conversion ratio, and all shares of Jasper Common Stock were
then converted into New Jasper Common Stock at the Exchange Ratio. Jasper&rsquo;s Series A-2 Stockholder received 8% of the Equity Value
of $275.0 million, or 2,200,000 shares of New Jasper Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 0; border-bottom: Black 1.5pt solid; font-weight: bold; padding-bottom: 0"><B>Jasper Former Stockholders Conversion <BR> (shares outstanding
    as of September 22, 2021):</B></TD><TD STYLE="padding-top: 0; font-weight: bold; padding-bottom: 0"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="padding-top: 0; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-bottom: 0"><B>Jasper<BR>
 Shares</B></TD><TD STYLE="padding-top: 0; padding-bottom: 0; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="padding-top: 0; font-weight: bold; padding-bottom: 0"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="padding-top: 0; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-bottom: 0"><B>New Jasper<BR>
Shares</B></TD><TD STYLE="padding-top: 0; padding-bottom: 0; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="padding-top: 0; padding-bottom: 0"><B>&nbsp;</B></TD>
    <TD STYLE="padding-top: 0; border-bottom: Black 1.5pt solid; text-align: center; padding-bottom: 0"><B>Exchange Ratio</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0; width: 60%; padding-bottom: 0">Common Stock Shares</TD><TD STYLE="padding-top: 0; width: 1%; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; width: 1%; text-align: left; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-top: 0; width: 9%; text-align: right; padding-bottom: 0">10,821,500</TD><TD STYLE="padding-top: 0; width: 1%; text-align: left; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-top: 0; width: 1%; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; width: 1%; text-align: left; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-top: 0; width: 9%; text-align: right; padding-bottom: 0">3,055,749</TD><TD STYLE="padding-top: 0; width: 1%; text-align: left; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-top: 0; width: 1%; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; width: 15%; text-align: center; padding-bottom: 0">0.2823780</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-top: 0; text-align: left; padding-bottom: 0">Series A-1 Preferred Stock Shares</TD><TD STYLE="padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; text-align: left; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-top: 0; text-align: right; padding-bottom: 0">69,136,642</TD><TD STYLE="padding-top: 0; text-align: left; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; text-align: left; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-top: 0; text-align: right; padding-bottom: 0">19,522,660</TD><TD STYLE="padding-top: 0; text-align: left; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; text-align: center; padding-bottom: 0">0.2823780</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-top: 0; text-align: left; padding-bottom: 0">Series A-2 Preferred Stock Shares (1)</TD><TD STYLE="white-space: nowrap; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-top: 0; border-bottom: Black 1.5pt solid; text-align: left; padding-bottom: 0">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-top: 0; border-bottom: Black 1.5pt solid; text-align: right; padding-bottom: 0">100</TD><TD STYLE="white-space: nowrap; padding-top: 0; padding-bottom: 0; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-top: 0; border-bottom: Black 1.5pt solid; text-align: left; padding-bottom: 0">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-top: 0; border-bottom: Black 1.5pt solid; text-align: right; padding-bottom: 0">2,200,000</TD><TD STYLE="white-space: nowrap; padding-top: 0; padding-bottom: 0; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-top: 0; text-align: center; padding-bottom: 0">8% of Equity Value</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-top: 0; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; text-align: left; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-top: 0; text-align: right; padding-bottom: 0">79,958,242</TD><TD STYLE="padding-top: 0; text-align: left; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; text-align: left; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-top: 0; text-align: right; padding-bottom: 0">24,778,409</TD><TD STYLE="padding-top: 0; text-align: left; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; text-align: center; padding-bottom: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0; text-align: left; padding-bottom: 0">Less: Former Jasper Stockholder (non-voting shares)</TD><TD STYLE="padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-bottom: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-top: 0; padding-bottom: 0; text-align: right">&nbsp;</TD><TD STYLE="padding-top: 0; padding-bottom: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; border-bottom: Black 1.5pt solid; text-align: left; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-top: 0; border-bottom: Black 1.5pt solid; text-align: right; padding-bottom: 0">(1,296,022</TD><TD STYLE="padding-top: 0; padding-bottom: 0; text-align: left">)</TD><TD STYLE="padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; text-align: center; padding-bottom: 0">0.2823780</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-top: 0; text-align: left; padding-bottom: 0">Former Jasper Stockholders</TD><TD STYLE="padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; text-align: left; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-top: 0; text-align: right; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-top: 0; text-align: left; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; text-align: left; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-top: 0; text-align: right; padding-bottom: 0">23,482,387</TD><TD STYLE="padding-top: 0; text-align: left; padding-bottom: 0">&nbsp;</TD><TD STYLE="padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-bottom: 0">&nbsp;</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Calculated
                                            as 8% of the Equity Value of $275,000,000 divided by $10.00 per share, or 2,200,000 shares
                                            of New Jasper Voting Common Stock.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Note 2
&mdash; Basis of Presentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X. The adjustments
in the unaudited pro forma condensed combined financial information have been identified and presented to provide relevant information
necessary for an accurate understanding of New Jasper upon consummation of the Business Combination. Assumptions and estimates underlying
the unaudited pro forma adjustments set forth in the unaudited pro forma condensed combined financial information are described in the
accompanying notes.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
unaudited pro forma condensed combined financial information has been presented for illustrative purposes only and is not necessarily
indicative of the operating results and financial position that would be achieved when the accounting for the Business Combination is
finalized. Further, the unaudited pro forma condensed combined financial information does not purport to project the future operating
results or financial position of New Jasper following the completion of the Business Combination. The unaudited pro forma adjustments
represent management&rsquo;s estimates based on information available as of the date of these unaudited pro forma condensed combined
financial information and are subject to change as additional information becomes available and analyses are performed. AMHC and Jasper
did not have any historical relationship prior to the transactions. Accordingly, no pro forma adjustments were required to eliminate
activities between the companies.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
unaudited pro forma condensed combined balance sheets as of June 30, 2021 assumes that the Business Combination occurred on June 30,
2021. The unaudited pro forma condensed combined statements of operations for the six months ended June 30, 2021 and for the year ended
December 31, 2020 presents the pro forma effect of the Business Combination as if it had been completed on January 1, 2020. The unaudited
pro forma condensed combined balance sheets also reflect the closing of the $100.0 million PIPE Investment and the redemption of an aggregate
of 9,262,099 AMHC Class A Common Stock for aggregate payments of $92.7 million.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
AMHC Public Warrants have been reported as liability-classified instruments that will be subsequently re-measured at fair value in future
reporting periods, with changes in fair value recognized in earnings. The Sponsor Earnout Shares issued pursuant to the Sponsor Support
Agreement, as amended, have been reported as liability-classified. The final accounting of the Business Combination, including Public
Warrants and Sponsor Earnout Shares, will be finalized by New Jasper and reported in the first reporting period following the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Note 3
&mdash; Pro Forma Adjustments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Transaction
Accounting Adjustments to the Unaudited Pro Forma Condensed Combined Balance Sheet as of June 30, 2021 are as follows:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">A.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reflects
                                            the liquidation and reclassification of investments held in the Trust Account to cash and
                                            cash equivalents that became available for general use by New Jasper following the Closing.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">B.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Represents
                                            estimated direct and incremental transaction costs of $8.4 million incurred by AMHC prior
                                            to, or concurrent with the Closing that were cash settled upon Closing in accordance with
                                            the Business Combination Agreement, excluding the $1.925 million of deferred underwriting
                                            fees related to the Initial Public Offering as described in adjustment note D below.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">C.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reflects
                                            the payment of AMHC&rsquo;s accounts payable outstanding immediately prior to the Closing.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">D.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reflects
                                            the payment of $1.925 million and the forgiveness of $1.575 million of deferred underwriting
                                            fees incurred during the Initial Public Offering upon the Closing. $1.575 million was forgiven based on negotiation with the underwriters.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">E.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Represents
                                            estimated direct and incremental transaction costs of $6.1 million incurred by Jasper prior
                                            to, or concurrent with, the Closing. Business Combination costs include legal, accounting,
                                            financial advisory and other professional fees related to the Business Combination.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">F.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Represents
                                            the redemption of 9,262,099 shares of AMHC Class A Common Stock for aggregate payments of
                                            $92.7 million prior to the Closing and the conversion of the 737,901 remaining outstanding
                                            shares of Class A Common Stock shares into an equivalent number of shares of New Jasper Voting
                                            Common Stock.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">G.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reflects
                                            the conversion of outstanding shares of Jasper Series A-1 redeemable convertible preferred
                                            stock into Jasper Class A Common Stock on a one-to-one basis.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">H.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reflects
                                            the forfeiture by the Sponsor of 200,000 shares of Class B Common Stock immediately prior
                                            to the Closing and the conversion of 2,300,000 shares of AMHC Class B Common Stock into AMHC
                                            Class A Common Stock upon the Closing.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">I.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reflects
                                            the proceeds of $100.0 million from the issuance and sale of 10,000,000 shares of AMHC Class
                                            A Common Stock at $10.00 per share pursuant to the Subscription Agreements entered into in
                                            connection with the PIPE Investment.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">J.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reflects
                                            the cancellation and forfeiture of the Private Placement Warrants effective on the Closing.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">K.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reflects
                                            the estimated fair value of 1,050,000 Sponsor Earnout Shares placed in escrow effective on
                                            the Closing (See Note 5 for details).</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">L.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Represents
                                            the recapitalization of Jasper Class A Common Stock shares and Series A-2 redeemable convertible
                                            preferred stock shares into New Jasper Voting and Non-Voting Common Stock shares and recording
                                            of new additional paid-in capital. Outstanding shares of Jasper&rsquo;s Series A-2 redeemable
                                            convertible preferred stock convert directly into 2,200,000 shares of New Jasper Voting Common
                                            Stock, or 8% of the Equity Value.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">M.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Represents
                                            the conversion of AMHC Class A Common Stock into an equivalent number of shares of New Jasper
                                            Voting Common Stock.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">N.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reflects
                                            the elimination of AMHC&rsquo;s historical accumulated deficit.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Transaction
Accounting Adjustments to the Unaudited Pro Forma Condensed Combined Statement of Operations for the Six Months Ended June 30, 2021 and
for the Year Ended December 31, 2020 are as follows:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">AA.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Represents
                                            the elimination of investment income related to the investments held in the Trust Account.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">BB.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Represents
                                            the income tax impact of the elimination of investment income related to the investments
                                            held in the Trust Account using a 10% effective income tax rate, which reflects the rate
                                            used by AMHC in its historical financial statements.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">CC.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Represents
                                            the elimination of the change in fair value of the warrant liability associated with the
                                            Private Placement Warrants of $1.2 million gain and $2.6 million loss for the six months
                                            ended June 30, 2021 and for the year ended December 31, 2020, respectively.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">DD.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Represents
                                            the elimination of the change in Jasper&rsquo;s fair value of the derivative tranche liability
                                            of $3.5 million and $10.9 million for the six months ended June 30, 2021 and for the year
                                            ended December 31, 2020, respectively. Assumes the tranche was exercised and Series A-1 preferred
                                            stock shares were issued as of January 1, 2020.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Note 4
&mdash; Net Loss per Share</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Represents
the net loss per share calculated using the historical weighted average shares outstanding and the issuance of additional shares in connection
with the Business Combination and other events, assuming such additional shares were outstanding since January 1, 2020. As the Business
Combination is being reflected as if it had occurred as of January 1, 2020, the calculation of weighted average shares outstanding for
basic and diluted net loss per share assumes the shares issued in connection with the Business Combination have been outstanding for
the entire periods presented. The shares of AMHC Class A Common Stock redeemed by Public Stockholders are eliminated as of January 1,
2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<BR>
December&nbsp;31, <BR>
2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six Months Ended<BR>
 June 30,<BR>
 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Pro forma net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(24,979</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(13,943</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Basic weighted average shares outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,154,492</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,154,492</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Pro forma net loss per share - Basic and Diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.69</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.39</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Weighted average shares outstanding- basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Former AMHC Class A Stockholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">737,901</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">737,901</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Former AMHC Sponsor Class B Stockholders (1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">PIPE Investors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Former Jasper Stockholders (2)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24,166,591</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24,166,591</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Totals</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">36,154,492</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">36,154,492</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount
                                            excludes 250,000 shares of New Jasper Voting Common Stock subject to forfeiture if the Applicable
                                            VWAP per share of New Jasper Voting Common Stock does not achieve $11.50 during the Earnout
                                            Period, excludes 500,000 shares of New Jasper Voting Common Stock subject to forfeiture if
                                            the Applicable VWAP per share of New Jasper Voting Common Stock does not achieve $15.00 during
                                            the Earnout Period and also excludes 300,000 shares of New Jasper Voting Common Stock subject
                                            to forfeiture if the Applicable VWAP per share of New Jasper Voting Common Stock does not
                                            achieve $18.00 during the Earnout Period.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount
                                            excludes 611,818 shares of New Jasper Voting Common Stock subject to repurchase related to
                                            the conversion of all outstanding shares of Jasper&rsquo;s founders&rsquo; unvested restricted
                                            common stock.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Note 5
&mdash; Earnout Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Sponsor Earnout Shares, which were deposited into escrow and which may be contingently released back to the Sponsor are expected to be
accounted for as liability financial instruments that are earned upon achieving the triggering events, which include events that are
not indexed to the New Jasper Voting Common Stock, which precludes it to be an equity-classified instrument. Liability classified instruments
were recognized at fair value upon the Closing and will be subsequently re-measured at fair value in future reporting periods, with changes
in fair value recognized in earnings. The estimated fair value of the Sponsor Earnout Shares is $8.6 million at the Closing.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
estimated fair value of the Sponsor Earnout Shares was determined by using a Monte Carlo simulation valuation model using a distribution
of potential outcomes on a daily basis over the three-year Earnout Period. The preliminary estimated fair values of Sponsor Earnout Shares
were determined using the most reliable information available. Assumptions used in the preliminary valuation, which are subject to change
at the Closing, were as follows:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Current
stock price</I>: the starting AMHC stock price of $9.94 per share was set as the deemed value for New Jasper Common Stock.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Expected
volatility</I>: the volatility rate of 75.0% was determined by using an average of historical volatilities of selected industry peers
deemed to be comparable to our business corresponding to the three-year expected term of the awards.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Risk-free
interest rate</I>: The risk-free interest rate of 0.50% was based on the U.S. Treasury yield curve in effect at the time of issuance
for zero-coupon U.S. Treasury notes with maturities corresponding to the expected three-year term of the Earnout Period.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Expected
term</I>: The expected term is the three-year term of the Earnout Period.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Expected
dividend yield</I>: The expected dividend yield is zero as New Jasper has never declared or paid cash dividends and have no current plans
to do so during the expected term.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
actual fair value of Sponsor Earnout Shares is subject to change as additional information becomes available and additional analyses
are performed and such changes could be material once the final valuation is determined at the Closing Date.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
vesting and issuance of the Sponsor Earnout Shares would dilute all New Jasper Common Stock outstanding at that time. Based on the actual
capital structure as of the Closing, the 250,000 shares, 500,000 shares and 300,000 shares of New Jasper Voting Common Stock issued in
connection with each earnout triggering event would represent approximately 0.7%, 1.3% and 0.8% of shares outstanding, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>






</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>amhc-20210924.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aBZo7xRiXgen8uEb3JcWaOFWcPtzpR3SelBtmp4bRnKHyMgDkM9/iyj44sGQV4F -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:AMHC="http://amplitudehealthcare.com/20210924" elementFormDefault="qualified" targetNamespace="http://amplitudehealthcare.com/20210924">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://amplitudehealthcare.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="amhc-20210924_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="amhc-20210924_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="amhc-20210924_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="AMHC_VotingCommonStockParValue0.0001PerShareMember" name="VotingCommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AMHC_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member" name="RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>19
<FILENAME>amhc-20210924_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://amplitudehealthcare.com/role/Cover" xlink:href="amhc-20210924.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://amplitudehealthcare.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_FormerAddressMember" xlink:label="loc_deiFormerAddressMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiFormerAddressMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amhc-20210924.xsd#AMHC_VotingCommonStockParValue0.0001PerShareMember" xlink:label="loc_AMHCVotingCommonStockParValue0.0001PerShareMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AMHCVotingCommonStockParValue0.0001PerShareMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="amhc-20210924.xsd#AMHC_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member" xlink:label="loc_AMHCRedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AMHCRedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode_50" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber_50" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension_50" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications_50" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial_50" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer_50" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_50" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle_50" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag_50" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol_50" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName_50" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle_50" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation_50" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm_50" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_50" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_50" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers_50" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_50" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_50" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory_50" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness_50" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_50" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod_50" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat_50" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_50" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_deiEntityInformationFormerLegalOrRegisteredName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInformationFormerLegalOrRegisteredName_50" xlink:type="arc" order="58" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>amhc-20210924_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_FormerAddressMember" xlink:label="dei_FormerAddressMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_FormerAddressMember" xlink:to="dei_FormerAddressMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_FormerAddressMember_lbl" xml:lang="en-US">Former Address [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="amhc-20210924.xsd#AMHC_VotingCommonStockParValue0.0001PerShareMember" xlink:label="AMHC_VotingCommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AMHC_VotingCommonStockParValue0.0001PerShareMember" xlink:to="AMHC_VotingCommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AMHC_VotingCommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Voting Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="amhc-20210924.xsd#AMHC_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member" xlink:label="AMHC_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AMHC_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member" xlink:to="AMHC_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AMHC_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member_lbl" xml:lang="en-US">Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US">Entity Addresses [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xml:lang="en-US">Entity Information, Former Legal or Registered Name</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>21
<FILENAME>amhc-20210924_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://amplitudehealthcare.com/role/Cover" xlink:href="amhc-20210924.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://amplitudehealthcare.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_FormerAddressMember" xlink:label="loc_deiFormerAddressMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiFormerAddressMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amhc-20210924.xsd#AMHC_VotingCommonStockParValue0.0001PerShareMember" xlink:label="loc_AMHCVotingCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AMHCVotingCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amhc-20210924.xsd#AMHC_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member" xlink:label="loc_AMHCRedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AMHCRedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_deiEntityInformationFormerLegalOrRegisteredName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInformationFormerLegalOrRegisteredName" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !T ,X# 2(  A$! Q$!_\0
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M&W0,6:0-NR<4FTG8TC2G*+FEHMSKZ***9F%%%&: "BDS2T %%&:* "BC-&:
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MG%)))JU^YMT5C1W.OF5!)I]HL98!F$Y) []JV:VA-2V1PRCRA1115DA1110
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M'93F>,1R<]5&?\336TZ(RQR*TB.D?E HV/E]*R<:G<J\2K>ZD]K<)&TD4:&
MR%W4GD$#MTZTMSJ4T&DP3^4JW4VT+$YP QY.?P!JXUG$\@D<%F\LQ'<<Y4]<
M_E34L(4^S\%OLZE8]QSC(Q_*AQJ:V87CIH5;C5,6-G<PE MQ(J[GY"@@G^E1
M-JEPMDDI1 S7(A#[3AES]X#K5Y=.MT2-%4A8Y3,HST8Y_3D\5)=6D=VBK)N
M1PZE3@@CI0XU&KW"\>Q5FO98;:&3*2%YTC)VE>"<=#4D5S--->Q)L4P.%4D9
MR"H//YU(]E')!Y,K/(NX,"S<@CD$&G6]K';*X3),C;G9CDL?>JY9W\A7C8ST
MU*X&A+?NL9=]I"@$ 98"IVNKB6]N;>W\M?LZJ29,_,QYQ[#'>IO[/M_L"V6T
M^0N,#//!SUI)]/@N)6D8,&==C[&(WKZ&ERSTU'>)!>WEQ Z[%18_++-(5+ -
MV!QT'7FI;N\:WTB6\0(S)%O SE2<>OI3Y;"&8@D,A">7E&VY7T^E/DLX9+)K
M0IB$ILVCCY?2G:>HKK0HW.JR6U]Y+1KY7D!]^>CG. ?8XIR7\\S644819)X#
M,[$9"@8X ^IJS+I]O.9/,3=YD0B89ZJ,_P"-(VGP&.!1O4P+MC=6PP&,8S4\
MM2[U*O&VQ- TC1+YVSS/XMAR/PJ:J\=K'#'$D>Y5C.0 W7Z^O6K%;*]M3-A1
M113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
:**** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>ea147929-8k_jasper_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:AMHC="http://amplitudehealthcare.com/20210924"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="amhc-20210924.xsd" xlink:type="simple"/>
    <context id="From2021-09-24to2021-09-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2021-09-24</startDate>
            <endDate>2021-09-24</endDate>
        </period>
    </context>
    <context id="From2021-09-242021-09-24_dei_FormerAddressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-24</startDate>
            <endDate>2021-09-24</endDate>
        </period>
    </context>
    <context id="From2021-09-242021-09-24_custom_VotingCommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AMHC:VotingCommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-24</startDate>
            <endDate>2021-09-24</endDate>
        </period>
    </context>
    <context id="From2021-09-242021-09-24_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AMHC:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-24</startDate>
            <endDate>2021-09-24</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-09-24to2021-09-24">0001788028</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-09-24to2021-09-24">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="From2021-09-24to2021-09-24" id="xdx2ixbrl0011">Amplitude Healthcare Acquisition Corp</dei:EntityRegistrantName>
    <dei:DocumentType contextRef="From2021-09-24to2021-09-24">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-09-24to2021-09-24">2021-09-24</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-09-24to2021-09-24">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-09-24to2021-09-24">001-39138</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-09-24to2021-09-24">85-2984849</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-09-24to2021-09-24">2200 Bridge Pkwy Suite #102</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2021-09-24to2021-09-24">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-09-24to2021-09-24">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-09-24to2021-09-24">94065</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-09-24to2021-09-24">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-09-24to2021-09-24">549-1400</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName contextRef="From2021-09-24to2021-09-24">Amplitude Healthcare Acquisition Corporation</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:EntityAddressAddressLine1 contextRef="From2021-09-242021-09-24_dei_FormerAddressMember">1177 Avenue of the Americas</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-09-242021-09-24_dei_FormerAddressMember">Fl 40</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-09-242021-09-24_dei_FormerAddressMember">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-09-242021-09-24_dei_FormerAddressMember">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-09-242021-09-24_dei_FormerAddressMember">10036</dei:EntityAddressPostalZipCode>
    <dei:WrittenCommunications contextRef="From2021-09-24to2021-09-24">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-09-24to2021-09-24">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-09-24to2021-09-24">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-09-24to2021-09-24">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-09-242021-09-24_custom_VotingCommonStockParValue0.0001PerShareMember">Voting Common Stock,     par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-09-242021-09-24_custom_VotingCommonStockParValue0.0001PerShareMember">JSPR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-09-242021-09-24_custom_VotingCommonStockParValue0.0001PerShareMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="From2021-09-242021-09-24_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member">Redeemable Warrants,     each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-09-242021-09-24_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member">JSPRW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-09-242021-09-24_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-09-24to2021-09-24">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2021-09-24to2021-09-24">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140658124039448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 24, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 24,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Amplitude Healthcare Acquisition Corp<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001788028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-2984849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2200 Bridge Pkwy Suite #102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">549-1400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">Amplitude
Healthcare Acquisition Corporation<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AMHC_VotingCommonStockParValue0.0001PerShareMember', window );">Voting Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Voting Common Stock,
    par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JSPR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AMHC_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member', window );">Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Redeemable Warrants,
    each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JSPRW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember', window );">Former Address [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1177
Avenue of the Americas<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Fl 40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New
York<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AMHC_VotingCommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AMHC_VotingCommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AMHC_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AMHC_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>25
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M:OUE87VB95KLYL^DUC(N#I? <6EB'L#[<RGUYL1\(*B^[YS\ U!+ P04
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M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " "AA#U3!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( *&$/5.^ QKQ[P   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( *&$/5.97)PC$ 8  )PG   3
M          "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MH80]4V ][X[$!0  ZQD  !@              ("!#@@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( *&$/5.?H!OPL0(  .(,   -
M          "  0@.  !X;"]S='EL97,N>&UL4$L! A0#%     @ H80]4Y>*
MNQS     $P(   L              ( !Y!   %]R96QS+RYR96QS4$L! A0#
M%     @ H80]4ZK$(A8S 0  (@(   \              ( !S1$  'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( *&$/5,D'INBK0   /@!   :
M      "  2T3  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( *&$/5-ED'F2&0$  ,\#   3              "  1(4  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  %P5      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>4</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>3</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea147929-8k_jasper.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://amplitudehealthcare.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ea147929-8k_jasper.htm">ea147929-8k_jasper.htm</File>
    <File>amhc-20210924.xsd</File>
    <File>amhc-20210924_def.xml</File>
    <File>amhc-20210924_lab.xml</File>
    <File>amhc-20210924_pre.xml</File>
    <File>ea147929ex10-14_jasper.htm</File>
    <File>ea147929ex10-2_jasper.htm</File>
    <File>ea147929ex10-3_jasper.htm</File>
    <File>ea147929ex10-4_jasper.htm</File>
    <File>ea147929ex10-5_jasper.htm</File>
    <File>ea147929ex10-6_jasper.htm</File>
    <File>ea147929ex10-7_jasper.htm</File>
    <File>ea147929ex10-8_jasper.htm</File>
    <File>ea147929ex10-9_jasper.htm</File>
    <File>ea147929ex14-1_jasper.htm</File>
    <File>ea147929ex16-1_jasper.htm</File>
    <File>ea147929ex21-1_jasper.htm</File>
    <File>ea147929ex3-1_jasper.htm</File>
    <File>ea147929ex3-2_jasper.htm</File>
    <File>ea147929ex99-1_jasper.htm</File>
    <File>ea147929ex99-2_jasper.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>31
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea147929-8k_jasper.htm": {
   "axisCustom": 0,
   "axisStandard": 2,
   "contextCount": 4,
   "dts": {
    "definitionLink": {
     "local": [
      "amhc-20210924_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ea147929-8k_jasper.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amhc-20210924_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amhc-20210924_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "amhc-20210924.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 69,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 2,
   "memberStandard": 1,
   "nsprefix": "AMHC",
   "nsuri": "http://amplitudehealthcare.com/20210924",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea147929-8k_jasper.htm",
      "contextRef": "From2021-09-24to2021-09-24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://amplitudehealthcare.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea147929-8k_jasper.htm",
      "contextRef": "From2021-09-24to2021-09-24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 3,
   "tag": {
    "AMHC_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50"
       }
      }
     },
     "localname": "RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member",
     "nsuri": "http://amplitudehealthcare.com/20210924",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "AMHC_VotingCommonStockParValue0.0001PerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voting Common Stock, par value $0.0001 per share"
       }
      }
     },
     "localname": "VotingCommonStockParValue0.0001PerShareMember",
     "nsuri": "http://amplitudehealthcare.com/20210924",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r12",
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Addresses [Line Items]"
       }
      }
     },
     "localname": "EntityAddressesLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesTable": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container of address information for the entity",
        "label": "Entity Addresses [Table]"
       }
      }
     },
     "localname": "EntityAddressesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Legal or Registered Name of an entity",
        "label": "Entity Information, Former Legal or Registered Name"
       }
      }
     },
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_FormerAddressMember": {
     "auth_ref": [
      "r11",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former address for entity",
        "label": "Former Address [Member]"
       }
      }
     },
     "localname": "FormerAddressMember",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://amplitudehealthcare.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 10-Q",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r12": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 8-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "308"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r17": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r20": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>32
<FILENAME>0001213900-21-050592-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-21-050592-xbrl.zip
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M;9N=YA2-87GJ7_]Z?'5Q=EFM?/KE[/+XXNSW3^<G5XXX_W!2,V=>)'RO'J#
M+6R>?7/;P'F1 ")UC\RY"S<6\4"VT4G1$1Y<51(+X+I [*,UD?N>B-P\J5""
M7B48VO?A]S;%R=8WZ.\#M]/1?[_S-JPC-[;>=NC[[B"&T]1_8L_%CTFD)[B1
M4>*U75]O&6Y&>S=^3#JY:\O9CNV;4]/O-'^XCP&D@!CN9(CA>= &(A5&%%M*
M_KT3CH8\"3LE0M/NSE^_W?S[0^OG_[GS$)J0(J(;+9&#*+Q!8I&5FF98Y\;K
M4^F[MT""9[%5))WQ>U 08BZ"KL <?MG9:S@L&O$1;K:9N=FWGB_A&$"N++[&
MP_-?@H_>+YW/.U_G8#7*SXF.Z<;VSE%C9RR\[KNZDZSH\<G]=JZ\\VV"Y$D7
MU.G^OK=[>>SNU[VY75#) C9>'^YM-X\.=P]WCV:\+OA7=#>:I_^T(%8" @?1
M!=3M0]#I(_$GJ/1QQR.EGY<_6/@:&/Q VO%L@K6EIR^&RUGA>/$GB!$87APO
M\<"09 B&PB=S2N>UR]I539R!%A".,!YE.4>5Q5SQ(:QE3RQ%R1<D"^4D-S/)
MF.2[&I+3?>AU <4Q\^X>_;"Q\#O)T_M&AMZKX$_UGW=>(!LENN:?AY\.HXO=
MR[W[RU1Y6E\P^<;K9K->%V\BKP.R_<77VY&X&GI ,__1J#<G$O[%0_=DSJEV
M<0)__!A]"F^#XG,\>GM[]-?7T[-/1[UYGV,Z]<;K2]FY#<..P-]*CLT1^0V=
M%6V(6-;'Z )$7^ 8)1+W0>OZ_,W7TP___FW>F\I-O_'ZY'@*&-Q)5IN$GBAB
MY22H14AT^27PJS:1F'$9=Q;]CHON^R($5<?_GS<HUZ_DE7?U\\]GO_Z[WIWW
M=6=FWWA]M%O?WUN8O%=R5O<\W4VU!;0D#2( 5F_@^D)^D^UAXMV@@0D8HXRW
MIJH5#X:Y.>T';D'@-8RMN("-KY;YY4DYF_)8N:>P$DGW<23=<CP<OCGZ^]_A
M;7MP-0\\M.?;>+VYOU??*L&\\5 0K=B_"P'9+GIA,%&Q?]/]^=W5R?G9X=]_
MSF'=^3DW7N_M'FTW=NOUV>)"5A(H4A? O_YQV&P<O(JKE43Z<H#[% %MU$$5
MSA\B6Q,N7!R<74<^A<T]7=P\R9DF3=([IU*]D]>N_S'BRY.1[)#_IC@DJOV_
MMZ>__7K^[8T_-QXZVWJL;,IJ94(ZI;(,/&$DFDG>F:KZ?!G_9BR?3KU4D%#W
MY>]14WYNWKS_>GQZ%VHW0W;B;/I4HW%P4*T<W\A@*'4PR3'-[L8S:P:G4TZN
MN9"3BX+3OQKO;_Z^^M_!TD^NN?'ZK2]VGS(/F>D2I^BK#[W"/[T_?WW_=_/R
MNG<7=?<!5V@KP7 XU<I_P^CKS'#^]KX:\$//Z2W(<+LW'_ZS.VPOYYS&].H/
M_RTYI;%#VKV?VOC0(WJ?_+=S_/$J^?/372Q0#SBBG"[:J-=W]I\P.=CDO>MP
MAXA<G#(2+N\6I,FNX,!"4"01)H3OQHF(*,9MB4$/"Y K5W*UZ]CJYZ)G_#F,
M$Z\[NO=23WJR_17T.Y#,W,$@"@>1AV["5OA-M*0?WB)FXD-$8'&X_9OH>CXJ
M?5X,&F B@PY@;!("TO:'?N(&,AS&_DC$(+['W1%]J3X(6[!@]LTH2= *>1K"
M.$ =W&"D'W9#'V;'#S'PP4.G6_QRM8_R^03>J,'KM>:>%]P?"TI"D#]'7@*0
M@][48:#\=7&QIGK:.)&?;H;O_SR92P1R6=&APA7AA1X=[.Z^*N6[!7;4^YZ5
M6@'LREZ"&*@(?40QI'EBM[G'R()(PK-:T?D8E+_9.! G;R]%<Z=>@[>W%FT\
M7:-+,;J,N[:N0JK' 'MX#R06Z*Q?#/2_#W?:.ZUD]^)0+A3JQ]<S'>3G >OI
MO !)//$XH#=VW>U&,P_KF?03 ^F[]1J_O@;V1P=V3>0O(HGD%,N14;XD2@K1
MQVZWS"Z_$S1;WFZG_??)SD*!OGQ=RP%^F'^[;2U@*L5O[':VFYNM+9[9X,,D
M5. /ULCP9 0E=1(E?",'LN=Q/)315(3R_G,*-/;L\,VG^SNZ[H%08ZM;5;3:
MD=N[F^T[H)7ZX*FAU:,M)Y5+JY7(>($R-V%R3I%>&0=!.YF[HO==D2HVQSPD
MGV)W=]8([YGM(9\P18Q7!/<LW79/M+%.VH,#W><4U-ZLSW_+D8LK5UK:J-\*
M_<T90G"6M.'9H_AGWC!Z>+-7+#4U!22_[7GMWH^M2)6L%2(E"K.$4[5@(]=1
M")0:<2*,7HKHNK79K.\ZS9U#I[FWMU4 \>/[*PR[FYN)XU"K>DS[1HUFBP"_
MV"FA*@?"ZV6E [^H&HS;VW<J</GE;[?S[K=VY^JO]Y?W].G<J\BHK5SF3F#C
M-0\E>"Q!@SE\80,W$C<XJ/@G#RL&6-NQ-REE:0("S7SID_"H,#ASGNB2@QQ=
MT$81#2872P>;0>_H_.+P8[CWW^;C@$UF^QNO?[VZN'RV(/!)6S7*HO T#FF9
MM#2B9Y$@L?]K[_;KSG];M_%=$JT>#!+Y'$CD)./ICT4GM %\*.ZX?Y6YE&ER
M\=Z-OLI$O'MW<G?&\[GG)7(%N,WIPKC-DFK5?OF[\2[Y<^?T<^#^<<\PFR77
M*)[(X=)%"+T*Q>%(&+K%U8A;?H+!V7H]".P"8RN)Y:'P5, KA9L(N'WUF<0P
M[S:]^T]:W[.EDF4&QCDSRJ5!_->K#U<)K'SOI/'4(+Z .7]^MG!7RIWS5'>^
MW'EI<'@;W)[__>[WG?U_/PTP?&R!X-D:^.8;!'$>=-#H"KC3&HDV!I?@;%^!
M^4E*.\\%?G@Q,36XD&MD>"!GW28]--X.,!;$C45'=KV Z^"P [R^5U"6+JU&
M1]7KV,+;;&TWJ9+:##7L:JM]JD_AYL_4)58KN5N<G,B@/_N9/CKA;TH<X[^Z
M@*G^T<ZO<_41)M%0C@=B%JY+.3/VRYP93^&>EKA&]:,78&[^2[$-JMX>9?C=
MD[9T,42LC%I@2A+3'I$E/=Y8N%D/"(OT93L!PA*$Y(H8@DB-;\%Z55 ;-I;D
MC!3N/$%2.L[ECPC*;SV8&^$[@/7"HTC> .N"U[S #=H8U."VJ7DB+A7;>G;<
MJ!-S.%NGS!&RL^D:1XA-IVIC6'24Q:)OG\QZN8)B,0H-;OYS_B'\W]MWH_NG
M@,_B%2Q;U<Q!5:OI^/EN.SI8'1L*/0Q6QX='#^5=O3LON#7<\2MX_Z\ANJQA
M6-X^*1SC-S'!G6/?,E93'KOH?:*XXX5.[+L9O-9]4,86$$GWZW9+ M+#*@>T
M:GO*_8(9<1EWG=(&B7E#@Q6)/Y<!YUP:\2$NMW.07L+.L)V$T:A:^1 F"TG"
M?4*!\#F1HU[;\P*@66,VW%NVX=YS7Z=#B6P;N;0/2])9T>3WQ.K,L4I= 3:?
MAI9813T3V:=:#2?#*$J+.:.75,?9._ )*$?E+X#J!#J61.&BZ_FL(26W(3K3
MDK@FC@/AZE:JO-3)HVW2"YCPW:R_RKY'/S9>;:&RQA/&PU8?XY59)N( ?]"T
M MXFIOA@K6><EK/$)2;ZD!0 4A'(#HF,8G4PYW04.[7ZCB/VX-\@477P#WN3
MCV<Y^MIR@.GQ!/(%;>AC4*V,U^U&$),&POPP1DC"(M\:OAPQ4ZM=E1ON"%?H
MPI;"JB9' !0.(Q"T04!NRS@.HVI%ZZ*;:G[LR)?."Y)O/.QC,'*'0'B LCQG
MLKA!  ?3A@>M(:P8:ZS 6"WL18:3V7MZHU\X25\PN#.P:^WC1X #3 /P+T6?
MBN/K2)*UT"%TZJ Y!-Y_[X[$7L&13AXCW6P+-]4!3:H?P@7@0?#!2_$>]"JX
ML*MARQ'G0;LV\8C1F^&/ML-;M,X 08B]CN=&E+^#8YJ33@=-EX#?_^H"/82;
M^=23D3N0P\1KQU.FW4S":[8BD>Y%=9'AYE .HO,QJ_ 0&-7\'WT]EY[_46A'
M<Y?#>-;$8UHD9QY1IN&&8CLV17'$IK?%)Y."GT"S 4")TMN18<(,*7ADD(D_
M,Q"KM'WK9<!%8G;#Z,:[P7DUA?%X.3P @3K\JPO8+J[Y1=GM@K9/27/#=L^\
M:(W=DFWDH6X9CI%1DY ,MZ'S9A$=*+T61E8#??I&%+/&&+?I>5O\6=$G:N/Z
MRS&L5&>1(J$ZD]FP$*\[@X5H,;'Y 9_>&D6? HJ> W]'VU;4<3%5F\ @96D(
M:@ #?RH@QP< 'RS^S<SPW(2M<80K6,$L\?JFA(C"Z4U*"U( =&;>Q+6FK,80
M G+!&P>[A6UM=K+'[&2'Q5O/0!#HR@C#EOEQ.$S(DD<9L/V^[&"RK \(.8@\
M!&C>;G8MXA9HA3L$S=@EAR4(%6T\-Q^$=@?MC3 8"#@]9/"(SF& KDVIZ)-*
MS/7A2XP42/4,;I^*?[KA8 '>1[5"*W4F!=4Y^%6*D8956S\5!" 842:DZD^B
M#:MT\;]>U![V\5C:""-!&&SSBDCJ,D?[T!5]@''+5\44+BL?I!]7*T7!AS;]
ML28JVC-(32[:=N'WK#R!U;&$! $U&?'>'":S!&TW,D[4K0X#_@N0[@'!.EPM
MB(1 B&-I767!X!GPM.&/I4$+"L4T(#1@5ZUX01J;BSJ<R_PK(B";N,3)0'*7
M@R(I%$Y+'Y<^(X&27X>;8L1)Y)&9_GYG-./I "MSXSSF98XD\JY[1,XB4"GP
ML\*EE4#1[(=2JU9 P\5C'X0QC FP# JWDE9F(IQ3)B X0(\]I^VW)+I?7?P<
M8'2 HGT?71;5"GP$NCJ\\L_F :CCHN_Y/DRU9LPKSYB5I<5! F$ILATO;H.(
MC#P' +W-EA7XW7!O52TTK<\P@^!MZ:(.BY84=,,4AB3<5MR./*8GKOXTSHC:
M5_8[9OC8L!M:H&8V'M&(,,H.<7%^<09"JGJ4$NV,TDWY![2Q[.L:_-/EMA1-
M##J& #)_89G;O.YAKAO+.T!6-6G)CNXP@L$WU[JQ6Z/N /?#_UFD@R*"&""/
MLW%_1M9/@"1947_(0VT.2DO6$Z%O-"9G8QL6&ZLOZBDB ^7-'^!;=EP&UT8*
M1S5 9)\)12F-O:08F-I*&YL 2FM2LNJD!*XV4(YI<[%:72WEK$H/=T16X"80
M)B 7;W+P/85?<W$:)?,7\.E,X*RVZQ'CX^F.<[P8\36M+D,Z.(\8,]4$3+:7
M9%"T6IDZN+B59++*RA$!<6!@OVC*+A+@)XM4:SQ993SY/?"!KC&,J@ *;K!R
MBT':$=Y\5&@'<;0A1#VYE?E?AG'^EW"8?D;Z3ID!!3-NNS*R34$SFUD90R::
M=6KB&+"$ID#OM9%3%0G0!ND0Q/CQ!>$;K5!)^!TXG39Q8<4IU#YFFT'1&GTD
MF2ER'(C">5PB9C%1MD3V!S[MK#6:2=Q)"QZ7OJWO),<R-S%UE]4-?Y11.S]9
MJUJ8[6LUO;<++%^7CZUHOA(?2;R,7^*P*MCJE:#THR6&7A3%O6>"= J&H)@)
M>W-Z6Z\$%JY\*8Y!0?7:KP1&.O/6/X2XH48FI$)_13%"SSS<8P' GB;\VPG^
M^0( ]USYS!%:$ZN3E 2)XN+'RI50K1(*;R\H97) ?-(>S)?=^P=M8I *T%J^
M][)_&K5ZHS:6!5Z<,?+0^%=8T!GV1E0JJBMT]2O@AETO\,@J9.C^V*K@0#$G
MP.XB]2QCUNYYN-[KXSX%T&*H;D=<2FI>B7_@Z%OBDY=H38O30_[QA;<Z_.79
MB:@8CC'N(;4DT>*XBU]"'RE=C"DQ&5G1]_H>7JGO >?QT;28CZZX&J#DF+I/
MV;'!)IQJ1=7^)6MM#R:14<ZNF['MJ)]^X1<MZ=<1MEC%&JJ:."-C9;_<REFH
MX$ 5P(K9X36SP(EOCMNBA#9%.8(B,*J54"7&X&'SRM62M:F)0]0=VZNF[6'R
M6UNR:"-BF: -B/5T%)8=[6K&JXE=GPHO=W"M7LL8^O 9&XBKE3C-D<EJI3U@
MU!PWHNNS]D4'7E6R<..POMUQ1\*'"]T>#G2\?$>R,:VC%X0GS-AEC9V:TW0]
M$((0-+##DIV"$IB-*1E 9/ETU:5F+(V9UZWP'W68&8V\6BFPY'-P$=V7LJJ7
MGEGFLZ2'UCO '7V2%&7D1O0=G0[LKAN%??9SH@H#_UTG)4TBE \R;='9MX>^
MJVC%9'17.1LQV5BSU8DC^T/R$BVI3/%<CV1:F:MG(?6J$RJ3>YOSE7O_]8^C
M_8.C5\L0:+W75T!7NKK,6@884;2JB6-@#R$:*- E@/8&CB8 -@#,1: 9!.$:
M)M^IBS8:*CLNL IW%%N0/DF$P-!@9>OJD+,%0Y)!9HAQ75D<B74.]%TH>SN$
MN]>+8,Y S N]+BF_5+99,U\+*X[9!!H. +B2[X[0&1N1O<X+AN$P1@>MQZ$K
MF A&E00CS.$"P0(TXC@,Z+R GP*#C7'!/?=&LO%XXAX[L@TT!@\E#65QBR^#
M@\2LBNG$%\(NW!ZS<&(--E=V.7G6##QQ)? 7O!05M94[8]RX23=+VQQGN>>9
M%3&K!"T\1:8=OZ2"G LH_6>(6=A G;8]$K?BA/WYQ1=C<\6LO =#C>!_7RD:
M3M7(1D## >$6C(##T>3Z#3Z(!#[KA+=D-"0''9GV(SI+C"<G+QC#FQ?9:[.8
M^JLT7X]X>!;DPP#@0Q6V9QG&EKB&%--0OBR5EYB$B>OC0KH,XL;%9R<M9E>E
M7/<QG!%CGH)0$.6^#3BM$=?R#7U_CHX<,+Y!1_QSQ_($LG1N!\O D"AR:H2V
M]M4/(\F$ KTN$S<7,,S>2O]&;H,D!$#'<F%MHC;]4&;9K#7V\FTG%UW8_Q&Y
M8VEW:)OI+?0T9J[-,8'1/GQ)8[SV[O5"YL"&+[SKZQ&J[W:!PR)V;!'TE.QG
MF:N7T2:P,P=%!*6\M83.I_E&=@%67,YQ.['5K'$-QD'J://+2.DZ:>^..%.W
M"%[0462ZCI&C&"L=-_Y&6K;6,'$9]GPH3Z.G"2F&RI96W8&89.F?6$_-6PQL
M$\9$W3BC5?,J4!G#AO&)KV(Y5*+2)&: 1(VH>O'19PC; @J'?&>D;2WXST!Q
MSH#?!S%B.,<(=F0_\+JJ[+4B-B#U="5^U@[CA&4]J3Y#L!]2?#,&\N;"/6PH
MCPOI"I&46Q C4!IIA5' 95]LO,394.XRL@)2.(Q%0\2.5<2SEC=AC:TH_"HC
M] CQFC/?]:E&#P<[JZU,PWPX&'(D&QD>A\V>@:(N/C8L%;@N$!8Q?Q.D5LG5
M&RSJX63WBU(K!;KP8T>?'.9ZICD>_##MIEM"7E1R);S,D5>3C1*HO<!F8]'&
M4*_MW-U;;9/4U7'\6T[.RPBO>HB1L*3Y<E)(08,W,J7/0RJE0B*V#Z=)R:_T
MBZ6%=-.>'UW0?00:A/';,JV%6!^=YI#Y$]4%2C-;64<BQC4<#'R9_HH64Z,W
MENS"4D'91C[YR-7TH5:/K)VFO[$"9._1%J1;ZC12HR@,$E">(F;/X3I(W:'D
M(GT,L7D9Y7*8R9=4B<U1D*YC'JAX2:+44OL,S>HP?JH[C +.-X !-6JU1C:H
M.DQ/+,B>! JE8&0),%UU=DHKF@8HL0TIU0H=HSV"WE!<= ?Q.)@5'-#T1; \
M9$\':MKX= Z>@,)&/E3. S,-D6F.;M?KN#=>8AT_+,K6)\LN8[+"M)8KUBK3
M$U:9+FV34%8]8/'%DC;B'O+RML2$%":E)10IE54FTW/*>""ZX$:^QS8E5<"^
M#8,!&7FYENE75*8_>*9"O9LSXZ=\/"]:<K$-MH0SR\^C"AFI6Q($;#N5LE22
MY\S-S$#52F8DM/,!3W(XG))3(QT4Y]$X00&=EDF 66$N3W2"_JPMP%:Z(S/
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MC7IH!_:E"<'K<)*UVZ=\209!'LMQ\XZ3?<A)PPOX$";(*$SE#$Z4 )X1IO5
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MD44R<)HBC<;-*L:]K%,,0;I;*: !&8.LN$24>=+;Q)Q5]UJB;Y6B !L[S3S
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M()T::#"'>?F*XLQ=#FI&G"%;IT$1W\5\EQEV6@B#<R2JCPT2Y.#0QY+"Q'<
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M5*VD-92"D.HG49%<TV8OK0NB"X5R?2[?BY-\S22W%=Y(K$[6;-;KXDWD=8"
M7GR]'8DKT+FE^$>CWG3$I>S<AF%'@'X^<L3)L3C:K>_OU6:&[2DL8HSMK S
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MY4 J%4[AE9$<@#QG.G76Q'N9N#Z<_%<Q-3"2RUC?R.O0>J-:.7$'F /#82K
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MU(RRH#3=1DB^ JVX8]6B,()7W<X-!FS=4NR#DK]T.2,[ @&/"/5S0"/)%@@
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M_)S[K!K[G;T<Q4G(OM%$^T9)3QZ^\L+#7$[+KA7#QZ5$Y^P^]^B<G75TSH.
M9\60:BVS+5QF6V:>V2F6!<5*>[EB,MAG1+$:75/FE3CSI7'PF5=?"<M,:;.H
M]#O3L029Y3%ZCJY3TT_^]=F$Q"<B<#U16S.5O]"0D;GMI5096L3^]$T\D16;
M U]7<5I$M0,6YU5_W'@F@3R+ I/;Y&9KZ)>/:7P#;%!/P\QLE)LHRI>Y)4D#
MR6M$JKBT]G52$]]UU[)'6?=#.DFR77:^'?K(('"/PF1I/?19&H7/WGZ22YS=
MK6OWT^@,.-8F?*:;KU:LBF=S;5AW[[:+A5W?K57.H6%=T667G#T!\#K):!FR
MB<'8:B5E?D] IM+'NZ2E+B\&05D:T0T6=;(ID9S=-U.Q"L<4CGCC^J[X0P9?
MW<2-7%K-;S(()(QYXGN8.-UA'>$/+^ZYOOC-'83HPI-4#@+CU\E71XZ^L:J*
MFHWIO$=-#K@7'_?VL(8HJ,J8+;A9K63)H3J5&D;XB9874O0Q6@@RE-JJ-DT!
M4>/3.+ *66P;GT ]=7/;<O+Y@(*=4VSAS=T#90M?(6*X!&DO-4G9)JB\B>K.
M>[,L3G#:;OOK=12"WK#=#OTP>HD'G4AXP.99^-%W![%\*?2?-LC$.,%2Q<:M
M#6V)M.Q/./(V[@6&"\); &"SFB:9O\Q-33<.W_LN2W;\$ *,MN$<^546GOP)
MJ,W^,"](*9ID^MFI91P< @ H4$J-S6B 'K>D/^1X+H!P,9KGK']H_LH!T_CM
M1->MS69]UVGN'#K-O;VM L JL)7>>[V?L=:.VQ?OO'CB*9=!_>+N=9Z[O #]
MAD+D'7'2\V176+(/3JODGYQ)X*3G>L!HC#1N$7E2[^]^N9\9]1:ZUU\E* GO
M76#HS_A"^1;32KUX<9K5CE_IB6:@6" CD@G695AYS/Q-@NPD/M3$+\ !9>2(
M][73VC.^TA3O_L!XM!1E>=9+&4LW A&/C=HWT@\'["$OND?C9%A(,.?\N>JB
M5,8%<'^0?9D(5BL@^8-0(^'6VO#*>="N42RF+F\(/V!6$DK7/DRV.*/]8G;Y
M"*Z&^=HF5>VO*PQ+Q<Z)P!A,94"R0-K!U7;D)I4['& TJ(H:5USO;O=MYUCS
M&]5*]A4=&<\Z9/$HKD^1W;GB0=<8AX:JD7J5 \;# 5O*=/#]^=5'JP2?E<V'
MD9A44E!I=[O-IF;RF<,N!2R&C=\#C*M7<9H)U2D\UZEYEQC^.<1%=[B:XM'A
M/J6?N7T.A-ZDE:B5XELF@5R!6BX*-\TX5/9B]F!@3// C73^(<9.>QT/.9Q6
M&[GU,(?.FV_9VJ#BY:L5/L\0DX<"C!T>DH\W<ZJ.CLH?8!:CQ_IWA*')\$BW
M24MC]V]!0"IZ@'TSS5, *M+EJ4$4_9;IL18JHP<_PO.@TD?I'K*='U1,MVF<
MBK"B6D2XII+DV$GD/R5@K%;8@=.2O@<7J:I=I>MH29TRF59Q+(9?JF_6#^$'
ME#]H!&R@Z T\\IS#6)1$B2-X$9"(;UY_V%=E[2B8S9(Z53?' 9Q,>T@X87+2
M0:PQEF/L&KJ-%B-Q@R%)C-EQHJ.157@<)IG$2=X,DU8(M&A##1%7I"FXJ8,K
M>S[7JF=DU\),=69H#@ID&\0S!$W8EN3Z?=;N, H\H<9[M%&4TQ!?PX%(L&#>
MD@I6KMU:=XQ\VWOND6^[WV?DV_*A;/57_%3Q^5.^M:S*XZ=:JJI0S7" %'C7
MV1VK^6S1Z$S99)UM9WH\IJRZG"M6*\@6)TE\*@O)ZJT:#"G7"XM03ET49_ZH
M=K-F<UTJLJF628MCV7@"S\ZV]@:&AE5GJ8SGKVXP1"Y&81OD;*$D3*J;(M)"
M$9AL19EO3M;(;SZGS+4F2SPJ@Q,>;[(;2*4K;F5?WVD(53*&"G,*B15@M*#H
M8U:ZJ3Z[^X-F[4F(C=,G'R*!AU41VVK[##]:27NF29;5SCHM:T$'@4E9S2W1
M= [V9@2E5R;U#+3]7G@+(D7DB(+>NB@<F+3^S#VXXAKK=?(*X*$:,!W$W"#>
M$SF+Z%4-*JX^/CXG+GDZ;=TUS!E F<IJN#VBSL3Z3KB7<#0R_9#3 J'(N #N
M5+4J4Q==BX!W64>F&*L23-,RX5';BPDY41^:*K!Z<4H$F-[Q]%@$AG(*%.CI
M@]/GVN$:S5RE-@5S'D+!NI@)U*U/,$ET'.!-DL=#(%[<$>"S0.ZHRLD&R.VC
MFC"1HZLNZZ1%@D2U.3?6=]B1*+]3 1N51DDX4!._3R&LMG#.9 SU>$ 9U7@>
M^W1C\DZ$DKSZK8,L)]-NP()2JMS/)TGE63)"O(<IK:KV#2B<5N)8D4K1=@=>
M0LFIT;"-(:D.XR$5@&+M,![X7H):(Q?$ROP88KJ/&L/[F[0=K VD&)FCRN40
M\C@I/E4K8V!0@"PS($5BRB&G5)>@+L<Q0:OU03E#\.#:7JPU(=2F*[F4R9#=
MUJJ><ZZV5.E*MM9:T#*#^_H8>&>*,>=J.F>",DKA)A^S=;^,/+M7:/%4.B=O
M<MQ58[=9$U=4REMM1F?=ISA?$-=63&Q$)YQ6NQJI1Z9X-=LY[/+58Y7#\ HG
M'FN:*HC5T<:+6.],+&*]$O$43P&9%NTET'&OS($O5".:13L+GD5.PE-U%$RZ
M\HQ!_.SJXB+K'B B$YLZKO@"L>60FQ)(130CK&9!5#F _5JV8NH P2;%W(OR
MFQ=348GT;5;*+#4B-6@:]0$.WX-G0-QH%2AH)SD#+CX@BV^AA7781E$J#8-5
MMFI=G,:VW]<(C7C3RB."ZY  %%@[1_Q>NZJ9Y=.Z]=%.%WU1OM;M'XQHQ#1[
M1+-TW1M8!_6G0"LSQ\>QQ)0Z4'920S(<E^W[P6>X]S"P^\-PMPA6(1"B0"9D
M!I%=BQ<7FJ^MWA*<<U&R$&I'G35<TQD.4+I.6*@SO@]S9NS5X 4H%F>?!]V^
M=2CN-_M@/*S?VE'V;+PJX*<W["[)2<^\"/3> )YX [;? RLRMYKZ*&Y[H5 M
MM"30 <&!A AY" 7\6H>4&-9Y 9$()(!/^HHC4Y%PKJAGVF&8\7SW5KF$5!%8
MK 2%3IA;5!WM!E/F"&'B$BTE[4C$]: D8Q,JV1UX6]>WTICH]DWW$56P)0,Q
M:X%W!<V$>[-:=J8H6P!(RA1(6&E;_I@G+<+TE\+P;(:^:F5V2U^A#40T<KD>
M-(JIQFBS,[<3#I(</F78;+62K:M4Z+";S<XB)IA8BFV*#6UA00O,_$TLQ39%
MTT.+[2ZZ:Y6&P6J%ITYMB.)A%L3,?$6F1*P0K: L" W 8 "[X@W9$;25_$[V
MQZRY(K"L#SF-LNUC.>:8KH>JF++A 1,',]8B@*_EV8;(0%=H'!(/M@WU972-
M=XMB ;H/76;MD0RC:S=0AB%GS%3D8'W75/>C=WA<DN(D%D_5?\)%XDF 0#>R
M"S)CI4$'>"4L  ,E(I0[(P;1N&>-P_3?]T!&P>6A2JV?52MM*VG#7+*#?)=.
MR/Y-_4)5F74$HW5 "$=>W_,12JU$L37#7%$+D2+Q\S$(V7F9,'"U,J/]9Z]^
M+_L/KGTF:T^U\B!S#Y&IB1W*]F<U[BRGV-$:.>811++_W(-(]M9!)$\).QYH
M$60[%]L#CC/51D4FX68Q%L,5.\O%PP V"$G[5O YSU+96ZNZ,M 6":I$*]+K
M$^6WE[%QX=\++WU*\>^B;"/*6,EF*>EL%M:5LY-92TS5=:U)LU)"@P:HU;7(
M).CZ2D;YY]X.-WD75N==EOFY;6N$C5'AK(GGXG_SFWZ# U[1@&D#+!(%1()R
M<J)F1KN8MJ"VPF!(4M%>W7CL<V--V:CKQV'66I#= >G*N%U;BT8[ %H+,S4:
M3'\P1[R'X\49M49&=D&N':X%).J?*MDEI6.8,3F:-&:E/F=TX4)5AY1B4%M)
M^\@?:*YQ/$5#J[#V8K-N^12B>(:/ Q,2CE.0Q1(AQ$2@J(V0_D4ZKSH9'3K=
M2HM6AG91R\EZ'9F:X]2ZL%-+;]\R#6AU?K8!W?0]G2^N 4<YUNDVL<TR0YL2
MI;UOVW! : L%\1AC#2RAO4,62_@+&X;Q!JQ/09J6D[\5^M.T6KYU[ :\FGL_
MT+K24)W,QZS,9P((Z!/,U%<;@L](,2_>#1DJN(NWUQ6J%YBE2(+BB,VG \G!
MV7V9U P*$'[A92E+-.GSJ9W:)- S)(!*X+N!CI&'L:[AYXCHD'OC@GZJ6EOC
MPDMN-<W;-S;OM1]V(;P2KKA:L9!9IO35>%>LCN]NLHT ZYCBY055]H&P:L!!
M"QO[!!!**/XL'9\<6X@#2"]P,JJ$KUN&4UNQFOA%V^[,D&B TB8X #!?NO##
M#O<TU[MP.S=<,$,5N<=&]2H@-4A7I!1:U!VM95GAH&4,9PV+"X5%98U$HF.Z
M K)UP;C"4(P9N"/5)8R\241Z['C&LD0I$2-$$7P,**4L]7^QWU:G@J?-0ON2
MC9HV[[PRH]BY:Y:U@NTFK=2U]1";3KJJF8MMY:I?Z7<M>+9K=A*VHYY:5 4O
M\RWZZ_7>.?!G6FVG7=6FDANA*D/33%6U,J:I28WOR0\R9DOJ#@&0;(-2]M*F
MF)8:]8FVI<+U9]>Q.K6TEQ&:LC@MV2YBL&)K?ZK$=GE*<GIY&?K)O]Q+2\Z7
M>["+.Y@*2QD=.3_9@[1D%>![/RV95_(@/7DWU93&1INZW7%=F40K_H(8;WH@
MJ=9;K2@UU]:6G4S,!NG#I)^JEL#L[<B'ZY"T92*L>%!T4V/%5B>G9-*BS*VG
M>B8(BO=7-(W,B)7 BU3.:<JT/3*H9'&1L@;\5*(,0^Y*"6?0T3H@"S+4I",(
M!89V*6\B\(WW5-%"=6MK.BRO6H8$=5QILF[6>ZK"U++GKZK(<9 279$.T"L)
M'!@W0<UZ+:GZ;^K>WN-:&L6&@+O<BJ(;U4KF5FH6H.<U6K%8A1:[9Z\UVB5J
M$5D0G9]2R] SLUJK>B9/46O5H M6;'6,9C*1/ZR!<L% .2?E-JO(K(Z>\=3\
M;R5EM59,R7@>B07+4SD*;S4CAO.#:J5HC-F==+G29*55R5@JYSD+EXUR?EX-
M$5.TD+T]IWFP6]L[NI\BHE93I(FP')E31<1D361\N)HXC?0-W$O@0B/LVH6P
M\FA]BKR-KWG.$I<%/W,4N>Q1ERAS3<#^-6 N&C"?AM3U5,.C5BMX\."Y!P_N
MKX,'U]@QEJAE)6*0O\Q+C646JS3-SM%PE]Q*F;$@<J*0RNY0'G?;1D%BK274
M%6;S5RMV?/>8&XX;,Q2M2+OC*+,QYX^+T2%WX."_#VD9\(>CLI:W5O\B7UM%
M7>KSL,[U7TH*_$6(!G^RU%]HEOH[-CAQQ2=;7HK$B<ER4;W%GT:F_U.E%,ML
M%3ZY/YAMDGEX'(*8,0RAO&J**F&2:V5^E4W@*2P_8KK^Z5 ZNTW7M/(K^[D>
M9]GDG9)5J&((]YUT;]>FM*M!%'-0WF3I:)60\X$D\1QVU@^ 4[9=;FQFM+_5
M"_Q_#N;&"67@C].^G,K\*$X!^B<8&[WLY=E2%-$K+3*AG)(M0CW>@8IM@592
MG5G,A%G2)$'N <HJ*?7[;$QH&#I#C)6^U_M!REIBFI/$I/IE5RN7EBV+0>A2
M%8"YH%9J8X1^]86EYT!."KH-CW7?+)6$=#/T.]^M9N+%$AG)"1F1K$#JV:_/
M%&GY].YC6M<XNTM<OHO</?>FC#GCIIQ,6SG847E[.!BA!+EP\?E6:74Z'^IE
M,_ZL=D"]9^S!?-F]O]@$:(H,A<TX9?_LU>K[M;%69NGBYDPW6#VDG*2K'D94
M:?:,,#^,QU8"AXA-?]*&/X\L1CWEYJ0H)KEH2AGZ)G[:)E!9>4FU"66CNBMB
MNJVV>IAO;LHR4!^#WS!N+%,7(=/D&!44$T<_O0MG82O4HDH(,ZJX!<I3O7D'
M>Q*+>JEFG;(,%N#2E9^C\:,S;%.CE0]A(C.-YW7?=_:B9HH:C'=_WW_Z-JTU
M%5\L%3\ G6&)5/Q27@]]I?:^/16G!B&60K^?K$HQ5VK^$<Y^6H"-*LCF8K6M
MF"I/4H4J-PA BVY/ZDQ?1'A5G<[,4(4E>H^.:@W3W6K61)L"0IMZ0#9-=;/,
M)%LX5DM26G$7"VX#E^I@$C66@Z/H&:*AB!UI04JL<4,EV&7?\#?> GF,N0QI
M;+</:QS^_^U=[5/J1A?_WIG^#YG;Z3-:7TA"0-)..Q-!$$5%T*KW2V>! )%
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M=4G K,A-Q AE8LQFVAE3>4A9[.2@7*]C7V ^4!]F:T*% T"&]8F$#C^C8R*
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M^K>57ONLKZ252SG=MX8E>N3_!U!+ P04    " "AA#U3>YBTG7@,  #!00
M&@   &5A,30W.3(Y97@Q,"TQ-%]J87-P97(N:'1M[5SK3QM)$O]NR?]#';J-
MC&2,@1"=P&MI,&9Q!-AG#XE6I_O0GFG;O9F9=J9G<+Q__55US]/8O$("MVPD
M'IZ>KJJNQZ^KJINTSNW+BW:UTCKO6J?X$^A?R^[9%]UV:]?\Q-'=9+AUTC_]
M'4;V[Q?=7[<F,HB.8*\YC\ 6/E=PQ1<PE#X+ZN9!'48\%),MG(A3!^5Y8^FY
M#YA\##X+IR(X GJU>0P1_Q;M,$],\5$HIK-HJ]W]-A-C$2&UQM[[UN[@A_%S
M>!#Q<*O]+ABK^?$S<=J)Y%QSRQZ,911)/WFVCK]UV;TZQ2\;[#Z,!OVK47\(
MH^O!H#^TP?IMV.W2X";YOE,)?\0J$I-E\E $+B>BS<:A".[3S(_D;)_W1K!.
M,=7*+<W4P641=X$ID!-D/(^X/^:A$7[_?1WVF_M[4(MF0L$[S_T:R^/6==OR
M>>#B5]3:O6Z_"_7C;<!7M%60G @B">,EL !)^S*8@N7//1'%+H=SSKQHYK"0
M5ROGZ" BF"JXN.C4@<$I]]@"1\ 3OB"Y/,'& B<NP9'^G 5+J*5BG+1'<QDH
M&;9V3S(AZFL9@>5\C842D9 !=&0XER&CWXLLJQ4G'RARL2[/.V46M*J/3,UY
M"/:,AVS.XT@X:+A>X#2*J]A T<PMT"2*=8CDE$=(KUI9B&@&R>HT-Y(!7YCQ
M@A$&+(P$5T43--Z6HUL-TG^UDFBB['W1C$4($V'$1)#I<A3/T2 16-.0<W+@
MLO]?LJ59S6'N^+G*,X>[3:;H']5*+0X\KI B67,A% >73T2 ;/ S%[A^A\U%
MA$O\$Y^AS+Z"6&7#H&;,\V#&;K@VN<]9H(.$*85*H2FT/.[C0O4+&\7:?A&S
MO)Q#G#1@$(<J9D%4K:"21MRAV$O0[+#&MLG*=ZJL?O<PBK:$,4=00P1$2Q#&
MP2)$9$&,2ZR#SXA&XI7'U0I&\-NR0T<'9JH!X\F,5.AJLVCE9;%I_)]0SI&!
MJS%:/<!,&+&3V/.6H'@$$QR<)>'S"D'P)^1!;S/5Z07D-$JX/-EE$[]!?^!3
MB3&I@\^@:!S%S,/7;WB ^& \CJ7^I%+L17+DE=PUVSQN)>BK%-R4T&!>PJ>,
MG&XLX\#@]7A9+X:[(:F]4WJ>7*BCMV61!')AKP'%1!%3S\U[YW7;X(71F$92
M0\482<7C[/-]N "4=J7@C$;(P6',D?8;,P9M>#I#FHA01:@,\F:'FU2_L#5^
M2%*.PL9&B@^YBM+LZ-F]67_?$\':Y3R[TO3W][?@,V=G<CR[X%LZD)7.(^L(
M(]KWA.]S5Z!.$ )R;R6/['A2X>]UV*LW#YOU9K.IDW9\CEF;6<P)C&;HG@K5
M'& ^Z B-)')1R!DRWK>XS4,A0[U[%KA!;3$3SJQ.+@Z.QS /033*;1GCIH&X
MZ&A&B&PWN.6F^?&J=%8JW3S)H& U@7K?.*B-*8-",5 &0T#VC&BP(ED2J)<\
MG')3P]#'DQ@'*37N2'\L H/9>;H*-0>52CQO<,WE@B?/OKLL#';Z,6&*EKB8
M?.>+1]3X RFE<G'EA')1AQOT:9*/)$*M33C6B@@9\U#>8(%($)-#ADZOL:HM
MQTHCX?7&H 0M7]8#/JF);;/!KAD1VQJ+S1;YDV%%R_QR:GV2#*A+J%FHS]X$
MB](X3(%EC@PD^FHH?9.R3##A*X5:'$3"TT_06T/2<8#Q$RH6+M,PS/"B'%$4
M23*.8*!YE)H<U0HF2A2X"$P+E',)M?WFME&4'3*=$IVRI8(:6C$M;_4>NPW4
MOL#8T7-1(II[D,ZE=(T[,44X%.BDRR3Y/GVV!D6RU4I"-UF,!IX$K# Z$3V8
M40G#_"\$_I7R/ S[?^[M-0Z;JVL^TUOAI< */9(!+W=V\-4 ]A/\WH0W"<80
MDFB+(-B$W.-,995Y-K6F8F>6EI_KJ28K606[%3$A,551W$:U4CM)U+KB-&7#
MUN&!MGRZX<R6H"WW:"L=-IJWK(2 @L7@G68Z;#ZOF382W&"A51'7FNA5X=H_
M=G;@3'#//<)J9<J/D='7F!)"E =V=I)#C]9I[U,J;+$>W=M?4Y!^H&=C&6(!
MECT[\9CS!0N 0Y1824^X6^U\^;>+UP=5O>E:\A6U=E'.-2*/T=&^[(PYE8!'
M,-?K+#+XL(8!+:TH9$'S12666!:4N4O:- I\64N_CGT,-S*$HVKE)?$HVTAP
M'WLL'OUK#1[9>F==!T<FMTU:]UIBS6X%O_,^Q"ILK,)*JJKL!;4&^P[NAJH[
MH"\K(<K8=P_!52%7U+$&^AZJEG2YF]23DMZDIDZQ_5."7CB3)D]B-U*X+*E[
M71F/$V)K250KZ'"XXCG5#O@^9ZB=6S;)RPS2<9;7)KN+#*BN(X;IJM:R2H@@
MOT "OZ'N!?_F<*ZGD)TB]$CF2\SO=,6^R33)*0";HD]/T:E?80/TAU8FSC98
MU4J =%?*$+=0#C+7I9Z>KI>3IX@ ?YG6QAW<3,B0,EK7[;.\Y$67ZI@6?*$Y
MEQ34U)'K3B:F$M_4C5@I^>G(;%/C0SVP\5&M9 9+BO,DMC1),^:*D&*3GKP+
M%:U-012R0$UH3YERT[G(GFAXRXDEDJ0-$-TX(6SPO.1$F*!*4A9)NTZYN4PO
M:W(I\;?9"DA;O/NZQ9NY"?5UM.=4*S9U3;+>+ZK4F)1G'A6CN4%$"@%/[^'X
MJ7QJ9DK=K-]+A[1 F"PF@CQBC G$&X.Y5.L'6NM7$OKFKL"E=%$ICO;08QAR
M=$O=XR4/O]UBW]PX-\$5R(@LY6NB:7B6C)GD8^D623O6/-+]4?YMCD]5Z4@N
M;:%E\\VQBID%CYB$LCW@H!"1;,/"Z%Q'!#$GXG1N2*R2#=JX90/ZP4J#)?=7
M[7^:55DLG1V$F<Z3G3CCK9.M!(!+ _4T2\H&B>ZF4>JAQ>@-83&W*HS)23J
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MX,/UG]7.QVBMRLT:1=FHG,%KP;',13!1F<.WW@V\&%0)+/L6K@3OSBS*XS!
M,\"'(=E[ALO5L&]!(2!/%'*PPQ>53<37BD>AL3&)P"@!^1B'HSC IX:3":LY
M7&=$9Y$EK9:&8S9L-,$ Y0BK4(( [L D@*?#X(;23Q%ZE@0&1P!;@T.@D1LG
M"P-0>.2:+>WGK).^$VW:$.=MMS3^SC/@=]X52$PBC\%Y%@8SU -LW&XV\MMM
MY-LTR,8-FT@W(442\$.HMHX)QI%F56]ZLX/?< >%^B1XP%*@D[?*^;P(1PC#
MS3?G\YOO[M$T2*Y""FP<P3.R-*YN*.Y@3L8'100GB.VZF3*"!".!(1D68"@B
M7(P08? O85A4*M8G2Q$CT")HDHE 1PZV#%S[9JQQBZ,L:6)%(/$K ;@[F8BT
M@1E$H4@S2.E3.%'CV+VK+"WG9$R!%1M'] 7^ZQ)LD!'6@\%,I+G+)HY8!)]_
M7.UM;$!A-L6;I1CWA%7W#G?_@1]/RP)M- J]U%ZO\BX*QH>((H6(8Z#^%KZ>
M7Z&QC.H$SM,;S"*SG0O[2[\<2HT[;M"X^$CX#O^9_I#.1?@)UF2CG9_-^07?
MKPXJ6,U,6AS W^SJ-]_5=NL8U,A];MC-UCZGD5=!E%&.8(5E5K&97@=OM_=E
M1'>UIY^PV<=ONX\8*W#";.]C!*_QNJSOR)>7H]XKXB"J(49Q.0YSIZ$)QB,&
M"='P B,:C"Q9F2B"N]*0M@QG,(WS>91L@['MPW?2[ J&\I_E-O4RV7HFF_',
MH#C[KR30^3=\ET"BO?)^1U ^_/FID#H\\03#D_%*\W>E\<QA[3I&19@<<S7D
M.KSR+F_G,-UN%@RCT2OO-)B%O%:G*:[ O@79D=_"OVS@1,]4]A]%6QZ',W9:
M)=3WCG=@M4+<V]_9VWE!2=7GO@QKMU>]X_?=BSO?:\;>',#>',"#=O@AG]X\
M]]FOWQ91)4R[Y2R%>=R@ZC.9_?IMD7# 8)-&#6%OE^^F_#:LW, JE%\/7E!.
M,RJJ"/1:V?%F$Q][$]]%\;T#*Y7+:F]S67V5'0)#ET<]V-X#_WH:QI/'L"TV
MV_75M^M@LUW/<9!U:B2LI51XEP>HP1>P4?O?P4:M2XC*36QUKQ 5PT_SU(N1
MCR3(J^E,P0$F*L ,4)Y=^;7F&_],!NFJ.$9=ZB@YWO@"WZH\I&_LDZ3R@QV#
M[?DZX+3G,>VUV!L'$^(]PU*;+7J*+3I)1Y^WR_E#0E*'&QOQ*^].NW7.-6++
M8AV2 L)!R23J/J/,J%_QSL-LAD7U8^]2@*G"M3<DUL6"U'L+?TRKR-SJUL[I
M0]X03+^$3J+@A!'X%.^8RA^H&G=L_'G,5;Q!@1S$B.2;ELF8P/U8GW#K=?9^
MV=V"3]WF[19#ZZH/];U4X.W"((LC^ 0]$T6("1IJRN [4 5K)T.+#%0E0PU4
M.[*BA9/6(1-!&<#'40IV,*@?O(:IRAM]DB]A-HIR<D'H1XZL,D/&Q.):L]XU
M#6-5M5Y14-%L%HX1K!G?BIK62-(S"G%L?FR4YZ6D/Q3JK=WBD8)XRM&1GV41
M77D"SUJ3?/#"YDHWTG@MZN$.KQ6!1_%K%6XB/5(":-JK/1)%.\+"$;5G(#*?
MP^+[X!K^YH.TN"Z#+]&LG+5;IR51U!)%NY3MQPB/'7X'^NZ9#'(I1^EJ?MW&
MYWZ2O2&&LTU,Y)D,TMJ?*&&==QE\#L?I3>)=3N$RP@CB S-MWP,L9%V,NX]@
MU<ABW44(Y2!9M5@:/ID*P')SS72EJI@^1-9*L%HQ-SD,RPJO%SVO4EU>J\>V
MWF666ZMJF!7JK3U5;NWI2NLU%^PGQV4>;""8-@3S8 /!?$YB[M3T3Z:_-1&X
MS>>]P$M?3)=^'X+R36'*M[O %[4\V51GK]=A5I%R,*IUJ'S!4:[R%!)5,\>Z
MN"8%C"!G^-WW.L$64@!QW2_*0?AE'MDL=Y7@L6_W#9.0 6)=3&<<OA7OCLS(
M%CY?EI+3AQI(91>/IMT2P^&]YB%9W(_U #'3Q@RWC-A;XRR]E2<I4XWWFB76
MD0__$MO%94->,!J!<8)VI.RM<FNR&RDV0<70;8U"])UHW&I%QFF2<YKU_6'(
MM$2T2-_C\7_.([>.?W1U=3L$NU3S+M\#L.6('^XORY<\YQ7Z3O8V#A)R'8]Q
M7Z-A^4 HW@J8R>>\--_)IJH8P;+B[KE)9$=UHN/%['=,*&SV+J,N#4)[PZ.-
M)^J/">:X7)88M%O5;Z5YL:TYU^AC^HL\-$I-X>!EQ 9^+5IQ\3"R$&\-O*ZB
M1. (U6 VXOCMQ-'50:!:WVQ:CV "\LPI,6OPTMPCAWN+(30I/3=!AGS;.:5'
M)2O0HJ?J/SF:6LG$*QHY\%]D$V'#!F'/48Z8$L2<0\Z%;=?D&7.,LF$66U5>
M')E+#I1INS2#;"P$$9 ;Y$)CJ?QI$G=KV*26OY('WO+9Q'7M86VQ>>ZB">(J
M6^C=>0?OO'44VFW:.]?P5]PZE00WM\_>,J-[!<DJ#ZL(B2M>LEP:* 5<4G'D
MD,$]BT:H$O4'Y"&K=-JXH/[.+UX0<Q-MB^9MDO*5R <K/BEUES0_K4K3BN[.
MR#S4SFVN4S_1/Q/R(0:RBR+.M[Y][5;5Y[1EW+X<1G%0(M,Q.IO8@ 3E=)C"
MQ0,SO@EN.=+.Y&'CZ#H:(SU^*CIQ>SEV!1?HBDK'@G8K6)E$P5O$H>!@3WB%
M9A:UF($+%"TL7UG4T_0FO,9\,?R2!,3GMI6\"$2Q/BKQ<0[?[]:O21.KXE&(
M1XOS( V>L3XRA([*:=W3$?P=5O WK].56VX[#B8-:V73*%$2Q*0@W,,B*Y2;
M@!LDK8T]JE3?)U/=64]"OQ7.H*_\S@S)7D$C(DDKD9,9&!^G7VRYU94)"KB/
MX3;S@<?C\U8L3R?:6CS9,#%.IC%,&XJ#K',N3WN+.72]!"YK)/B/)C"2(D3R
M_ S6HO+BA#AQX9CAC0$S'Z;I9XPV(-,OW",T/?R,#A? V4&:_E"TCT#E0Y2Z
M9<:#4]&'RI3&80Q;QXJPWJ>96'6I=RHE$@J#IUKY*<U2@B,4N;S5FIF!;CP2
MV\%1#/=>T*&0V4'C6H.O'QM?-P<DBFM1QDA<X%OVD,SK%G4H/P84*;4%)C4F
M65J\#'4L*(%9&5^1V=LH^!WL)D_BF:3>=1J7,[)%P%9+& C$QPQNN!)$2:^O
MP4 L5Q %>0L%MM<P1?LD+9^EJML"_=O94_=%908P-G&E')I3;K<:YRQN#'NY
M\I76BWN2=M[53V)E<EBR1$S?65I>35'1>L,L_8SZ?1S"DA*'.;T%6W91;QAD
M@W0)KZ3*$7\TWFF2YJRE^?]].2Z.F(@-0K!$W?=L0UN2A%)-JB=1*;ZXO=@.
MG&?AG'4NBN&$JL,KC]4  M\  9"1*JV%<3HJZ=8ARV0&5XZ^I(II:)[GW'WH
M=',VX\:B4R2--U3R5V!,<$,FZUQ2M)9$W]?WKGL*NFFVNL,W^(.[X0]>;/ '
M-O[@Q09_L%'=+M7=;O6^S,,D7UHC $8+.&3;<_#R0M&)(A3?9)?PPJWF?67R
M8%>,0OP9GZC<^FI/G/59U;65!^U^QK'=3L^'?<J+RFT[P9RD$6FBGZO^*7\V
M=W8?4=?L.]6WII^,84TR"J;CG9EFR*U4@JR0Y\W#ZR>CG2T51>/P&GS7, =5
M#0>&&<Q.@F9 "W^7T,3"\5KNUQI+FO3D46;091M[IMZHFF(FKSHXV A=RC_?
M>G%P8PD@7$PY2 ):8!.9+P<'8@B.E#;AT ?%[C*RXY'L0O1)>R"YL[>F>NW?
M)2PJA00BP4COCO9L^E$_L5#)> 0VQ$)EY6/'M3P/$PHF%F$<SJ=8U4ARP;&4
M6R5W:SGE-=XL&?W1A[;=:CZUU=,J E]K.?4UWK3>G38-345\]3RD]PO/E@*8
M(H*#@>$R*0+#O:Z"FT3$AQMRF)$"JBF&:Q\/<%;D/EHLHCF;B"&K= I\J<Q$
M%655K==BT6NY,VLL4^],HU-9 0W-K3GL(VQ2J>=-H[3F=5A(#)"G\TIS/ALX
M82 P1'A&H/L(QA.(,).^/\0K1^F<HI"<@91Y)%&K[)O137%4*/"9*S2',>T1
M)L^*@%HQRDM*E:JX#0T*Q:[CWJ^QU+[?(B,1_&!E.!;@39QA.R5R<%W&J&GC
MHB&"H7SJUVS=;Y0[$67NC<:E\*.T2N5">FKGQ)(<4 %^-31I.^3P2A51Q<JN
MO\C-@E7:QK;2F)R2:EG11JL*_$[";3C!UPKA"?]UN.OO[NYR6AD]>RJM IT=
M&DU,62$OJ%M_QEN^OL*Z(,XS:"@9K/:\;0A*$[8"6Z9G^0+]5,/'4%(^CU0_
MKPB4K=$[6=_Q3.KD1-PMB)7[IE8W_,-&S-R60_>G2]Z@-/<T&D9%+E'@=\3;
MN1^_.1_?\GS\789Y81#D/P7OPW->G>]C7P<&G.5./.":_OO -Q"Y=R']?LYK
M])WLKH.^N(;=1LIC;["]QXEEW_S=@4@V"T#$0*-H^/<+L-VJVIQQ*QLI^,92
ML$K-C0.$0 @?M\G28/Q0"W3MFNKV;C;D30 MT3BH I>\%WN'*X*3G$@=SF @
M9Q49-1N[^MO+GD2K++2G;9_1AKE(%01BP7A*!0=$W HZ=25SCC7J)&7P(M1*
ME:)9']\(RC<4%*;=? PN\,TV?L-M!!-AE$5S]J,?U%9]LZO/:E?9\!,M,1JT
M[ ,+/I?T7GC.J_6]['-V'=XZM##N7.X=144P#F/O8QD7T?8 MS^\NF4V4#3)
M/@88=/7>@;WFG13C#1+S;DC,PPT2TT9B'JXY$O,Y'_OO0V%=3J-LO(W$[K?8
M!$@6CB*4;7JO*.6/0AGTG$=N;;!P\Y8%L; "4Q?]@:^8YS W0>/HBP0@9B_"
M.*8*2KB\1*6/*D!6?[["TF#*F2/2@FQ9JTY85MS<4'6O*/$3%7[6X_2?L!(P
M U,GON6*3_D3%0&!U ;#.,JGDKD1?-6,RB8I;S\O"ZIQO8:Y88&5+)^##\81
M_'XLLE95D"G\?1R:#QI1:L;Q)/RFD'UY()CBF?ZZ]U)F*JWFCY77,8[ )E/G
MTFVN^B/6<PK6W 1S7;1$==A71MY,.O8B=T2?(HK*&SC1H:B7Q5I47Y;U4N4H
M;&DZBT:<6^6+@HG#TYL$'C:-YG)#)2&2&.'--.2!<!QI:A9-$1R6&3S#HH@Y
M7:4P<O6J01KG*,BGEHCX5%S3&6TI?$^2I"4,4+&,)K0\R,7$DL:!*\UB)$9C
M]0O@VF.C]'BCIKZ=FC)@LHL+O(Q8JBCS [%6FF51:S*BT\\0"3.G'&HCR()B
MJHA"P"_ .9%R"IJ*WJBH$)DN?WL6?*9O8?IW21.TY[P=WYD@P8ZV6W)+%X;K
M+5<\DLA^$QQ>@1!FH2Q!M61(UIA.HFQ&W)A1P<S$"J=%Y0QXJYCEIQ*\0*IM
M(SK/173L\/G792Q_SBOT?>SM'V!KC;/@!GE03],B&CVTV_/+[X"#G@<Y1%5V
MWY%6(AGVZ!\T]N[%9?_HI =>:?_UVPL8^47O?7]P>=&][)^=#M9S3NM[F%#D
M8:B?WM2CUW@0UG%*WVXS]AZ\%7OM5C<'(P24$5FU:'LR$!?91I+40Z8#U1HJ
MRI"[ZV!W"QW8,!DC0T%PFS?0DU$3MP[^QF[LS2!U_&M%=6[Y-FL,:]*\'((!
M)-QHQ#0X(0V-[1<(L>Q"R<#_6CW&::C\TUT;D8L* >Q5&-DF7H2@4'!3KZC?
M&,P!/<6@@NKQ[SYZ<&3MX>^M,GR!+*HM.T$TD-$9<4(^ V;E;F:AI&_"S:B
M:!7['UJWG7%8(%L15K@$;.S>I%YG?PMD2?#-D;0H^F7RV;DN8LNC/02//KAE
M'C",#$5)F9:Y-PSR*)?D;S (7$.$M*)IC,QN\+M;K*Y1@';PVM.,,:]T#].+
M>!''(;CKU#)0XVS=!T!3.8O2#5$]X3N/AJ3,RBC4T?FRY<&M'^)Q^;5V7! L
ML[>_6_FMEAPIT^ Z8I AMR2*VQ]BT =60E'$74?AC31 ")Y31QIM+3JFQ)5S
M*^08?=C.WJ[XR=X\H[F<%G$Q4*2ORG S1&Q(>"IPJLD30D8S_+18J"VC#$JU
M<5%<>(X#2S-F-BM[XN%83AW>:W[*8, 6Y%4H)OB5'6^@W\)2)9C85 F?%OP%
MR'&%^";AB&Q6)%R=65A,4R'0BFN19(3_DG.!!:Q9<!U$,3V_X20CLZ^WF-A7
M;F#* /",L<(4+?.-DA\O"6:*WR5*=KS+FM:=!5&"U6I*^SAHTG!=\,3GGCP9
M^HQR(50H2Y_<2IN#(1KG;D+K&\'P?A4,CP=7<')9C7H^A^%<#5^K$UAJ]5A?
MKSK7IY3,D,=LZS1<64Y"2Z:V642H\>?(R<+G% Y!P^YB\M$E!ZJ8J@*Q*V$"
ML0B,PCTNH)VXQ/!_J(Y2K"->$+?:\?I"4UUSC%?O.>Y0+NXE=5F(N\ZW/MFL
M@3VW A;]-A68M7(7>1U92+D0TVI4@FPQ,9Y]=_,WEFIR0V>Y+^7*$ZV3(<-U
ML$%#^')@T<]%>156SS\K^FR?E\Y7^B6X3B,^3+#?X[0<%KZML]P///B&,8"'
MV9OK;"?OL\^R2$1I5[P^)Q&$T@DIE,R)BQ6X+2<"6\DGR0M$X@%/.]R@<;/I
M19'$ F\^@\+0<7#]5<7+7_6(4R52P+QA<TRJ!4CFJC]X:YW$$65*C L>OWR%
MU\SJ!*!&P10C32,<Q0J:*!W2A2:T+8R6M"\'<U2.$1$;,,!\+CI/D[Z4@R(S
M2":;: );OFV7MELKJL65EXPN/G/)Z$X6K(_&=[!V<R3Z@X#I4L8%%8#B^!\^
M3>5Z89Q[/(X$HTT#\!R+4)PZO!,XS)H5:QFJE@Y_6>H4_INL-G7[+G?V6USV
MK]-Y\6OH>8)-.NPU5A#>JC ^E N"\3_P$E8$[.8!K*Q[(Z4OJ:^5Z7E7ENL&
M]XK9=CI#,6 RXISC;5JRI9:>MX*AIVSCKVGI-="D:D,/1G%/2Z\K<^BKKAJ+
MU#"LAT6*E*,R)EWY$EN*SP8\9<<[4[GW^X]'8 ] ,N98=9 A9[EXO,,\\^YH
MG1'6]6[&&5YZ][3.GH-!\R1PR[U5P98O-V!+&VSY<@.VW#@@50?D@!R0KK:]
MW)J?G9#!<B/?QT_R3Y$=%1!>AX@4(7@S;S2=^--T*UGT2:A&I?&U)*YK638^
M=R"00!H1OU*V*(])>-+MEC(T[A*.( /(-@X7]0IDWXTBX@PZ"R/&P=FWH!$;
MF#-U"<=J81+:[A !#^V_#&\]QO,SNK AXD6PLN&M)I%>\0YE2TI/. ]FH=.8
M6Q@V,>Q<S0&MG(*5AZ+N<R,F6XT?OE+2NK KAB&Z-6.$7Y,F\2VSSVA23UH'
MT1TA6':,)-8P53N?H@K&/K0J:'\;!AD).F5.I"G'Q7.*DNE?08Y?DK8E._BP
M,5=7<%K0C('OX=F9@=:6J03LD]@YD*Q3;F\KKX]E$Q%Z4H7\@A2R8./@G5U0
M-;NZ8N;HBQGZH1!ZE<P!T;()R9(^QR(^D*/.;8JY^PJ@+455M,OYH!F=%C,M
MN4],NR4;##G$OJ,@O8IRS)WBJ+$XK>+U8^Q?W!3,BX/N&JD!4:D,NE^W85WD
MQ#4C.3GKEML4@;:[+[0[:@-L(I$XIK= 0&H3[;]Y94S35HDK*3_A!I$O:P"9
M%]9V1^(R3.6\^9'"O15W'V4W&UOKRJKP5/5(89EHMZJ;Z\OG(0@?YE;*U&&1
M7C$2G.27T>DUR?!%"UOX=$&!+3%B< ]'85-@C+G ?!494WK8]_[K8->#PQ^C
MI#0DX#Y&230K9WJY+D%7YV@A.79OQ\-?>MTXEL)95Q)5<&"NW5XBH(:5NX*5
MP2YI8K\2@IQ)D5-6DT":,EZ"L.FJ2U&6?HF0\,E+RMF0&\4TG6#7YHF%6B T
M[(3#TA1(*57=IRH<+HNNIK+ @S1AC=H8%\D6PHXY/2PKB%@;(44==L!)J2?0
M7#2[DWS;9 *.TJLD^@_A]+$DB3M5!,EG;&97L41JEAR'^F@)KV%FUBA$@KE,
M#$%#>40E2%4M?&NSR2NLWRU>J24F FHSLBC&M)+MUD+S8-&5XPMSPUM@;>31
M%Z_S<H6'P7)8^@YTH:HI=^6/Q0*9%IA00?KEDF)PD48:EYELNU+<A/$UZ)'.
MG@S-SN#.GJ(E%*7C'>\T+7 +5&-"^ X6TUS)#>9:(RJ J4S CJ[2#NBZ#^>%
M8"^'LO7U7;R4_**:</35'5/Q&FKG86/H/:FA=R@,O7$YDF:$4R14_H]0OT$2
M7.$NFZ!^4_OC47<8'-660O"1JS0%^R\ R4:S8GP=Y38BB(6WSG\I]8O\.5/$
M<=X<25>VB76%]'&5 =$\&[6."1R87G1F&ZY/S5QW%^NN$U'*:LL %*D8=+LU
M3F/LDQ3,D*89%WC9+:?CU\TK5A^HIT8Q#G-L0:<J% N8=((6EFFRD!E&/S9T
M*U5%=W;'3&M\4AWQ&W.5B) LCNX7(%!B\1L(HRCD!EZENZ%IM)!]_Y/R<9O%
MIMCDS'P<>LJXD<6=8-A9(F>J1B%_NCNI9-3.C=)A7QANN3A;7\@,J^V]_(.6
M 9Z\U?N/*4&#9*&%HR8HR6+AW,$XL!5OP"I>9!B5R63;GWPFP4]3:7BS4@=9
M'!#[)?K.T5.&P3"*1<]40:*E0E/:$*(?[S#_6E4DIF85V2[#;5V&KGC0J7J0
M&6&L@$==AY:NL+IK(OT(EU#I&BO,M& 4N])U[>Y'J<$9,=K1#J6T:3[C>@_G
MQG.T !>(&%#PLR=1EA=-"KHFB5+86-C)RL!O+MH-KP.3]. L!1A-I3B5#&[.
MA26RFD8DD[-FO$^#7*N%=FL8>C6*VT47@6H]IPS0U09#ZJV!U[G=(HUE0!OO
M-BCFTE7YY1SKE3&]7N_)O&SM<22RO2JI3UA"BR,/A?@JQ;'+$N%HRU]ZP]QS
M1^MQ>=K2VIOTBZS-O>LR-NXMP1=7W%S',CQT<^6A(F%UGZJE&[O)WJZ>O?WG
M)GMK9V__N<G>;GS(J@_YDGQ(73O*ON*YQ)(9*"BA&8V."*K488QI,C209+7#
M7#//PW.,GS0X'E.CG(YEC@$R*I9I4?_.O18X^B=ZG2R\-G0XD(T;%0^4($5.
M=2R]?B14%EV^5 )F;T#YYRG5F5AY9*Y/X89H8)=Y=ZOH=;JE=M!0W8:+W'UU
M\:I$A$4U(A>@W5II!=S)TDIFP''!4G0K%KZ\"LO*>8CL?$B9I269 KI&&T/B
MWDU:PO]G5#+>Q;#Z.14)B1S1ZAD$%:Y?-"#QU"7152DU<@<,JZH[P2,(ADS5
M3:*@CMR=A!J$<VQ6QE>7RSL&K8NH*+'2Z@Y?%G.2[Z9J+7GV)/L_/0?\<%PT
M\CM<C '8XB=&EU)F< +1%MUI\:-).\<Z*<90JJG7PZ$54F&92W0_.@NC&37@
ML@O:9$L9*V(J^[LZHT^+UJS=ZN@R3/0A\TK N9Z%"CQE<1NIPEK?+3VFQ[#+
M%[M:=[9[7\GRM3&]0]6AZB0OIB1O[>/ >D!6Z<ASOU BW9U24AE$B68S,+'A
M#!'8-QRQO8TM=M (\E>('<I  :Q",*:V0XPG7SPL/E*L6R@K5)V]5YL\-F2S
MHR$KG:0=[YU518F3C.:*/$I?)A[?)2[@ML(MP0MO@FPL;N3:=V5J@0,05MA@
M"HLC>R,AC#D N44^HD('5ZI9NE73(T+;-N='5(X211^S<3)+86IU^\0L:G 7
MU&0,S2)*6B.FRRA>6 7-^Y+5'2\9'7J\=>O'38O^/+A=<-CM1(_TXX?R$O<X
M?J!$7/8+NB/+Q[,U7M>9:&*?B2;<#/,;'ITG=X/VD6W"WA *_EN),ZEDA!F8
MBQ[=83-%0F,I2M5TJ*HGBE0YPKJ8;[4:.K,RT64%V+\;8:8YV:Z( !1LC#)?
MZPN@*Q:^DG8DRD7'JR:HZ%#+442-FXU2K94L0Y"_FECYD"J16(=#V56'1/QJ
MT3=UQWO=&,]L>;^Z.="HDG%[MRR-W+B5'6FF&#"KU$S%Z.UD0M@M7=G$W4Y<
M]PL\+YS-X_0V%&LAF435U@[#))Q$8/3&*+>@W1F% D/5C=HGHL6%&H_=CP7\
M%#1ZW%@2>(QH3V]GM9B)TL 1-,)G156.-]A^0;N=PQ[%C#^=L460A<A'P;6%
M-E>EAKE03Y>]%X?-9Z:QC0NM-@A)9RS7FQ?(7(YQ."P4BF&Y^%=E$9V'T'RZ
M1["PD(@,#/P.[1)%#UPY)N39JL*EI#E?S];A:NEXM(&!;*9^=$"EVRVF!(&S
M@TX6 W4L$@VJ'11I+3K8B;375&?8L0#HU&T1?4!2)F E<TV2R28-:;2*9-7A
MV?X319I2E==C!)78%-ZN3B17*,1V%4.Q/)S3)"?^=AY6SAI'!FK^D7X/N2)H
MD.&?.=?:R25)SX2(@E4RUE>A BS\DY*@)&45((?.J->'0LFF*%(O%^S'5+^P
MLM3AI](Y.J=E@F<(3>-**M6E,>D/RV%_*-,&-M<S\+0FZ$)0$T_P?'4.3;GF
M0@'#$Z+'5<Y@IVF8Z(#;/"?2/EC8*6O+1%/;YO8^U_0YZ]]M0(U9D-Y8">#.
M>[K-2MQO%@?#K[P[9X:JV7")'Y$86Y%%N>0-8[+K7!OF:7+%6&)9A08U7?1L
MWL&Z5XYG(4IB1;R$JU"HZH/*4R14,F<W_U9=;<T714.;54NJN/C%GKFD).=+
MGRG!(V>\QX$,=W#?-*N8"MRCX/H6B92%T>?BK;K22MD*"\;0M,&NXAKC2&M(
MJ\6)3IDPR0:N>X!3;$!]#@TJ<"/ HL]NV=I0TS=$$*:N>S4KP*(;4C.\M5C>
M-LG6U9.MOVR2K7:R]9=-LO5[B_L\/,JP7P?L+H@!/12Q6RL1XNO/T-6V&5,S
M01R0WAIVM]DTU)%?HL(1#=N<TZ7 ;A5"6T<1&NC!1P>O-N!EE1- M_1=WZK-
M[X!>Q%Z&S?69J6ZJ%2L!TRX$WU(IA$685L^$M!H-,T2>"FR-G'@],KQ<A>VB
MXQ[-.VHEB=!8H-O8-SR'!9:;.6L+6ZOFIFV[%0(V^VS%F91^,(PGV*'%^^.<
MP^(-6H(YAO&OOF$+8&TV.GD1L(P\DN2W]5.KW_ Z>&"XO!-LM5M]NW)U@<"A
M J>S1WI*Q6&K\3P1EW7EQ0S'7%6]5J+.[C=WNBJ2J4##7T,#T^%KMQ8"CY=*
M\BNO\_:;(&B[6\MPUU+#BAB]F UB/?C8JX;9_(XHT_=S]6YM5I849:#0MN(^
ME2 "_]Y(;/2+)#[ 0 7DZ5V  5;SF?N KPNLJVF XS9$WIP#D.&^!PJ:X ,[
M4O=/E-U/V+P[REJN3R3588+ W_-0WOOZ<]S@=C[ZR:Z_!?;*(^WS.EXN:WPM
M#N]\+=KI! %B&][>7XA,PZ@QG;/L.FT:\/UO4[-:3)]<&2$TJRCK$_?O/O/F
MT]-N/?5][%21HNW4T]W'S?P$J]S'CW$1>\Y[^"Z%4(]Q"S?5Q-B7,'GU7_T6
M7N$"7J%8[4$WL+?J!0SGYA%#!$N\:,X6NF_:=HM%W-(B^'FC6:[G[)6+72YQ
M.8JI#.D@T=8HBQBXH(!YJUV^RW<&]O<8^T-@DX2O:UR!XZ'WUL<]]81]]Y4]
MGH=K6!IG3UTKD\=<JD5*5B^5KX\A#>;XZUFDY*;>ZT \T"9EH(:Z6F&+[FM4
MZ$":K+->>NX>4U;6T2Q<8X-V=#>#%L_/POJ6JL$K$1%#F;#%G.<B,B7CVS88
MV(H:/++9:^A%OC@$C1$??^-.J>"3#Y^$M?@INA ^UB!72,?^NDG'VNG87S?I
MV.]0,S\X(7NP (?O58MBNYI[N/EF[UAHXGI)U\TTS1VUI:*T<AGI$K?.B@F<
M::"^?8VSN4)6V(2Q4JY*CZU&VKOJ4)H@/?>O;[U[96J[99:F3I&3><J?0KR:
MLTC5J-)MF,#<+&ZNM1:I7=,&UIF1W*Y^8<YBP(;WNZ"RC6.M(V6K27LRS+].
MB?;B657:<M11MJ(EF$9\VW1\G9LI9]JQ)[FH--#P T_V/M%.<"ZC)67,96V:
M7'629F8]EA'\6]D!,,[3%B%-E40U]\"TY('Y>81 .,O)&C:9^1M)*.!$C:)L
M5,ZP&&ZD$)K2Z!(BL&6Q\#;+,Z6&%Z"V'\),:&DZIZ:Q<I &S_;C%.<UHTGT
M@KBJ]##D4(>*4I3N8%,*]^0W,)-5?TJHM =VNF%+S7JL=Y5B6&R;"EZ$19OJ
M$DAFOF]"(/'!61&(H@D-V%NRJ44I \\MF^Y24T_BN;!8R7SE1DZ?L+01= .7
M;'ZDNPTU:#+>!M]6 /7<M5WNN'LM%F9!R"G^54.\VS:1 @3BGW2Q@ID5H'@?
M<BE0>V+,<(Q*2C# QZ,1FU#C*(,14^&899<)J@3\IJ@_PY( O)[9\E6L!6@0
M75/O@1%="(?_4,7'1K._QAA@I:RR"A=<E+K H6$$M5*XYG-*OEJ9;G)NUY;6
MA:[T&6;.P5 -$$1#9H)_G<&1%<Q_:58(]/[$]^(410>LI_$54AC**"<VF?*F
MMW/\842U5)B7&U%XSO>NLB#AVUP4_\D[4>@X>K+U**X/""5*_^Y)AWJ5IAG
MQ$<WEC MX&/=DI3(^&BSQ_0XN!54R,2!(;@?<>GPI=1( )_!^:/F70&S; @J
M.TGH%+$!+4O3D-M2EC[:94X8&YT34T/X90[KE&-';BZ]$%) 7XAAR;;+N5%?
MD&;22M==:9W#,G:&OHW/- S,G RMGG$X+5%?DB5KE'4IHL0=CZ<;K4-=$%&?
M#U9(!=?ZN%M3P%HB&H2@E^Z8?=<]KM7$ UUP<5"QM%PFCJW2+2RS3=R?%K3I
MTM\@  >=@T.XN,D)-UV009E=A[?H0I'PZ4O^P&PR@!X0%:,)IL&:JRZ[E>/B
MGHBE&N Y0A=%/[?=T@]&7:">BZ=&Q^GY  8CP2@.^R_Y/8IIEI97PEKMG_>\
M=^#0)*.%7-G/X\I;*:0YQ#3$?4=:B?W9HW_0V+L7E_VCDUZ[U>_W7[^]@*$?
MG7T\[Y[^Z9U?G!WUCC]=] 9/,#-EQ#SBU-;7ACJ XTPVU'NP*3(P*,ZS=!3"
ME2%[@S584:*!=C+^F8Z:'1"KYR?NTAU8*+NZA^RJSGM8(=Y<M%PUR^_P$Y1K
M8;-%WZQ<U%Z?G"^NL9!T)U%@8;EWFI,S_4W0VS\J:0A*\QZFL#"D)#HA-30V
M:NQBUA16<H;=FDHL$ !ZYP+>197\SCYL%'>>89-JL],N=H,U"=*J]2)&<[I%
M;Z18-'4DEQ B]V374$S66;SW5Q1O;EPG>P*R?=?4,3!WT=V874A4(S\=AF9=
M31:4BE*3)L0@[3!<XMTUDX5*F ;-J;'V7&>R$V$B-S)@V$[_PC01A[/5!+3A
M2!'N,L:M@'>7,0>DV1F!YW#A8$X-AV6,7RQ.5DG2S#@B7V'?T7P\=7X5>J\&
M\9CO+S1B!5Y'K:\IXMVP%DN4A'=W'8%2*)LB5"Y:!I$MOFDMA,&27302(#6Y
M6\.C_+P*Q?=V-] $&YJPM[O!)FPNW^KE>R"[O#'+'+?E:M99YLTH+B)UYU9U
M&GL7OC<ILR3*IPJ5.YK"C-1U8M$(M5L*E;ER_7<MA&BGK=5%+YXD*AB].+P*
M8DJAY&&,#>OF(F#)#*U-UT.-GIERLR(HKI>"WVKJ]T67@1T%4XQT</O"?19^
MF49#M+JENX;/'J>CDNT<^'2:S=,L$-9(%D[@8WBP"Z:=$?E1O7.+5\P>EAH)
M#0_,-,R?)1CXT\_;,A99$,NHT8E<NA4#O/_65K9%Q*^MG52P$0>A4]5\P\>2
M>B?A#T;8?@CCO!3PM;EQ*@4>EO>!"0MM5XA7OO*J39SK,&T#(9.D!BZ AB,.
M#<&YU7+.2_C0*+YEJ:/(O_A@ UZDBM/O(4--EB;1R#M&NN?W 6X8GOIN$L2W
M><3;<Q&"21-BS\?!+9BE,Z]C\5/UCM]W+ZIL5&NH -=9<;\P%#?EM4@T+#;"
MIGJK.[CQBEQ2%2C!&_\N85$F-0[[)I>\V0T3Y1&5'EWX"B%N0S#@O/SSK003
MQ<&-ALC_!9_/QQ%[*KJ)643U2?0.I7\>>(M45'5,4#:[AT&31["%:52M<3J,
M@4*MX(5$[3B2C0$"S)'>5HBKC.*.IL!,AL47X0R$3"/2LHJ:Y!T3^+@M45 L
M&T!AH;]PKCDDFH1(?1GP8);SPZVVU7Q;&GXNNU2I["]KJ%"^1!AAB-]%II$2
M; ?-]B$<6CU0^.IUE!6EHB\<EGE$4#N<:CH/9=/X2D:2[U*F7+7;"@:C0EY5
M<)S$/M3>B\-']AKI((=\@A[E>K/6#K-7Y6S6<#TMB1C7CXN[=X:O?CM-;Q!D
M2;\41?GUF\O1X5:JABN.O7,2:YSJ[1!P?G,PV,@=^Q04HF$&/E:G.HT74'Q&
MO@$UGTR/"[E593SJ438AG!@4J)KL6I"BSC$WD.?\M"^\[F;%@7.<8*6*E#V6
M+NBAYJE\VQK>*>M\%Q[>(S2](%1DGDN4A&K*!J0JCBCZ)Z.2DB0YKX QL!#O
M*@DD)R \8VR05%%F&Z:$>!>,W==I'\&**^NQM8 I=!,UBLQXT1INX3J+WDMJ
M&D_W>:"0.UYP)?SA&Z+(*O@7U>:C(MW!PI6I-C"+E#GX"8C*-XH 50BTW5J!
M/WD-5WF=I>.?LE\UN_<(KS':TC;9YZH["M,*PVW&]RWQ"Y.SR)S>R,A?8*[L
M<Y+>$!A,97JEG8,*! /8A-"F6ZU(Y\+IU5I%9UC I4]4@6>M9F%)0)O#X]P'
M3;KGH(+!.A8.">&SZ<KE*E+%DRHA:)32D;._@TK'7DT2.R6G[-5GS-X2+QIW
M'3!0VY%L%JP_GT^E%<&*> VE<)U/SR]P>I!0/L@+%^GVW-T\L'9C-P0PE\8O
M'3$[X5<V/TR&:CR;"[,Y2$?DPTO.E?&:#E@:*CB(;1U<P4'J*4;K@9[2.#18
M"'JRFT-WM/H8=2!11:4P7GHKM0UC7%96<+*L2D3LUE XU_E0_=IN4;&<37%N
MUOG<H&D9F%)'I8"B6F>1K$:YY0P.T0".(XX.N!INM%L@ANJNFH)I9%X5 @]+
MP%1=C,4>WOTBVKZ(!Y&/Q[>;+[^+N6[O(^AY&R/ U>GH?V>9PG"9'R/+W<CZ
MN@LK#KAWFEE8L8;RL\YRO[>KFFBR7-4[AQB400*5AX*'8&X,0HFR!O/8^/4,
MEF<FL.AZ*8HT2T(.%3%I9H UGJ"MP0JI)P[\2FUJI;F=[TE>)H,F1+%R2B(N
MS=.)!3\AU[FI:E!&VX@+;6$I*D]#-V.HLH"**@\8M"SRX)B9[#;$%#0EH9FY
MOA !(_P2%YRFW1K>ZN"+O?:^73DQ88!SP*T2L;,HI_N<R]U4V&?.^AXA,<<H
M:X399H\!',,$@[X(;T=P>*#["T8"3,.IM"'799J+5(T2RTI0KN:QC"'0UR'A
MZ:G'PRA.\S+3]C .VMB(-3S/SPQJLK>!FE2@)GL;J,GF!J[=P'MPVW# 0O4[
M&B'4#AQ\M)Y4DB\L4&52-LMUZ>"(,$R!E[B13Q()4*WT54ZPZ;[7G<)\1Y<7
M+A^Z-AI)@;Z4S8;PL=272WX)%L%,A"V=GDI-RE(OHREPF#4 %F3$L/%."%@^
M7&A4U9B'+ "K"%)"%M9/K-;Z..Q34T-57;@DQZL]*8J:8:F(13GAJBTI-#&?
M)=QV?T1A V(@ "3:ET%%S&7/HX2LJC$%!>@=8S)"L1Q> &Z4_2/#AF9;<Z.^
MU!U!Q.X?8RR7%.F]1NETT;@8YK9]4AD2),_KLC:H>/CEGS&:P2XFIZ)Y!="S
M'8;X>&RNF,BSZQYHQ7YOP!Z1?\!;:^J0.JFI& (O0((,JH1TS\&F(Q-1Z),U
M/ 5K?7H/7.YD4RW^PI/JVWW(QNC4T0U$9#5&SUT.H50ZE>F,([YE-!5V/RJ(
MO.)?E#DU;<%[S;KJ?.T0N0J/UW"'UEJR7B!D")$-UT$42V )RD(N:XH55Z=1
M\66H&*/XB_H7AT&64#!8!ZV4NB0U1C7S),$RW%[<A#&F%#M[^R+D/H-I3'.C
M,E[)#/&+4_&]#:Y1!AM_8%+&L3<"L4S& 2&2J"R?4UQ6MDD5VU?UM!E]%SJ:
M[!_9()3\]ES ?-QQN+V]3K"E(W'B)942%4) EG$HOG+XBUF6HCHTVQV"56\@
M([:X@40^\<DYY!;>YEW?V*RLF9V40[5W@DG:YQ7Y\Q,,QR@ZE!KNS [JV=Z'
MY%)+@S%F(&\TDYH,,W&EE,:C-52F<<&2:8LLI(#X=IR]/Z[$OH3K6Z*%ZJUY
M4P8N6AM\PRWST!A6N$TM.\%(46-4[,YAZ-6J%BL$(2H"7:'*8&^7.#6DI]"U
MVJ-6(JLU"V?#(;5HW \89856CP^\8D]WT18X,)L*OV25&E EJ([65U0IZI))
M19>()A'P!FP/@:2<P4R6)52\+Z.JM(&\2MJTNO]*<IW&UUR?9,&;J6FR.8JG
MD;;UD*U'Y];8WQ&]11T\BDROT5-$2!H'*3,J'B,)_+H+KK@8T0HUH)FLSA2G
MXQ"3.T)]J>S'CM=GBIV1 D+5>GC7^IG(1P:9[R9"6*TI-44%X,*'#_LT<#,\
M(6O-1@IBQ5X\)F4P2 D+.\S2SZ#CK^#8AKC0=N1 $IR.TIS1Z%9[G4KFF4__
M.)P0!HN!X<*6<"ZU+PT+QI8INP8'PED\<T] .=B%5K6XCUCJ;Z+LUY<>Y.%'
M\D >25+IK+TQ]G:N;W>.<36A-K3>%4>XD:VUSLY:X6]5%9SRF(W3D+'R\I8Q
MKR0Z=VAB:\M$?*VOKQ[[%D.KAC%0X;)C:M4CJ6R"<?6LA+B*;,-=L@7C#EC-
ME1#GR:!#55/*^"I1+M!8,B(Y=ZMY69F]N.N *P6OM#514G)S15"_PN-F)FN,
M)-3>3!1)P9B)TWS$'#/,0,,+:!LJ#LP")LKJ9<X\RDOI FU2ZDK$EF"F=6R\
M=M3+)$;8J@&3,,:OZMJ8W8Y"SPA>6Q%588Z9=PED(<KU/2?6PPS4^1R3\VW"
M"*P'BX.1(/ZV&BJ;=5'5FB55O 57RSP."Z6QB:&/>?&T5\ -V\!*#[ MD._-
MTQN1QY)P"9^R:K.$$<C\:$'M9ZP3-UP2G7ID'VVUN_HC7'1%O]2#L(J"W8YK
M9 /%E,M!F^):RW:K<3&MYM1,YDNGZ3J-QA(>/$[+H>B,1SHE%[=FL.+E;T#3
M=!+%""8<,-6S2>S'3&!%E4=%TIG2FC5U17.W'OWFCM:3,  ^UB!7P7/L;_ <
M%3S'_@;/L;$\ZY;G"[8\!U0V(I7G #7S*Z\[OH8[)O2.%0#M%:@J5-8B1)56
M#%*#>GT=5V-]PY OD&#PTYP@F:,PFC/,VFBL B>]"L9AVW8UIABR0(,(?=\*
MP)K\<1M2*_LWD%-+_@$YRVS"5LN>&RY*Y@*;4E>+D*L-1/M2JI\:&V0O@5'Q
MP9645 Z"^7=K @3^5HWO3/AW)RH$-( ,%+!VTG&=Z@/-TB$CA)(@445+-NE=
MA8^.>O\9E#++<GU&+HUP_-)PXBW<(F"Q:VDP<D)%:F132+/.-CJ-&O R5\DY
M8XF409>#D3?>!'R?]/SNJ\9_7/;C"_\HKI;P:6]P+/>Q\0Q;H)AZ5955,4)E
M<N!3(:R=S/AJLDLPV3MN!5_V 3"_24:N[&^SL#IJ8@#!U:',A;CBZ2H3*X]>
M!2CQ4<(XWFTJ $;5]#7%-M*X%H?PN0755411:2Y;K.A-W1A'4Q18]0/C, YN
MK0*VK&GOF)U?E&B*W?,7+HX$8#$%/K8OTIE^VK<.^$VB&Q"#6%3+A2JOOB)N
MV-OW" D@0 -;.B RMM-75:^5O1<5!N$0@%G\25$'C:<QORL:9V-!/ :+N%.J
M]!.K+M<+;IOBV_5-1)A/H5U:/S@A,]!3&$) GG[:2&9S,>Y ?("X_Z@83N1+
M@F&*U0C\<;<V- NF:B?'U;()\S,!AJQ2$261[2 :[CB[PY5HWJ1GY#E*O,0H
MPR_S2#N=%&9AH1!-%0A8@<6Q:M7'[E5?6.BTN0">U! _E"'@.9QTW,4S#1L3
M305S+TY%FP<=G16M#&Z2!C&S=!Z5'N'G"QH."$H<ZN+T8<C54CR =FLD9--=
M>^K;IA"9/_C8^)8HD@0$E;"KN:1W4@D:T0O)(@NN!TNOP#(*I<K;$DF..2$V
M*D6*W%ZM&F53QA3!D<0[%S1MRKV] QM<I)LL[1UVQA;LB',U5C4NI?137?XN
M:VW-,\S9^*P,!3J=8W^F/2M#F*+^]Y4.2?*-Z*23DQT'[T0G1R1P>O/'&/NC
M&1"A'26 ]<.(HD0"F*U+T'PF]TRSU3GWY;74W02;M%-D6XD01]K%:#0P0GY2
MW+ZV\#=B[.-809$%>EH)#/M!>'?B!\2_@O3)#+JK<++JF2-74O7-F89QM?A/
M461F%NK-53I+(F,(/O4ULV*)3 I&@JED %YG -M>O"!I*^,KBJ0WOJ;#Q>U$
M2[T,\K9I-_(4[49^YVXC_=/CWL?3_KO^4?>R?W;J=4^/O2-X^$7_[2?\Q7I.
M<WTOXA>R]4B?DRF2<6\3U'IB6^X%=\TP+PW=QDIDNB9@T-A:WNK6%0<W=JN[
M!82:!-07I= "X&%40TORW&H.\F::2M\RMVZ!CJ'79V$@*1'JFAFLFBL,K+%9
M!OXTHCJP3V4T0]\RF 57^(LX"H;(;4N,"Y2:*XOM=+(]AVLH+#3,0_/]JHO(
MN%8,A(C,&BJ "T)&MKA.G!:/#3\R5)C4*KRB"X9^H]QT\HZ1TC!#=Q?+V&2H
ML(%[S:A+/Z^T%781$]<97J3I:#&]B+PX,@.)CM/2W#'&KG^'(1-[T!5SDN8W
MEJPIU+_:)-2D4 BYY2I<(3]+U!P>O"D.B2A.=96#/4XG@6I-3,1Q5#FD5ER$
M=JRU,\$$VA0S8GR5>(@P1B005#>RHTB"X # <3J]3WFJ'$5:["HWGQ#//"#F
ML1"=,*R"^CN<#C$_6BYQQ@,[26_A)9U0Q<A6Y8HP@==HX^<^J4['0*<[>M(<
MQ.1*D6"I&L<XN 6(]BVE+-(2?(R4?R#/@'&H:C@>JO0#V1\'UY&F1)??K'L@
MN3IN39&BU6FI.O@JB[N[#K"J$GDSSG#9U>@X]08=!4Y4'7'?/OK$A5@_]PT7
MH[E6*QU](A4R;D8$+JYP,WI?XV($QYIN1L:($.4=.I"K78_>@MN1PL3-G&*+
M2J<>]>[T[G9U(L?25[H[O>K5B;%M:M)I2S*&"L2ULLH69'KX4;[XBL7GR&..
M7,#.*]=V^,$T7'S'+B>1ONOM6Z/J"?#&=]R]-73_5[]Z,7ND[M[*O5O!!BX'
M=-GM%/3Z&&D#&62BFT5%LK!ZZQIYHGT2J;]@>**?A_QU,$MMR/,BWT"6K1=I
M$<2U64D%=&O"SGB,(ACF'B0N(#4BR71UQMB3S>W%XB=AX0FV32/Y70DYJ<R^
M[#[IG@B(R$*V :5>OG8 Z+MB#CK8(,TJ2+.#-4>:K8&0/VL+_P#,-\Y)VC8A
M_1.S;JLJ46$ L&Y4R&YDZG!GY:NNW2WE[\'TOY4I43(4Z\7$JKM 'H:?\]HX
M.G:NA2ZX((J1>PV[#QCC$>/0N. (;K4HD^E8&WP.1H*-/J=4;--"J.:)ALW#
MN1 Q%%&CI^PP A&%?X%Y.V++R[$N6QS'4JAS@:V7X PU#J1APL_KH6K;&-YP
MQ4 FHL&+(P:6J&Z9P["XP:11[8EXLYE#@JL(W;0P%\4@< FY*[AH%Q67H_5<
M8\OQ[LP1M>2)\BFT^15XBI[!C]>%3])C U,AJ)'RU5=CQ^N+I\FG(^2*WCGV
MFR31*M<TFEB0/Z.LAHE*S81%(4QRHOP5V<S:6)0#PY7M24X8-K25>;KB-];;
MRZ12?XRIJZT=KYLX!H[T.:DG&F08IY;0*R&VGQ*],U*_8=T#L>C6&(0Y)RI6
M)6;&5:FF,"Q(KQ3:?<'@>5)VS)49WC9*QR+!TJ> \?QU49><Y_5M:#@$6J(;
MCX/XOJ 7E84U[L_A1,T9<)V+F@)6>C7*GJ]$I> "KUS,R"E7OOJ$5#W@12A]
MJA<D8[(;7!(AS(;DLGX=!8D4>_H3.UN4OJ=)Y+I\_5;YR2ER?G94[1/_'"%D
M$CX6C:OGP937:H\TN^Q$#V^+&CHP[X@>LRIPDW5<7(]<@G>>< 45V%GX2.5
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M-K$'Q+NF\>9691+<T@O#Z@H_=REB8M* O55/'W!%D=7O"0N"94V9&@57=2(
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MZ!NWB'5\S .BL,<JA%%IMYE=@=K^CPB4R+#D@@_!7NEZ;#YC40["5UJEO&*
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M9I#6&O\ZR>;/;\^._R2+Y\/EQY,W_Q]02P,$%     @ H80]4V<S]0F.A0
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M5*ZUBM)W(Q:10CZR)[T0?]LD59ZA<QL4EG;8?BY-Z+$&T;PS<=3;PCN_@XV
MP_AE?$M!/!55O6D 3UTKW;2.CN!UGSJ%\$YR/N,P%[LAGL*_8-?91C O@FR:
M[0'2C8@%F[&?;FO8)\= E4,TZ%)M%LX^Q-,'[=W-N3[2UD9VJC>.RMT=RGO
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MLIZ#%BKS5K)O5?3/#.0L]8#2#TG,.IH.=9"D_CDHD[E_3*=Z $D0T1WM*8^
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M&]1IMBQ(X64[;#-8FQ)[:6.<&^M/N2W=:)U<@:FJVAAKQ4,%0(I?[6#YKV;
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M*<_'6>[/\N1ZF:S>_?4U6,XH+T)FC#1T@^VA^]@P31ZW*MNM]>82(EWPAZK
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MX*P<C@ &D%H&]&S=95>WS#V^TMJV?>,2AMIF$=Q9H\U1FW)@P>RSJ2%"T][
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MX-\@^I3_>OSP^S>_OOI[W7S_5_POD4;1&0$>#=9D13N32 A>P$9\"JH2)+L
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M!F[K!KO*9$D>Y>4*JP3@XDU;4&:)0HF4(,<('5_1-EP%PTEXVJ1;L /@Y]Q
M>\6]H>GWE:G+O+7D"=A3H%C1U9A1-MB_/<8@9F7@SXHX]_-,NL;QGY6#Z<7P
MLN "'"=<0=D^ND;,$958DXPT/*!(D%4 E @>4?@/M;MC3'5Q@H^]9(\#V%+;
M'40X4OB3:#9+W7W=1YX%_?(/'9?^H4QWT<)#%/=<IUY>;?+U/3M=FM-%4F3_
MXN./H]@)'Z0_)W6:_"YA#:Z@B$D<_[>LWLG'+]ZO&%XBL.$?:>EQ\5X6*0B]
M1T!BU_5S.ZZI5\&GF\\G@SA^/4$<+<3QZPGB^(F$\A1WU*T5*H4G,H9<AXU5
MTMD._VZ+GY_Q@4>*-^;*/'=JPH&S-14H?!MO[D1NU3$!?PW'K&-&FO#96V(Q
M4_?;UU+<"??GKZ2N2J%6\(\WYZ_Q/Z],A7W*N=?3M7A;.+-?:,CTT700G.9\
M%NN]8CN?N=SQL"691-<5^M%%E+@D\](TU\84H<N$UF6 ,#*(-0430JC Q)>"
MGX$IF$JHD*M;N>)Y/GL[4$UW80JT/7-A@JH;U^ K;$XE7 A^D *$M(^WLZC;
MS4:E:N3V?G3SF1K>6+$S/HV=M$QU?.IA0).\A*<[*)<>\+1;3G(^BXNQW4+.
M^XB2QY>[](5_0L33#2K82&=J:IB3,6?W(P1W6-\D(JRA1C=3>7,0Y'*U[XF^
M;#X+K[-P0[I>7'\PR(RN292Q\6U[(U,]^,:'YSG<,L0"TMY99LS]AS!R^%*S
MLTT2?Y+S65PJB0<Y]T+_S&9N!!UQGN*8^*3 V;_LGA2(NV(?LB.!L3=O"+%?
M*UAUMUS:D<LX"ZD#?9_//+#*?>ZA4#X]_X)\<;2-,,SL^ 495 N&V+;AX(/F
M%PRS[/#OJFPO+F&"U07BQO'')2&^F*2A,MKIQN##*E@T_ 3L-9_NB#EA#SN1
M#D<PLNR_<*,ZVX_7BMKVHG481SD("O:E+"H,RW 2!<U&=Q\,_M%:P8'5X&,1
MDF"BX,,\^[VEL6, T U@56Z6JI[#LDL8%P_PGZU< <K*)6(0$[8BPA"V"6$@
M&0AC4B&%! 8NB$>$?L(<>YH+3P0!M0J*BTTROL$PDP52^T#$^6I5M@4-_PV2
MC!+0@378T%=8F)IF:\PUXMS>EMMLQ:+^MX??D,[#5PQ*;F7JFJ,>H!S+L\-,
MILP3@"LLBR9$E?!)DW%HQD5_2T<^PR+E(-6@.(D+P%!GZB0*MUOD=]ND.$]R
M/@$70& J/$M D'NFPJ4$XU!9DO<&9W&VE(ZD-ME@2_WWV]R!C2F&KY4OCNQC
M*92[)[6XS800WK.Y"C[4/B%65TBBI4=]&;+*XF.%W4;NJ.JI/32 57X(A (E
M/E!R U^L,;Z;U9=E 6IC%]-V09SG!DP7L,M;C/]BW 5&"@]:9_ )ID"BM 55
M@^4:2.Q!M0F@3->H]0C:BE M+EE8)WGME )!_IBLDU</689L^BE*RU4K=1<8
M+L;N[/73#F!K:!HN/+Y.LAPU(R[=,O/&7 ?$18K*2#$=3E%% TJLJ ?1]&Y_
M[$XR7_85^Q]61L+!5$M2K%'+-S 85,7,/9K@^A"FMJS>;?-D1=H,GTO=D/VM
M9&W<@I#"]B[1&:W%H<5H"XEA(P $]D6,KY)2N%M8(QY\*D>$,V>SCFX%17Q!
MBI5?IOTKJ9&8A>H)[7%4;A&%W182,M<[0Q0^?(JVKIO5P;5E_3TTMVS#)S;.
MB^QC$-*\K.DP7 _+E'XE!(2F=3 -RG!64)2%P-JXMK9J"6^B1!C>TLIQ7 5$
M>^217M)IXF00;/8JDSR#@+/+8D@*(W$"W%C=%Y79MDUBH=O+MLX0%0\J;7%U
MX.7#E7S"V9U [T]J-%!"MQQ9XC"9ETQXL>B(I+BM41+9J+-*L6"7GTHG&TU
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M?Q3#22@)TE$L;;LMX9BS* [7_GR!HRA*EZ==JR\=P*& 51<: 'HVI9<=H87
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M0(DIULW*ZLT' BL3"P:RTZ(\2:BBIJ:EH9K;*A'U==88+#?\?<-AZK;4*_Q
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M]R<A.S+QYJ\_?_CG]_B7OUW_]./W_P902P,$%     @ H80]4UM;TO/H'
M3J8  !D   !E83$T-SDR.65X,3 M-%]J87-P97(N:'1M[5U[;QNWEO]?@+X#
M-]A;V OYE2;=WM@U8,=NZT6:9!.U%T%QL:!F*(DWHZ$Z#]NZGW[/@^1P1B-+
M=FPYB9(6<2S-\'G>Y\?#HU_[O[TZ[G:.?CT_.8.? O\<]2_ZK\Z/C_;X)WR[
M9[\^.GUS]D&\[W]X=?[3DZ%)BQ?B8']:B+Z>J%R\5E?BG9G(M,<?],1[E>GA
M$W@17GU[V_<.Q41F(YV^$/CH_J$HU'6Q(Q,]@H\R/1H73XZ/3H_/K\=ZH MH
M</?9T=XI#/OM_73XY/B[=)!/#Q<U.#!)_*G3B%1:J SF\?.;U_VP^9U<_UO!
MH)].BT-!'US*3$OL-Y_()-F)Y#1_<OP_,I^JK-OICU4FIZHL= 3]7J31[M'I
M.QCU^\)$'\6;::%-*G[)X'WQVL!#BK\^VL-^6WIO[6SKZ?[3 W'^5ZF+&?8!
M8]>72KQ-9+KM6EK#6MV\*Y_8R;_*O-##F5M9,;^P8JL8*_%=$O]5FD.@OZ.+
MXY=F,I7I[&COXA@I\+N,OMON=3O3,LM+7/7""%WD//3%R]C2-GX\U[ 8RUR,
M<#M5C$W/3"FV:J_QEH]AV576?+W;@9X,TP2\#&.,H#TEL.^TG Q@VF8H\K',
M8!'A7_@Y3'$"CS,]Y:H FLR*L1BHQ%RUC)J[;W:\*SZ8,G/DJ/-N)R\'_U(1
M+0_0F>L,MGF2"YG&(C)IK/%I^#4/^H5=43JE1^ 'OD/+A[_C+S6R/QEE2DU@
ME7NNCZNQCL8"IB=D4<AHK.)N!UO$45"+D<FF)I.XNK8G[D5G G<+GISMBI=R
MJ@L@FW_C'M"(4U,(=3U-=*2+9"9B-=2I;Z(G!F7A/PM';;)JT-W._*AA)V#<
M8WG)6S11,M7I*%R.1:VU+0&LY!2'* >)VGUH+FKP:O_D]-6Y>'G^ZM7[MR<O
M+U[_\M.3_2?T^]N3LS/W^ZU'<J7C8HR/[O_M$$1-!C2_$YDD :D%,M3]ZPGI
MMZ/^.]?!I<J K67B1EV8Z1.K X_Z9^XIV_CSOU6SZ9\M?.S9\[\M6(J0(U^T
MMV&'/C!%828OQ&DB80L/=I_#"N0FT;&?Z;/]1;W<.+B#_?HDX*]WMUN4&Y>@
M=4!GP$7(<Z1\[CSO%>:Z[HG]H> ?Z8@DHP(ICNPE<+9?TR1?>W7PWJN#FBIX
M7PEP)O"O:?;GURJ+-&C&MQF83&+K+2P%K</VUS3+O@$M)NIS_9KF=WX]U:#+
M40\^#GOND=I[4#U[;WJ<_]Y]KM/5-/J]]'>P^[397Z*&A?U$I['"MG?H,?+Y
M^K,I*I5NA[0*FI@O! ]L];__K$SOT%;ZISCZ_?C-NZ.]WX_%GZ_!\"QD418F
MF]6?>O %L N^8 W6M LW#X*<;RLUP&Z^5^?[LUZ6FXG3&@;@?*-G42:*Z3/0
ME&B?A^;@=UF._E$.JA4(,BU-F>-X+E'I%./,E*.Q4!)=%F^YBTMK?L0@TGI!
MBV B@K. WX*IW^T,P?@U5_D+]/<%_?7G__D__]S%:,"5+L9 Y>!H07/8$/@4
M:F3@MY[OA5T0]')TB@9=.376Y9 HK#6XOX6?A7L,1X-,.C^K^_,[[K!%ZXD?
M "&$6RQ.HH^IN4I4/")+,6>B.)VA[YZ!(PQO@Z !EY1<ZAZZ<8.94 F03&92
M'0D916H*VP0T =_)$E8_13W)OC3XOKAO$_K"9.24POO6=<?H1(^B!"4L1D:[
M3:ZN1,<0GI)HFC^2*QBZ?DW7\!\79_U??WJ"GMT=_$(>U@X8$#0T_X%3\O 9
M;-12RV/>D=K???J<N)T4_>*OY^)J0SG1R0R$P6PR, DLRD3'L2D.??BLWEZ[
MO5;QNL[%R,"H4[?;\,'"D%_/AT>FF;G4.455;,1E/GK2%HB8"Y],9 RB7TQ!
M"'!+T']LHA(?WQ6_IXG*H0MH,[M")4']QO7H1X_?"@>Z;"!BJS CA:VRX&N)
M/%4/-V-0,.89!6H&,'P3ZZ%6,<P,'L6! 6=E"M8&/U/7R'#,6E>99IF.?,J+
MC=Q$+"1 QL]"OC/#(<PB"T)GR'^[E578;A&N0*T<"EXMZ/Z-W^Z)WRZ&H7K5
M&)@4[;9C3V@@SFE26J(7IBR\9FU_Q8=QNQV.XVZ+2*:6/H<:1+4 HE9L9J'B
M1WI&20_$FY'D3L5_PG;U]O?WD50O95*"ISI1,@=E0H2JG(TV1<]NFP@ZG4$W
M"="\S,1,R6Q7G*0SHO@<C 84*4&K,&.QT!)>-UE_NII:0I]WXIMFG WC<YO.
M-Q] 0$9 -HK3'YF*E*80=D/<]VZ,5X=Z H,3)I^"251R>@#H&*B56 V?V<E4
M0D%[IX/RA@T5JP2& !1,&L:0XB+K%4S:,(;NC&X,IZ<[B4[)Y@H:RF=YH28"
MK&/@29U3!@';G$B=%E*G<]87V6PI#Q56((NI;\P1L.4W]\(W=?$%DSWE:C(E
MK9$-@II:UB!MT=NZP0B[F1F<852QP6ZW<\&$JRZ1T: I$NXF'8*GB%JDN%(J
M;?9(Q-[*A_.=VH12@_6J/!V/OMNIAA]^S@S%_B.,"O@G^4;:7RAI]UOH [.0
MN4U#$AE2?C3P,]'V<53H;.90,&9J)#,?>Y#17R70*/8!DKV1;,!7\W(*#2N0
MF^2.@$T#]&DRF="W:*<7T)%TPX,M ;*?@/E#9+M'!OXT4ZB5)!M@%,F0,!$.
MT/0J%F4/P V%A;?BO+V\@D'GT#9X"Z;,P0%HI..M>OI&ZE\FJ3M"4I-I8F9$
MZ#(0B<,AD$*BX!'P07,0O1D%9H)'7 /5EU.;G9\:D,PSE*O.=IFCVIK8=HR"
M%(64!;*;@H$18S:0<D$NHR.;!]*7OQB;,HEMC( E_N-8[=_H\I[H\J4I$06%
MQF-.H0QP$ZU5"[+G4DNP-*)<0T>@SP.#%0S31&SI-$I*DK73>,@F:<T^]E'(
M;B<"JDMF^*@7A[_OOM_EC1R"_$61>_[^XI?7XB1"N\-AF\!K%+^G&H.1_-%Y
MU7X?."&7$<M=>BVS8C6(;"?R:MM_ 6XQO@,"' T7,5'%V,0])UW!HO#+(7)3
MK42/P^"T.,!1))7)*!L@5W' !IH ;UG'A-1Q*XB?PEOT!?VB@-4C=-LQEIZQ
MSBFSJ0&%\KA,=%LXS1U]TWN#T[Q\@Z-\_=.3IVV\T0HX/#I=#,/C;%/%.$L2
MQ'?KO8;9$<TN;Y^\;L$4G<[N 0RT$C2IB?ZY*]+IS@.[^WK=! -=A@-PS[]W
MLFT5<GFP?N\ >.CK(KDK:J%]N.T??@(XXE-19??5]9(9+OOPGB$;RVR/2I"O
M*9;YZ8AXW]1_[.R(G[5*XA?BK1RI0WC^KQ)A<-"LV-EQZWMV\4>;,F18>V/$
M/^!GR[>[J5[GIKK\@3T85LL(!YF2'W<&"O/?+\24IA6.^H>60>-,5AE3V&6P
M=GNX>+Q>7_R)A3L=4%B,A;<G%.:/,02IO:_JS$$#KD @K"?')[G(U!!-:)]V
MS!J)T5KNM'X,H';DHYD)76A;]58_XX G$;H=%_O@P(<[6T QH'L\]E [K"#G
MCBJTQ(L*&\8)$V#@/\<(F^ T-"UG?0%7/LRP[ ! MU-#^X/S'4156PX#U(;A
MHJX45%WY!$"S"7J]VZF#_G''JQCM+#B2@6<L;"RA?50<O&NB#*I@(.9["EV4
MA:JUZQ]XX ,'[2ST>,R+"SU2*?G*;8=:8&<JOY<#A]5>X/$4C*Q: -=&+1PP
MWL'NX@C*DE[# W2DB,7<G]N>??N%0F@8#B&!=683C%X%G1XW#S>)QMFFUIP/
M9TWF7AV6&45%&DUHBG5DRD:N+6S%AKFS,N$8-T;4R\0]PF"=B9SUQ# S$U'
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MKISP/F@BR!Y29$GS(!"?2N)N9[Z4$16I:=(09^I<;C4<MQ]M6,N@M8W* )X
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M2GV&K<:EF\$F57K\^6>5'E\ B3C3H*^X,CWX2#X\4SNI=E$_/]:X*ZA>QRY
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M*9X PS\/M=6,QT!YX5AHM38(.AXTE/Y;2;^JDOX&8D"H7*&DM<2@#32BEH7
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MAC\I:/5HYFJ)J?&%'N>V"8#CQWGLLJ$I9L@TJ,N4/A*?S+JM2ZMA44&(\*C
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MN&[P@E=63 TKQ0*C4IF.+(#9$ ' MC6!3I146D;^][?&.&\_6_W/0>G?*C@
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M\=2QY48SGUN.YUB(X0P<P+U8NWT3@[N7 ]&4*3"6OR#TV7T,5T^E _YR)^D
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M\R0:D((9MB1^.?[XI?75F%CA"3L?%D6THZN3_^BF)K8%UY- \'$%@Z:7.]H
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M R,B>GF8?84Q%F@N7^FFU>&[T\&DWE/"% RS->)4*N-;DSD#9A%7J3. 0G_
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MBS=':_[U]G6:_*C:7/V6_*VL%["%WY(';T $O G""R)_,8TD1 >FH,]%2U8
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M\HDJE:EQAG-@E4-0I<M,B2*-E!7I(<3/@-2 FVAX9G4%213HR_1 RV83JD1
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MZ^S4X[UW![\CH3[^^>R7X]?_#U!+ P04    " "AA#U3LO#,?P,H  #(V
M&0   &5A,30W.3(Y97@Q,"TX7VIA<W!E<BYH=&WM/6E3'$>RWXG@/]33>^N
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MJRLXS<]*5;CT0GR0$YFV/QY\5C',>:'"3S<7;?T=X?[^R/MT<'ATOO_^[&]
MRP-QLG]Z?C0 DOYX/C@51-U-D@;:@=U?71G*4A-U(BV,\C3-+W4V%B,95S!O
MC=125D \\+ D6@6"AOF P,I7#T0:]X+$_4V!>#I'' 6G2B2JU 4,7TUD13AS
MIP9.L5#369K/X=C#P<8?PR^!#\2R*.8BK_G+!#Y3C%08<088!>&2:GH(T\2%
M'N)("K8$SG^:KJ[PI@'(Q92_BW/8&=H, 3Q#Z4R.X$=1J@H04E23ASJ]][)%
M!YN"U0N[3WXKW"X![XUCX+NBK..)V1YDW$C_]*@/EX\::Q^/?X,/?QJ<#MX>
MGPX0=Q&<:5Q]J>&P,ZTR/P"I,<P!FX6*=273$MZSL@<(DPF.4(=$.:VK&F1*
M#!]D,JL8I[,BG^H2@(;A*ZFSYF<Y?%>(<9XG]-<+F=9RF*HF+!%# C H#0O#
M%\MZ--*Q5ED\1T@O)QHV$B4CC@TG3WV>P>:7*0C7^%.67Z8J&:N$!A(S6?"I
M0Q&.@IEYWH,QLSN:A#;W[3%H+B$M587,2F $H-76,] L8EDJ(H+MS<;+",3&
M2$YU.G]U'1CT;JG_K1CJ)WNB]0^J]SCX'FO(_,<#TB[]\<-M?$/\C]7+@[V>
M0[?,\_! YW#;G,+MS>WE[(#'?HAOAV34+1M2*<E5:<_-!'AF!)KK6(Z-$DL#
MM,1<CH=7R&KC4J>I(/TA@B,Y_$/%%3)<)Z%8Z0Q$E#^73D AZR'EVJG4R(WB
MM$:%(Q)#$)597HE43S7RG"I'+,0\W N"\24SJW (7J6#>'4E7*21!_@I\P
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M"<<E@0/?@6-]$PQB/E866U&+0?$&%0I <2CHA8RWWG]H=WDM,*@'QZ$U'!!
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MW%R"C27B0B&+E\AG1\!6*X2$AE1EQ22!XHGE0H=?L^1DGL$,#H7:Z@I)-72
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M \ 0CMZGC:%"%O1*S CJ$*B7/3 AH'[L8-Q@_4\1 ;SF>][8>Q&PS^]%P![
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M&5C$2&[H$2,&-&2],2<CNT_G\8;Y1$DP2(%I ,W!D:X+,+8K&"A%P"BH#A9
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MF03DP'QX,0+UVML'$:FK&JS$GY1,JTF,/KO]&"2@"?TV2A/1!HJ"9','&Y=
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M1IJ#,@_YLBB7DT$EPMJFF;6Y[->_]3<(9+Q\Y(&,E]\"&5^<U%U6TZO%;&9
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M3;$3G H_B4Y"ADMP7.9UFH2MM>W%G>T.\0X!V$>$,6"3S4&MD,GB+PVX(UV
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M%^SOWLZ/.Y$P6-,8'B3YI<?&3$ENW##)L8((T$+Y;<K_KKGUEW#K'U?,K<\
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M,S>>)6YVN'K8)>,KCBXW:MQ/7'R8%TQ3X\51R\&(0HMTB';&/C@07UQ;P\_
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M6G;$.RJ!_NQ2?&M_CU=(FZ<K+<Z+G'[MWQ@QUR$)V23-\P+,1X=?!;:F$X"
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MQ3>QR6E7Y(:NS_28YX[QP1%;TLEXF<S-? RRH&M;,OD5\[G)"SHJDK'S K0
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M)U(G==KEI-BJE@/\KG7E:D((G[I<F&R]'A4\NS#NCJ4^S+Y5-_2L8EAN=$'
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MI#_6]Z@LO0[A_ 2]ZMP2A?"_!T.*H@R'&]C<H8UFQ4!P[2W:ID4;ODC=4(P
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M??7L=R OW?_Y]-=??OK_4$L#!!0    ( *&$/5-@GR2P. (  ' )   9
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M^F8.E^QF#"; 0=LU)'V%\!9-([8T'K5"KWH*6DV.M8!\Y[R)_\\T"2-QIR0
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MI;X.Q"&ZQDZ9WGP_G/D#L.9\ ?.85AF2V$Y%$V !9 "\!KPR7H3 %4$FXH0
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M92PXJUN:O9\A<:H';  H&IT"A#FN;591$M:W][B-A<NY%IK/K:";!!51A$M
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M.<'QA<,X_KP#8CJAF)G9-F980"L(U.X$1XA2?[Q5V2I?2>:NN&J"=^LCW[O
MU36Q,G7/\CKR=9&;:0>08&T9/)E@YCI4?!<WR-^(HQM0\1VH_OMP="TJOK-Y
M7HNC4P.;-P7-.01^0F>/!)T=O^FM'^ARJM'O&(U<K-1(!:%,3-@] 29@<-R
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M%;[(3+VQST9,)%'TPI1F1K$"I;GV>1HTH>?9H>+?&2?)&(Y>_3):R&$!LXT
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M"*;R!8K9^.8H*?VF -EUX7G'\]C8YEYT7KMT(G0(VZO8'IRN7%,BUZ6X)+S
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M5':]N^,669MRD?I"NAV:-"CMF2G)J/9[7U4YL@ :>J<@9M+0_#WBV8L@Q94
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M]K'I9^H,)"R.&]G^3OK7R&C(6!)/85!2BS,-S-%L6FLX0TF]<4B]C[(EDX=
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MNVRUX4!G8(1UA>>$:0V@;^[H5X\1%A7-,-A(?T),GLS)'GE+3C0;(]MG>Z]
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MQAFY:7Q3UXX@4&5JZ+P"=[=YFVL2-PF'3S-IGT55GZ3Y_2ME8N0VV*LLN)-
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M'Z7]6.I>[S/G;Z43=9K ,>U.UMITJM.#XKM$6U (]!.>QXIL=X<TF=;RB!D
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M97(N:'1M[5SO<]O&T?[.&?X/]WI:CS-#TJ)B.Y7M9")1<JU4MC62&D\^=8[
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M+]WUML0;?./8Y(OM3-7$KE%].SNVIV:<U\"G*A(E'&<S:KG4_5#&>^ *FJU
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MK6:KU8SS5J)UL.'R^#W#Q8(AD_AS?]BLJEKB<:0K>*1>$\^@:ROC.4XR2VE
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M_PY[_6&$P,7FM&"(#>;RD(9)@3] MX Y5ZC(JFDF7*R!US4\@W$:^&!T(H-
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MUT#A]RS[1HP+$Z.JK#?)]4P4^7"384I+217HRHVE02X6\R5F_L,M$Q%4WGD
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MHP@YXE3?L^<#$(X[9G">; 3FHO\^_7QZ??X?=@?^Z]VWKY__/U!+ 0(4 Q0
M   ( *&$/5,#Q!7Q  0  'T/   1              "  0    !A;6AC+3(P
M,C$P.3(T+GAS9%!+ 0(4 Q0    ( *&$/5/$3KLZH D  )MQ   5
M      "  2\$  !A;6AC+3(P,C$P.3(T7V1E9BYX;6Q02P$"% ,4    " "A
MA#U3V5M]U,8,  #%F   %0              @ $"#@  86UH8RTR,#(Q,#DR
M-%]L86(N>&UL4$L! A0#%     @ H80]4R+3Q&;H"   CFH  !4
M     ( !^QH  &%M:&,M,C R,3 Y,C1?<')E+GAM;%!+ 0(4 Q0    ( *&$
M/5,L!S+G!8$  $L_!  6              "  18D  !E83$T-SDR.2TX:U]J
M87-P97(N:'1M4$L! A0#%     @ H80]4WN8M)UX#   P4$  !H
M     ( !3Z4  &5A,30W.3(Y97@Q,"TQ-%]J87-P97(N:'1M4$L! A0#%
M  @ H80]4\8B"GM19   4]<" !D              ( !_[$  &5A,30W.3(Y
M97@Q,"TR7VIA<W!E<BYH=&U02P$"% ,4    " "AA#U39S/U"8Z%   BB0,
M&0              @ &'%@$ 96$Q-#<Y,CEE>#$P+3-?:F%S<&5R+FAT;5!+
M 0(4 Q0    ( *&$/5-;6]+SZ!P  $ZF   9              "  4R< 0!E
M83$T-SDR.65X,3 M-%]J87-P97(N:'1M4$L! A0#%     @ H80]4^=];V#V
M&   JWL  !D              ( !:[D! &5A,30W.3(Y97@Q,"TU7VIA<W!E
M<BYH=&U02P$"% ,4    " "AA#U3CWF,K]DZ  "UG@$ &0
M@ &8T@$ 96$Q-#<Y,CEE>#$P+39?:F%S<&5R+FAT;5!+ 0(4 Q0    ( *&$
M/5-M1"1HT"8  /K1   9              "  :@- @!E83$T-SDR.65X,3 M
M-U]J87-P97(N:'1M4$L! A0#%     @ H80]4[+PS'\#*   R-@  !D
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M<&5R+FAT;5!+ 0(4 Q0    ( *&$/5,B/ (%?"$  )ZW   8
M  "  0'2 @!E83$T-SDR.65X,RTQ7VIA<W!E<BYH=&U02P$"% ,4    " "A
MA#U3A%^#NX9H   530( &               @ &S\P( 96$Q-#<Y,CEE>#,M
M,E]J87-P97(N:'1M4$L! A0#%     @ H80]4P\9<EOS$0  ,4T  !D
M         ( !;UP# &5A,30W.3(Y97@Y.2TQ7VIA<W!E<BYH=&U02P$"% ,4
M    " "AA#U3B,:M>_ ]  #.$P, &0              @ &9;@, 96$Q-#<Y
I,CEE>#DY+3)?:F%S<&5R+FAT;5!+!08     %0 5 +L%  # K ,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
